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Abstract
Chronic pain, particularly neuropathic pain, is a major clinical problem which
currently represents a largely unmet therapeutic need.
To identify novel analgesic strategies for chronic pain, we investigated the
phenomenon of analgesia produced by cutaneous cooling. The recent identification
of specific cold sensory receptors has allowed, for the first time, investigation of the
molecular mechanism underlying cooling-induced analgesia.
We have shown that the cold-and-menthol receptor, TRPM8, is critically involved
in cooling-induced analgesia. Activation of TRPM8 in a subpopulation of sensory
afferents (by either cutaneous or intrathecal application of pharmacological agents or
by modest cooling) elicits analgesia in neuropathic and other chronic pain models in
rats, and inhibits the characteristic sensitisation of dorsal horn neurons that occurs
ipsilateral to nerve injury. This analgesia is abolished following antisense
knockdown of the TRPM8 receptor.
In contrast, activation of the related putative cold-receptor TRPA1 produces
hyperalgesia in naive and neuropathic rats.
TRPM8 expression was observed in small diameter sensory neurons in dorsal root
ganglia and on afferent terminals in the spinal cord, with increases in specific subsets
of sensory neurons following nerve injury.
We further found that the central mechanism of TRPM8-mediated analgesia is
mediated through inhibitory Group II/III metabotropic glutamate receptors, and is
opioid-independent.
These results identify TRPM8 as an essential molecular mediator of cooling-
induced analgesia. We propose a novel analgesic axis in which activation of TRPM8-
expressing afferents by innocuous cooling or chemical ligands leads to activation of
inhibitory Group II/III metabotropic glutamate receptors in the spinal cord, which
then exert inhibition over nociceptive inputs. These findings suggest that both
TRPM8 and the inhibitory metabotropic glutamate receptors are promising targets
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1.1 Physiological and chronic pain
Pain is a normal part of human experience. Physiological pain serves a useful
purpose: alerting organisms to damaging stimuli and triggering withdrawal reflexes,
or forcing a state of rest to promote recovery from injury. In contrast, chronic pain
persists long after the original injury has healed, and therefore does not serve any
such useful purpose. Although definitions (and thus reports) of chronic pain vary
immensely, chronic pain is a major clinical problem: a recent epidemiological study
of more than 46,000 people in 16 European countries found that nearly one in five
adults were affected by chronic pain (www.painineurope.com). Common sources of
chronic pain are neuropathic pain, cancer pain, arthritic pain, back pain and
headache. Chronic pain has major implications for the social, economic, and mental
health of sufferers - for instance on the ability to work, or incidence of depression,
and therefore poses a major socio-economic burden (Nicholson & Verma, 2004).
Chronic pain states involve changes in the nervous pathways that process pain
signals, so that they become more excitable, which results behaviourally in
symptoms of hyperalgesia (lowered thresholds to painful stimuli), allodynia (the
perception of normally innocuous stimuli as painful) and spontaneous pain. In order
to understand the changes in the nervous system that may underlie chronic pain
states, a consideration of the mechanisms of normal pain processing is necessary.
1.2 Introduction to basic mechanisms of nociception
The term nociception refers to the detection of noxious stimuli, which may result
in the perception of pain. Noxious stimuli to the periphery or the internal organs
activate specialised sensory afferents, which synapse in the dorsal horn of the spinal
cord. Spinal cord projection neurons in turn connect to various specific brain areas.
This outline is discussed in detail below.
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1.3 Somatosensory afferents
The axons of primary afferent neurons run from sensory endings in target tissues
to central synaptic terminals in the central nervous system (CNS), and have their cell
bodies in dorsal root ganglia (DRG) near the spine or in the cranial nerve ganglia in
the head (Gardner et ah, 2000). The peripheral terminals of the primary afferents
constitute the receptive part of the neuron, and have contact with specific skin areas
from which the afferent fibres can be excited (known as the receptive field). The
peripheral receptive terminals of the afferents are specialised to respond to specific
sensory stimuli such as temperature, mechanical pressure and chemical agents.
Proprioceptive afferents are a specific class of somatosensory afferents that detect
internal information about the position and movement of the body and limbs; this
class will not be discussed further in this thesis. Peripheral sensory stimuli activate
the receptive terminals of sensory neurons, producing a local depolarisation of the
neuronal membrane, which, if it is of sufficient strength, will trigger the firing of
action potentials (Gardner & Martin, 2000).
Sensory afferents can be classified experimentally by their conduction velocity, by
their selective responses to sensory stimuli, and by differential expression of certain
characteristic proteins.
1.3.1 Conduction velocity of sensory afferents
Afferent sensory neurons can be classified into 3 main types by fibre conduction
velocity. Aa fibre neurons have the largest diameter myelinated axons, and the
highest conduction velocity (>30 ms"1 in the rat), and are often grouped together with
Ap fibres, which also have large-diameter, myelinated axons and a high conduction
velocity - 14-30 ms"1 in the rat. A5 fibres have medium-diameter, thinly myelinated
axons, and a conduction velocity of between 2.2-14 ms"1 in the rat. C fibres have
small-diameter, unmyelinated axons, and conduct slowly - <2.2 ms"1 in the rat
(Harper & Lawson, 1985).
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1.3.2 Selective sensitivity of afferents to sensory stimuli
Different classes of sensory afferents respond selectively to specific sensory
stimuli. Non-nociceptive mechanoreceptors respond to a variety of innocuous tactile
sensations including light touch, pressure, vibration, stretch, and hair movement
(Gardner et ah, 2000; Lynn & Carpenter, 1982; Willis & Coggeshall, 1991). These
innocuous mechanoreceptors are generally associated with Aa and AP fibres (Lynn
& Carpenter, 1982). However, a population of A8 fibre neurons is associated with
low-threshold mechanosensitive D hair follicle receptors (Djouhri & Lawson, 2004;
Lynn & Carpenter, 1982), constituting -27% of A8 afferents in the rat sural nerve
(Leem et al., 1993). A significant population of low-threshold mechanosensitive C
fibres also exists, which were found to constitute up to 15% and 33% respectively of
the total C fibre population within rat plantar and sural nerves (Leem et ah, 1993;
Lynn & Carpenter, 1982).
Non-nociceptive thermoreceptors respond to innocuous warm temperatures and
warming, or to innocuous cool temperatures and cooling (Iggo, 1959; Iggo, 1969)
and are mainly associated with A5 and C fibre neurons. Afferents responding to
innocuous cool temperature information will be discussed in greater depth later in
section 1.19.1
Nociceptors, as defined by Sherrington, are activated exclusively by noxious
stimuli that may be expected to evoke pain (Sherrington, 1906). The majority of
nociceptive neurons are generally accepted as being associated with AS or C fibre
neurons (Gardner et ah, 2000). However, recent evidence indicates that a substantial
population (approximately 20% in rat) of Aa/p fibre neurons may also respond
preferentially to noxious stimuli (Djouhri & Lawson, 2004; Fang et ah, 2002; Fang et
ah, 2005; Lawson, 2002).
All AS nociceptors respond to high-threshold noxious mechanical stimuli, but a
percentage (-25%) is also responsive to high-threshold heat stimuli (Fang et ah,
2005; Leem et ah, 1993; Raja et ah, 1999). Varying percentages of AS nociceptors
responding to noxious cold have been reported - these and noxious cold-sensitive C
fibres will be discussed in greater depth in section 1.19.2.
Most C fibre nociceptors are polymodal, responding to noxious heat, chemical,
and mechanical stimuli, and in some cases to intense cold (Bessou & Perl, 1969;
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Fang et al., 2005; Leem et al., 1993; Raja et al., 1999). Noxious stimuli evoke both a
rapid sharp component of pain, and a delayed, dull component; it is thought from
psychophysical evidence and from differences in the conduction velocities that A
fibre nociceptors mediate the former and C fibres the latter (Basbaum & Jessell,
2000). Some nociceptors are classified as "silent" or "sleeping" nociceptors, as they
do not appear to be active under normal circumstances, becoming responsive only
when sensitised by tissue injury (Handwerker et al., 1991; McMahon & Koltzenburg,
1990; Schmidt et al, 1995).
Most classical descriptions refer to cutaneous nociceptors; however, nociceptor
properties vary significantly with tissue type. In certain tissues such as the cornea or
teeth, pain is evoked far more easily by stimuli which would be innocuous elsewhere
(Julius & Basbaum, 2001), whereas visceral pain is poorly localised and dull and has
no separate fast and slow components (Gebhart, 1996). These differences must be
taken into account when considering pain arising from such tissues.
1.3.3 Sensory afferents show selective expression of characteristic proteins
Sensory afferents show differential expression of certain characteristic proteins,
which can be useful experimentally. Myelinated afferents can be specifically labelled
by antibodies against higher molecular weight neurofilament proteins (150-200 kDa)
(Lawson & Waddell, 1991), whereas C fibre neurons can be specifically labelled by
antibodies against the intermediate filament protein, peripherin (Amaya et al, 2000).
There are two main populations of C fibres: a population of peptidergic neurons
which contain the peptides Substance P (SP) or calcitonin-gene-related-peptide
(CGRP), and which express the high-affinity nerve growth factor (NGF) receptor
trkA (Averill et al., 1995); and a non-peptidergic population which can be labelled
selectively with the plant lectin isolectin B-4 (IB-4 - Snider & McMahon, 1998) and
which expresses the Ret receptor glial-derived neurotrophic factor (GDNF - Bennett
et al., 1998).
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1.4 Molecular mechanisms of nociception
Recent years have seen great progress in elucidating the molecular basis of
sensory transduction, with the cloning of receptor proteins which transduce specific
sensory stimuli and are expressed by afferent neurons (Julius & Basbaum, 2001).
The majority of these receptors are ionotropic cation channels, which upon activation
allow cations into the afferent terminal, leading to depolarisation and potentially to
the generation of action potentials. The classic example of such a receptor is the heat-
and-capsaicin-sensitive receptor TRPV1 (transient-receptor-potential-vanilloid-1,
earlier called VR1) (Caterina et al., 1997). When expressed in heterologous cells,
TRPV1 is activated by noxious heat, with an activation threshold of approximately
44°C, and by capsaicin (Caterina et ah, 1997). This activation threshold and the
response to capsaicin match the properties of native noxious-heat-sensitive sensory
cells (Cesare & McNaughton, 1996), suggesting that TRPV1 at least partially
mediates the sensory response to noxious heat (Caterina et ah, 1997; Cesare et ah,
1999). Electrophysiological and behavioural studies of TRPV 1-knockout mice
demonstrate an almost completely abolished response to capsaicin (Caterina et ah,
2000; Davis et ah, 2000). However, the knockouts show normal behavioural
responses to noxious heat (Caterina et ah, 2000; Davis et ah, 2000) and appear to
have at least as many neurons sensitive to noxious heat as normal mice (Woodbury et
ah, 2004). Therefore, TRPV1 appears to be the key determinant of capsaicin
sensitivity, but is probably not the sole mediator of noxious heat sensitivity (Caterina
et ah, 2000; Davis et ah, 2000; Woodbury et ah, 2004). However, TRPV1 does
contribute significantly to inflammatory thermal hyperalgesia, as this is strongly
reduced in the knockout mice (Caterina et ah, 2000). TRPV1 is also sensitive to
protons (Caterina et ah, 1997; Tominaga et ah, 1998) and a significantly reduced
response to H+ was observed in dissociated DRG neurons in TRPV 1 knockout mice,
suggesting that TRPV1 may also partially mediate the response of afferent neurons
to acid (Leffler et ah, 2006). The discovery of TRPV 1 has resulted in much research
on the role of this channel in pain and temperature sensation in vivo and in vitro, and
has stimulated the discovery of more sensory TRP (transient-receptor-potential)
channels.
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Further heat-sensitive TRP channels are TRPV2, TRPV3 and TRPV4. TRPV2 is
activated by temperatures of around 52°C, but not by capsaicin, and is expressed
predominantly by A8 fibre neurons (Caterina et ah, 1999). Therefore TRPV2 may
underlie the capsaicin-insensitive high-threshold heat response, which is
characteristic of a class of A8 nociceptors (Leem et ah, 1993; Nagy & Rang, 1999).
TRPV3 and TRPV4 are sensitive to innocuous warm temperatures and warming,
with activation thresholds of ~35°C and ~34°C respectively (Peier et ah, 2002a; Xu et
ah, 2002; Smith et ah, 2002; Guler et ah, 2002), and TRPV3 is also activated by the
chemicals carvacrol, thymol, eugenol, camphor and menthol (Moqrich et ah, 2005;
Macpherson et ah, 2006; Xu et ah, 2006).
TRP receptors responsive to cold and to decreases in temperature form the basis
of this thesis, and will be discussed in detail in section 1.24-1.25.
Additional receptors have been identified which are sensitive to peripheral stimuli
such as acid (Leffler, 2006; Waldmann et ah, 1999) and adenosine triphosphate
(ATP) (Burnstock, 2005; Chen et ah, 1995); a full discussion of peripheral sensory
receptors is beyond the scope of this thesis. The identification of these specific
receptor proteins has greatly advanced our understanding of the molecular
mechanisms of pain sensation, although much further work remains to clarify the
roles of individual receptors in in vivo responses to noxious stimuli.
1.5 Primary afferent termination in the spinal cord
The first synapse in the pain pathway is in the dorsal horn of the spinal cord,
where primary afferent neurons terminate and form synapses with dorsal horn
neurons (Basbaum & Jessell, 2000). Within the spinal cord grey matter, the pattern
of afferent termination is highly ordered. The rostrocaudal and mediolateral
organisation of the central terminals generate a somatotopic map of the body surface
(Doubell & Mannion, 1999), at least in the superficial laminae (neurons in deeper
laminae may not be somatotopically organised - Craig, 2003). Dorsoventrally, the
spinal cord has a distinct cytoarchitecture, which was classified by Rexed (in the cat)
into 10 laminae (Rexed, 1952). Figure 1.1 shows this laminar structure, adapted for
the lumbar cord of the rat (Molander et al., 1984). Laminae I - VI (LI-LVI) comprise
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the dorsal horn of the spinal cord. Different afferent types project to different
laminae.
LI is the thinnest layer of the dorsal horn and receives input primarily from A8 and
C fibres (Willis & Coggeshall, 1991). Primary afferents terminating in LI generally
form synapses directly with projection neurons, whose axons ascend to the brain
(Giesler et al., 1979; Todd et al., 2002; Trevino & Carstens, 1975; Spike et al., 2003).
LII (also known as the substantia gelatinosa) receives input predominantly from C
fibres, with some input from A8 fibres (Basbaum & Jessell, 2000; Willis &
Coggeshall, 1991). Afferents terminating in LII contact an interneuronal pathway,
which relays the signal from afferents to projection neurons in LV (Braz et al., 2005;
Snider & McMahon, 1998; Woolf& Fitzgerald, 1983).
LIII-IV receives input from A fibres, including both non-nociceptive AS fibres,
originating from hair follicles, and large-diameter A(3 fibres originating from
cutaneous mechanoreceptors (Brown & Iggo, 1967; Light & Perl, 1979). LIII-IV
neurons also receive input from nociceptive fibres via excitatory interneurons (Willis
& Coggeshall, 1991). The majority of afferents terminating in LIII and LIV form
synapses directly with projection neurons that connect to the brain (Basbaum &
Jessell, 2000; Giesler et ah, 1979; Todd et ah, 2002; Trevino & Carstens, 1975).
LV receives direct input from AP and AS fibres (Basbaum & Jessell, 2000;
Basbaum & Fields, 1984; Craig, 2003; Willis & Coggeshall, 1991). LV neurons also
receive input from C fibres, either onto their dendrites which extend dorsally into the
superficial dorsal horn, or indirectly via excitatory interneurons (Basbaum & Jessell,
2000). Some LV neurons also receive nociceptive input from visceral structures
(Basbaum & Jessed, 2000). Many LV neurons project directly to the brain (Basbaum
& Jessell, 2000; Suzuki & Dickenson, 2005; Willis & Coggeshall, 1991).
Lamina VI only exists in the cervical and lumbosacral enlargements of the spinal
cord where it represents the transitional layer between the dorsal and ventral horns.
The main input to this lamina is from non-nociceptive afferents responding to joint
manipulation (Basbaum & Jessell, 2000; Willis & Coggeshall, 1991).
The cranial afferent nerves terminate directly in the brain (in the brainstem)
(Basbaum & Jessed, 2000). As this thesis has focussed on nerves in the body that
terminate in the spinal cord, the cranial nerves will not be discussed further.
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Figure 1.1 Laminae of the spinal cord
Figure adapted from Molander et al., 1984, shows the rat spinal
cord at the rostrocaudal level L5, classified into laminae l-X.
Laminae l-VI comprise the dorsal horn. "Liss." = Lissauer's tract
"Pyr." = Pyramidal tract, "LSN" = lateral spinal nucleus, "VM" =
ventromedial nucleus.
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1.6 Responses of dorsal horn neurons to primary afferent input
Dorsal horn neurons may be classified into three basic types according to their
response characteristics to primary afferent input. The first class responds
exclusively to noxious information. These neurons receive inputs mainly from AS
and C fibre neurons, and are located primarily in LI and LII (Christensen & Perl,
1970; Gregor & Zimmermann, 1972; Light & Perl, 1979). The second type of
neurons respond only to innocuous information: these receive inputs from
innocuous-mechanosensitive A(3 fibres, or from AS and C fibres signalling innocuous
temperature information, and are located predominantly in LIII and LIV, and LI
respectively (Craig, 2003; Willis & Coggeshall, 1991). The third class comprises
multireceptive neurons, often known as "wide dynamic range" (WDR) neurons,
which respond to both innocuous and noxious information. These neurons are most
frequently found in the deeper dorsal horn laminae III-VI (Besson & Chaouch 1987;
Willis & Coggeshall, 1991), but have also been identified in the superficial laminae
(Iggo, 1974; Menetrey & Besson, 1981; McMahon & Wall, 1983; Woolf &
Fitzgerald, 1983).
1.7 Dorsal horn neuronal output
Dorsal horn neurons are either long-distance excitatory projection neurons, whose
axons ascend to the brain, or interneurons. The majority of dorsal horn neurons are
interneurons (Willis & Coggeshall, 1991). Interneurons can be excitatory or
inhibitory. They are activated by primary afferents, other interneurons, or descending
fibres, and in turn, they synapse onto the presynaptic terminals of afferent neurons,
onto the pre or postsynaptic terminals of other interneurons, or onto projection
neurons (Willis & Coggeshall, 1991). Therefore, interneurons mediate a number of
different roles within the spinal cord.
Neurons that project to the brain are found in LI and LIII-VI (Giesler et al., 1979;
Spike et ah, 2003; Todd et ah, 2002; Trevino & Carstens, 1975), and these projection
neurons connect to the thalamus, brainstem, midbrain, amygdala, hypothalamus, and
striatum (Brooks & Tracey, 2005; Millan, 1999). The cerebral cortex is in turn
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activated by projections from these areas. Processing of pain in the brain is outside
the scope of this thesis and will not be discussed further.
1.8 Neurotransmission in the dorsal horn
There are extensive synaptic connections between primary afferents, interneurons,
projection neurons, and descending fibres in the spinal cord, and a rich variety of
neurotransmitters are involved in transmission at these different synapses. In general
there exist multiple receptor subtypes for each neurotransmitter; therefore the effect
of any transmitter is dependent on the particular receptor subtypes expressed at the
synapse where the transmitter is released. The effect of neurotransmitters on dorsal
horn processing is also determined by the type of neurons that they exert their effects
at: for example, the activation of an inhibitory receptor located on an excitatory
neuron will produce an inhibition of transmission, but the activation of the same
inhibitory receptor on an inhibitory neuron will cause disinhibition, and thus increase
dorsal horn excitability. Thus any one neurotransmitter can potentially exert a
variety of effects, and this fact, coupled with the existence of multiple
neurotransmitters, underlies the complexity of signal processing in the dorsal horn.
Key neurotransmitters involved in dorsal horn signalling are discussed below.
1.8.1 Glutamate
The excitatory amino acid L-glutamate is the principal excitatory neurotransmitter
of the nervous system (Kandel & Siegelbaum, 2000). In the spinal cord, glutamate is
released by all primary afferent neurons, and is also released by excitatory
interneurons (Willis & Coggeshall, 1991). Glutamate activates ionotropic receptors
to directly open ion channels, and G-protein-coupled metabotropic receptors to cause
longer-term modulatory changes. Ionotropic receptors comprise a-amino-3-hydroxy-
5-methyl-4-isoxazole proprionic acid (AMPA) receptors, N-methyl-D-aspartate
(NMDA) receptors, and kainate receptors (Hollman & Heinemann, 1994; Kandel &
Siegelbaum, 2000). Metabotropic glutamate receptors (mGluRs) comprise mGluRl-8
and are subdivided into Groups I-III.
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1.8.2 AMPA receptors
AMPA receptors (AMPARs) are predominantly postsynaptic in the dorsal horn
(Coggeshall & Carlton, 1997; Henley et ah, 1993), and mediate the majority of
glutamate-induced postsynaptic excitatory current (Dougherty et ah, 1992).
AMPARs are composed of combinations of four possible subunits (GluRl-4), which
form a tetrameric receptor (Hollmann & Heinemann, 1994). The GluR2 subunit
undergoes post-transcriptional editing, which confers a low Ca2+-permeability on the
tetrameric receptor (Burnashev et ah, 1992; Washburn et ah, 1997), and thus the
effect of AMPAR activation is a fast inward Na+ current, producing depolarisation
and therefore possible action potential firing (Kandel & Siegelbaum, 2000).
However, studies also indicate significant expression of Ca2+-permeable AMPARs in
dorsal horn neurons (Albuquerque et ah, 1999; Tong & MacDermott, 2006), and
activation of Ca2+-permeable AMPARs can produce a transient change in synaptic
strength at dorsal horn synapses (Engelman et ah, 1999; Gu et ah, 1996). Thus in
addition to their primary role in postsynaptic excitation, AMPARs may also
contribute to synaptic plasticity in the spinal cord.
1.8.3 NMDA receptors
NMDA receptors (NMDARs) are composed of NR1, NR2A-D and NR3A/B
subunits, which form a tetrameric receptor, composed of two NR1 subunits together
with two NR2 subunits, or with one NR2 and one NR3 subunit (Hollman &
Heinemann, 1994). NMDARs are strongly expressed in the dorsal horn with NR1
and NR2B being particularly concentrated in the superficial dorsal horn, and are
predominantly postsynaptically located (Coggeshall & Carlton, 1997; Tolle et ah,
1993; Petralia et ah, 1994).
Under normal circumstances, the NMDAR is blocked in a voltage-dependent
2+ . . i
manner by a Mg ion in the channel pore, and requires simultaneous depolarisation-
induced relief of this block and glutamate binding in order to open; therefore this
receptor could be considered to function as a coincidence detector (Bliss &
Collingridge, 1993). The NMDAR is also regulated by a glycine-binding site
(Kleckner et ah, 1988). Glycine appears to function as a co-agonist of the NMDAR,
and antagonists of this site can attenuate the hyperalgesic effect of intrathecally
11
applied NMDA in vivo (Kolhekar et al., 1994), and the effect of NMDA on dorsal
horn neuron responses (Dickenson & Aydar, 1991) highlighting the importance of
interactive effects of neurotransmitters in the spinal cord.
The NMDAR is permeable to Ca2+, and thus its activation leads to activation of
2"hCa -dependent intracellular signalling pathways, and resultant longer-term effects
on neurons. The coincidence-detection properties and Ca2+-permeability of the
NMDAR allow it to play a crucial role in synaptic plasticity in the dorsal horn as in
other nervous system areas (Bliss & Collingridge, 1983; Dickenson & Sullivan,
1987; Dougherty et al., 1992). The contribution of the NMDAR to spinal cord
plasticity and the development of central sensitisation will be discussed below in
section 1.15.2.
1.8.4 Kainate receptors
Kainate receptors are composed of the subunits GluR5, GluR6, GluR7, KA1 and
KA2, forming a tetrameric receptor (Dingledine, 1999) that carries an excitatory
current. Kainate receptors are strongly expressed in the superficial dorsal horn on
postsynaptic terminals (Coggeshall & Carlton, 1997; Petralia et al., 1994) and are
also found on presynaptic afferent terminals (Kerchner et al., 2001; Lucifora et al.,
2006).
1.8.5 Group I metabotropic glutamate receptors
Group I mGluRs comprise mGluRl and mGluR5. Immunoreactivity for mGluRl
and mGluR5 is concentrated in the superficial dorsal horn, and is seen at high levels
on postsynaptic terminals of spinal cord neurons (Berthele et al., 1999, Jia et al.,
1999). Group I mGluRs are also expressed in afferents, as immunoreactivity is
observed in DRG (Hudson et al., 2002) and on peripheral terminals (Zhou et al.,
2001). Group I mGluRs are coupled to phospholipase C (PLC)-mediated
phosphoinositide hydrolysis and to formation of cyclic adenosine-monophosphate
(cAMP) (Aramori & Nakanishi, 1992). Both of these effects contribute to cell
excitability, and Group I mGluRs are therefore presumed to play a facilitatory role in
synaptic transmission. In the spinal cord, Group I mGluRs are implicated in
nociceptive behaviour and neuronal responses to noxious stimuli, as intrathecal
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application of Group I mGluR agonists elicits nociceptive behaviours (Fisher et ah,
1996), whereas antagonists inhibit dorsal horn neuronal responses to noxious stimuli
(Young et ah, 1994, 1995, 1997).
1.8.6 Inhibitory metabotropic glutamate receptors
Although most glutamate receptors are excitatory, the Group II/III mGluR
subtypes exert inhibitory influences. Group II and Group III mGluR subtypes are a
focus of this thesis, so will be covered in more detail than the other neurotransmitter
receptors of the spinal cord.
1.8.7 Group II metabotropic glutamate receptors
Group II comprises mGluR2 and mGluR3. Activation of Group II mGluRs is
coupled through the Gj/G0 protein to inhibition of cAMP formation (Bushell et ah,
1999; Conn & Pin, 1997; Gereau & Conn, 1995). Activation of Group II mGluRs has
9+
been shown to inhibit N, L, and P/Q-type Ca currents (McCool et ah, 1996;
Neugebauer, 2002; Robbe et ah, 2002) which would cause functional inhibition of
neurons.
Group II mGluRs are found in the spinal cord (Carlton et ah, 2001; Jia et ah, 1999;
Petralia et ah, 1996; Tang & Sim, 1999). Immunohistochemistry reveals that these
receptors are located both presynaptically on the terminals of primary afferents in
superficial laminae, with dorsal rhizotomy removing much, but not all, staining
(Carlton et ah, 2001); and on dorsal horn neurons and glia, particularly in deeper
dorsal horn (Carlton et ah, 2001; Jia et ah, 1999; Tang & Sim, 1999). In afferent
neurons, mGluR2/3 expression is particularly high among presumed nociceptive
populations. Approximately 76% of mGluR2/3 immunoreactive DRG cells are IB-4
labelled, and in turn approximately 67% of IB-4-positive DRG cells are mGluR2/3-
positive. Both myelinated (28%) and unmyelinated (32%) axons are mGluR2/3-
positive (Carlton et ah, 2001). In the dorsal horn, staining is particularly high in inner
LII (Carlton et ah, 2001; Jia et ah, 1999), which is consistent with a high expression
in IB-4-labelled afferents (Braz et ah, 2005). Electron microscopy shows that Group
II mGluR immunoreactivity in spinal cord neurons is found both at postsynaptic
terminals and on the presynaptic terminals of both glutamatergic and GABAergic
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interneurons (Jia et al., 1999; Neugebauer, 2002). mGluR2/3 immunoreactivity
appears to be primarily located at extrasynaptic sites rather than at the synapse itself
(Azkue et al., 2000), which is consistent with a potential heterosynaptic mechanism
of activation. The localisation of the Group II mGluRs in the spinal cord is therefore
consistent with a potentially complex role in the influence of nociceptive
transmission, by presynaptic and/or postsynaptic mechanisms.
Group II mGluRs have been strongly implicated in an inhibitory role in spinal
cord pain processing. Intrathecally applied specific agonists of Group II mGluRs
attenuate pain behaviours in models of sensitised pain states: both in carrageenan and
formalin-induced inflammatory pain (Dolan & Nolan, 2002; Simmons et al., 2002)
and in the chronic constriction injury and spinal nerve ligation models of neuropathic
pain (Fisher et al., 2002; Simmons et al., 2002). Electrophysiologically, Group II
mGluR agonists reverse the sensitisation of spinal projection neurons produced by
peripheral capsaicin or carrageenan-evoked inflammation, with little effect on
normal transmission (Neugebauer et al., 2000; Stanfa & Dickenson, 1998). Group II
mGluR agonists were also shown to inhibit A fibre-evoked potentials in dorsal horn
neurons, an effect which appeared to be mediated presynaptically, as the frequency,
but not the amplitude, of postsynaptic potentials was affected (Gerber et al., 2000).
Therefore the evidence suggests that spinal Group II mGluRs play an inhibitory role
in nociceptive transmission, which appears to be significantly upregulated in
sensitised pain states.
1.8.8 Group III mGluRs
The Group III mGluRs comprise mGluR4, mGluR6, mGluR7 and mGluR8, of
which mGluR4 and 7 have been shown in the spinal cord. Similarly to Group II,
Group III mGluRs are linked through the Gj/G0 protein to inhibition of adenylyl
cyclase (AC)-stimulated cAMP formation (Neugebauer, 2002; Okamoto et al., 1994).
mGluR7 and mGluR4 activation has also been shown to inhibit N-type and P/Q type
Ca2+ channels (Millan et al., 2003; Perroy et al., 2000). Therefore activation of
Group III mGluRs has an inhibitory effect at the cellular level.
mGluR7 is highly expressed by DRG cells, and is found presynaptically on
afferent terminals in the dorsal horn, with high levels in superficial laminae
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(Kinoshita et al., 1998; Li et al., 1996; Li et al., 1997; Ohishi et al., 1995a,b). Dorsal
rhizotomy removes most expression, indicating a location predominantly on afferent
terminals (Ohishi et ah, 1995b), although low levels ofmRNA are found in the spinal
cord, suggesting expression by spinal neurons also (Berthele et al., 1999; Boxall et
al., 1998; Valerio et al., 1997). Electron microscopy shows an almost exclusive
location in presynaptic active zones (Kinoshita et al., 1998), indicating that any
expression of mGluR7 on spinal cord neurons is almost entirely due to expression on
presynaptic terminals of spinal cord interneurons (Neugebauer, 2002). Of mGluR7-
labelled primary afferents, roughly 33% and 10% also stain for IB-4 and SP
respectively, and most IB-4-positive afferents, together with some SP-positive
afferents, are labelled by mGluR7 (Li et al., 1997), which indicates a high degree of
expression by nociceptive afferent populations, and is consistent with the high levels
of mGluR7-immunoreactivity in dorsal horn superficial laminae. mGluR4 protein is
also seen in small to medium DRG cells, and in the superficial dorsal horn,
particularly LII, which is again consistent with expression by nociceptive primary
afferents, and electron microscopy indicates that most mGluR4-immunoreactivity is
in presynaptic terminals (Azkue et al., 2001). Low levels ofmGluR4 mRNA are also
found in the spinal cord (Berthele et al., 1999; Valerio et al., 1997), indicating
possible expression by some spinal cord neurons. The location of both these
receptors on the terminals of nociceptive primary afferents, and to a lesser extent on
spinal cord neurons, is consistent with a role in modulating nociceptive transmission.
Spinal Group III mGluRs have been shown to inhibit transmission of nociceptive
information. Intrathecally applied Group III mGluR agonists (which currently are
unable to select between mGluR4/7) slightly decreased nociceptive responses in the
formalin test (Fisher et al., 2002), and produced analgesia in a model of neuropathic
pain (Chen & Pan, 2005). Ionophoresed agonists decreased the responses of spinal
dorsal horn neurons to both innocuous and noxious mechanical stimuli, in both
normal and capsaicin-sensitised animals (Neugebauer et al., 2000), suggesting that
Group III mGluRs are less selective in their inhibitory effect than Group II mGluRs,
which only affected sensitised responses. However, in a model of neuropathic pain,
agonists inhibited the responses of sensitised ipsilateral dorsal horn neurons, but had
no effect in nai've animals, and had similar effects behaviourally, suggesting that
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Group III mGluR function may in fact be elevated in the neuropathic state (Chen &
Pan, 2005). Similarly to the Group II mGluRs, agonists have also been shown to
inhibit A fibre-evoked potentials in dorsal horn neurons, through an apparently
presynaptic mechanism (Gerber et al., 2000). Overall, the evidence supports a role
for the Group III mGluRs in the inhibition of spinal nociceptive transmission,
although this may not be completely selective, as they have also been shown to have
inhibitory effects on responses to innocuous stimuli (Neugebauer et al., 2000).
1.8.9 GABA and glycine
The amino acids gamma-amino-butyric acid (GABA) and glycine are inhibitory
neurotransmitters that are released by populations of spinal inhibitory interneurons
(Willis & Coggeshall, 1991).
Immunoreactivity for GABA is found in approximately 33% of LI-III spinal cord
neurons (Hunt et al., 1981, Todd, 1996). Ionophoresis ofGABA results in inhibition
of dorsal horn neuron activity (Curtis et al., 1959, 1977; Zieglgansberger & Sutor,
1983), and intrathecal application of the GABA-A receptor antagonist bicuculline
produces behavioural allodynia in rats, indicating that tonic inhibitory GABAergic
mechanisms may control behavioural sensitivity (Yaksh, 1989). GABA receptors
comprise ionotropic GABA-A receptors, which couple directly to CI" channels, and
metabotropic GABA-B receptors, which are coupled to AC inhibition. Expression of
both receptor types is observed in the spinal cord, with high levels in superficial
dorsal horn, and is strongly decreased, but not abolished, by dorsal rhizotomy,
indicating expression both on primary afferent terminals and on dorsal horn neurons
(Alvarez et al., 1996; Coggeshall & Carlton, 1997; Price et al., 1987). Therefore
GABAergic inhibition may operate by both pre and postsynaptic mechanisms.
Glycine is also implicated in inhibitory control of nociceptive transmission as
intrathecal application of the glycine receptor antagonist strychnine produces
behavioural allodynia in rats (Yaksh, 1989). Glycine receptor expression is observed
throughout the dorsal horn, with the highest staining observed in deeper laminae
(Coggeshall & Carlton, 1997; Todd & Spike, 1993); and is predominantly observed
on postsynaptic membranes (Coggeshall & Carlton, 1997; Todd, 1996; van den Pol
et al., 1988). Therefore glycine may produce inhibition by a mainly postsynaptic
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mechanism, and may produce a stronger inhibitory effect on neurons in deeper
laminae.
1.8.10 Neuropeptides
A variety of neuropeptides exert effects in the dorsal horn, including SP, CGRP,
opioids, neuropeptide-Y, cholecystokinin (CCK), galanin, vasoactive-intestinal
peptide, pituitary adenylyl cyclase-activating polypeptide, somatostatin, vasopressin,
and others (Dickinson & Fleetwood-Walker, 1999; Wiesenfeld-Hallin et al., 2002;
Willis & Coggeshall, 1991). Neuropeptides act on receptors coupled to second
messenger systems to produce slower, longer-lasting effects than those exerted by
conventional transmitters on ionotropic receptors, including changes in gene
expression (Hokfelt et al., 2000). Because there is generally no specific reuptake
mechanism as there is for conventional transmitters, neuropeptides can diffuse
considerable distances from their release site and exert effects on more neurons
(Basbaum & Jessell, 2000; Hokfelt et al., 2000). Neuropeptides contribute to the
complexity of dorsal horn processing, as the same neuron may release conventional
transmitters such as glutamate or GABA together with several different
neuropeptides (Hokfelt et al., 2000; Ju et al., 1987) and may thereby exert a variety
of potential effects on target neurons. Neuropeptides exert significant effects on
dorsal horn pain processing but are not a focus of this thesis and therefore will not be
covered in further detail, apart from opioids, which are important in endogenous
analgesic mechanisms and are discussed below.
1.8.11 Opioids
The importance of the opioidergic system in pain processing is underlined by the
pre-eminent role of the opiate drug morphine in pain treatment. Opioids exert effects
at peripheral, spinal and supraspinal levels (Basbaum & Fields, 1984). In the spinal
cord, intrathecal administration of morphine produces behavioural analgesia (Yaksh
& Reddy, 1981), and ionophoresis of opioids produces a strong inhibition of dorsal
horn neuron responses to noxious stimulation (Fleetwood-Walker et al., 1988a). The
main endogenous opioid peptide subtypes are the enkephalins, the dynorphins, P-
endorphin, and endomorphins 1 and 2 (Basbaum & Fields, 1984; Millan, 1999;
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Zadina et al., 1997), all of which are found in the dorsal horn (Cruz & Basbaum,
1985; Basbaum & Fields, 1984; Dun et al., 2000; Glazer & Basbaum, 1981; Gutstein
et al., 1992; Martin-Schild et al., 1999, 1998; Tsou et al., 1986).
Opioid receptors form three classes: p., 5 and k opioid-receptors, all of which are
coupled to AC inhibition, activation of hyperpolarising K+ currents and inhibition of
2+ • • ....Ca currents (Connor & Christie, 1999; Millan, 2002), thus causing inhibition of
transmitter release from primary afferents and hyperpolarisation of excitatory
postsynaptic neurons (Dickenson & Suzuki, 2005). Enkephalins act as agonists of the
p and 5-opioid receptors, (3-endorphin and endomorphins 1 and 2 are selective
agonists of the p-opioid receptor, and dynorphin acts preferentially at the K-opioid
receptor (Millan, 2002; Zadina et al., 1997). All three classes are expressed in the
dorsal horn, with high levels of expression in superficial laminae, which is where
most nociceptive afferents terminate, and are thus well-placed to influence
nociceptive transmission (Arvidsson et al., 1995; Coggeshall & Carlton, 1997; Elde
et al., 1995; Mansour et al., 1996).
1.9 Modulation of spinal cord excitability and the gate control theory
The first theory proposing modulation of nociceptive transmission in the spinal
cord was the gate control theory of Melzack & Wall (Dickenson, 2002; Melzack &
Wall, 1965, 1982). In this theory, which is shown as modified by Melzack & Wall,
1982, in Figure 1.2, both large AP fibres and small C/A8 fibres activate dorsal horn
transmission neurons and therefore the output from transmission neurons depends on
the nature of the peripheral stimulus. Flowever, AP fibres also activate inhibitory
neurons in the substantia gelatinosa (SG; LII) which function as a "gate" by
presynaptically inhibiting afferent activation of transmission neurons. The activation
of AP fibres by innocuous tactile stimulation activates inhibitory neurons, partially
closing the presynaptic gate, and thereby inhibiting transmission neuron firing. For
pain to be produced it is necessary for the noxious stimulus strength to overcome this
inhibition, and this in turn can be overcome by further stimulation of Ap fibres, by an
increase in the presynaptic inhibition of small cell firing. This suggests how rubbing
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or other innocuous tactile stimulation of an injured area, or the use of transcutaneous
electrical nerve stimulation (TENS) can relieve pain.
The gate control theory proposes that transmission through the dorsal horn can be
modulated by activity in other classes of afferents. Such modulation has been
demonstrated experimentally, for example the phenomenon of primary afferent
depolarisation (PAD) (Rudomin & Schmidt, 1999; Willis, 2006). PAD is elicited in
afferents by activity in neighbouring groups of afferents, and results in an inhibition
of neurotransmitter release from the depolarised terminals (Eccles, 1961; Frank &
Fuortes, 1957; Rudomin & Schmidt, 1999; Willis, 2006), demonstrating the
existence of inhibitory effects produced by one class of afferents on another. In
addition to proposing modulation of transmission by afferent input, Melzack and
Wall emphasised the importance of descending control from the brain affecting
dorsal horn neuron responses. While the experimentally known properties of the
spinal cord do not precisely match with the gate control theory, the central tenets of
modulation of dorsal horn nociceptive processing by activity in other classes of
afferents and by descending controls from the brain remain fundamental to our









Figure 1.2 The Gate Control Theory
Illustration of the Gate Control Theory, adapted from
Melzack & Wall., 1982. Both large Ap fibres and small
C/A5 fibres activate dorsal horn transmission (T) cells;
therefore the output from transmission cells depends on
input stimulus. Ap fibres also activate inhibitory cells in the
substantia gelatinosa - SG. These function as a "gate" by
inhibiting T cells presynaptically. Activation of Ap fibres by
innocuous tactile stimulation activates SG cells, closing
the presynaptic gate, and thereby inhibiting transmission
cell firing. For pain to be produced it is necessary for the
noxious stimulus strength to overcome this inhibition.
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1.10 Descending control of spinal excitability
Stimulation of brain areas such as the rostroventromedial medulla (RVM) (which
includes the nucleus raphe magnus) and the periaqueductal grey matter (PAG), or
microinjection of opiates into these areas, produces analgesia (Basbaum et al., 1976;
Basbaum & Fields, 1984; Fields, 1977; Murfin et al., 1976; Willis et ah, 1977). This
analgesia can be blocked by lesion of the dorsolateral funiculus tract which descends
to the dorsal horn, indicating that this mechanism operates via a descending pathway
to the spinal cord (Basbaum & Fields, 1984). This descending pathway represents a
major endogenous analgesic system, in which activation of an opioid-activated
pathway from the PAG to the RVM, or direct activation of RVM neurons, results in
activation of descending serotonergic and noradrenergic pathways from the RVM to
exert inhibitory effects in the spinal cord (Basbaum & Fields, 1984; Fields 2004;
Millan, 2002). RVM neurons synapse onto dorsal horn projection neurons, producing
a direct inhibition via release of their transmitter: noradrenaline or serotonin (also
known as 5-hydroxytryptamine - 5-HT) (Fields, 1999; Giesler et al., 1981). RVM
neurons also synapse onto intemeurons and may inhibit excitatory interneurons, and
activate GABAergic and opioidergic inhibitory interneurons (Fields, 1999; Sorkin et
al., 1993). Opioidergic interneurons of the spinal cord play a key role in this
descending inhibition, as demonstrated by the fact that intrathecal naloxone can
block the inhibition caused by stimulation of the RVM or by supraspinal opioid
administration (Fields, 1999; Levine et al., 1982; Zorman et al., 1982). A number of
different 5-HT receptor families are found in the dorsal horn: 5-HTi, 5-HT2, 5-HT3
and 5-HT7 (Coggeshall & Carlton, 1997; Suzuki & Dickenson, 2005) and of these
the 5-HTi receptor family appears to play a significant role in the analgesic effects of
descending RVM neurons, as ionophoresis of 5-HTi antagonists blocks the inhibition
of dorsal horn neurons elicited by the electrical stimulation of descending fibres from
the RVM (El-Yassir & Fleetwood-Walker, 1990).
Other brain areas are also implicated in descending inhibitory controls.
Noradrenaline is released from fibres descending in the dorsolateral funiculus from
the locus coeruleus, subcoeruleus, and A5 nucleus, in addition to the RVM (North &
Yoshimura, 1984; Westlund et al., 1983; Yoshimura & Furue, 2006). The overall
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effect of adrenergic transmission in the dorsal horn appears to be antinociceptive
(Yoshimura & Furue, 2006), as intrathecal administration of adrenaline or the 012
agonist clonidine is antinociceptive (Reddy & Yaksh, 1980), and 012 agonists are used
clinically as analgesics (Racle et ah, 1987). Fibres releasing the monoamine
dopamine descend to the spinal cord from brain areas including the All nucleus of
the diencephalon, and stimulation of this area produces an inhibition of spinal neuron
responses to noxious stimuli (Fleetwood-Walker et ah, 1988b), as does spinal
application of dopamine (Gao et ah, 2001; Tamae et ah, 2005) demonstrating an
antinociceptive role of this transmitter.
In addition to descending inhibitory control, descending input can also be
facilitatory. Activation of certain cells in the RVM (termed "on cells") can produce a
facilitation of dorsal horn neuronal responses to noxious stimuli (Fields, 2004;
Neubert et ah, 2004; Suzuki et ah, 2004; Zhuo & Gebhart, 1992). This facilitation
may also be mediated through release of 5-HT from descending fibres, as 5-HT can
produce facilitatory effects by its actions at excitatory receptor subtypes (Suzuki et
ah, 2002, 2004). For example, the 5-HT3 receptor (which is a ligand-gated ion
channel, whereas the other 5-HT receptor families act through G-proteins; Maricq et
ah, 1991) is implicated in a pronociceptive role in the dorsal horn, as antagonists of
this receptor reduce behavioural and neuronal responses to nociceptive stimuli (Ali et
ah, 1996; Green et ah, 2000). A full discussion of descending facilitatory input is
outside the scope of this thesis, however, the existence of both facilitatory and
inhibitory descending systems increases the range of modulation which can be
produced by descending input, contributing to the complexity of pain processing.
1.11 Development of sensitised pain states
Following injury, sensitisation develops in the nervous system pathways that
signal pain, and is manifest behaviourally as hyperalgesia, allodynia, and
spontaneous pain. Both peripheral and central mechanisms are normally involved in
the development of sensitisation. Inflammatory mediators, such as bradykinin and
prostaglandins, produce sensitisation of the peripheral terminals of nociceptive
neurons by modifying receptors and ion channels to result in increased sensitivity of
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the nociceptor terminal to activating stimuli (Chuang et al., 2001; Julius & Basbaum,
2001). Centrally, there is a facilitation of dorsal horn neuron responsiveness to
afferent input (which will be covered in section 1.15), which results in increased
transmission from the dorsal horn to brain areas, where the pain signal is ultimately
perceived. The phenomenon of sensitisation is a normal part of pain processing
following tissue injury or inflammation, and is of benefit to an animal, promoting
rest and guarding of an injury. As the injury recovers, the sensitisation resolves.
However, in chronic pain states, this sensitisation becomes pathological, as it does
not recover in parallel with recovery of the injury. Such altered pain states require
long-lasting changes in the nervous system. One form of chronic pain is peripheral
neuropathic pain, which is the principal type of chronic pain investigated in this
thesis.
1.12 Neuropathic pain
Neuropathic pain is defined by the International Association for the Study of Pain
(IASP) as pain initiated or caused by a primary lesion or dysfunction in the nervous
system. Peripheral neuropathic pain arises from damage to the peripheral nerves
whereas central neuropathic pain arises from damage in the CNS; the focus of this
thesis is peripheral neuropathic pain. Peripheral neuropathic pain has a variety of
causes including: physical damage to peripheral nerves such as compression, cut,
stretch or various other injuries, as a result of accidental injury or surgical trauma,
(Bridges et al., 2001; Macrae & Davies, 1999; Morley-Forster et al., 2006);
demyelination of afferents as occurs in Charcot-Marie-Tooth and Guillain-Barre
syndromes (Asbury, 1990; Carter et al., 1998); ischaemic injury caused by diabetes
or alcoholism (Morley-Forster, 2006); damage to nerves by viral infection as occurs
with HIV infection (Verma et al., 2005) and postherpetic neuralgia (Schmader et al.,
2002); compression or invasion of neural structures by tumours, frequently within
the bones (Coleman, 1997; Luger et al., 2005; Peters et al., 2005); and use of certain
neurotoxic chemotherapy agents (Quasthoff & Hartung, 2002). Peripheral
neuropathic pain affects 2.4% of the UK population, rising to 8% with age
(Neuropathy Trust UK; www.neuropathytrust.org). Currently, neuropathic pain is
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inadequately treated (Morley-Forster, 2006; Woolf & Mannion, 1999). Opioid drugs
are less effective in neuropathic pain states than in other pain states, and require
much higher doses to produce an analgesic effect (Moulin, 2006), which induce
adverse side effects. The most effective medications in current use are anti¬
convulsant drugs such as gabapentin, and tricyclic antidepressants such as
amitriptyline. All of these show variable efficacy, achieving clinically significant
effects in less than 50% of patients (Bridges et ah, 2001; Sindrup & Jensen, 1999),
and may cause deleterious side effects. There is therefore a great need to develop
new analgesic therapies for use in neuropathic pain conditions. Much of what is
known about the mechanisms underlying neuropathic pain has been learned from
animal models, which are discussed below.
1.13 Animal models of neuropathic pain
A number of experimental animal models have been developed to model pain
resulting from peripheral nerve damage. One of the first models of peripheral nerve
injury was that of complete sciatic nerve section or axotomy, which results in
biochemical and functional changes within the nerve and the CNS (Wall et ah,
1979). However, a key disadvantage of this model is that the whole sciatic territory
is completely denervated, and this major sensory loss means that it is very difficult to
perform behavioural measurements on this model. Therefore, this model has been
largely abandoned in favour of partial nerve injury models, in which behavioural
tests can be performed on the affected ipsilateral hindlimb, to measure the reflex
sensitivity to mechanical and thermal stimuli. Additional models have also been
developed to mimic specific neuropathic conditions, such as a varicella zoster virus
model of postherpetic neuralgia (Fleetwood-Walker et ah, 1999), a streptozotocin-
induced model of diabetic neuropathy (Malcangio & Thompson, 1998), and a model
of demyelination-induced pain (Wallace et ah, 2003). The model of demyelination-
induced pain was used in this thesis and is described below with the surgical models
of neuropathic pain.
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1.13.1 Chronic constriction injury
The chronic constriction injury (CCI) model (Bennett & Xie, 1988), which was
used in experiments in this thesis, is produced by loosely tying four chromic cat gut
ligatures around the common sciatic nerve, at mid-thigh level. This results in the
development of lowered behavioural reflex thresholds to thermal and mechanical
stimuli, and de novo withdrawal reflexes to 4°C cold, ipsilateral to injury, that are
most manifest between 1 to 2 weeks following surgery (Bennett & Xie, 1988; Kim et
al., 1997). Guarding behaviour of the injured limb is also observed (Bennett & Xie,
1998; Kim et al., 1997), which may indicate spontaneous pain.
Following the set-up of the injury, a neuroma forms at the site of injury, and
swelling of the nerve is observed, resulting in compression and consequent axotomy
of some of the axons (Bennett & Xie, 1988; Coggeshall et al., 1993; Maves et al.,
1993). From day 3 to 2 weeks post-operatively there is an extensive loss of axons
distal to the injury, with a particularly marked loss of large myelinated A|3 fibres
(Basbaum et al., 1991; Coggeshall et al,, 1993). An immune response to the chromic
sutures may at least partially underlie the changes observed, as chromic gut but not
plain or silk gut sutures produce altered paw position and thermal hyperalgesia
(Maves et al., 1993).
This model was used in the following experiments. It was found to be easy to set
up, and reliably generated behavioural sensitisation. Animals were not used (and
hence the surgery deemed to have failed) if the sensitised limb showed a difference
in latency of withdrawal to a thermal stimulus of less than 4.5 s, and a difference in
mechanical threshold of less than 1500 mN/mm . Based on these criteria the failure
rate was approximately 1 in 50. Furthermore, very low rates of surgical
complications were observed, with less than 1 animal in 100 developing any
problems associated with the surgery.
1.13.2 Partial nerve ligation
The partial nerve ligation model (PNL) involves a tight ligation of approximately
one third to one half of the sciatic nerve (Seltzer et al., 1990). This model produces
lowered behavioural reflex thresholds to thermal and mechanical stimuli and
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development of cold allodynia in the ipsilateral hindlimb (Kim et al., 1997; Seltzer et
al., 1990).
1.13.3 Spinal nerve ligation
Spinal nerve ligation (SNL) involves the tight ligation of the L5 and L6 spinal
nerves, which contribute to the sciatic nerve, or alternatively ligation of the L5 nerve
only, as this produces much the same effect (Kim & Chung, 1992; Kim et al., 1997).
The nerve is ligated just distal to the DRG, thereby transecting all axons within the
L5 branch. This model develops lowered behavioural thresholds to thermal and
mechanical stimuli and withdrawal reflexes to 4°C cold ipsilateral to injury (Katsura
et al., 2006; Kim & Chung, 1992). A key benefit of this model is the fact that the
surgery is standardised, with the same group of fibres affected every time. This
model also allows easy comparison of changes in damaged and undamaged afferents
by comparison of the damaged L5 DRG with the spared L4 DRG (Bridges et al.,
2001; Campbell & Meyer, 2006). One disadvantage of this model is that it is
comparatively difficult surgery to perform, leading to raised rates of complications.
1.13.4 Spared nerve injury
In the spared nerve injury (SNI) model, the tibial and peroneal branches of the
sciatic nerve are severed, leaving the sural intact (Decosterd & Woolf, 2000).
Mechanical hypersensitivity and cold allodynia develop in the area innervated by the
spared sural nerve branch. However, in contrast to other models, there is no decrease
in latency to a noxious heat stimulus, although there is an increase in the duration of
withdrawal to the stimulus, which perhaps demonstrates an increased noxiousness of
the stimulus (Decosterd & Woolf, 2000). The key difference between this and the
other models is that the damaged (severed) axons are separate from the spared axons,
as they form separate branches of the nerve, distal to the injury. Despite this
separation, hypersensitivity develops both in the area innervated by the spared sural
branch of the nerve and, to a lesser extent, in areas innervated by the saphenous
nerve, which is completely separate to the sciatic innervated area (Decosterd &
Woolf, 2000). This indicates that there must be interactions between the damaged
and undamaged afferents elsewhere, which could occur via mingling of intact and
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injured peripheral terminals in the skin, as the sural and saphenous nerve territories
lie immediately next to and overlap to an extent with the tibial and peroneal
territories (Swett & Woolf, 1985), or alternatively could occur via mingling of
injured and uninjured cell bodies in the same DRG (Decosterd & Woolf, 2000).
1.13.5 Lysolecithin model of demyelination-induced pain
Peripheral demyelinating diseases are associated with pain (Asbury et ah, 1990,
Carter et ah, 1998). The lysolecithin model was set up to model the pain associated
with demyelination. Focal application of the myelin toxin lysolecithin to the sciatic
nerve produces demyelination of afferents with no axonal loss (Wallace et ah, 2003).
Behavioural thermal hyperalgesia and mechanical and cold allodynia result
ipsilateral to the injury (Wallace et ah, 2003; Results section 4.1). Spontaneous
discharge in afferents is observed, and immunohistochemical analysis of the DRG
shows some changes similar to those observed in surgical neuropathic models,
including a decrease in expression of Navl.8, and induction of Navl.3 expression,
and induction ofNPY expression (Wallace et ah, 2003), suggesting some similarities
between demyelination-induced pain and neuropathic pain. However, no changes in
expression of the peptides galanin and CGRP were observed, suggesting some
important differences between this model and surgical models (Wallace et ah, 2003).
A summary of key changes which have been observed in the surgical animal
models of neuropathy and clinical cases are summarised in Figure 1.3, and include
both peripheral changes in primary afferents, and central changes in the dorsal horn.
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Figure 1.3 Alterations in pain processing pathways in
neuropathic pain
Figure 1.3 summarises the alterations that occur following nerve
damage which may underlie neuropathic pain. Peripheral nerves
show axonal loss, altered firing properties, demyelination and
changes in expression of neuropeptides and of receptor proteins.
In the spinal cord, central sensitisation, and a loss of inhibitory
tone occurs. Alterations also occur in descending input from the
brain. All these effectively make the spinal cord more excitable and
lead to behavioural hyperalgesia and allodynia.
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1.14 Alterations in primary afferent neurons following peripheral neuropathy
The sensitisation of peripheral neuron terminals by inflammatory mediators is
thought to play a much lesser role in neuropathic pain, as neuropathic pain can arise
without significant tissue damage (Bridges et al., 2001; Treede, 1992). However,
neuropathic pain models are associated with significant, neuropathy-specific changes
in primary afferents, including alterations in electrical properties and in the
expression of key proteins, and these changes are thought to contribute significantly
to the generation of neuropathic sensitisation.
1.14.1 Alterations in afferent firing properties and ion channel expression
following peripheral neuropathy
Following peripheral nerve injury, there is an increase in the level of spontaneous
firing in afferent neurons within the nerve (Bridges et al., 2001). This firing can be
described as ectopic, as it originates from areas other than the peripheral sensory
terminal of the neuron. Such firing was first described in recordings from the
neuroma (the area of nerve damage) (Wall & Gutnick, 1974). However, further
studies demonstrated that spontaneous firing could also originate from the DRG and
other points along the nerves (Wall & Devor, 1983), indicating that abnormal firing
properties are present throughout the neurons, rather than localised at the neuroma.
Spontaneous firing has been recorded in both damaged afferents and in their
undamaged neighbours - for example, following SNL, spontaneous firing has been
recorded in both neurons of the L5 (damaged) DRG (Liu et al., 2000; Ma et al.,
2003; Wu et al., 2001) and in neurons of the spared L4 DRG (Ali et al., 1999;
Djouhri et al., 2006; Liu et al., 2000; Ma et al., 2003). Microneurography in human
patients with peripheral neuropathy has documented spontaneous firing in afferents
(Calvin et al., 1982; Campero et al., 1998; Ochoa & Torebjork, 1980; Torebjork et
al., 1979), supporting a role for such abnormal electrical phenomena in clinical cases
of neuropathic pain.
The firing properties of afferent neurons are dependent on their expression of a
repertoire of voltage-gated ion channels, and alterations in the expression of such
channels has been observed in models of neuropathy, which may contribute to the
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altered firing properties. Voltage-gated Na+ channels mediate the majority of the
action potential and therefore alterations in expression of these channels would be
expected to have significant consequences on afferent firing properties. Nociceptive
afferents express both tetrodotoxin-resistant (TTX-R) and tetrodotoxin-sensitive
(TTX-S) Na+ channel subtypes. Following CCI, there is a decrease in the TTX-R Na+
current in DRG neurons, and in transcripts of the TTX-R channels Navl .9 and Navl .8
in the DRG (to levels of approximately 60% of normal levels; Dib-Hajj et al., 1999).
Conversely, there is an increase in TTX-S Na+ current in small-diameter DRG
neurons, and de novo transcription of the TTX-S Nav1.3 Na+ channel, which is
normally only found in DRG during development (from 0 to ~ 15 % DRG cells
showing transcripts; Dib-Hajj et al., 1999; Wood et al., 2004). These changes may
provide at least a partial basis for the hyperexcitablity of DRG neurons observed
following CCI and axotomy. For example, the upregulation of the Nav1.3 channel,
which recovers rapidly from inactivation, could allow the neurons expressing this
channel to fire repetitively at abnormally high frequencies (Cummins & Waxman,
1997). The importance of Na+ channels in neuropathic pain is further suggested by
the clinical usefulness of drugs that act on voltage-gated Na+ channels, such as the
anticonvulsant carbamazepine (Bridges et al., 2001; Rizzo, 1997).
1.14.2 Changes in neuropeptide expression following peripheral neuropathy
Changes are observed in the expression of neuropeptide transmitters and of their
receptors in the dorsal horn following peripheral nerve injury (Hokfelt et al., 1994;
Wiesenfeld-Hallin et al., 1999). For example, a decrease in the expression of SP
(Kajander & Xu, 1995; Nahin et al., 1994) and CGRP (Nahin et al., 1994; Noguchi et
al., 1993) is observed following peripheral nerve injury, whereas levels of galanin
increase (Ma & Bisby, 1997; Nahin et al., 1994; Shi et al., 1999). Such alterations in
expression may be accompanied by functional alterations - for example intrathecal
administration of galanin attenuates sensitisation in CCI but not in normal rats (Liu
& Hokfelt, 2000), suggesting an increased inhibitory role of this peptide following
peripheral nerve injury. Neuropeptides exert significant long-lasting
neuromodulatory changes in the dorsal horn and therefore alterations in neuropeptide
expression following neuropathy may significantly influence spinal cord processing.
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1.14.3 Changes in expression of peripheral receptors following peripheral
neuropathy
Receptor proteins that transduce sensory stimuli in the periphery also show altered
expression in neuropathic pain models. Such changes may be expected to affect the
responsiveness of afferents to peripheral noxious stimuli, and thus could contribute
to the abnormal pain behaviours observed following peripheral nerve damage.
An example of such a receptor that shows altered expression following nerve
injury is the heat-and-capsaicin receptor TRPV1. In the SNL model, TRPV1-
immunoreactivity decreases in L5 DRG, but increases in L4 DRG, suggesting that
TRPV1 expression is lost from damaged afferents but is upregulated in spared
neighbouring afferents (Fukuoka et ah, 2002; Hudson et ah, 2001). The situation
following CCI is less clear: Western blots of spinal cord tissue showed an increase in
TRPV1 protein ipsilateral to injury following CCI (Kanai et ah, 2005), but
immunohistochemical analysis of DRG tissue showed a decrease in TRPV1 levels
(Schafers et al., 2003). If, as the SNL results suggest, TRPV1 expression is increased
in undamaged afferents and decreased in damaged afferents, the discrepancies in the
CCI model could be due to the mixing of damaged and undamaged afferents in the
same DRG, which would lead to a much less clear picture of TRPV1 expression
changes than the SNL model. Alterations in the expression of TRPV1 would be
expected to affect the sensitivity of the affected area to noxious heat, and could
thereby contribute to the abnormal processing of noxious heat information that is
observed in neuropathic pain models. Similar changes in the expression of other
receptors could contribute to the altered sensory processing observed in neuropathy.
1.14.4 Relative contributions of injured and neighbouring afferents to
neuropathic sensitisation
Following partial nerve injury, the nerve contains both damaged and neighbouring
undamaged afferents, both of which groups show altered firing properties (Liu et al.,
2000; Ma et al., 2003) and altered protein expression (Hudson et al., 2001, 2002),
and both of which may have a role to play in behavioural sensitisation.
Support for the role of injured afferents comes from data showing that, in the SNL
model, low doses of local anaesthetics (Sukhotinsky et al., 2004) or tetrodotoxin
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(Lyu et al., 2000) directed at the L5 DRG reduce behavioural hypersensitivity,
suggesting that the activity of injured afferents is necessary for ongoing behavioural
sensitisation. Some groups (Sheen & Chung, 1993; Sukhotinsky et ah, 2004; Yoon et
ah, 1996) have found that cutting the L5/L6 dorsal roots abolishes SNL-induced
behavioural sensitisation (Gold, 2000). However, other groups have not observed
such a reversal of SNL-induced neuropathic sensitisation following L5 dorsal
rhizotomy (Eschenfelder et ah, 2000; Li et ah, 2000), and neuropathic pain behaviour
was produced following an L5 ganglionectomy, in which afferent input is removed
altogether (Sheth et ah, 2002), suggesting that the input from damaged afferents may
not in fact be critical for hypersensitivity. In the SNI model, hypersensitivity is
observed in areas innervated by the undamaged sural branch of the sciatic nerve
(Decosterd & Woolf, 2002), suggesting that the undamaged afferents contribute to
neuropathic hypersensitivity. Further support for this role of undamaged afferents
comes from data showing that selective abolition of the input from undamaged
afferents, by L4 rhizotomy, abolished pain behaviours evoked by L5 SNL (Li et ah,
2000; Yoon et ah, 1996).
Overall the evidence suggests a role for both injured and uninjured afferents in the
abnormal processing of pain signalling following nerve injury.
1.14.5 Role of neurotrophic factors
Following peripheral nerve damage, damaged and undamaged neighbouring
afferents experience altered exposure to neurotrophic factors, and this could account
for some of the changes in afferent properties observed (Millan, 1999, Pezet &
McMahon, 2006). Neurotrophic factors are produced by target tissues and act on
receptors expressed on the terminals of sensory neurons to cause both peripheral
effects and a retrograde signal that travels to the neuronal cell body to exert
transcriptional control (Lindsay & Harmar, 1989, Pezet & McMahon, 2006). Axonal
denervation such as occurs distal to nerve injury disrupts the access of neurotrophic
factors to afferent cell bodies, and thereby disrupts transcriptional regulation (Pezet
& McMahon, 2006). Evidence suggests that such disruption may significantly
contribute to neuropathy-induced abnormalities. Intrathecal infusion of NGF
prevented axotomy-induced changes in the levels of the neuropeptides SP, CGRP,
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VIP and galanin (Averill et al., 2004), and decreased behavioural hyperalgesia in the
CCI model (Ren et al., 1995). Similarly, intrathecal infusion of the neurotrophic
factor GDNF reduced neuropathic pain behaviours following PNL, and reduced the
spontaneous activity recorded in L4 and L5 DRG neurons, and alterations in Na+
channel expression observed following SNL (Boucher et al., 2000).
In parallel with this loss of neurotrophic factor access, the remaining spared axons
may have access to increased levels of neurotrophic factors due to decreased
competition, and this increased access could affect the properties of the spared
neurons. Therefore, the altered exposure to neurotrophic factors of both damaged and
spared axons may play a role in the alterations in protein expression and afferent
properties observed following peripheral nerve damage.
1.15 Central spinal cord changes in neuropathic pain
Significant changes in pain processing occur in the spinal cord occur following
peripheral nerve damage, principally including central sensitisation of dorsal horn
neuronal responsiveness, and decreased inhibitory input.
1.15.1 Central sensitisation in neuropathic pain
Synaptic plasticity, the modification of synaptic strength and structure, is a
fundamental property of the nervous system. Increased input to the spinal cord
results in a facilitation of synaptic transmission, termed central sensitisation (Ji et al.,
2003; Wall & Woolf, 1986; Woolf, 1983). The classical definition of central
sensitisation is an increase in the excitability of dorsal horn neurons, such that their
firing threshold is decreased and receptive field area is increased, following and
outlasting, a short barrage of nociceptor input (Cook et al., 1987; Woolf & Wall,
1986; Woolf, 1983). Most input to dorsal horn neurons is subthreshold, and does not
evoke an action potential output (Woolf & King, 1990). However, after a brief (~20
second) period of stimulation of afferents at intensities sufficient to activate
nociceptors, increased synaptic efficacy allows dorsal horn neurons to be activated
by previously subthreshold input (Woolf & King, 1990). Thus the dorsal horn
neurons have become sensitised, allowing activation by lower inputs. In neuropathic
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pain states, it is thought that central sensitisation may be driven by continuous input
from spontaneously firing afferents (Ji et al., 2003).
Central sensitisation is generated by input from nociceptive fibres and includes a
potentiation of this input, but can also include a potentiation of synapses made by A(3
fibres onto dorsal horn neurons, a phenomenon which is classified as heterosynaptic
facilitation (Garry & Fleetwood-Walker, 2004a,b; Ji et al., 2003; Woolf & King,
1990). This may allow these low-threshold fibres to drive nociceptive dorsal horn
neurons, and may thereby account for the phenomenon of allodynia, in which low-
threshold touch is perceived as noxious (Ji et al., 2003).
A key example of dorsal horn neuronal sensitisation is the experimental
phenomenon of "wind-up", a frequency-dependent facilitation of dorsal horn
neuronal responses caused by repeated C fibre input. Wind-up is observed as a
gradual increase in the neuronal response to C fibre input, with continued firing up to
several minutes following the cessation of stimulation (Dickenson & Sullivan, 1987;
Mendell, 1966). Wind-up is observed particularly in deeper WDR neurons rather
than superficial neurons and may therefore particularly account for sensitisation of
these neurons (Dickenson, 1990; Seagrove et al., 2004).
Activity-dependent sensitisation has been reported in rodent, cat and primate
dorsal horn neurons (Dougherty & Willis, 1992; Kenshalo, 1982). A central
sensitisation-like phenomenon can also be generated in the RVM, anterior cingulate
cortex, and amygdala (Neugebauer et al, 2003; Porreca et al 2002; Wei & Zhuo
2001), demonstrating that pain areas beyond the spinal cord show the capacity for
sensitisation to their inputs.
Underlying the synaptic facilitation of central sensitisation are changes in ion
channel and receptor activity including both short-term post-translational changes,
such as the phosphorylation of glutamate receptors and altered trafficking of
receptors to the membrane, and long-term transcriptional changes (Ji et al., 2003;
Kawasaki et al., 2004; Li et al., 1999; Woolf & Salter, 2000). As is discussed below,
glutamate receptors, and signalling pathways engaged downstream of glutamate
receptor activation, play a key role in the generation of central sensitisation.
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1.15.2 NMDARs in neuropathic pain
The NMDAR only opens in the presence of both glutamate and depolarisation-
induced removal of its Mg2+ block. Increased input from afferents following nerve or
tissue injury acts to remove the Mg2+ block, allowing glutamate released from
2+afferents to activate NMDARs, resulting in Ca entry and consequently in medium
and long-term changes. NMDARs are crucial to the sensitisation of spinal neurons
that occurs following injury (Ji & Woolf, 2001). NMDAR antagonists reduce wind-
up, but not the initial response itself, of dorsal horn neurons following repeated C
fibre stimulation or mustard oil application, demonstrating a selective involvement in
neuronal sensitisation (Davies & Lodge, 1987, Dickenson & Sullivan, 1987,
Dickenson & Aydar, 1991, Woolf & Thompson, 1991). Behavioural experiments
also show an important role for the NMDAR in hypersensitivity. Intrathecally
administered NMDA causes behavioural sensitisation in normal animals (Aanonsen
& Wilcox, 1987; results section 4.10), and NMDAR antagonists attenuate
neuropathic pain behaviours (Chaplan et al., 1997; Mao et al., 1992, 1993; Tal &
Bennett, 1993).
NMDAR activation leads to Ca2+ entry and subsequent activation of downstream
signalling pathways such as the kinases PKC (Vaccarino et al., 1987), Src (Platenik
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et al., 2000; Salter et al., 1998), and Ca /calmodulin dependent protein kinase II
(CaMKII) (Bayer et al., 2001; Garry et al., 2003a). NMDAR activation is also linked
to activation of the extracellular signal related kinase - mitogen activated protein
kinase (ERK-MAPK) pathway, as in hippocampal neurons glutamate induces ERK
activation, and this effect is blocked by NMDAR antagonists (Bading & Greenberg,
1991). Activation of these kinases results in changes in the phosphorylation state of
certain proteins, thereby affecting their function; and can also lead to activation of
transcription factors (Ji et al., 2003). Examples of such transcription factors are
members of the CREB (cAMP response element binding protein) family, which can
be activated by multiple signalling pathways, including the PKA, PKC, CaMKII and
ERK-MAPK signalling pathways (Lonze & Ginty, 2002). Increases in
phosphorylation of CREB in the spinal cord are observed following partial sciatic
nerve ligation (Ma & Quirion, 2001) and following CCI (Miletic et al, 2002), which
can be reversed with inhibitors of PKA, PKC or ERK (Miyabe & Miletic, 2005).
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Transcriptional changes induced through factors such as CREB are likely to underlie
some of the long-term changes involved in chronic pain states.
1.15.3 AMPARs in neuropathic pain
In addition to a role in mediating acute nociceptive responses, AMPARs are
implicated in sensitisation. Intrathecal application of AMPAR blockers attenuated
behavioural sensitisation following CCI, at doses that had no effect on contralateral
or naive reflex sensitivity (Garry et al., 2003b). This perhaps indicates an increased
sensitivity of AMPARs in neuropathic states, so that low doses of AMPAR
antagonists can attenuate sensitisation without affecting normal responses.
As AMPARs mediate the majority of glutamate-induced excitatory current in the
dorsal horn as elsewhere in the nervous system (Dougherty et al., 1992; Ehlers, 2000;
Kandel & Siegelbaum, 2000; Malenka & Nicoll, 1999), modulation of AMPAR
expression will have profound consequences for glutamatergic transmission.
Increased overall expression of the AMPAR GluRl subunit (Harris et al., 1996) and
of the GluR2 subunit (Garry et al., 2003b; Harris et al., 1996) has been observed in
models of neuropathic pain, suggesting an increased AMPAR current in such states,
which may contribute to increased spinal neuron excitability.
1.15.4 Decreased inhibition in neuropathic pain
In addition to the facilitation of excitatory glutamatergic transmission described
above, there is evidence for a decrease in endogenous inhibitory mechanisms in
neuropathic pain states, which may contribute overall increased excitability.
Evidence for a decrease in GABAergic transmission
Spinal cord levels of GABA and of GABA-B receptors are reduced following
peripheral axotomy (Castro-Lopes et al., 1993, 1995), and levels of the GABA
synthesising enzyme glutamic acid decarboxylase-65 kDa are decreased ipsilateral to
CCI or SNI injury (Moore et al., 2002), suggesting a decrease in GABAergic
transmission in neuropathic states. In CCI and SNI models, the incidence and
magnitude of afferent-evoked IPSCs were substantially reduced, particularly the
bicuculline-sensitive component (Moore et al., 2002), suggesting that the decrease in
GABA levels is reflected in a functional decrease in GABAergic transmission.
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However, another study showed no change or indeed a slight increase in the
GABAergic inhibitory tone, indicated by an increased effect of bicuculline, in the
SNL model (Kontinen et al., 2001), and other studies have seen no change in GABA-
immunoreactivity following CCI (Polgar et ah, 2003). Therefore it is not clear to
what extent a decrease in GABAergic transmission contributes to spinal cord
hyperexcitability in neuropathic pain states.
Evidence for a decrease in spinal opioid transmission
In animals with a peripheral nerve injury, higher doses of intrathecal morphine are
required to produce behavioural analgesia (Bian et ah, 1995; Dickenson & Suzuki,
2005), and there is a reduced inhibitory effect of systemic morphine on the responses
of spinal neurons (Dickenson & Suzuki, 2005; Matthews & Dickenson, 2002;
Ossipov et ah, 1995), in comparison with normal animals, suggesting a decrease in
spinal cord opioidergic transmission in neuropathic states. For many years the
clinical consensus was that opioids were ineffective in neuropathic pain (Arner &
Meyerson, 1988), but higher doses of opioids have been shown to be clinically
effective and are recommended for neuropathic pain (Moulin, 2006), in line with the
animal studies which demonstrate an inhibitory effect of opioids, albeit reduced, in
nerve-injury models.
Opioid receptor binding sites and p-opioid receptor-immunoreactivity are
decreased in animal models of neuropathic pain (Besse et ah, 1992; de Groot et ah,
1997; Porreca et ah, 1998). Therefore the decreased sensitivity to intrathecal opioids
observed behaviourally (Bian et ah, 1995) may be due to decreased spinal expression
of opioid receptors. Another reason underlying this decreased efficacy may be an
increase in levels of the neuropeptide CCK and its receptors. Intrathecally
administered CCK reduces the analgesic effect of exogenous opioids, an effect that is
blocked by antagonists or antisense knockdown of the CCK-2 receptor (Cesselin,
1995; Vanderah et ah, 1994; Watkins et ah, 1985; Wiesenfeld-Hallin et ah, 1999,
2002), indicating an antagonistic effect of CCK on opioidergic transmission.
Following peripheral nerve injury, mRNA levels for both CCK and the CCK-2
receptor are increased in primary afferent neurons (Hokfelt et ah, 1994; Wiesenfeld-
Hallin et ah, 2002; Xu et ah, 1993), which may result in increased inhibition of
opioidergic transmission. In support of this, intrathecal administration of CCK-2
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antagonists restored opioid efficacy in the SNL model (Nichols et ah, 1996) and
axotomy (Xu et ah, 1993) models of neuropathy.
1.16 Historical background of cooling-induced analgesia
The first record of cold as an analgesic therapy was left by the father ofmedicine,
Hippocrates (Figure 1.4), who recommended application of cold water for the
treatment of bruises, joint pains and ulcerations (Adams, 2006; Sprengell, 1735).
Similar uses are recorded by Galen and other eminent early physicians (Siegel,
1970). This traditional therapy is still found useful today, with clinical trials showing
beneficial effects of cooling on chronic back pain, dental pain, post-operative pain,
and muscle injuries (Cohn et al., 1989; Levy & Marmar, 1993; Melzack et al.,
1980a,b; Ross & Soltes, 1995; Scheffler et al, 1992; review by Sauls, 1999). Nursing
practice reports encourage the use of cold as an adjunctive therapy to be used
alongside pharmacological interventions (McCaffery, 1980; 1990) and cold sprays
and gels for muscle and joint pain have been used to some effect in general practice
and sport (Traherne, 1962). Therefore local cooling has been shown to be an
effective analgesic in a variety of pain states, including both chronic states such as
chronic back pain (Melzack et al., 1980a) and acute states, as in the use of cold
sprays in sport (Traherne, 1962). Animal experiments show an analgesic effect of
cool environmental temperatures on nociceptive thresholds (Osgood et al., 1990;
Schoenfeld et al., 1985) and a similar effect has been demonstrated psychophysical^
in humans (Hardy et al., 1951; Strigo et al., 2000). Studies on pain thresholds in
humans using microelectrode stimulation to evoke pain demonstrate an analgesic
effect of local cooling (Bini et al, 1983; Bugaj, 1975; Miller & Weber, 1990; Saeki,
2002). Cutaneous cooling inhibits nociceptor-driven dorsal horn neuron firing
(Kanui, 1985), demonstrating an effect on spinal cord nociceptive processing.
Therefore there is significant clinical and experimental evidence for an analgesic
effect of local cutaneous cooling. It should be noted that a variety of cooling stimuli
have been used in the studies described, from topically applied ice to ether
evaporation, and the resulting skin temperature rarely measured, and therefore it is
difficult to state precisely the temperatures that evoked analgesia in these studies.
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Cooling-induced analgesia appears to be at least partially mediated centrally, as
local cutaneous cooling of the skin (from 30 to 20°C) prevents pain produced by
downstream intraneural stimulation of afferent neurons in humans (Bini et al, 1984;
Bugaj, 1975).
1.17 Menthol and analgesia
Menthol and menthol-containing mint oils produce a sensation of cooling (Green,
1986, Green, 1992), and menthol is known to activate cold-sensitive afferents and
cold-sensitive receptors (Hensel & Zotterman, 1951, Peier et al., 2002b, McKemy et
al., 2002). Preparations containing menthol or mint oils have, like physical cooling,
been shown to have analgesic effects and menthol is a common ingredient in over-
the-counter pain relief remedies. In humans, topical mint oil alleviated
experimentally thermally-elicited pain (Gobel et al., 1994) and application of
menthol caused a short-term analgesia in the mouth against pain elicited by oral
capsaicin (Green & McAuliffe, 2000). In animals, systemic administration of (-)-
menthol increased pain thresholds in the mouse hot-plate and acetic acid writhing
tests (Galeotti et al., 2002), and co-injection of menthol attenuated the licking and
shaking behaviour elicited by intraplantar injection of capsaicin (Premkumar et al.,
2005). Notably, menthol and mint oils appear effective against pain of neuropathic
origin. Topical mint oil is used to relieve neuralgia in both traditional Chinese and
European herbal medicine (Wright, 1870, Blumenthal et al., 1998). Recently,
effective clinical treatment of a case of postherpetic neuralgia by application of
topical peppermint oil (containing 10% menthol) was reported (Davies et al., 2002).
The cooling effect of menthol, together with the fact that both menthol and cool
temperatures can produce analgesia, suggests the possibility that cooling and menthol






Figure 1.4 Historical Analgesia
The father of medicine, Hippocrates, recommended cold
for pain relief in his writings, and mint is used in traditional
Chinese and European medicine for relief of neuralgia.
Images courtesy of the Wellcome Trust History of
Medicine Library.
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1.18 Sensory detection of cold
In order to understand how topical cooling may produce a centrally-mediated
analgesia, it is necessary to consider how cold is detected and processed by the
somatosensory system. In vivo recording studies of afferents, first carried out in the
1950s, identified populations of cold-sensitive sensory neurons, and further
electrophysiological studies have examined spinal cord neurons responding to cold.
Studies on cultured DRG and trigeminal ganglion cells have continued this study of
cold-sensitive neurons, and pointed towards possible transduction mechanisms
underlying cold-sensitivity. Recently, molecular biology has enabled the
identification of specific proteins which act as cold-sensitive ion channels.
1.19 In vivo recordings of cold-sensitive afferents
Cold-responsive primary afferents have been recorded in man, primates, rodents,
cats and dogs. They fall into two loose groupings - fibres activated by low threshold
"cool" temperatures (responding to skin temperatures between ~15-30°C) (Darian-
Smith et al, 1973; Dubner et al, 1975; Kenshalo & Duclaux, 1977), and fibres
responding to high-threshold (intense) cold temperatures (under 15°C)
(Georgopoulos, 1977; LaMotte & Thalhammer, 1982).
It is difficult to collate the data to form a precise categorisation of cold-sensitive
afferents. Recordings have been performed in different species and in different
nerves, and these different preparations may show significant differences in the
neuronal populations that respond to cold - for example, AS fibres comprise a much
higher proportion of cold receptors in primates than in rodents (Iggo, 1969).
Different studies have used different protocols to stimulate cold-sensitive fibres, such
as a Peltier device, or application of ice. In general, cold-sensitive neurons constitute
a low proportion of the total number of neurons in a nerve, and therefore most
studies generate much lower numbers than comparable studies on for example
mechanoreceptors, further complicating data interpretation.
1.19.1 Low-threshold cold-sensitive afferents
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Low-threshold cold-sensitive - "LTcold" - afferents show steady state discharges
to skin temperatures between 15 and ~30°C, temperatures which evoke a sensation of
innocuous cooling (Croze & Duclaux, 1978; Chen et al., 1996; Stevens, 1979).
LTcold afferents exhibit spontaneous activity at normal skin temperature (Hensel &
Zotterman, 1951). LTcold afferents generally respond specifically to cold and
cooling and are insensitive to other stimuli (Kenshalo & Duclaux, 1977; Fang et al.,
2005; Hensel et al., 1960; Hensel & Iggo, 1971; Iggo, 1969). Recordings of afferents
show that afferents respond maximally at particular static temperatures, with a
gradual decrease in firing frequency either side of this preferred temperature (Iggo,
1969). These afferents discharge maximally to temperatures between ~20 and 35°C
(Darian-Smith et al., 1973; Dubner et al., 1975; Iggo, 1969; Iriuchijima & Zotterman,
1960; Kenshalo & Duclaux, 1977). Afferents show a greater dynamic than static
range, in that they may be excited by decreases in temperature outside of their static
range (by approximately 5°C) (Darian-Smith et al., 1973; Iggo, 1969; Kenshalo &
Duclaux, 1977), and also respond more vigorously (with a higher firing frequency) to
a decrease to a particular temperature, than they do to the static temperature (Dubner
et al., 1975; Kenshalo & Duclaux, 1977; Iggo, 1969). A proportion of cold-sensitive
neurons have also been identified to respond to strong heating (Campero et al., 2001;
Dodt & Zottermann, 1952; Long, 1977), which may underlie the psychophysical
phenomenon of paradoxical cold sensation, in which strong heat applied to a spot on
the skin innervated specifically by a cold-sensitive neuron elicits a sensation of cold,
rather than heat (Norrsell et al., 1999).
In primate glabrous skin, LTcold afferents appear to be exclusively A8 fibre
neurons (Darian-Smith et al., 1973; Hensel & Iggo, 1971; Iggo, 1969), but both AS
and C fibre LTcold afferents have been found in hairy skin (Iggo, 1969). LTcold
afferents with C fibre conduction velocities have also been recorded in
microneurographic studies in humans (Campero et al., 2001). LTcold afferents
appear to be exclusively C fibre neurons in rodents (Fang et al., 2005; Iggo, 1969;
Iriuchijima & Zotterman, 1960; Lynn & Carpenter, 1982), and in cats (Bessou &
Perl, 1969; Hensel et al., 1960; Jiang et al., 2002). It is generally agreed that LTcold-
sensitive afferents comprise a relatively low proportion of the total nerve. Studies
have shown between 3 and 6% of C fibres responsive to small decreases in
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temperature in a range from 32 - 20°C in recordings of rat saphenous nerve (Lynn &
Carpenter, 1982), rat lumbar DRG (Fang et al., 2005), cat femoral nerve (Bessou &
Perl, 1969), and a variety of nerves in monkey hairy skin (Treede et al., 1992).
However, an extensive study of the rat sural and plantar nerves identified a
significantly higher proportion of LTcold C fibre neurons, constituting 21% and 23%
of rat sural and plantar nerves respectively. This study also found 5% of A8 afferents
in the sural nerve were sensitive to cool temperatures (Leem et al., 1993), although
slightly lower stimulation temperatures were used (in a range of 32 to 17°C). In vivo
recordings of cool-responsive DRG C fibre neurons showed that these had higher
conduction velocities and shorter action potential durations compared with
polymodal C nociceptors (Fang et al., 2005) indicating that even though LTcold
afferents are C fibre neurons, they show properties distinct from those of nociceptive
neurons.
1.19.2 High-threshold cold-sensitive afferents
Cooling the skin to temperatures below 15°C produces sensations of pain in
humans (Chery-Croze & Duclaux, 1980; Chery-Croze, 1983; Wolf & Hardy, 1941;
Yarnitsky & Ochoa 1990). Afferents responding to temperatures below 15°C,
described here as high-threshold cold-sensitive (HTcold) afferents, have also been
described in in vivo fibre recordings in primates (Georgopoulos, 1977; Iggo &
Ogawa, 1971; LaMotte & Thalhammer, 1982), cats (Iggo, 1959) and rodents (Bessou
& Perl, 1969; Koltzenburg et al., 1997; Leem et al., 1993; Lynn & Carpenter, 1982;
Simone & Kajander, 1997). Similarly to LTcold afferents, HTcold afferents fire at
particular static temperatures, but show an increased discharge rate to a decrease in
temperature (Iggo, 1959). Many studies also describe HTcold afferents as responsive
to high-threshold mechanical stimuli, suggesting that they are polymodal nociceptive
afferents, although frequently only the response to mechanical stimuli has been
measured (Georgopoulos, 1977; Iggo & Ogawa, 1971; Koltzenburg et al., 1997;
Lynn & Carpenter, 1982; Leem et al., 1993). In primates, HTcold responses are
associated with both A5 and C fibres (Georgopoulos, 1977; Iggo & Ogawa, 1971;
LaMotte & Thalhammer, 1982). In cats and rodents, initial studies identified HTcold
afferents with C fibres (Burgess & Perl, 1967; Iggo, 1959; Lynn & Carpenter, 1982).
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However, further studies have also identified A5 fibre HTcold afferents in rodents
(Koltzenburg et al., 1997; Leem et al., 1993; Simone & Kajander, 1997). Varying
proportions of neurons responding to HTcold temperatures have been found in
rodents. One study found that 11% of AS nociceptors responded to lowering the skin
temperature to 10°C, but that by 0°C this had increased to 30%, and by -18°C to
100% of AS nociceptors (Simone & Kajander, 1997), although it is possible that the
nociceptive responses in this study were due to damage associated with freezing at
these very low temperatures. Other studies have shown that approximately 10% of
AS nociceptors are sensitive to stimuli below 12°C (Fang et al., 2005; Koltzenburg et
al., 1997; Leem et al., 1993). Estimates of C polymodal nociceptors responsive to
temperatures below 12°C have varied between 3.5% to 30% (Bessou & Perl, 1969;
Fang et al., 2005; Koltzenburg et al., 1997; Leem et al., 1993). Discrepancies may be
due to differences in protocols or differences between recording sites: for example
Leem et al. found 8% of C fibres in the plantar nerve were cold sensitive, but only
3.5% in sural nerve.
1.20 Cold-sensitive dorsal horn neurons
Noxious and innocuous cold signals also appear to be processed differently in the
superficial dorsal horn. In both primates and cats, neurons responding exclusively to
innocuous cool temperatures applied to the skin (temperatures between 34 and 15°C)
have been recorded in LI of the dorsal horn (Burton, 1975; Craig et al., 2001; Han et
al., 1998; Iggo & Ramsey, 1974, Mokha, 1993). The population of nociceptive
specific neurons in LI, which are activated by noxious heat and pinch stimuli
(Christensen and Perl, 1970) include a subpopulation of neurons that respond to
noxious cold (Craig et al., 2001; Han et al., 1998). Cold-sensitive nociceptive-
specific cells responded to temperatures between 24°C to 9°C, so there is some
overlap in the temperature ranges of these two types of neurons (Craig et al., 2001).
Although a detailed analysis of the distribution of these cells has not been attempted,
cold-specific cells comprised 28% and cold-sensitive nociceptive specific cells
comprised 15% of labelled LI cells in the cat (Han et al., 1998). In the cat, the
morphology of cold-specific cells was distinctive from that of the nociceptive-
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specific cells, the former showing a pyramidal structure and the latter a multipolar
structure (Han et ah, 1998). Cold-specific cells and the nociceptive-specific cells also
showed different conduction velocities, different spontaneous discharge rates and
different thalamic terminations (Craig et ah, 2001; Craig & Dostrovsky, 2001),
suggesting that these are two fundamentally different types of cells. Therefore
innocuous cool and noxious cold input appears to be processed differently in the
dorsal horn.
1.21 Cold transduction in sensory neuron cultures
The fine structure of peripheral sensory neurons presents too great technical
difficulties for electrophysiological study of peripheral transduction processes. In
contrast, the cell soma can easily be recorded from with microelectrodes. When
dissected from its axon and cellular neighbours and cultured, the cell soma appears to
display many of the functional processes assumed or known to occur at the
peripheral terminal (Cesare et ah, 1996; Gold et ah, 1996; LaMotte, 2006).
Therefore, recordings from the somata of isolated DRG and TG neurons have been
used as a model of peripheral sensory neurons to study transduction processes.
Experiments in sensory neuron cultures seem to indicate two broad populations of
cold-sensitive neurons; one which shows activation thresholds around 30°C, and one
with lower activation thresholds of around 20°C (Babes et ah, 2004; Nealen et ah,
2003; Thut et ah, 2003). These populations resemble the LTcold and HTcold
afferents observed in in vivo afferent recordings, supporting a correlation between
the properties of sensory cultures and neurons in vivo. A key property frequently
found in cold-sensitive neurons is sensitivity to menthol (Reid et ah, 2002; Thut et
ah, 2003). Classic work by Hensel and Zotterman (Hensel & Zotterman, 1951)
demonstrated that menthol potentiates the response of trigeminal fibres to cold, and
proposed the existence of specific cold receptors, which are also menthol-sensitive.
The identification in cultured DRG neurons of an inward Ca2+-permeable cationic
current that is activated by cooling (with an average threshold of 30°C), and is also
activated and potentiated by menthol, suggests a common transduction mechanism
that underlies the neuronal response to low threshold cold temperatures and menthol
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(Reid & Flonta, 2001a; Reid et al., 2002). Such a mechanism has since been
discovered: the TRPM8 (TRP-melastatin-family-member 8) receptor, which shows
remarkably similar properties to the native cold-and-menthol-sensitive current.
1.22 Cold-sensitive ion channels and their potential role in cooling-induced
analgesia
In recent years ion channels such as TRPM8 have been discovered that are
activated by temperatures in the range for the physiological detection of cold, and
that therefore represent candidates for the physiological molecular receptors of cold
temperatures and cooling. The identification of such ion channels allows for the first
time study of molecular mechanisms underlying cooling-induced analgesia. The
most extensively studied cold receptors to date are TRPM8 and TRPA1 (TRP-
ankyrin family member 1), which are both members of the TRP channel family.
Other identified cold-sensitive channels include the 2-pore domain K+ channels
TREK-1, TREK-2 and TRAAK, and the epithelial sodium channel ENaC (Askwith
et al., 2001; Kang et al., 2005; Maingret et al., 2001); these are discussed further in
section 1.26. Cold-activated conductances have been described in sensory neurons
which do not match the properties of TRPM8 or TRPA1, supporting the existence of
alternative cold transduction mechanisms (Babes et al., 2004; Madrid et al., 2006;
Munns et al., 2006). At present, however, the alternative channels and cold-activated
conductances described are too poorly defined to allow investigation of their precise
role in cooling-induced analgesia, and therefore I have concentrated on the cold-
sensitive TRP channels. I have focussed on TRPM8 as the most promising candidate
for a molecular mediator of cooling-induced analgesia. This is because TRPM8
responds to moderate cooling and to menthol, which has also been shown to have an
analgesic action, and therefore TRPM8 may underlie the analgesic actions of both
cooling and menthol. TRPA1 appeared a less promising candidate, firstly because
there is uncertainty as to whether it does indeed respond to cold (Bautista et al.,
2006; Jordt et al., 2004; Nagata et al., 2005), and secondly because it is activated by
noxious chemicals, application of which have been shown to produce hyperalgesia in
animals (Bandell et al., 2004) and pain sensations in man (Namer et al., 2005), and is
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expressed in apparently polymodal nociceptive populations, suggesting that it may be
primarily involved in nociception (as is discussed further below). Therefore these
studies have concentrated on TRPM8, rather than TRPA1.
The following sections will discuss: the TRP family in general; TRPM8 in detail,
as the main focus of these studies; TRPA1, and its potential role in cold sensation;
and finally current knowledge of non-TRP mediators of cold transduction.
1.23 The TRP family of cation channels
TRP channels constitute an ancient and diverse family of non-selective cation
channels. The first TRP channels were discovered for their role in Drosophila
phototransduction (Montell & Rubin, 1989); TRPs have since been identified in
eukaryotes from yeast to mammals (Ramsey et al., 2006), and show a remarkably
diverse range of properties and functions, from Mg2+ homoeostasis to nociception.
Mammalian TRPs are divided into subfamilies based on sequence homology: the
TRPC (canonical); TRPV (vanilloid - so named because the first identified member
is activated by the vanilloid capsaicin); TRPM (melastatin, named for the role of the
first member of this family in melanoma metastasis); TRPA (ankyrin, named for the
14 predicted ankyrin domains in the N-terminal tail of this subfamily member);
TRPP (polycystin, named for involvement in polycystic kidney disease); and
TRPML (mucolipin, mutations in this channel are associated with mucolipidosis)
subfamilies (Clapham, 2003; Moran et ah, 2004; Ramsey et ah, 2006). Figure 1.5
shows this classification based on the homology of their DNA sequences. The
genetic sequences and structures of TRP channels are so diverse that the only
similarity shared by all identified TRPs is a structure based on six transmembrane
(TM) domains (Clapham et ah, 2003; Ramsey et ah, 2006). The TRP channels








































Figure 1.5 The TRP channel family
Figure shows the varied members of the TRP channel family based on
sequence homology. Figure adapted from Moran et a I., 2004.
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1.24 TRPM8
The TRPM8 protein was originally identified as a Ca2+ channel in prostate tissue
and named Trp-p8 (Tsavaler et al., 2001). The cloning and identification of TRPM8
as a cold-sensitive ion channel was accomplished in 2002 by two separate groups
(McKemy et al., 2002; Peier et al., 2002b). As described above, work on trigeminal
fibres and cultured DRG neurons identified a current that could be activated by cold
and menthol (Hensel & Zotterman, 1951; Reid & Flonta, 2001a). McKemy et al.
used this information to isolate the TRPM8 channel by screening a cDNA library for
menthol-induced elevation of cytosolic Ca2+, measured by fluorescence, a method
analogous to that used to clone TRPV1 (Caterina et al., 1997; McKemy et al., 2002).
Peier et al. used a strikingly different method, searching human genomic databases
with a hidden Markov model constructed from TRP proteins of different species to
identify exon sequences similar to TRPV1. Based on this information, primers were
designed and used on newborn mouse DRG tissue to amplify a fragment of a mouse
homologue of a TRP channel by RT-PCR (reverse transcriptase-polymerase chain
reaction). From this initial sequence and exon prediction programs, rapid-
amplification-of-cDNA-ends-PCR (RACE-PCR) was used to obtain the 5' and 3'
ends of TRPM8. Thus the entire TRPM8 gene was cloned and sequenced, and was
then expressed in cells and characterised as a cold-sensitive receptor (Peier et al.,
2002b). TRPM8 is part of the TRPM subfamily of the TRP family, based on amino
acid sequence homology.
1.24.1 Temperature sensitivity of TRPM8
TRPM8 is activated by cool temperatures and cooling chemicals such as menthol
and icilin (McKemy et al., 2002; Peier et al., 2002b) and carries a non-selective
cation current, similarly to other TRP channels. When TRPM8 is expressed in
heterologous systems, the mean activation threshold is between 19-25°C, with
increasing activation as temperature is decreased further, saturating at around 10°C,
demonstrating that TRPM8 is active within the range of both innocuous and noxious
cold temperatures (de la Pena et al., 2005; McKemy et al., 2002; Peier et al., 2002b).
The temperature activation threshold of native sensory neurons that are activated by
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menthol and cooling and that are inhibited by the non-selective TRP channel
antagonist BCTC (N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)-
tetrahydropyrazine-l(2H)-carboxamide) is somewhat higher: around 28-30°C
(Madrid et ah, 2006; Nealen et ah, 2003; Reid, 2005), suggesting that TRPM8 alone
may not fully account for the native cold-and-menthol-sensitive current. It is possible
that TRPM8 sensitivity may be modulated in sensory neurons by intracellular
signalling molecules, or by interaction with sensory neuron-specific scaffolding
proteins, as occurs for TRP channels involved in Drosophila phototransduction (de la
Pena et ah, 2005; Montell, 1998). In support of such a modulation of TRPM8
function by intrinsic cellular proteins or pathways, recording from excised patches in
native sensory cells shifts the temperature threshold of the native cold-and-menthol
current to lower temperatures, by as much as 13°C (Reid & Flonta, 2002).
Alternatively, the native TRPM8 could exist as a heteromultimer of TRPM8
assembled with subunits of other ion channels, or an assembly of different splice
variants of TRPM8, which could alter the temperature sensitivity of the resultant
channel (de la Pena et ah, 2005; Reid, 2005). However, the temperature-sensitive
TRPV channels preferentially assemble as homomers (Hellwig et ah, 2005) and
certainly heteromeric assembly of TRPM8 has not been demonstrated (Schaefer,
2005). Alternatively, the cold threshold of native TRPM8-expressing sensory
neurons may be the result of combined expression of TRPM8 with additional cold-
sensitive ion channels (de la Pena et ah, 2005; Reid, 2005).
The mean threshold of 30°C of the TRPM8-like cold-and-menthol-sensitive
current in sensory neurons is consistent with the thresholds of LTcold-sensitive
neurons recorded in vivo (Iggo, 1969; Reid & Flonta, 2001a; Reid, 2005), suggesting
a role for TRPM8 in innocuous cold transduction. However, TRPM8 is still active at
temperatures below the 15°C psychophysical threshold for noxious cold sensation,
saturating at around 10°C (McKemy et ah, 2002; Peier et ah, 2002b), and so could
also play a role in noxious cold sensitivity.
1.24.2 Chemical sensitivity of TRPM8
TRPM8 is activated by chemicals that elicit the subjective experience of coolness
including menthol, icilin (Wei & Seid, 1983), eucalyptol, and a range of Wilkinson
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Sword manufactured chemicals (Behrendt et al., 2004). Chemical agonists such as
these also result in a functional sensitisation of TRPM8, shifting the activation
threshold to higher temperatures (McKemy et al., 2002; Peier et al., 2002b),
demonstrating co-operativity between temperature and chemical-based stimuli. The
effect on TRPM8 of various agonists is shown in Figure 1.6. Of these chemicals,
icilin and menthol are the most comprehensively studied agonists. The effect of
menthol on cool fibres is stereoselective, with (-)-menthol exerting a stronger effect
than (+)-menthol (Schafer et al., 1986). Similarly, (-)-menthol has a higher potency
acting at TRPM8 than (+)-menthol (Behrendt et al., 2004). Icilin (Wei & Seid, 1983),
which is structurally unrelated to menthol, was until recently the most effective
TRPM8 agonist known, acting at TRPM8 with about 2.5-fold greater efficacy and
nearly 200-fold greater potency than menthol (McKemy et al., 2002). Very recently,
a report found that the Wilkinson Sword-developed cooling chemical WS-12 had an
even higher affinity for TRPM8 than icilin, with an EC5o of 39 nM compared with
500 nM for icilin in similar conditions (Beck et al., 2006), and may therefore be a
promising agent for future studies of TRPM8.
Interestingly, systemic (intraperitoneal) administration of icilin (doses of ~
0.5mg/kg or ~ 500 nmol per average rat) in rats evokes vigorous shaking known as
"wet-dog shakes" (Wei & Seid, 1983), a phenomenon similar to that seen following
morphine withdrawal (Collier et al., 1974). This shaking has been reported to be
antagonised both by agonists of p- or K-opioid receptors acting centrally, but not
peripherally (Werkheiser et al., 2006a), and by intracerebroventricular administration
of adenosine (Tse & Wei, 1986). Although the mechanism underlying these actions
is unclear, these results indicate that the shaking behaviour elicited by icilin is
produced centrally in the brain, and therefore appears to be separate from the
peripheral action of icilin at the TRPM8 receptor.
Menthol and icilin appear to activate TRPM8 through different mechanisms. In
contrast to menthol and cold activation, icilin activates TRPM8 with a variable
latency, and has no effect on TRPM8-expressing cells in the absence of extracellular
Ca2+ (Andersson et al., 2004; Chuang et al., 2004; McKemy et al., 2002). In fact, an
9+
increase in intracellular Ca is required for icilin activation of TRPM8 (as icilin's
9-f- • ,
action is abolished by chelation of intracellular Ca ), and it is suggested that icilin
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alone can activate TRPM8 to a low level, which allows some Ca2+ into the cell,
leading to a positive feedback loop and full icilin activation of the channel (Chuang
et al., 2004). A further difference is that icilin causes rapid and strong desensitisation
of TRPM8 currents, whereas desensitisation to menthol is more variable (Andersson
et al., 2004; Chuang et al., 2004; McKemy et al., 2002; Weil et al., 2005). Therefore
there are substantial differences between the activation mechanisms of these ligands,
and in line with this, sensitivity to these ligands is conferred by different parts of the
TRPM8 molecule (see section 1.24.5).
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Figure 1.6 Icilin and menthol-evoked currents in TRPM8-
expressing cells
a) Currents elicited by menthol (100 pM) cyclohexanol (500
pM, control), icilin (300 nM) and the TRPV1 agonist capsaicin
(1 pM) in Xenopus oocytes expressing TRPM8, measured
under voltage clamp at -60 mV. Bars denote the duration of
agonist application.
b) Concentration-response curves for icilin and menthol,
normalised to those responses evoked by 500 pM menthol,
shown as mean ± SEM.
Both figures taken from McKemy et al., 2002.
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1.24.3 Properties of the TRPM8 current
Other than the difference in threshold discussed above, the properties of cold-and-
menthol-sensitive currents in TRPM8-transfected cells match well with currents in
native cold-and-menthol-sensitive sensory neurons, and therefore TRPM8 is
generally accepted as being the molecular mediator of this current (McKemy, 2005;
Reid, 2005). Both the native cold-and-menthol-sensitive current, and currents in
TRPM8-transfected cells show a relatively high permeability to Ca2+, and little
selectivity among monovalent cations (McKemy et ah, 2002; Peier et ah, 2002b;
Reid et ah, 2002; Reid, 2005). In sensory neurons, the majority of the increase in
2_|_intracellular Ca produced by cold or menthol stimulation appears to be a result of
depolarisation-induced opening of voltage-gated Ca2+ channels, as it is reduced by
blocking voltage-gated Ca2+ channels with Cd2+ (Reid, 2005; Thut et ah, 2003), and
the majority of depolarisation depends on Na+ as it is prevented by replacing Na+ in
the external solution (Reid et ah, 2002; Reid, 2005).
Additional properties demonstrated by the cold/menthol current in native sensory
neurons and TRPM8-expressing cells are a steep outward rectification (McKemy et
ah, 2002; Reid et ah, 2002), and a Ca2+-dependent adaptation (McKemy et ah, 2002;
Peier et ah, 2002b; Reid et ah, 2002; Reid, 2005; Reid & Flonta, 2001a;). Adaptation
is observed as a decline in cold-activated current at steady temperature, with a time
constant of approximately 1 minute for both decline and recovery, and a shift in
temperature sensitivity, so that the same maximal current may be elicited but requires
stronger cooling (Reid et ah, 2002; Reid, 2005). Adaptation is absent in excised
outside-out patches (Reid & Flonta, 2002), and therefore is not a feature of the
9+
channel itself but must involve intracellular processes, and is dependent on Ca , as it
• 2"h • 2"bis prevented by replacing extracellular Ca with Mg or by chelating intracellular
2+ . . ... 9+Ca , indicating that it is elicited by a rise in intracellular Ca (Reid et ah, 2002).
This effect is similar to that observed in in vivo cold-sensitive neurons, where raised
2+extracellular Ca can inhibit the stimulatory effect of menthol (Schafer et ah, 1986).
These results suggest a simple feedback mechanism in which cooling elicits raised
intracellular Ca2+ through activation of TRPM8, which then causes Ca2+-dependent
adaptation and closing of TRPM8, shifting the activation threshold to a slightly lower
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temperature (Reid et al., 2002; Reid, 2005). Thus the threshold of the TRPM8-
carried current is dynamically modulated in response to the input stimuli.
1.24.4 Endogenous activators and modulators of TRPM8
There is evidence for TRPM8 protein in the spinal cord (Baccei et al., 2003,
Tsuzuki et al., 2004; Results section 4.5.4), and in other non-peripheral tissues such
as the prostate (Zhang & Barritt, 2004), where activation by cooling temperatures
(<28°C) is not a possibility. This therefore suggests the existence of endogenous
chemical agonists of the receptor. Several endogenous agonists of the related
TRPV1 receptor have been identified, all of which are arachidonic acid derivatives,
for example anandamide and N-oleoyldopamine (Julius & Basbaum, 2001).
Similarly, TRPM8 has been shown to be activated by several endogenous lipid-based
chemicals. Several phospholipids have been shown to activate TRPM8, although
whether their primary function is as activators or as regulatory molecules is
unknown. In addition, PKC, NGF and pH have all been shown to regulate the
function of TRPM8.
PI(4,5)P2
One endogenous substance which appears to function as a co-activator of TRPM8
is the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2),
which has been shown to play a key role in the regulation of TRPM8 function (Liu &
Qin, 2005; Rohacs et al., 2005). PI(4,5)P2 can elicit TRPM8 activation at
temperatures up to 10°C above the normal activation threshold (Liu & Qin, 2005;
Rohacs et al., 2005). In addition, PI(4,5)P2 depletion (produced either by intracellular
application of "scavenging" polyvalent cations or by wortmannin inhibition of the
phosphoinositide 4-kinases which are involved in PI(4,5)P2 formation) inhibits both
cold and menthol activation of TRPM8, suggesting that PI(4,5)P2 is required for the
activation of TRPM8 by these stimuli (Rohacs et al., 2005). Given this important
facilitatory role of PI(4,5)P2 in TRPM8 channel regulation, it has been suggested that
PI(4,5)P2 depletion is linked to channel desensitisation (Rohacs et al., 2005). In line
with this, application of exogenous PI(4,5)P2 to excised patches restored TRPM8
currents after desensitisation (Liu & Qin, 2005), and co-expression of the type I
phosphatidylinositol-4-phosphate 5-kinase, which catalyses formation of PI(4,5)P2,
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in TRPM8 expressing cells, significantly attenuated TRPM8 current desensitisation
(Rohacs et al., 2005). Further results suggest that PI(4,5)P2 is hydrolysed following
TRPM8 activation, as application of the TRPM8 agonists menthol and icilin induced
translocation of fluorescent-protein-tagged PLCS pleckstrin homology domains
constructs from the plasma membrane to the cytosol in a Ca2+-dependent manner
(Rohacs et al., 2005), an effect which has been previously shown to reflect PI(4,5)P2
depletion (Varnai & Balla, 1998; Stauffer et al., 1998). Therefore it is suggested that
elevated Ca2+ due to TRPM8 channel activation activates a Ca2+-sensitive PLC,
which causes hydrolysis of PI(4,5)P2, and that this depletion accounts for channel
desensitisation (Rohacs et al., 2005), although it is not clear whether PI(4,5)P2
depletion can account for the full extent of channel desensitisation. Additionally,
these effects have only been studied in TRPM8-transfected cells, and thus the
involvement of this mechanism in native cold-and-menthol-sensitive sensory neurons
remains to be investigated.
Lysophospholipids
A recent study suggested that the lysophospholipids lysophosphatidylcholine and
lysophosphatidylinositol can activate TRPM8. Application of these lipids activated
TRPM8-like currents in excised patches from TRPM8-expressing cells, and
9+
inhibitors or antisense-knockdown of the Ca -independent phospholipase A2 enzyme
which catalyses the formation of these phospholipids, inhibited menthol-evoked Ca2+
increases in TRPM8-expressing cells, suggesting that these phospholipids can
facilitate the activation of or directly activate TRPM8 (Vanden Abeele et al., 2006).
PKC
PKC activation has been shown to downregulate TRPM8 function. Menthol-
evoked currents in TRPM8-expressing cells and in native sensory neurons are
significantly attenuated by PKC activation (Premkumar et al., 2005, Abe et al.,
2006). This effect appears to be dependent on dephosphorylation of the TRPM8
receptor produced by PKC-mediated activation of protein phosphatases (including
protein phosphatase 1, and possibly protein phosphatase 2A), as it is prevented by
inhibitors of PKC or of such phosphatases (Premkumar et al., 2005). PKC-dependent
downregulation of TRPM8 can be elicited by application of the pro-algesic agent
bradykinin (Abe et al., 2006; Premkumar et al., 2005). Analysis of DRG neurons
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showed that 29% of neurons with a TRPM8-like cold-and-menthol-sensitive current
responded to bradykinin, and that in these neurons, bradykinin application decreased
the temperature activation threshold by ~2.6°C, which was inhibited by coapplication
of a PKC inhibitor (Linte et al., 2006). Therefore PKC-mediated downregulation of
TRPM8 may have significant effects in vivo. For example, in peripheral
inflammation, bradykinin could produce inhibition of TRPM8, and this inhibition of
a receptor that normally contributes to cool temperature sensation could potentially
contribute to the feeling of heat which accompanies peripheral inflammation.
Linte et al. also showed that 48% of presumed TRPM8-expressing DRG cells were
responsive to the inflammatory mediator prostaglandin E2 (PGE2), and that PGE2
decreased the temperature activation threshold of these neurons by -5.1 °C, which
was blocked by an inhibitor of PKA (Linte et al., 2006). These results suggest firstly
that TRPM8 is functionally modulated by PKA, and secondly that TRPM8 may be
doubly inhibited in inflammatory states, by both PGE2 and bradykinin-mediated
effects.
pH
TRPM8 is functionally modulated by pH (Andersson et al., 2004; Behrendt et al.,
2004). Acidification of the extracellular solution inhibited the responses of TRPM8-
expressing CHO (Chinese hamster ovary) cells to both icilin and cold, as measured
7+ •
in Ca -imaging studies (Andersson et al., 2004). The half-maximal inhibitory effect
on Ca2+ responses evoked by 1 pM icilin or by a 17°C cold stimulus was observed at
pH 6.3 (Andersson et al., 2004). In inflamed tissue, extracellular pH levels as low as
5.4 have been recorded (Steen et al., 1992), and therefore the effects observed of
extracellular pEl on TRPM8 may well be physiologically relevant in peripheral
inflammation. Modulation of the intracellular pH via the recording pipette in voltage-
clamp experiments also altered icilin-evoked currents through TRPM8, suggesting
specifically an intracellular site of action (Andersson et al., 2004). Decreasing the
intracellular pH from 7.12 to 6.9 significantly increased the latency of icilin-activated
currents and decreased the amplitude, and similarly, lowered the temperature
activation threshold of TRPM8 currents. Interestingly, the response to menthol
appeared completely unaffected by extracellular or intracellular pH (Andersson et al.,
2004). Another study did show that responses to menthol were reduced by lowering
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extracellular pH to 6.3 or 6.8, but the responses to menthol were less sensitive to pH
changes than responses to icilin (Behrendt et ah, 2004). This difference in pH
sensitivity suggests a difference between the activation mechanisms of the agonists
icilin and menthol, in agreement with other results indicating that icilin-mediated
activation is Ca2+-dependent whereas menthol-mediated activation is not (Chuang et
ah, 2004) and results showing that sensitivity to these ligands is conferred by
different residues (Bandell et ah, 2006).
NGF
TRPM8 is mainly expressed in trkA positive neurons (Peier et ah, 2002b;
Kobayashi et ah, 2005), and in line with this, TRPM8 function appears to be
modulated by NGF levels. In DRG cultures, the fraction of cold-and-menthol-
sensitive neurons declines with time in culture, and NGF antagonises this effect
(Babes et ah, 2004; Reid et ah, 2002), suggesting that it maintains TRPM8
expression. NGF also sensitises the response of these neurons, shifting the thresholds
of activation to warmer temperatures by approximately 2°C (Babes et ah, 2004). This
sensitising effect may reflect either an NGF-induced increase in the expression level
of TRPM8 in these DRG neurons, or a biochemical modulation of the TRPM8
molecule that facilitates TRPM8 activation, as a result of intracellular signalling
pathways that are engaged downstream of NGF-receptor activation, as neurotrophins
are known to affect neuronal function by both such mechanisms (Pezet & McMahon,
2006). The effects of NGF on TRPM8 suggest that TRPM8 expression and function
could potentially be altered in neuropathic states, (in which afferents experience
altered access to neurotrophic factors).
The overall picture emerging of TRPM8 is of a receptor which functions as an
integrator of a number of chemical and physical stimuli, rather than a simple detector
of cold temperature stimuli. The response properties of endogenous TRPM8
receptors, and therefore the response properties of the relevant subset of cold-
sensitive neurons, will be determined not just by the nature of the particular
activating stimulus, but will also be affected by the stimulus-history (such as
previous exposure to cold or chemical ligands) and the intracellular environment
(such as pH, or activation of signalling pathways which modify TRPM8) of the
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TRPM8-expressing cells. It is likely that in future, additional activators and
modulators of TRPM8 function will be identified.
1.24.5 TRPM8 structure and relationship to function
A high-resolution X-ray crystallographic structure of a TRP channel has not yet
been achieved, but in common with other 6 TM domain cation channels, TRP
channels are thought to exist as tetramers, forming a central pore with the loop
between transmembrane segments 5 and 6 (S5 and S6) acting as the selectivity filter
(Kedei et al., 2001; Tsuruda et al., 2006). Figure 1.7 illustrates the general 6TM TRP
channel structure.
Analysis of channel conductance properties and kinetics shows that TRPM8,
TRPV1, TRPV3, TRPM3 and TRPM4 (and possibly other TRPs) are weakly
voltage-dependent (Brauchi et al., 2004; Hui et al., 2006; Voets et al., 2004). They
show some similarity to the better-known voltage-gated K+ channels, which are also
members of the 6TM superfamily, and therefore their structure and properties have
been compared with the voltage-gated K+ channels. In Kvl.2, and in the voltage-
sensitive TRP channels, voltage-sensitivity is conferred by residues within the S4
domain (Nilius et al., 2005).
Molecular biological studies have also identified sequence motifs which confer
ligand sensitivity. Studies of channel mutants have established that residues within
the putative TM segment 2 and the part of the C-terminal domain known as the TRP
domain, confer menthol sensitivity, and that residues within the same domains also
affect sensitivity to icilin (Bandell et al., 2006). Residues within the TRP domain
also confer stereoselectivity between different menthol isomers (Bandell et al.,
2006). Specific amino acids in the TRP domain have also been shown to be critical
for cold sensitivity, for activation by PI(4,5)P2 and for channel gating kinetics
(Brauchi et al., 2006; Rohacs et al., 2005). However, the residues conferring menthol
sensitivity are different to those conferring cold sensitivity, as mutations which
abolish menthol sensitivity do not affect temperature sensitivity (Bandell et al.,
2006). Whereas menthol sensitivity is conferred by residues in S2 and part of the C-
terminal, the intracellular loop between S2 and S3 is critical for icilin-mediated
activation of the channel (Chuang et al., 2004), suggesting fundamental differences
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between the mechanisms of icilin and menthol-activation of TRPM8. Interestingly,
the chicken orthologue of TRPM8 is insensitive to icilin, because of differences in
the coding sequence for this intracellular loop (Chuang et ah, 2004), and similarly,
differences in the coding sequence of the same region underlie the insensitivity of the
chicken version of TRPV1 to capsaicin (Jordt & Julius, 2002).
A coiled-coil structure in the C-terminal domain, which is conserved among all the
TRPMs, is necessary for channel assembly and sufficient for formation of the
tetramer which constitutes the channel (Erler et ah, 2006; Tsuruda et ah, 2006). This
suggests that there may be a common strategy, among the TRPM family at least, for
channel assembly.
1.24.6 TRP channel gating
Analysis of the voltage-sensitivity and channel kinetics of TRPM8 and other
temperature-sensitive TRPs has led to a general model for the gating of these
temperature-sensitive channels. Voets et al. found a tight link between voltage-
dependent activation and temperature-dependence in both TRPM8 and TRPV1, and
therefore proposed that temperature changes activate these channels by shifting the
voltage-dependent activation curve to physiologically relevant potentials, resulting in
activation (Liman, 2006; Nilius et ah, 2005; Voets et ah, 2004). The effect of ligands
such as menthol may therefore be to shift the voltage-activation curve, so that the
channel becomes active at higher temperatures (in the case of TRPM8) (Voets et ah,
2004). Voets et al. further proposed a thermodynamic and kinetic model for
temperature-sensitive channel gating, in which temperature sensitivity of channels
will occur whenever there is a significant difference between the activation energies
associated with opening and closing of the channel. If the activation energy for
opening the channel is much less than that for closing the channel, as for TRPM8, the
overall open probability of the channel will increase upon cooling. Conversely, if the
activation energy for opening the channel is much greater than that for closing the
channel, as for TRPV1, then the open probability of the channel will increase upon
heating (Nilius et al., 2005; Voets et al., 2004).
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Figure 1.7 TRP channel structure
Figure illustrates:
a) the basic structure of TRP channel subunits, with 6 transmembrane
domains (S1 to S6), with the loop between S5 and S6 acting as the selectivity
filter.
b) space-filling molecular model of the selectivity filter of the TRP channel
pore.
c) schematic to show tetrameric TRP channel structure in the membrane.
All figures kindly provided by Bernd Nilius.
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1.24.7 TRPM8 expression
TRPM8 expression is observed in subpopulations of sensory neurons in DRG and
trigeminal ganglia (McKemy et al., 2002; Peier et al., 2002b), and in nodose ganglia
(Zhang et al., 2004) and dental primary afferent neurons (Park et al., 2006). Nervous
system expression appears to be confined to the peripheral nervous system, as
Northern blots showed no mRNA expression in spinal cord or brain tissue (McKemy
et al., 2002; Peier et al., 2002b). In situ hybridisation studies have shown TRPM8
mRNA in 5 - 10% of DRG neurons, in neurons with diameters consistent with those
of C fibre neurons (McKemy et al., 2002; Peier et al., 2002b). Slightly higher levels
of TRPM8 expression have been reported by another group - up to 23% of DRG
neurons - using high-sensitivity cRNA hybridisation and immunohistochemistry,
(Katsura et ah, 2006; Kobayashi et al., 2005). This group also observed TRPM8
mRNA in up to 19% of myelinated afferents, which also had small diameters,
suggesting A8 fibres (Kobayashi et al., 2005). TRPM8 mRNA does not appear to be
co-expressed with the nociceptor markers CGRP or IB-4 (Peier et al., 2002b).
However, TRPM8 is generally (-98%) co-localised with the NGF receptor trkA
(Kobayashi et al., 2005; Peier et al., 2002b), which typically marks small-diameter,
peptidergic afferents (Averill et al., 1995); although the lack of co-expression with
CGRP suggests that TRPM8 may be found in neuronal populations distinct from
peptidergic nociceptive afferents. The issue of TRPM8 co-expression with TRPV1 is
controversial. Several in situ hybridisation studies have shown no overlap in
expression (Kobayashi et al., 2005; Peier et al., 2002b), whereas another group
suggested that 29% of TRPM8-expressing cells also expressed TRPV1 (Okazawa et
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al., 2004). Ca -imaging studies have shown up to 50% of menthol-sensitive cells
also respond to capsaicin in cell culture (Babes et al., 2004; McKemy et al., 2002;
Xing et al., 2006). Some reports have suggested that co-expression of TRPM8 and
TRPV1 is an artefact of culture produced by NGF as co-expression of capsaicin and
menthol responses was readily detected in cultures with, but not without NGF (Story
et al., 2003; McKemy, 2005). However, TRPM8 and TRPV1 mRNA co-expression
has been observed in tissue in some reports (Okazawa et al., 2004), and co-
expression of capsaicin and menthol responses has been observed within as little as 2
hours after culture, or in cultures without NGF (Babes et al., 2004, Reid, 2005).
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There may be a species difference, as co-expression has only been reported in rat
tissue (Babes et al., 2004; McKemy et ah, 2002; Okazawa et ah, 2004), and not in
mouse (Peier et ah, 2002b) - however, lack of co-expression has also been reported
in rat (Kobayashi et ah, 2005). Therefore this issue remains unresolved.
The expression pattern of TRPM8 is therefore consistent both with expression in
populations of non-nociceptive neurons, (which do not express typical nociceptive
markers such as IB-4, CGRP or TRPV1, and which are presumably innocuous cold-
sensitive neurons), and with expression in some nociceptive neurons, (due to the data
showing co-expression with TRPV1). Analysis of cold-sensitive trigeminal neurons
showed that those responding to low-threshold cooling (with thresholds between 30
and 25°C) were much more likely to express TRPM8 mRNA (as shown by single
cell RT-PCR) than those with thresholds under 25°C (Nealen et al., 2003),
suggesting that TRPM8 may be predominantly expressed by innocuous cold-
sensitive afferents. A recent report examined dissociated DRG neurons without
culture and identified two classes of menthol-sensitive neurons, one of which had
non-nociceptive properties including capsaicin-insensitivity, ATP-insensitivity, and
expression of TTX-S Na+ currents only, and a second population which had
nociceptive characteristics including sensitivity to capsaicin and ATP and expression
of both TTX-S and TTX-R Na+ channels (Xing et al., 2006). The non-nociceptive
population showed greater sensitivity to menthol: whereas both populations could be
activated by 100 pM menthol, three times as many non-nociceptive neurons could be
activated by 10 pM menthol as nociceptive neurons, and the non-nociceptive
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population also responded to 100 pM menthol with larger increases in Ca -induced
fluorescence or single-cell currents (Xing et al., 2006). This report therefore suggests
that TRPM8 may be expressed by both innocuous cold-sensitive neurons and cold-
sensitive nociceptors, but is expressed at higher levels in innocuous cold-sensitive
neurons, conferring greater sensitivity to TRPM8-activating stimuli on these.
TRPM8 protein is presumed to be on peripheral terminals of sensory neurons,
however electrophysiological evidence also suggests a location on central terminals
of primary afferents (Baccei et al., 2003; Tsuzuki et al., 2004). Studies of the primary
afferent: dorsal horn synapse in spinal cord slices (Baccei et al., 2003) and in DRG
afferent: dorsal horn neuron co-cultures (Premkumar et al., 2005; Tsuzuki et al.,
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2004) found that TRPM8 activation by menthol increased mEPSC frequency but not
amplitude (Baccei et ah, 2003; Premkumar et ah, 2005; Tsuzuki et al., 2004)
suggesting a location at presynaptic afferent terminals in the dorsal horn.
TRPM8 expression outside the nervous system
In addition to a location in sensory nervous tissue, TRPM8 mRNA and protein is
also found in prostate tissue (Bidaux et al., 2005; Thebault et ah, 2005; Tsavaler et
al., 2001; Zhang & Barritt, 2004, 2006) in the bladder (Stein et al., 2004; Tsukimi et
al., 2005) and in pulmonary arterial and aortic smooth muscle (Yang et al., 2006).
These locations suggest a role beyond sensory thermotransduction, adding to the
intriguing diversity of TRP channel functions. In prostate tissue TRPM8 is found
both in the plasma and endoplasmic reticular membranes of secretory epithelial cells
(Bidaux et al., 2005; Thebault et al., 2005), where it appears to function as an
androgen-sensitive Ca2+ channel (Thebault et al., 2005; Zhang & Barritt, 2004,
2006,). TRPM8 is upregulated in prostate tumours (Thebault et al., 2005; Zhang &
Barritt, 2004), and is found in primary tumours of the breast, lung and skin, where it
is not normally expressed at all (Tsavaler et al., 2001), suggesting that it may play a
role in tumour development. The TRPM8 agonist menthol can induce apoptosis in
cancerous prostate cells (Zhang & Barritt, 2004, 2006), suggesting TRPM8 may play
a role in cancer cell survival. In the bladder, TRPM8 is found in the urothelium and
nerve fibres, and increased expression is correlated with painful and overactive
bladder syndromes in humans (Mukerji et al., 2006).
1.25 TRPA1
A second cold-sensitive TRP receptor is TRPA1 (formerly known as ANKTM1)
(Story et al., 2003). TRPA1 is unique among the TRPs and constitutes the sole
member of the TRPA family; it is distinguished from other channels by the presence
of about 14 ankyrin domains in its N-terminal tail (Clapham et al., 2003; Ramsey et
al., 2006).
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1.25.1 Activation properties of TRPA1
TRPA1 carries a non-selective cation current. When expressed in heterologous
systems, TRPA1 shows a rather variable threshold between 12 - 24°C, with maximal
activation at temperatures below 17°C (Story et ah, 2003), and therefore is activated
by significantly lower temperatures than TRPM8. In addition to cold, TRPA1 is
activated by a range of noxious, pungent chemicals. These include cinnamaldehyde
(from cinnamon); allyl isothiocyanate (found in mustard oil, horseradish, wasabi and
brassicas) and related compounds; allicin (from garlic) and related compounds;
carvacrol, eugenol (from cloves); methylsalicylate (wintergreen oil); acrolein (found
in tear gas and traffic fumes); tetrahydrocannabinol (the psychoactive component of
cannabis) and bradykinin (which appears to activate indirectly, through a PLC-
dependent mechanism) (Bandell et ah, 2004; Bautista et al., 2005, 2006; Jordt et ah,
2004; Macpherson et ah, 2005;). Icilin is also a TRPA1 agonist, although shows a
much lower potency than at TRPM8 and a delayed (possibly indirect) mode of
TRPA1 activation (Story et ah, 2003).
There is currently controversy surrounding the role of TRPA1 in cold
transduction. Other groups have studied TRPA1 and did not find that this receptor
was cold-sensitive (Jordt et ah, 2004; Nagata et ah, 2005). The generation of
knockout mice was expected to resolve the function of TRPA1, but instead has
increased confusion surrounding the role of this receptor, as two separate groups
found different results. One group found a 50% reduction in withdrawal responses to
a 0°C cold-plate test, suggesting TRPA1 is involved in responses to noxious cold
(Kwan et ah, 2006), but the second group reported normal responses to 0, -5 and -
10°C cold-plate tests (Bautista et ah, 2006), and thus the involvement of TRPA1 in
cold sensitivity remains controversial. However, other results support a role for
TRPA1 in noxious cold sensitivity. Genetic analysis of human populations showed
that genetic variations in TRPA1 contribute to variations in cold pain sensitivity in
humans (Kim et ah, 2006), suggesting that TRPA1 is involved in noxious cold
sensation. A role for TRPA1 in cold hypersensitivity is suggested, as antisense
knockdown produced a decrease in the development of cold allodynia in the SNL
model of neuropathy and a model of inflammatory pain (Katsura et ah, 2006; Obata
et ah, 2005). In contrast, there was no such effect of antisense knockdown of TRPM8
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(Katsura et al., 2006), suggesting a role for TRPA1, but not TRPM8, in cold
allodynia. Therefore while the controversy remains, a number of reports suggest a
role for TRPA1 in noxious cold processing.
The role of TRPA1 in response to noxious chemical stimuli is clearer, as many
reports demonstrate that TRPA1 is sensitive to a variety of noxious chemicals, and
indeed both groups of TRPA1 knockout mice showed deficiencies in licking and
flinching behaviour evoked by topical mustard oil (Bautista et al., 2006), intraplantar
mustard oil (Kwan et al., 2006) and intraplantar bradykinin (Bautista et al., 2006;
Kwan et al., 2006), suggesting that TRPA1 is indeed a key mediator of sensitivity to
these noxious stimuli.
TRPA1 is also found in the inner hair cells of the cochlea, and has been proposed
to play a role in the mechanosensitive transduction of the inner hair cells (Corey et
al., 2004; Nagata et al., 2005). However, TRPA1 knockouts show normal auditory
function, suggesting that TRPA1 may not be responsible for inner ear hair cell
transduction (Kwan et al., 2006; Bautista et al., 2006). TRPA1 has also been
implicated in somatosensory mechanotransduction, as one group of knockout mice
showed a decrease in sensitivity to von Frey hair application (Kwan et al., 2006).
However, this decrease was slight and the second knockout group showed no such
decrease (Bautista et al., 2006), and so further studies are needed to resolve the
extent to which TRPA1 may contribute to mechanosensation in vivo.
1.25.2 TRPA1 expression
TRPA1 is expressed in trigeminal, dorsal root and nodose ganglia (Nagata et al.,
2005; Story et al., 2003; Zhang et al., 2003). Different studies have shown very
different levels of TRPA1 mRNA expression - from 3% (Story et al., 2003), to 32%
(Obata et al., 2005) to 55% (Nagata et al., 2005) of DRG neurons. TRPA1 is
expressed in small unmyelinated fibres, and co-expression has been observed with
CGRP, SP, and TRPV1 (Nagata et al., 2005; Story et al., 2003). These data suggest
that TRPA1 is expressed primarily in peptidergic C fibre nociceptors, which are
likely to be polymodal, as co-expression of TRPA1 and TRPV1 would confer
sensitivity to noxious heat, noxious cold and noxious chemicals. In contrast,
TRPA1/TRPM8 co-expression has not been observed (Kobayashi et al., 2005;
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Nagata et al., 2005; Story et al., 2003), suggesting that these receptors are expressed
by distinct neuronal populations. Northern blots show that TRPA1 mRNA is absent
from the CNS, suggesting that its role is confined to the peripheral nervous system
(Story et al., 2003).
1.26 Alternative cold-sensitive channels
Additional mechanisms beyond TRPM8 and TRPA1 are implicated in cold
transduction (Reid, 2005). As discussed above, the difference in threshold (~6°C)
between TRPM8-transfected cells and native TRPM8-like cold-sensitive currents
suggests either intrinsic modulation of TRPM8 or the existence of additional cold-
sensitive currents in native sensory neurons (Reid, 2005). Furthermore, TRPM8 and
TRPA1 expression cannot account for all cold sensitivity in DRG neurons.
Populations of cold-sensitive neurons (with thresholds between 30 and 20°C) have
been identified that do not respond to either the TRPM8 agonist menthol or to the
TRPA1 agonist mustard oil (Babes et al., 2004; Munns et al., 2006), and that do not
express TRPM8 or TRPA1, as shown by RT-PCR (Babes et al., 2006). Treatment
with the TRPM8 channel blocker BCTC blocks responses to menthol but not all
responses to cold in cultured trigeminal neurons and in corneal neuron terminals,
suggesting that TRPM8 is involved but cannot does not wholly mediate sensory
neuron responses to cold (Madrid et al., 2006; Viana et al., 2006). Sympathetic
neurons of the superior cervical ganglia respond to cold but do not generally respond
to agonists of either TRPM8 or TRPA1, indicating that alternative mechanisms may
mediate cold sensitivity in the sympathetic nervous system (Munns et al., 2006).
Additional cold-sensitive currents and receptors have been identified. These
include a hyperpolarising K+ current which is deactivated by cooling, thus leading to
depolarisation (Reid & Flonta, 2001b; Viana et al., 2002). Several 2-pore domain K+
channels have been identified which are deactivated by decreases in temperature, and
could thereby mediate this effect. TREK-1 is activated on warming, with a threshold
of ~25°C (Kang et al., 2005) and maximal sensitivity between 32 and 37°C, and is
expressed in small and medium-sized DRG neurons (Maingret et al., 2000).
However, in argument against a role for TREK-1 in sensory cold transduction,
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TREK-1 blockers had no effect on responses of cold-sensitive DRG neurons (Thut et
al., 2003), and TREK-1 knockout mice show unaltered cold sensitivity (Alloui et al.,
2006). TREK-1 is expressed at high levels in the hypothalamus, and this together
with its high sensitivity at temperatures around 37°C suggests that it may be involved
in temperature homeostasis (Maingret et al., 2000). TREK-2 (Bang et al., 2000) is
also temperature sensitive, with a threshold of around 25°C (Kang et al., 2005).
Currents with properties resembling those of TREK-2 have been detected in up to
28% of DRG neurons (Kang et al., 2005). The K+ channel TRAAK is also
deactivated by decreasing temperature, with a threshold of around 31°C, and
TRAAK-like currents are observed in around 8% of DRG neurons (Kang et al.,
2005). These and potentially other K+ channels may contribute to cold sensitivity in
DRG neurons.
In addition to these K conductances, the epithelial Na+ channel ENaC has also
been demonstrated to respond to cold with an increase in conduction, half-maximal
stimulation occurring at 25°C (Askwith et al., 2001). However, as yet little is known
about the contribution of this channel to in vivo cold transduction. Inhibition of the
Na+/K+ ATPase has also been implicated in cold sensitivity, as blockade of this with
ouabain facilitates cold receptor firing (Pierau et al., 1974). However, later work
suggests that this role is probably minor as ouabain elicited only a minor
depolarisation, and no action potentials, in cold-sensitive DRG neurons (Reid &
Flonta, 2001b).
Therefore in conclusion it is clear that cold sensory transduction is a complex
process, involving multiple receptor mechanisms. Much more work is needed to
resolve the contribution of the mechanisms desciibed above to cold transduction in
vivo.
1.27 Aims of the project
To examine the role of the TRPM8 receptor in pain processing. The initial
hypothesis was that the TRPM8 receptor could be the molecular mediator of the
phenomena of both cooling-induced analgesia and menthol-induced analgesia, and
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therefore I examined the effect of TRPM8 activation in models of chronic pain and
normal animals.
To examine the localisation of TRPM8 in afferent neurons and the spinal
cord, and any changes in such localisation that occur in chronic pain states.
To investigate mediators of the effects of TRPM8 activation -I specifically
investigated the role of the Group II and Group III mGluRs in mediating effects
occurring downstream of TRPM8-expressing neurons.
To compare the role of TRPM8 with that of the related TRPA1 receptor in
pain processing; although TRPA1 was a minor focus of this project.
These aims were addressed experimentally by:
Topical and intrathecal drug application in models of neuropathic and
inflammatory pain and in naive animals. The effects of TRPM8 and TRPA1 agonists,
and agonists and antagonists of various other receptors, principally the Group II and
Group III mGluRs were assessed by measurement of behavioural reflex thresholds to
sensory stimuli.
Saphenous nerve recordings to assess the response of primary afferent
populations to selective TRPM8 activators.
In vivo antisense knockdown of TRPM8 followed by behavioural testing,
electrophysiology, and protein studies in order to assess the involvement of this
receptor in mediating the effects of TRPM8 activators.
Western blot and immunohistochemical studies of spinal cord and DRG
tissue in order to investigate TRPM8 and mGluR localisation and changes in
expression in chronic pain models.
In vivo extracellular recordings of spinal cord neurons to assess the effect of




• Halothane (Zeneca Ltd., Cheshire, UK)
• Urethane (Sigma Chemical Co., UK)
• a-chloralose (Acros Organics, Geel, Belgium)
2.2 Animal models
• Surgical instruments: scalpel, blunt forceps, blunt scissors, fine curved and
straight watchmaker's forceps, needle holders, bonecutters, iris scissors, fine
scissors (InterFocus Ltd., Haverhill, UK)
• 25Gxl needle (Terumo, New Jersey, USA)
• 1 ml syringe (BD Biosciences, Oxford, UK)
• 5.0 coated vicryl sutures (Ethicon Ltd., Edinburgh, UK)
• Lysolecithin (a-lysophosphatidylcholine; Cat. No. L4129, Sigma Chemical
Co., UK)
• Chromic cat gut (USP 4/0) (SMI AG, Hunningen, Belgium)
• Freund's complete adjuvant (Cat. No. F5881, Sigma Chemical Co., UK)
• Antisense and mis-sense oligonucleotides (MWG Biotech, Ebersberg,
Germany)
• Alzet Minipump, models 2001, 2002 (Charles River Ltd., Margate, UK)
• Vinyl tubing and polyethylene tubing for canulae (Charles River Ltd.,
Margate, UK)
• 0.9% sterile physiological saline (Sigma Chemical Co., UK)
• Hibitane (5% diluted 1:1000, Zeneca Ltd., Cheshire, UK)
2.3 Behavioural testing
• Hargreaves' thermal stimulator, supplied base and glass table (Linton
Instrumentation, Diss, UK)
• Semmes-Weinstein von Frey filaments (Stoelting, Wood Dale, Illinois, USA)
• Clear Perspex cages (made on site)
70
• Clear Perspex box with raised aluminium floor for cold test (made on site)
• Thermistor (Model 2751 -K, Digitron Instrumentation Ltd, Devon, UK)
2.4 Drug administration
• 25Gxl needle (Terumo, New Jersey, USA)
• 1 ml syringe (BD Biosciences, Oxford, UK)
• Clear plastic tank, 25cm by 25 cm by 20cm for topical application of drug
(made on site).
• 0.9% sterile physiological saline (Sigma Chemical Co., UK)
• Dimethylformamide (Sigma Chemical Co., UK)
• Dimethylsulphoxide (Sigma Chemical Co., UK)
• Ethanol 100% (BDH, UK)
• Icilin - 3,4-Dihydro-3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-(lH)-pyrimidin-
2-one (Cat. No. 1531, Tocris Cookson, Bristol, UK)
• LY 341495 - (2S)-2-Amino-2-[(lS,2S)-2-carboxycycloprop-l-yl]-3-(xanth-
9-yl) propanoic acid (Cat. No. 1209, Tocris Cookson, Bristol, UK)
• UBP1112 - a-Methyl-3-methyl-4-phosphonophenylglycine (Cat. No. 1369,
Tocris Cookson, Bristol, UK)
• 2R, 4R-APDC - 2R, 4R)-4-aminopyrrolidine-2,4-dicarboxylate (Cat. No.
1208, Tocris Cookson, Bristol, UK)
• ACPT-III - (lR,3R,4S)-l-aminocyclopentane-l,3,4-tricarboxylic acid (Cat.
No. 1113, Tocris Cookson, Bristol, UK)
• AP-4 - (L-(l)-2-amino-4-phophonobutyric acid (Cat. No. 0103, Tocris
Cookson, Bristol, UK)
• Naloxone - (5a)- 4,5-Epoxy-3,14-dihydro-17-(2-propenyl)morphinan-6-one
hydrochloride (Cat. No. 0599, Tocris Cookson, Bristol, UK)
• NMDA - N-methyl-D-aspartate (Cat. No. 0114, Tocris Cookson, Bristol,
UK)
• ACPC - 1-aminocyclopropanecarboxylic acid (Cat. No. 07626, Sigma
Chemical Co., UK)
71
• Capsaicin - (E)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-
nonenamide (Cat. No. 0462, Tocris Cookson, Bristol, UK)
• Resiniferatoxin - 4-Hydroxy-3-methoxy-
[(2S,3aR,3bS,6aR,9aR,9bR, 1 OR, 1 laR)-3a,3b,6,6a,9a,10,l 1,11 a-octahydro-
6a-hydroxy-8,10-dimethyl-11 a-(l -methylethenyl)-7-oxo-2-(phenylmethyl)-
7H-2,9(3-epoxyazuleno[5,4-e]-l,3-benzodioxol-5-yl]benzeneacetate (Cat. No.
1137, Tocris Cookson, Bristol, UK)
• (-)-menthol - (1R, 2S, 5R)5-methyl-2-propan-2-yl-cyclohexan-l-ol (Cat. No.
588733, Sigma Chemical Co., UK)
• Isomenthol - (IS, 2R, 5R)5-methyl-2-propan-2-yl-cyclohexan-l-ol (Cat. No.
58929, Sigma Chemical Co., UK)
• (+)-menthol (IS, 2R, 5S)5-methyl-2-propan-2-yl-cyclohexan-l-ol (Cat. No.
224464, Sigma Chemical Co., UK)
• Cinnamaldehyde - 3-phenyl-2-propenal (Cat. No. W228605, Sigma
Chemical Co., UK)
• Ruthenium red - ruthenium (III) chloride oxide ammoniated hydrate (Cat.
No. R2751, Sigma-Aldrich Co. Ltd, UK)
• Allicin - 2-propene-l-sulfinothioic acid-S-2-propenyl ester - (Cat. No.
A4440, LKT Laboratories Inc., St Paul, MN, USA)
• Diallyl disulphide (Cat. No. D3201, LKT Laboratories Inc., St Paul, MN,
USA)
• Prism 4 (GraphPad software Inc.)
2.5 Tissue processing and Western blotting
• Mercaptoethanol - 2-hydroxy-l-ethanethiol (Sigma Chemical Co., UK)
• Sodium dodecyl sulphate (Sigma Chemical Co., UK)
• Tris-hydroxymethylaminoethane (Sigma Chemical Co., UK)
• Urea - diaminoethanal (BDH, UK)
• Thiourea - sulphanylmethanimidamide (Sigma Chemical Co., UK)
• Protease Inhibitor Cocktail III (Cat. No. 539134, Calbiochem, Merck
Biosciences Ltd., Nottingham, UK)
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• Hand-held glass homogenizer
• Ystral homogeniser (Scientific Industries Intl. UK Ltd., Loughborough, UK)
• NuPage Gel Electrophoresis System (Invitrogen Ltd., Paisley, UK)
• SeeBlue Plus prestained standard molecular weight markers (Cat. No.
LC5925, Invitrogen, Ltd., Paisley, UK)
• Glycerol (Sigma Chemical Co., UK)
• Bromophenol blue (Sigma Chemical Co., UK)
• 4-12% Bis-Tris NuPage gels (Cat. No. NP0321, Invitrogen Ltd., Paisley, UK)
• 3-8% Tris-Acetate gels (Cat. No. EA0375, Invitrogen, Ltd., Paisley, UK)
• MOPS running buffer for electrophoresis (Cat. No. NP0001, Invitrogen, Ltd.,
Paisley, UK)
• Tris-Acetate running buffer for electrophoresis (Cat. No. LA0041, Invitrogen
Ltd., Paisley, UK)
• Immobilon- PSQ membrane (Millipore, Watford, UK)
• NuPage Transfer buffer (Cat. No. NP0006, Invitrogen Ltd., Paisley, UK)
• Methanol 100% (Fisher Scientific UK Ltd., Loughborough, UK)
• Ethanoic acid 100% (Fisher Scientific UK Ltd., Loughborough, UK)
• Coomassie Blue (GE Healthcare UK Limited, Bucks, UK)
• Albumin Bovine Serum Fraction V (Sigma Chemical Co., UK)
• 0.1M PBS, pH 7.4
• Tween-20 (Sigma Chemical Co., UK)
• Marvel milk powder
• Enhanced Chemiluminescent Detection Reagents: Lumiglo & hydrogen
peroxide, (Cell Signalling, Danvers, Massachusetts, USA)
• Hyperfilm for ECL (GE Healthcare UK Ltd., Bucks)
• Scananalysis programme (Biosoft, Cambridge UK)
2.5.1 Antibodies
• Rabbit polyclonal anti-TRPM8 (residues 278-292 and 1090-1104; human;
Cat. No. ab3243, Abeam pic, Cambridge, UK)
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• Rabbit polyclonal anti-TRPVl (Cat. No. AB5889, Chemicon International
Ltd., Harrow, UK)
• Rabbit polyclonal anti-mGluR7 (Cat. No. ab07-239, Upstate, Charlottesville,
Virginia, USA)
• Rabbit polyclonal anti-mGluR2/3 (Cat. No. AB1553, Chemicon International
Ltd., Harrow, UK)
• Rabbit polyclonal anti-mGluR3 (Cat. No. ab 10309, Abeam pic, Cambridge,
UK)
• Rabbit polyclonal anti-mGluR4 (Cat. No. 51-3100, Zymed, Invitrogen Ltd.,
UK)
• Mouse monoclonal anti-GAPDH (Cat. No. MAB374, Chemicon International
Ltd., Harrow, UK)
• HRP-linked donkey anti-rabbit secondary (Cat. No. AP182P, Chemicon
International Ltd., Harrow, UK)
• HRP-linked donkey anti-mouse secondary (Cat. No. AP192P, Chemicon
International Ltd., Harrow, UK)
2.5.2 Cell culture and antigen pre-absorption
• Dulbecco's modified Eagle's medium (DMEM; Gibco, Invitrogen, Paisley,
UK)
• 10% normal calf serum (Gibco, Invitrogen, Paisley, UK)
• 100 units/ml penicillin (Gibco, Invitrogen, Paisley, UK)
• 100 pg/ml streptomycin (Gibco, Invitrogen, Paisley, UK)
• 20 ml Hank's Buffered Saline Solution (HBSS; Gibco, Invitrogen, Paisley,
UK)
• 10 ml Trypsin -EDTA (trypsin 0.5g/l, EDTA 0.2g/l, NaCl 0.85g/l; Gibco,
Invitrogen, Paisley, UK)
• 12 well plates (Greiner Bio-One, Gloucestershire, UK)
• 2% Ultroser G (USG; Pall Biosciences, Portsmouth, Hampshire, UK)
• Human TRPM8 cDNA clone (Cat. No. TCI22185, OriGene Technologies
Inc., Rockville, MD, USA)
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• pCMV6-XL4 expression plasmid (OriGene Technologies Inc., Rockville,
MD, USA)
• GeneJuice Reagent (Novagen, Merck Biosciences Ltd., Nottingham, UK)
2.6 Immunohistochemistry
• OCT embedding compound (Cell Path pic. Powys, Wales, UK)
• Isopentane (BDH, UK)
• Cryostat chucks
• Freezing spray (Greenhill Chemical Products Ltd., Burton-on-Trent, UK)
• Toluidine Blue (Sigma Chemical Co., UK)
• Glass coverslips (22 x 50mm) (Merck-BDH, UK)
• Poly-L-lysine coated glass slides (Merck-BDH, UK)
• Normal goat serum (Vector Laboratories, Burlingame, California, USA)
• Triton X-100 (Sigma Chemical Co., UK)
• Fish skin gelatin (Cat. No. G7765, Sigma Chemical Co., UK)
• Vecta-Shield mounting medium (Vector Laboratories, Burlingame,
California, USA)
• ImmEdge hydrophobic barrier marker pen (Vector Laboratories, Burlingame,
California, USA)
• 0.1M PBS, pH 7.4
2.6.1 Antibodies and peptides
• Rabbit polyclonal anti-TRPM8, (residues 656-680, rat, Cat. No. H-050-50,
Phoenix Peptides, Arizona, USA)
• TRPM8 peptide antigen (residues 656-680, rat, Cat. No. 050-50, Phoenix
Peptides, Arizona, USA)
• Mouse monoclonal anti-neurofilament 200kDa, phosphorylated & non-
phosphorylated (Cat. No. NO 142, Sigma Chemical Co., UK)
• Mouse monoclonal anti-peripherin (Cat. No. MAB1527, Chemicon
International Ltd., Harrow, UK)
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• Mouse monoclonal anti-neuronal nuclei (Cat. No. MAB377, Chemicon
International Ltd., Harrow, UK)
• Rabbit polyclonal anti-mGluR7 (Cat. No. abl3363, Abeam pic, Cambridge,
UK)
• AlexaFluor 568 conjugated goat anti-rabbit (Cat. No. A11036, Molecular
Probes, Oregon, USA)
• AlexaFluor 488 conjugated goat anti-mouse (Cat. No. A11029, Molecular
Probes, Oregon, USA)
2.6.2 Detection and analysis
• To-pro-3-iodide nuclear stain (Cat. No. T3605, Molecular Probes, Oregon,
USA)
• Leica TCSNT confocal microscope (Leica Microsystems GMBH, Germany)
• UTHSCSA Image Tool Version 3.0 image analysis software
• Adobe Photoshop Version 7.0
2.7 Electronhysiology
• McLab Chart programme version 3.6 (AD Instruments Ltd., Oxford, UK)
• AC coupled differential amplifier (3160, Digitimer Ltd., Welwyn Garden
City, Herts, UK)
• Digitimer (D100, Digitimer Ltd., Welwyn Garden City, Herts, UK)
• Dual beam oscilloscope (D13, Tektronix Inc., Beaverton, Oregon, USA)
• Isolated stimulator (Mark IV, Lectromed Limited, St Quen, Jersey, Channel
Islands)
• Agar (Sigma Chemical Co., UK)
• Liquid paraffin
• Motorised rotating brush
• Spike 2 programme (Version 3.2, Cambridge Electronic Design, Cambridge,
UK)








3.1.1 CC1 model of neuropathic pain
The chronic constriction injury (CCI) model of neuropathic pain (Bennett and Xie,
1988) was used. Animals were anaesthetised in a halothane/oxygen mixture (Zeneca,
Cheshire, UK), the sciatic nerve was exposed proximal to the trifurcation at mid-
thigh level, and four loose ligatures of chromic cat gut (SMI AG, Hunningen,
Belgium) were tied around the nerve, as viewed under x 40 microscope, before
suturing and recovery. Rats between 180-250 g were preferred as it was observed
that these produced a stronger development of neuropathy. Peak reflex sensitisation
was observed between days 9 and 16, when further experiments - drug-testing, tissue
removal or electrophysiology - were carried out. Development of sensitisation was
always measured behaviourally before carrying out further experiments. Animals
were monitored for signs of autotomy, which was very rare, and were culled if this
developed.
3.1.2 CFA model of inflammatory pain
A model of inflammatory sensitisation was generated by injecting 100 pi
Complete Freund's Adjuvant (CFA; Sigma Chemical Co., UK) into the plantar
surface of the hindpaw of anaesthetised rats using a microsyringe and 25-gauge
needle. The needle was held as close to the skin surface as possible to minimise
observed bleeding and avoid systemic effects due to CFA entry into bloodstream.
Any further behavioural experiments were carried out at 24 or 48 hours post-
injection and tissue removal was carried out at 48 hours. Controls were performed
with 0.9% saline injections.
3.1.3 Lysolecithin model of afferent demyelination-induced pain
This model was set up as described by Wallace et al., 2003. Animals were
anaesthetised in a halothane/oxygen mixture, the sciatic nerve was exposed proximal
to the trifurcation and surrounding fat removed under x 40 microscope. A 5 mm wide
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piece of folded parchment paper was carefully inserted under the nerve to prevent
spillage of lysolecithin onto surrounding tissue. Lysolecithin (15 mg/ml in sterile
0.9% saline, Sigma, UK) was applied dropwise over a 2-3 mm length of nerve using
a 25-gauge needle microsyringe (Terumo) over a period of 10-13 minutes, ensuring
that the nerve was kept moist at all times. Excess lysolecithin was removed by
applying sterile saline and dabbing on cotton wool before suturing and recovery.
Peak reflex sensitisation was observed between days 4 and 10, when further
behavioural experiments or tissue removal was carried out.
3.1.4 Targeted knockdown of TRPM8
Knockdown of TRPM8 and controls were carried out by delivering antisense and
mis-sense oligonucleotides to TRPM8 into the intrathecal space of rats from osmotic
minipumps.
Antisense and mis-sense oligonucleotides were 22-mers with phosphorothioate
bonds at the last two positions at 5' and 3' ends (MWG Biotech, Ebersberg,
Germany). Antisense extended from base -10 to base +12 relative to the start of the
open reading frame for the rat TRPM8 gene:
5'C*T*CGAAGGACATCTTGCCGT*G*G 3', where * represents phosphorothioate
linkages. Mis-sense was designed with 4 inversions of C/G or A/T as appropriate at
residues 3, 11, 14 and 22, preserving overall G/C content. BLAST searches of both
oligonucleotides indicated no significant complementarity to any known gene
sequence.
14-day or 7-day osmotic minipumps (Alzet Minipump, models 2001, 2002;
Charles River, UK) containing oligonucleotides (0.25 pg/pl in sterile saline) were
sewn into the rat and connecting vinyl and polyethylene canulae inserted under the
dura of the spinal cord to level L5/6, infusing a dose of 0.5 pl/hour. The minipumps
were filled 24 hours prior to insertion and maintained at 37°C until implantation. In
some cases a CCI was set up at the same time, in which case 14-day pumps were
used so that oligonucleotides were delivered over the same period as that over which
sensitisation develops; in non-CCI animals 7-day minipumps were used. At the end
of behavioural testing, electrophysiology experiments, or prior to removal of tissue
for biochemistry, a laminectomy was performed and the position of the canula
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checked. Only results or tissue from animals where the canula was in place and the
animal was healthy were taken. The minipumps were weighed before insertion and
following removal to check that they had functioned properly and the whole dose had
been ejected. Occasional complications of the surgery included motor effects on
hindlimbs (rate of 1 in 15) and swelling of the back (1 in 10); these animals were
culled and any results discarded.
3.1.5 Dorsal root rhizotomy
A unilateral dorsal root rhizotomy was performed in rats to establish whether
TRPM8 expression in spinal cord was pre or postsynaptic. Under deep anaesthesia, a
laminectomy was performed to expose the dorsal roots, which were then transected
at the lumbar L5/6 level. The wound was sutured and animals recovered for 8 days
before tissue removal and processing for western blot or immunohistochemistry. This
time period gave sufficient time for loss of presynaptic input while minimising the
time of this severe procedure.
3.2 Behavioural testing
Behavioural reflex responses to noxious thermal, punctate mechanical and 4°C
cold stimuli were measured. For each test, a minimum of 3 tests was performed to
establish a consistent baseline before drug application or to measure development of
sensitisation before any other type of experiment. Animals were habituated to testing
by performing a series of 3 baseline readings (mechanical and thermal, and cold if
that was to be tested) each day for 3 days before performing tests from which results
were recorded. Without habituation animals gave erratic baseline results and also
showed behaviours that were problematic to the testing procedure (such as
attempting to escape). Where a stable baseline was never obtained animals were not
used in further testing - this happened in approximately 1 animal in 20.
3.2.1 Thermal sensitivity
Sensitivity to a noxious thermal stimulus was assessed by measuring latency (s)
of paw withdrawal in response to an infrared beam (55 °C, Hargreaves' thermal
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stimulator, Linton Instrumentation, Diss, UK) directed to the mid-plantar glabrous
surface of the hindpaw. The same area of the paw was targeted each time. The
withdrawal response latency was recorded to the nearest 0.1s, and only clear-cut paw
withdrawal flicks were recorded: disruption of the beam due to locomotion was
discounted, and a repeat test carried out. A maximum cut-off value of 20 seconds,
and a minimum of 5 minutes recovery time between each test avoided tissue damage
and sensitisation (as established by previous experimentation).
3.2.2 Mechanical sensitivity
Sensitivity to mechanical stimuli was assessed by measuring the 50% withdrawal
threshold to calibrated Semmes-Weinstein von Frey filaments (Stoelting, Illinois,
US). Threshold was recorded as the indentation pressure (mN/mm ) required to elicit
withdrawal to >50% of hair applications, from a series of increasing hair pressures
(Chaplan et al., 1994). Threshold was recorded as that established by the series of
increasing pressures - the response to applying decreasing pressures was not
recorded. A minimum of 6 applications of the hair to the foot was used to establish
the withdrawal threshold. A maximum hair of pressure 4830.62 mN/mm was set to
avoid tissue damage. The hair pressures used and their corresponding forces in
grammes are displayed below.













Sensitivity to cold develops de novo in the CCI and lysolecithin models of pain.
Responses to cold were measured by the suspended paw elevation test. Animals were
placed in a Perspex box with an elevated aluminium floor, containing ice-cold (4 °C)
water to a depth sufficient to immerse the hindpaw, but not touch the body of the
animal. Rats were allowed 10 s to acclimatise and then the number of seconds the
animal raised its hindpaw above the water over a 20s period was recorded as the
suspended paw elevation time (SPET). Tests were repeated at 10 minute intervals to
allow recovery of hindpaw temperature between tests.
3.3 Drug administration
Drug effects were assessed by behavioural measurements of threshold to noxious
and innocuous stimuli. A minimum of three pre-drug tests were performed to
produce a mean baseline value. Following drug administration, tests were repeated
every 5 minutes for 60-80 minutes for thermal and mechanical stimulation (measured
in the same experiment) or every 10 minutes for SPET response. An n of 6 rats was
considered sufficient for most drugs. Rats were tested in groups of 3 and thermal and
mechanical values were ascertained at the same time - in other words a thermal test
was performed followed by a mechanical test, every 5 minutes over the time period.
3.3.1 Intrathecal application of drugs
Drugs were administered into the L5/6 intrathecal space of anaesthetised rats in a
volume of 50 pi, using a 1 ml syringe with 25-gauge needle (BD Biosciences,
Oxford, UK). Prior experiments with Pontamine Sky Blue dye (Merck-BDH, UK)
established the correct site of injection. Testing commenced 15 minutes after
injection to allow recovery from anaesthesia: to avoid a false analgesic result and
prevent tissue sensitisation caused by delayed responses. Previous experiments by
our group and others (Garry et ah, 2003a, b Soliman et ah, 2005) found complete
recovery from anaesthetic by 15 minutes.
The following drugs were applied intrathecally: icilin (2.5-200 pM in saline with
0.2% dimethylformamide, DMF), LY 341495 (10-100 pM in saline), UBP 1112 (10-
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200 pM in saline), 2R, 4R-APDC ((2R, 4R)-4-aminopyrrolidine-2,4-dicarboxylate),
300 pM in saline), ACPT-III ((lR,3R,4S)-l-aminocyclopentane-l,3,4-tricarboxylic
acid), 3 mM in saline), AP-4, ((L-(l)-2-amino-4-phophonobutyric acid), 3 mM in
saline), naloxone (0.5 mM in saline), NMDA (75, 600 pM in saline) and ACPC (1-
aminocyclopropanecarboxylic acid, 15, 120 pM in saline), capsaicin (2-5 mM in
saline), resiniferatoxin (10 pM in saline) (all from Tocris Cookson, Bristol, UK), (-)-
menthol (4 mM in saline), cinnamaldehyde (0.5, 1.5 mM in saline) and ruthenium
red (5 pM in saline) (all from Sigma-Aldrich Chemical Co. Ltd, UK) and allicin (0.5
mM in saline with 0.5% DMF) and diallyl disulphide (DADS, 1 mM in saline with
0.5% DMF) (LKT Laboratories Inc., St Paul, MN, USA). Appropriate vehicles based
on 0.9% saline were also tested as controls.
The effect of icilin on thermal and mechanical sensitivity was assessed in nai've
animals and CCI, lysolecithin and CFA rats at the peak of behavioural reflex
sensitisation (assessed by baseline measurement immediately prior to injection). The
effect of icilin on cold hypersensitivity was measured in lysolecithin animals.
Responses to icilin at four different doses (0.125 nmol, 0.5 nmol, 2.5 nmol and 10
nmol) were assessed in CCI animals. Dose-response effects were analysed with
Prism 4 (GraphPad Software Inc.). The effect of the TRPM8 agonist (-)-menthol was
assessed in CCI animals. The effects of icilin co-administered with the p-opioid
receptor antagonist naloxone, the group II mGluR antagonist LY 341495, the Group
III mGluR antagonist UBP 1112, or these antagonists alone were tested in CCI
animals. The effects of LY 341495 and UBP1112 were also tested in naive animals.
The effects of the Group II mGluR agonist 2R,4R-APDC and the Group III mGluR
agonists AP-4 and ACPT-III were assessed in naive, CCI and CFA-injected animals.
The effects of the TRPAl agonist cinnamaldehyde alone or together with icilin were
assessed in naive and CCI animals. The effects of NMDA, NMDA with the glycine
site agonist ACPC, and the NMDA/ACPC combination with icilin were assessed in
naive and CCI animals. The effects of the TRPV1 agonists capsaicin and
resiniferatoxin were assessed in naive and CCI animals but not pursued. Intrathecal
icilin (10 nmol) was also tested in the formalin model.
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3.3.2 Topical application of drugs
The effects of topically administered drugs were investigated by applying drug
solution to the hindpaws for a 5 minute period, followed by sensory testing for 60-80
mins. This was accomplished either by placing rats in a 1 cm deep waterbath
containing drug solution, or by very lightly anaesthetising rats and immersing
hindpaws in small tubes (modified 15 ml centrifuge tubes) containing 5 ml volume of
drug solution. Drug solution was maintained at 30°C to avoid temperature effects.
The waterbath was designed to allow the rat to be placed in a shallow volume of
drug, such that a standard volume of 400 ml covered the hindpaws but did not wet
the body of the rat, and to give sufficient space for the rat to move reasonably freely.
Topical application by immersing hindpaws in small tubes was carried out when
higher concentration of drug made a 400 ml volume prohibitively expensive.
Anaesthetic was maintained at the minimum required and control experiments with
vehicle demonstrated that anaesthetic was not sufficient to affect sensitivity.
Following removal from the waterbath the rats were rinsed and loosely dried which
should have removed most of the drug. No licking or washing behaviour (beyond
what is normally observed) was observed following drug administration.
Sensory testing commenced 5 minutes after waterbath application, or 15 minutes
following application if anaesthetic was administered. The effects of icilin (2.5 - 500
pM in water with 0.2% DMF) administered as a waterbath were investigated in CCI
and nai've animals. The effects of higher doses of icilin (1 mM-5 mM in vehicle of
45% DMF in 0.2% aqueous Tween 20) were measured following administration in
small foot-tubes. The effects of topical footbath (-)-menthol (4 mM in 25-80%
ethanol) and its stereoisomers isomenthol and (+)-menthol (4-16 mM in 25-80%
ethanol) were assessed in CCI and nai've animals. The effects of cinnamaldehyde (1.5
mM in water, as footbath), and cinnamaldehyde with icilin (80 pM in 0.2% DMF)
were assessed in CCI and naive animals. The effects of icilin (80 pM as footbath)
were further assessed in CCI animals that had undergone antisense and mis-sense
treatment for knockdown of TRPM8, and animals which had recovered from this
treatment. The effects of icilin applied immediately following intrathecal injection
with either LY 341495 or with UBP 1112 were also investigated in CCI animals. All
appropriate vehicles were tested.
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The effects of paw immersion at different temperatures (10-22°C water for 5 min)
on CCI rats were assessed by mechanical testing only. Testing was carried out
immediately after removal of animal from the waterbath, and repeated every minute
for 5 minutes. Actual skin temperatures were measured by subcutaneous thermistor
probe in an anaesthetised rat and were found to equilibrate to around 0.5°C above
bath temperature. The effect of a 16°C immersion on CCI rats following intrathecal
administration ofLY 341495 or UBP 1112 was also measured.
3.4 Western blot analysis of proteins
3.4.1 Tissue removal and processing for Western blot
DRG and spinal cord tissue from L4-L6 was collected from live animals under
deep anaesthesia. A laminectomy was performed to expose the spinal cord, and
tissue was dissected out. Spinal cord from injury models was hemisected into
ipsilateral and contralateral sections. Spinal cord tissue samples were kept on ice
before processing as quickly as possible. To minimise degradation of DRG tissue,
DRG were collected onto ice-cold foil, weighed, and homogenised directly.
For preparations of whole lysates, tissue was homogenised in 20 volumes of
Laemmli lysis buffer (85% Tris buffer (tris-hydroxymethylaminoethane, 50 mM, pH
7.4, Sigma Chemical Co., UK), 5% mercaptoethanol (Sigma Chemical Co., UK), and
2% sodium dodecyl sulphate (SDS, Sigma Chemical Co., UK)), heated to 70°C for 5
minutes, cooled, aliquoted and stored at -40°C. In some conditions samples were
treated with Laemmli buffer containing 6 M urea and 2 M thiourea.
For preparations of crude particulate fractions, spinal cord or DRG tissue was
homogenised using a Y-stral homogeniser in 20 volumes of ice-cold Tris buffer (50
mM, pH 7.4, Sigma Chemical Co., UK) containing 1% protease inhibitor cocktail III
(Calbiochem, Merck Biosciences Ltd., Nottingham, UK) and spun at 2000 rpm for 5
minutes at 4°C to remove cell debris. The supernatant was decanted and re-
centrifuged at 11000 rpm for 45 minutes at 4°C. The supernatant cytosolic fraction
was decanted, and 15% of this volume of SDS/mercaptoethanol 2:1 mixture was
added. The crude particulate fraction pellet was re-suspended in 1/10 of the original
fraction volume of Laemmli lysis buffer.
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Tissue from CCI, CFA, naive, mis-sense and antisense oligonucleotide-treated,
and lysolecithin-treated animals was processed.
3.4.2 Western blot procedure
Western blotting was used to detect changes in protein levels in DRG or spinal
cord tissue from pain models and naive models.
Proteins were separated by SDS-PAGE (sodium dodecyl sulphate-polyacrylamide
gel electrophoresis) using the NuPage XCell SureLock™ Minicell gel
electrophoresis system (Invitrogen, Paisley, UK). Samples (5-8 pi) were mixed with
1 pi loading buffer (0.04%w/v bromophenol blue in glycerol) and loaded into wells
on either 3 - 8% Tris-Acetate or 4 - 12% Bis-Tris NuPage gels (Invitrogen, Paisley,
UK). Pre-stained standard molecular weight proteins (SeeBlue Plus, Invitrogen,
Paisley, UK) were run alongside as a guide. Samples were electrophoresed using
appropriate running buffers (Tris-Acetate buffer or MOPS running buffer, NuPage,
Invitrogen, UK) and a 200 V potential. Proteins were transferred to a polyvinylidene
difluoride Immobilon-PSQ membrane (Millipore, Watford, UK) at 30 V in transfer
buffer (5% NuPage transfer buffer, Invitrogen, UK, 10% methanol). Efficacy of
transfer and protein loading was assessed by staining membranes with Coomassie
blue (0.1% in 30% methanol, 10% ethanoic acid, GE Healthcare Ltd., UK) and
destaining in 30% methanol/10% ethanoic acid.
Membranes were incubated in 5% Marvel in phosphate-buffered saline (PBS; 0.1
M, pH 7.4) to block non-specific activity either for 2 hours at room temperature or
overnight at 4 °C. Membranes were then washed and incubated with rabbit
polyclonal antibodies specific to TRPM8 (1:1000 - 1:100; Abeam pic, Cambridge,
UK), TRPV1 (1:100; Chemicon International Ltd, Harrow, UK), TRPA1 (1:50;
Abeam), mGluR7 (1:100; Upstate), mGluR2/3 (1:500; Chemicon), mGluR4 (1:60;
Zymed), mGluR3 (1:500; Abeam) or a mouse monoclonal antibody to
glyceraldehyde -3-phosphate dehydrogenase (GAPDH, 1:750; Chemicon), either for
90 minutes at room temperature or overnight at 4°C. Membranes were washed and
incubated with peroxidase-linked secondary antibodies: goat anti-rabbit (1:5000 -
1:2500; Chemicon) or goat anti-mouse (1:10000; Chemicon) for 1 hour at room
temperature. Antibodies were made up in 2% bovine serum albumin (BSA) in 0.1M
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PBS containing 0.1% Tween-20. Staining was detected by peroxide-linked
chemiluminescent substrate and film development (ECL; Cell Signalling, MA, USA,
hyperfilm; GE Healthcare UK Ltd., Bucks, UK). Densitometry analysis of protein
bands to quantify staining was performed using the ScanAnalysis program (Biosoft,
Cambridge, UK). Note: Where two concentrations of antibody are listed, this was
due to differences in strength between two different batches supplied. Antibody
conditions were optimised for each antibody and for each batch.
3.4.3 Preparation of cell membranes for antigen pre-absorption controls
To identify whether the anti-TRPM8 antibody was indeed specific to TRPM8 a
pre-absorption control was carried out by incubating antibody with membranes taken
from TRPM8-transfected cells, prior to use on immunoblots.
3.4.3.1 Cell culture
COS 7 cells were continuously cultured in Dulbecco's modified Eagle's medium
(DMEM; Gibco, Invitrogen, Paisley, UK), supplemented with 10% normal calf
serum (Gibco), 100 units/ml penicillin (Gibco) and 100 pg/ml streptomycin (Gibco)
and kept at 37°C in a 5% CO2, 95% O2 humidified environment.
In order to passage or plate out cells, 20 ml Hank's Buffered Saline Solution
(HBSS) (Gibco) was applied to the cell surface and left for 20 sees. The HBSS was
then removed and the cells were exposed to 10 ml Trypsin -EDTA (trypsin 0.5g/l,
EDTA 0.2g/l, NaCl 0.85g/l (Gibco). After one minute this was aspirated off and the
cells were incubated at 37°C for 5 minutes. Following incubation, the cells were
resuspended in the appropriate medium (as above) before being passaged into 75 cm2
flasks or 12 well plates (Greiner Bio-One, Gloucestershire, UK).
3.4.3.2 Cell transfection
Cells were grown to 60% confluence, then transfected with human TRPM8 cDNA
in pCMV6-XL4 expression plasmid or empty vector (both OriGene Technologies
Inc., Rockville, MD, USA), using GeneJuice Transfection Reagent (Novagen, Merck
Biosciences, Nottingham, UK), according to the manufacturer's instructions.
GeneJuice reagent was added to the cDNA at a 3:1 ratio for COS 7 cells, and left to
incubate for approximately 15 mins. The medium was removed from the cells and
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replaced with 2% Ultroser G (USG; Pall Biosciences, Portsmouth, Hampshire, UK)
DMEM. The Gene Juice-cDNA complexes were added to the cells in appropriate
quantities. Cells were then grown for 48 hours at 37°C in a 5% CO2, 95% O2
humidified environment.
3.4.3.4 Preparation of membranes
Cells were scraped into ice-cold 0.1M PBS containing 1% protease inhibitor
cocktail III (Calbiochem, Merck Biosciences Ltd., Nottingham, UK) and
homogenised using Ystral homogeniser before centrifuging at 1000 g for 10 min.
The supernatant was then centrifuged at 48,000 g for 30 min and the pellet from this
was resuspended in antibody buffer.
Rabbit polyclonal anti-TRPM8 antibody (Abeam pic, Cambridge) antibody was
added to TRPM8-expressing or control membrane suspensions and rolled at 4°C for
16 h prior to use.
3.5 Immunohistochemistry analysis of protein localisation
3.5.1 Tissue processing for immunohistochemistry
As for Western blot, a laminectomy was performed to expose the spinal cord, and
DRG and spinal cord tissue from L4-L6 were dissected out. Tissue was collected in
OCT compound (Cell Path pic. Powys, Wales, UK) and fast-frozen in isopentane
suspended in liquid nitrogen or dry ice before storing at -80°C prior to cryostat
sectioning.
3.5.2 Immunohistochemistry procedure
Immunohistochemistry was used to compare protein levels in nerve-injured and
nai've animals, and also to examine co-localisation of particular proteins.
15 pm tissue sections were cut on a cryostat at temperatures of -20°C for DRG and
-14°C for spinal cord, and thaw-mounted on poly-L-lysine slides (Merck-BDH, UK).
Slides were encircled with hydrophobic barrier pen (ImmEdge, Vector Laboratories,
CA, USA). Slides were blocked for 1 hour at room temperature in block containing:
10% normal goat serum (Vector Laboratories, CA, USA), 4% fish skin gelatin
(Sigma Chemical Co., UK), 0.2% Triton X-100 (Sigma Chemical Co., UK) and 0.1
M PBS. Slides were incubated overnight with appropriate primary antibodies in
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buffer (4% normal goat serum, 4% fish skin gelatin, 0.2% Triton X-100, 0.1 M PBS).
Antibodies used were: rabbit polyclonal anti-TRPM8 (Phoenix Peptides, 1:450),
mouse monoclonal anti-NF-200 (Sigma, 1:1000), mouse monoclonal anti-peripherin
(Chemicon, 1:250), guinea-pig anti-TRPVl (Chemicon, 1:50), rabbit anti-mGluR7
(Abeam pic, 1:50). Slides were washed, incubated with appropriate secondary
antibodies: goat anti-rabbit AlexaFluor 568 1:750, goat anti-mouse AlexaFluor 488,
1:500, or goat anti-guinea-pig AlexaFluor 647 1:500 (all Molecular Probes, OR,
USA) in the same buffer excluding Triton X-100. Nuclei were stained with To-Pro-
3-iodide nuclear stain (1:1000, Molecular Probes, OR, USA). Slides were
coverslipped using Vectashield (Vector Laboratories, USA) and sealed with nail
varnish. Concentrations and washing conditions were optimised for each antibody.
Sections were visualised under a Leica TCSNT confocal microscope (Leica
Microsystems GMBH, Germany). Image analysis was performed with Image Tool
software (UTHSCSA Image Tool Version 3.0) and images prepared using Adobe
Photoshop. Cell counts were performed on five to eight randomly selected DRG
sections (separation of 100 pm) from each of three animals in each experimental
group being analysed, and only neurons with clear nuclei were counted. Fluorescence
intensity in spinal cord sections was assessed with Image Tool software and
compared between ipsilateral and contralateral dorsal horns, from at least 5 sections
from each of three animals in each experimental group to give a rough estimate of
ipsilateral-contralateral differences.
3.5.3 Antigen nre-ahsorption control
Specificity of the antibody against TRPM8 (Phoenix Peptides, CA, USA) was
assessed by pre-incubating with the peptide (656-680; Phoenix Peptides, CA, USA),
which was dissolved at a stock concentration of 1 mg/180 pi in PBS, and used at a
ratio of 5 pg peptide: 1 pg antibody, by rolling at 4°C for 16 hours. Control aliquots
were treated with PBS alone.
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3.6 Electrophysiological analysis
3.6.1 Peripheral recordings of saphenous nerve afferents
Recordings of saphenous nerve were made in naive animals (n=7) and from
animals treated with antisense or mis-sense oligonucleotides to TRPM8 over a period
of 4-5 days. Rats were anaesthetised with 25% urethane intraperitoneally
(0.6ml/100g) and the saphenous nerve was exposed and dissected from its associated
vein and artery. Further dissection under liquid paraffin enabled the identification of
afferent preparations comprising a small number of units. The dissected afferents
were placed over a bipolar recording electrode and the whole nerve preparation was
submerged in liquid paraffin. The hindpaw of the treated animal was secured to a
footplate using plaster of Paris coated gauze and the receptive field of the afferent
preparation was identified by the induction of impulse activity via gentle brushing of
the hindpaw. The electrophysiology apparatus was set up as follows: afferent
activity, detected by the bipolar recording electrodes, was amplified using an AC
coupled differential amplifier (3160, Digitimer Ltd.) with a band width setting of 80
Hz to 2.5 kHz. Shapes and latencies of individual impulses were identified using the
storage facility on the D13 oscilloscope (Tektronix Inc.) and single frame or
overlapping multiple frames converted to TTL (transistor-transistor logic) pulses
using a spike processor (D130, Digitimer Ltd.) which was connected to a second
oscilloscope with audio display and to the MacLab Chart programme (version 3.2).
Conduction velocities were measured using electrical excitation of receptive fields
with a bipolar needle stimulating electrode. A Digitimer D100 (Digitimer Ltd.)
triggered an isolated stimulator (Mark IV, Lectromed Ltd.) to deliver square-wave
pulses (0.5-1.0 milliseconds, 0.1-100 V) at levels selected to be just above threshold
for few-unit preparations via the stimulating electrodes. The conduction velocity of
single identified afferent fibres was determined using bipolar electrodes and the
peripheral stimulus technique (Iggo, 1958). An electrical stimulus was delivered to
the peripheral receptive field and any resulting action potential discharge was
recorded from the nerve preparation. The distance between stimulating and recording
electrodes was measured and the time taken for a spike to reach the recording
electrode was measured by counting the time between the stimulating potential and
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peak action potential on the oscilloscope. Following isolation of few-unit
preparations, icilin (200 pM in 0.2% DMF), (-)-menthol (4 mM in 25% ethanol),
resiniferatoxin (1 mM in ethanol) or vehicles alone were applied to the hindlimb
receptive fields and neuronal responses recorded using the Chart programme. The
firing of individual neurons was counted by reading from the Chart recording over a
30 second time-period, and thus the firing rate was calculated. One reading was taken
from the background (pre-drug) firing. Three readings were taken following drug
application, at what was deemed to be the peak period of firing (or from equivalent
times in animals which did not respond to the drug) and the mean calculated, and
three readings were taken from the recovery period and the mean calculated.
3.6.2 Central recordings of single dorsal horn neurons
Recordings of spinal dorsal horn neurons were made in CCI animals. Following
initial induction with halothane, the jugular vein and trachea were canulated and
intravenous anaesthetic delivered: a-chloralose (0.6 mg/kg, Acros Organics Ltd.,
Belgium) and urethane (1.2 mg/kg, Sigma Chemical Co., UK), with supplementary
doses of chloralose (10 mg/ml) throughout the experiment as required. Core body
temperature was maintained at 37-38°C by means of a thermostatically controlled
heated blanket. The animal was placed in a stereotaxic frame, and the thoracolumbar
spinal column was supported using three pairs of swan-necked clamps. A
laminectomy was performed at L2-L5, and agar (2% in saline at 37°C) was delivered
over the exposed cord to increase mechanical stability. Above the recording region
the agar and spinal cord dura were removed and liquid paraffin poured over.
Extracellular recordings were made from single multireceptive neurons in laminae I-
IV through the centre barrel of a seven- barrelled glass microelectrode filled with 4
M saline (tip-diameter 4-5 pM, DC resistance 5-8 Mf2). Recordings were made at
depths of 0 - 1000pm from the spinal cord surface as monitored by the microdrive
reading. The output from the electrode was filtered using a pre-amplifier and
magnified xlOOO using a second pre-amplifier. The output from the second pre¬
amplifier passed both to an oscilloscope (Tektronix), allowing monitoring of cellular
activity, and to a spike processor (Digitimer 130) which digitised the signal. Spike
processor output was sent via a 1401 converter to a computer, where it was recorded
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and analysed using the Spike2 programme (version 3.2, CED, UK). Sustained firing
was recorded as the number of spikes fired integrated over 1 s bins, plotted against
time. The receptive fields of hair-follicle innervated neurons on distal hindlimb were
identified by an innocuous brush stimulus and multireceptivity established by
response to noxious pinch. A motorised rotating brush applied to the receptive field
was then used to continuously stimulate neuronal firing. Icilin (200 pM in water with
0.2% DMF) or vehicle (0.2% DMF) was then applied peripherally (via a drug-soaked
gauze patch) to part of the receptive field. This part of the receptive field was
immediately adjacent to the rotating brush stimulus - obviously it was impossible to
simultaneously stimulate with rotating brush and apply drug to the same area, so the
drug was applied to the immediately adjacent area. The effects on neuronal responses
were recorded and analysed using the Spike2 programme (Version 3.2, CED, UK).
The mGluR antagonist UBP 1112 (200 pM in water, pH 8.5), and control saline (1 M
saline, pH 8.5) were ionophoresed from the side barrels of the electrode using
currents of between 20 nA and 80 nA (Neurophore BH2 ionophoresis system,
Medical Systems, Great Neck, NY) to measure effects on neuronal response to icilin.
3.7 Statistics
Data was analysed for statistical significance using Sigmastat software (version
2.03). All data is stated as mean ± standard error of the mean (SEM) and p values
<0.05 considered significant. Parametric statistical tests were used to analyse data
generated from the Flargreaves' thermal test. Differences in thermal sensitivity
between the paw ipsilateral to nerve injury and the contralateral paw were analysed
using Student's t-test. Effect of drug treatment was analysed by One-Way ANOVA
followed by Dunnett's post-hoc multiple comparisons test. The equivalent non-
parametric tests for mechanical sensitivity were Wilcoxon rank test for ipsilateral:
contralateral differences, and Friedman Repeated Measures ANOVA followed by
Dunn's test for drug effects. Western blot densitometric values were compared with
the Wilcoxon test, immunohistochemistry cell counts were analysed by One-Way




4.1 The development of sensitisation in models of chronic pain
Sensitivity of behavioural reflexes to noxious thermal, graded mechanical and cold
stimuli was measured to assess the degree of sensitisation in animal models of
chronic pain. The models used were the chronic constriction injury (CCI) model of
neuropathic pain, the lysolecithin model of demyelination-induced pain, and a model
of chronic inflammatory pain generated by injecting Complete Freund's Adjuvant
(CFA) into the hindpaw; the timecourses of behavioural sensitisation in these models
are shown in Figure 4.1.
Figure 4.1a-c shows the timecourse of behavioural sensitisation following CCI.
Significant sensitisation of ipsilateral paw responses to thermal and mechanical
stimuli, and de novo development of withdrawal reflexes to 4°C cold were reliably
induced following CCI, with no effect on contralateral paw values. Sensitivity
peaked between days 9 to 17, and further experiments (such as drug testing,
biochemistry or electrophysiological recordings) were carried out in this period.
Figure 4.1 d-f shows the timecourse of behavioural sensitisation in the lysolecithin
model. As with the CCI model, there was sensitisation of ipsilateral paw responses to
thermal and mechanical stimuli, and de novo development of withdrawal reflexes to
4°C cold, with no effect on contralateral paw values. Sensitivity peaked between
days 4 to 10, when further experiments were carried out.
Figure 4.1 g-i shows the timecourse of behavioural sensitisation following injection
of CFA into one hindpaw. The ipsilateral paw showed significant sensitisation of
responses to thermal and mechanical stimuli, as was expected, which peaked
between 24 and 48 hours. There was also a small trend towards sensitisation of
contralateral thermal responses, which was significant at some timepoints, and a
slight, non-significant lowering of contralateral mechanical threshold. To further
investigate these effects, saline injections were carried out as a further control, and
these had no discernible effect on behavioural thresholds. Therefore the small
sensitisation of contralateral thermal responses observed in this study following CFA
appears to represent a small, but significant effect of CFA treatment. This could be
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due to CFA entering the bloodstream following injection and becoming systemic.
Alternatively, it could represent a contralateral effect of the ipsilateral treatment.
Contralateral sensitisation has been observed in other pain models such as the PNL
(Seltzer et ah, 1990), and SNI (Erichsen & Blackburn-Munro, 2002) models of
neuropathic pain. These effects are specific to the area of sciatic innervation,
suggesting that the contralateral effects are not mediated by humoural mechanisms
but must be mediated by a more specific mechanism. Dorsal horn commissural
neurons connect homologous regions of the spinal cord (Szentagothai, 1964), and
electrical stimulation of primary afferents terminating in the superficial dorsal horn
can affect the responses of contralateral dorsal horn cells, suggesting that
commissural connections do indeed have a functional role (Fitzgerald, 1983), and
could thereby mediate contralateral changes pain models. The effect observed in the
CFA model could reflect these connections between different sides of the spinal
cord.
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Figure 4.1 Timecourse of sensitisation in models of chronic pain
a, b, c) Timecourse of sensitisation following CCI. Behavioural data show (a): paw
withdrawal latency (PWL; s) to a noxious thermal stimulus, (b): paw withdrawal
2 ...threshold (PWT; mN/mm ) to graded mechanical stimuli and (c): suspended paw
elevation time (SPET; s) for a 20 s exposure to 4 °C water. Data show pre-surgery
baselines and measurements taken up to 20 days following CCI, mean ± SEM, n=6
animals. Ipsilateral paw (O) values show development of behavioural sensitisation
with little effect on contralateral (■) paw values.
* indicates significant (p<0.05) ipsilateral-contralateral differences, as measured by
Student's t-test for thermal data, and Wilcoxon test for mechanical/SPET data;
t indicates significant (p<0.05) difference from pre-surgery baseline values, as
measured by One-Way RM ANOVA followed by Dunnett's post-hoc test for thermal
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d, e, f) Timecourse of sensitisation following lysolecithin application to the sciatic
nerve. Behavioural data show (d): paw withdrawal latency (PWL; s) to a noxious
thermal stimulus, (e): paw withdrawal threshold (PWT; mN/mm ) to graded
mechanical stimuli and (f): suspended paw elevation time (SPET; s) for a 20 s
exposure to 4 °C water. Data show pre-surgery baselines and measurements taken up
to 15 days following lysolecithin treatment, mean ± SEM, n=6 animals. Ipsilateral
paw (O) values show development of behavioural sensitisation with no consistent on
contralateral (■) paw values.
* indicates significant (p<0.05) ipsilateral-contralateral differences, as measured by
Student's t-test for thermal data, and Wilcoxon test for mechanical/SPET data;
t indicates significant (p<0.05) difference from pre-surgery baseline values, as
measured by One-Way RM ANOVA followed by Dunnett's post-hoc test for thermal
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g, h, i) Timecourse of sensitisation following injection of CFA (g, h) or saline (i) into
the hindpaw. Behavioural data in (g) and (i) show paw withdrawal latency (PWL; s)
to a noxious thermal stimulus, (h) shows paw withdrawal threshold (PWT; mN/mm2)
to graded mechanical stimuli. Data show baseline values and measurements taken up
to 48 hours following injection of CFA or saline to right hindpaw, mean ± SEM, n=6
animals. Ipsilateral paw (O) values show development of behavioural sensitisation
following treatment with CFA but not saline, with limited effects on contralateral (■)
paw values. Cold allodynia was not observed after CFA.
* indicates significant (p<0.05) ipsilateral-contralateral differences, as measured by
Student's t-test for thermal data, and Wilcoxon test for mechanical data
f indicates significant difference (p<0.05) from pre-injection baseline values, as
measured by One-Way RM ANOVA followed by Dunnett's post-hoc test for thermal
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4.2 TRPM8 activation as a strategy to investigate the molecular mediation of
cooling-induced analgesia
4.2.1 Rationale
The TRPM8 receptor is a good candidate for a molecular mediator of analgesia
produced by innocuous cooling, as it is activated by innocuous cold temperatures,
and is expressed in sensory neurons. (For a fuller discussion, see Introduction section
1.26). The role of this receptor in cooling-induced analgesia was investigated by
examining the effect of TRPM8 activation on behavioural reflex sensitivity in awake,
behaving animals. The CCI model of neuropathic pain was used as the principal
model of a sensitised pain state, and behavioural reflex thresholds to noxious thermal
stimuli (Hargreaves' test) and punctate mechanical stimuli (Von Frey filaments)
were measured.
4.2.2 Chemical activation of TRPM8
Temperature stimuli may activate other transduction mechanisms in addition to
TRPM8 and can produce additional physiological effects, such as cold-induced
vasoconstriction. Therefore the effect of TRPM8 activation was initially investigated
using chemical agonists. The two best-characterised TRPM8 agonists are menthol
and icilin. These compounds are structurally unrelated: icilin is a 1,2,3,6-
tetrahydropyrimidine-2-one (Wei, 1983), whereas menthol is a cyclic alcohol. Both
structures are shown in Figure 4.2. Icilin was our first choice agonist, as it is the
TRPM8 agonist with the highest potency and efficacy (Behrendt et al., 2004;
McKemy et al., 2002). Of the various menthol stereoisomers, (-)-menthol has the
highest potency (Bandell et al., 2006; Behrendt et al., 2004). Efficacy and potency
data for icilin and menthol are shown in Table 4.1.
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Figure 4.2: Structure of (-)-menthol (left-hand side) and icilin (right-hand side).
Drug Efficacy as % Icilin Effect EC5o(mM)
Icilin 100 0.2 ± 0.1
(-)-menthol ~71 ± 2 4.1 ± 1.3
(+)-menthol -68 ±4 14.4 ± 1.3
Table 4.1: Efficacy and potency data for TRPM8 agonists
Data adapted from Behrendt et al., 2004.
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4.3 Effects of peripheral activation of TRPM8
4.3.1 Topical administration of TRPM8 agonists is analgesic in sensitised pain
states
For the least invasive method of application and to model potential clinical usage,
icilin and menthol were administered topically to the paws by placing awake rats in a
waterbath containing 1 cm deep drug solution, to cover the feet, for a 5 minute
period. Rats were unrestrained to minimise stress, and the waterbath was large
enough to allow movement. Drug solution was maintained at 30 °C approximate skin
temperature) to avoid any effects of local temperature changes. The ability of both
icilin and menthol to exert effects when applied topically is known (Wei, 2003, Wei,
2005, Williams & Barry, 2004), so topical application is a sensible strategy.
After 5 minutes, icilin (80 pM) caused a striking reversal of the behavioural reflex
sensitisation to thermal and mechanical stimuli that occurs ipsilateral to CCI. Icilin
produced a significant increase from ipsilateral baseline values (p<0.05) and
abolished ipsilateral-contralateral significant differences for up to 25 minutes
following the application period. There was a mean percentage reversal of ipsilateral-
contralateral differences of 82.4 ± 4.3% for thermal and 59.3 ± 5.2% for mechanical
values (mean ± SEM, calculated over 10-25 minutes following drug
administration). In contrast, there was no effect on the sensitivity of the uninjured
contralateral paw (Figure 4.3a). Vehicle (0.2% DMF in water) had no effect on either
paw, which demonstrates that the effect was not due to either vehicle or to the testing
procedure (Figure 4.3b). To further investigate the effect of icilin, experiments were
carried out using different concentrations of drug, under the same conditions.
Concentration-dependent effects of icilin on ipsilateral thermal and mechanical
analgesia were observed between 2.5 to 500 pM, as shown in Figure 4.3c.
I then investigated whether the same effects were produced by topical application
of a second TRPM8 agonist, menthol. I initially used (-)-menthol, as this is suggested
to have the highest potency at TRPM8 of the menthol isomers, and found that topical
application of (-)-menthol (1R, 2S, 5R-(-)-menthol, 4 mM in water with 25% or 80%
ethanol) produced a similar reversal of ipsilateral sensitisation in CCI animals
(Figure 4.3d, shown for 80% ethanol vehicle), with no effect of either vehicle. As
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with icilin, the analgesic effects appeared somewhat more marked on thermal than
mechanical responses, although it is difficult to directly compare the results from
these different tests with each other as they represent different types of data
(parametric and non-parametric). The stereoisomers isomenthol (IS, 2R, 5R-
menthol) and (+)-menthol (IS, 2R, 5S (+)-menthol) are slightly less potent agonists
of TRPM8 - for EC50 data see Table 4.1 (Bautista et ah, 2006; Behrendt et ah, 2004).
Initial tests of isomenthol at a concentration of 4 mM in 25% ethanol vehicle
produced no significant effects on behavioural thresholds (data not shown), and
therefore higher concentrations were tested. At concentrations of 8 mM and 16 mM,
isomenthol and (+)-menthol also produced a reversal of sensitised responses,
although to a lesser extent than (-)-menthol (Figure 4.3e). Solubilisation of these
higher concentrations required a vehicle with a higher percentage of ethanol (80%)
and therefore the 4mM (-)-menthol concentration was repeated with this new vehicle,
and is shown as such in Figure 4.3d in order to compare with the data on (+)-menthol
and isomenthol.
Neither icilin (Figure 4.3f) nor (-)-menthol (data not shown) had any effect in
naive animals, in agreement with the lack of effect on contralateral values. This
suggests that the analgesic effect produced by these compounds is specific to the
sensitised state.
4.3.2 Topical application of high doses of TRPM8 activators produces
hyperalgesia
To further examine the concentration-response effect of icilin, the effects of
topical application of much higher concentrations were examined, testing
concentrations of up to 5 mM icilin. It was not possible to use the large 400 ml
volumes used for waterbath application with such high concentrations, and therefore
a different method was used. Rats were lightly anaesthetised, and the drug applied in
small foot-tubes (modified 15 ml centrifuge tubes) which covered the paw without
constricting it. As before, drug was maintained at approximately 30°C for 5 minutes.
There was no effect of vehicle applied in this way, demonstrating that there was no
lasting effect of the vehicle or the anaesthetic procedure. 5 mM icilin produced
increased reflex sensitivity, both ipsilateral and contralateral to CCI and in naive
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animals (Table 4.2), that was statistically significant in mechanical and (after a
delay) thermal tests. 2.5 inM icilin produced a trend towaids sensitisation, although
this was not significant, whereas 1 mM had no effect. This hyperalgesic effect was
distinct from the analgesia produced by low concentrations of icilin, as it was not
specific to a sensitised state and may be due to weak interaction of the drug with
other targets or non-specific actions.
4.3.3 TRPM8 activators are only effective when applied to the area of injury
To investigate whether it is necessary that TRPM8 activators be applied directly
to the area innervated by the injured nerve in order to have an effect, rather than to
any area of the skin, I examined the effect of applying icilin only to the contralateral
paw in CCI animals. Icilin (80 pM in water with 0.2% DMF) was topically applied in
the small foot-tubes used for application of high doses, but was only applied to
contralateral paw. There was no significant effect of drug on either ipsilateral or
contralateral behavioural reflex sensitivity: mean ± SEM percentage reversals of
ipsilateral-contralateral differences, calculated over 15-30 min following application,
were -1.2 ± 8.6% for thermal and 0.0 ± 0.0% for mechanical values. In broad terms
this result shows that in order for topical icilin to have an effect, it must be applied to
the area from which sensitisation originates.
4.3.4 Activation of TRPM8 by cool temperatures produces mechanical analgesia
To investigate whether temperature activation of TRPM8 produced analgesia, I
investigated the effects of paw immersion in waterbaths at temperatures from 10-
22°C for 5 minutes. Only mechanical thresholds were measured, as the physical
cooling of the paw would obviously interfere with the effectiveness of the heat
stimulus used in the Hargreaves' test. The same procedure as waterbath
administration of icilin was followed using water at different temperatures. Initial
experiments which performed the first measurement 5 minutes after removal from
the waterbath saw no change in mechanical threshold. However, further experiments
which measured mechanical threshold immediately after removal from the
waterbath, observed a statistically significant mechanical analgesia ipsilateral to CCI
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after immersion in temperatures between 16 - 20°C, which was fully recovered by 5
minutes post-waterbath. This is shown in Figure 4.3g, using measurements taken
immediately after removal from the waterbath. Therefore temperatures in the range
of TRPM8 activation do produce a mechanical analgesia, supporting our findings
with chemical agonists, and suggesting a TRPM8-mediated mechanism of analgesia.
The reason for the much shorter effect of temperature is probably the recovery of
local skin temperature, and resultant "switching off' of the TRPM8 receptor,
whereas chemical agonists that penetrate the skin can exert a more prolonged
activation of TRPM8.
Recordings from a subcutaneous thermistor probe in anaesthetised animals showed
that deep skin temperatures were approximately 0.5 °C above bath temperatures after
5 minutes in similar conditions. This demonstrates that the bath temperature in these
experiments does approximate to the subcutaneous temperature, although the
stronger blood flow in unanaesthetised animals will probably result in higher deep
skin temperatures in the unanaesthetised state.
In contrast to the effect of temperatures between 16 and 20°C, immersion
temperatures below 14°C elicited withdrawal reflexes of the ipsilateral paw for the
duration of the immersion period, in agreement with the temperature range for
noxious cold sensation (Chery-Croze, 1983; Chen et ah, 1996; Wolf& Hardy, 1941).
4.3.5 Topical icilin activates a subnopulation of slowly conducting afferents
Icilin is expected to activate TRPM8-expressing afferents. To investigate this, in
vivo recordings of saphenous nerve afferents following topical application of icilin
were carried out. The nerve was dissected to produce small-number preparations of
afferents, with conduction velocities of up to 2.6 ms"1 - representing C- and A8-fibre
afferents (Harper & Lawson, 1985). Small numbers of fast-conducting innocuous
mechanosensitive afferents (presumed large A fibres) were present in each
preparation; these were not analysed but were used to identify the receptive field area
of the preparation by response to an innocuous brush stimulus. Drug or vehicle was
applied to the receptive field via a soaked gauze patch.
Icilin (200 pM in water with 0.2% DMF) applied to the receptive field caused a
significant increase in firing frequency in approximately 21.6% (40 out of 185) of
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recorded fine afferents with a mean 7-fold increase in firing frequency from baseline
of 4.5 ± 2.5 spikes per minute to 31.6 ± 3.4 spikes per minute (p<0.05, One-Way
ANOVA on Ranks), and a mean time to peak effect of 3.3 ± 0.5 minutes. The mean
time to peak effect of icilin is consistent with the onset of behavioural analgesia
observed within 5 minutes of icilin application. Recovery was consistently observed,
and similar results were obtained from both hairy and glabrous skin. A typical
recording is shown in Figure 4.3i. There was no discernible effect of vehicle, as
shown in Figure 4.3h indicating that the activation of afferents is specific to the drug.
Icilin effects were apparent for up to 20 minutes following application of the icilin-
soaked gauze patch. The effect of icilin on TRPM8 channels in vitro, where icilin
activation is followed by extensive desensitisation (Andersson et al., 2004; Chuang et
al., 2004), does therefore not appear to translate to a similar rapid desensitisation of
afferent neuron firing in vivo. The majority of afferents activated by icilin showed
conduction velocities <2.2 ms"1, indicating that these were C fibres (Harper &
Lawson, 1985). Only 5% showed higher conduction velocities, and, the highest
conduction velocity recorded was 2.6 ms" , which is at the lower end of the A5 fibre
conduction velocity range, described by Harper & Lawson as being between 2.2 to
14 ms"1 (Harper & Lawson, 1985). In order to ascertain whether the effect of icilin
was specific to slowly-conducting afferents, separate recordings were made of fast-
conducting mechanoreceptors. These were identified by conduction velocities of 6.8-
20 ms"1, consistent with Ap and A5 fibres, and by response to innocuous mechanical
brushing and stroking of the receptive field. These afferents were found to be
unaffected by icilin, as shown in Figure 4.3j Therefore icilin appears to
predominantly activate C fibre neurons. A summary of these results is provided in
Table 4.3.
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Figure 4.3 Peripheral TRPM8 activation and moderate cooling are analgesic
following CCI
a, b) Behavioural data from CCI animals show that: (a) topical application of icilin
(80 pM) significantly reversed ipsilateral sensitisation of paw withdrawal responses,
with no effect on contralateral threshold, but (b) topical application of vehicle (0.2 %
DMF in water) had no significant effect on behavioural reflexes.
Graphs show mean ± SEM (from an n of 6 animals) PWL (s) to noxious heat and
PWT (mN/mm ) to graded mechanical stimuli, before and following topical
application (5 min paw immersion in a shallow 30 °C water bath) of icilin or vehicle
to paws.
O: ipsilateral paw values, ■: contralateral paw values. * indicates significant
(p<0.05) ipsilateral-contralateral differences, as measured by Student's t-test for
thermal data, and Wilcoxon test for mechanical data; f indicates a significant
(p<0.05) difference from pre-drug baseline values, as measured by One-Way RM
ANOVA followed by Dunnett's post-hoc test for thermal data, and Friedman
ANOVA on Ranks followed by Dunn's post-hoc test for mechanical data,
c) Concentration-response curve for percentage reversal (mean ± SEM) of ipsilateral
sensitisation produced by topical icilin in CCI animals, for thermal (O) or
mechanical (♦) tests, plotted on a logarithmic scale. Values calculated over 10-15
min following 5 min immersion in water bath containing concentrations of 2.5, 10,
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d) Behavioural data from CCI animals show that topical (-)-menthol (4 mM in water
with 80% ethanol) significantly reversed ipsilateral paw sensitisation, with no effect
on contralateral threshold. The vehicle had no discernible effect on reflex responses
(data not shown).
Graphs show mean ± SEM (n=6) PWL (s) to noxious heat and PWT (mN/mm2) to
graded mechanical stimuli, before and following topical application (5 min paw
immersion in a shallow 30°C water bath) of (-)-menthol to paws.
O: ipsilateral paw values, ■: contralateral paw values. * indicates significant
(p<0.05) ipsilateral-contralateral differences, as measured by Student's t-test for
thermal data, and Wilcoxon test for mechanical data; t indicates a significant
(p<0.05) difference from pre-drug baseline values, as measured by One-Way RM
ANOVA followed by Dunnett's post-hoc test for thermal data, and Friedman
ANOVA on Ranks followed by Dunn's post-hoc test for mechanical data.
e) Reversal of ipsilateral sensitisation by paw immersion in (-)-menthol at 4 mM, and
by higher concentrations of the less potent stereoisomers (+)-menthol and isomenthol
(8 and 16 mM). Values were calculated over 10-25 min following paw immersion
from experiments, f indicates significant differences from pre-drug baseline
(p<0.05).
f) Data from naive animals show that topical application of icilin (80 pM) has no
discernible effect on behavioural reflex thresholds. Graphs show mean ± SEM (from
• • 9
an n of 6 animals) PWL (s) to noxious heat and PWT (mN/mm ) to graded
mechanical stimuli, before and following topical application (5 min paw immersion
in a shallow 30°C water bath) of icilin to paws.
■ : naive paw values, t indicates a significant (p<0.05) difference from pre-drug
baseline values, as measured by One-Way RM ANOVA followed by Dunnett's post-
hoc test for thermal data, and Friedman ANOVA on Ranks followed by Dunn's post-








I I I I I I I I I 1 1 7









1 7 I I I I 7 7 I I I I




















(-)-menthol 4.- . . 4.. ..
isorrenthol - 816 - - - 816 - -
(+)-menthol - - - 816 - - - 816
Topical menthol concentration (mM)
Thermal Mechanical
Naive
icilin (topical) 1 1 1 1 1 r
















g) Behavioural data from CCI animals show the mechanical analgesic effect on
ipsilateral paw of brief (5 min) paw immersion at indicated temperature range.
Graph shows mean ± SEM (n=6) PWT (mN/mm2) to graded mechanical stimuli
measured over 5 min following paw immersion at different temperatures. O:
ipsilateral paw values, ■: contralateral paw values. * indicates significant (p<0.05)
ipsilateral-contralateral differences, measured by Wilcoxon test; f indicates a
significant (p<0.05) difference from pre-immersion baseline, measured by Friedman










h, i, j) Electrophysiological recordings from small-number preparations of saphenous
afferents. (h): shows a recording of C-fibre afferents before and following topical
application of vehicle to the receptive field area, (i): shows an electrophysiological
recording of icilin-responsive C-fibre afferents fibres before, 2 minutes (peak effect)
and 12 minutes (recovery) following topical application of icilin (200 pM) to the
receptive field area; observations typical of 40 similar recordings, (j): shows a
recording of A-fibre afferents before and following topical application of icilin (200






























(MM) NaTve CCI Ipsi CCI Con
Pre-drug
Baseline 15.5 ±0.2 9.7 ±0.2 16.4 ±0.2
15 mins 50 mins 15 mins 50 mins 15 mins 50 mins
0
(vehicle!
15.1 ± 1.2 14.9 ±0.8 9.8 ± 1.1 9.7 ±0.9 15.2 ±0.6 15.1 ± 0.7
1000 15.1 ± 1.2 14.8 ±0.9 16.4 ± 0.8| 8.6 ±0.2 16.1 ±0.5 15.2 ± 0.4
2500 14.9 ±0.3 13.2 ±0.8 16.4 ± 0.9f 8.4 ± 0.6 16.8 ±0.9 15.3 ±0.7
5000 15.3 ± 0.5 13.1 ± 0.7§ 16.7 ± 1.0f 7.2 ± 0.6§ 16.1 ± 0.9 13.4 ± 0.7§
Mechanical PWT (mN/mm2)
Naive CCI Ipsi CCI Con
Pre-drug
Baseline
4830.6 ± 0.0 805.7 ±26.3 4793.6 ± 37.5


















































Table 4.2: Analgesic effects of topically administered icilin against
neuropathic sensitisation revert at very high concentrations to a general
nociceptive effect
Significant effects of drug on reflex responses are indicated: t denotes significant
increase from baseline indicating analgesic effect of icilin, § denotes significant
decrease from baseline values indicating hyperalgesic effects, One-Way RM
ANOVA followed by a Dunnett's test for thermal, Friedman ANOVA on Ranks















































9.2 ±2.4 13.5 ±2.6 - - -
Table 4.3: Summary of afferent recordings following topical icilin application.
* denotes significant difference from baseline in firing frequency (p<0.05, ANOVA on
Ranks).
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4.4 Central administration of TRPM8 activators is analgesic in CCI and in
other chronic pain models
4.4.1 Intrathecal administration of TRPM8 activators is analgesic in CCI
animals
As TRPM8 is present on the central terminals of primary sensory neurons (Baccei
et al., 2003; Tsuzuki et al., 2004; see also Figure 4.5f,) I investigated whether
intrathecal application of TRPM8 activators would also produce analgesia.
200 pM icilin (in saline with 0.2% DMF) produced robust reversal ofCCI-induced
behavioural reflex sensitisation in thermal and mechanical tests. There was a
significant increase from baseline, and reversal of ipsilateral-contralateral
differences, for up to 55 min (Figure 4.4a). An equivalent volume of vehicle (0.9%
saline with 0.2% DMF) had no effect (data not shown). A second TRPM8 agonist, (-
)-menthol, produced similar effects . An initial dose of 25 nmol (-)-menthol (in
saline) produced no discernible effect on thermal or mechanical threshold. Flowever,
a higher dose of 200 nmol (-)-menthol (in saline vehicle), caused a significant
reversal of ipsilateral sensitisation in CCI rats, lasting up to 40 min (Figure 4.4b).
The higher doses of alternative menthol stereoisomers tested topically could not be
tested intrathecally, due to the higher ethanol concentrations of vehicle required to
dissolve these. In conclusion, both menthol and icilin produced significant analgesia
when applied topically and intrathecally. However, because of the higher potency
and efficacy of icilin (Behrendt et al., 2004; McKemy et al., 2002), and the
possibility of additional effects of menthol (Eccles, 1994; Macpherson et al., 2006),
most further experiments used icilin to activate TRPM8.
I then tested for a dose-response relationship, in similar experiments to those
performed topically, using doses of 10, 2.5, 0.5 and 0.125 nmol. Icilin produced
dose-dependent analgesic effects on ipsilateral reflex sensitivity in both thermal and
mechanical tests that were statistically significant at 0.125 nmol and increased to
almost complete reversal of sensitisation by 10 nmol. Figure 4.4c shows the dose-
response curve, plotted on a logarithmic scale. From this graph, the calculated
maximal effects of icilin were similar for thermal and mechanical thresholds (91.6 ±
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9.9 and 82.6 ± 6.8% reversal of sensitisation, respectively), as were ED50 values
(dose for 50% of maximal effect: 0.17 ± 0.02 and 0.31 ± 0.02 nmol, respectively).
4.4.2 Intrathecal icilin is also effective in other chronic pain models
In further experiments it was investigated whether the sensitised behaviours
caused by other pain models were susceptible to icilin-induced analgesia.
Investigation of the CFA model of chronic inflammatory pain required work-up of
this model, to investigate the timecourse of peak sensitivity (as described in section
4.1). The effect of intrathecal icilin (10 nmol in saline) in this model was then
measured, and icilin again significantly reversed behavioural reflex sensitisation
(Figure 4.4d), demonstrating that icilin is an effective analgesic in inflammatory as
well as neuropathic pain states.
Following on from this, the lysolecithin model of demyelination-induced pain was
investigated, which has some similarities to neuropathic pain models, but also
important differences (Wallace et ah, 2003). Because this model represents another,
distinct example of chronic pain, and because demyelination-induced pain states are
associated with abnormal processing of sensory cold (Ochoa & Yarnitsky, 1994), this
was an interesting model in which to further investigate the effects of icilin. This
model was set up and a timecourse established as described in section 4.1, and then
the effect of intrathecal icilin was tested at the period of peak sensitivity. There were
no obvious acute effects of lysolecithin, or any behavioural effects beyond those
reported. Fysolecithin is another name for lysophosphatidylcholine, which has been
identified as a TRPM8 agonist (Vanden Abeele et ah, 2006). Presumably however,
the administration of a high dose of lysolecithin to the outside sheath of the sciatic
nerve primarily causes demyelination of the axons travelling within the nerve, rather
than causing effects on the peripheral TRPM8 receptors. Intrathecal icilin (10 nmol
in saline) significantly reversed reflex sensitisation in this model (Figure 4.4e). This
demonstrates the effectiveness of icilin as an analgesic against a variety of sensitised
pain states, both inflammatory and neuropathic, adding to its potential clinical utility,
and also demonstrates that there is no apparent desensitisation of icilin's analgesic
effect caused by the application of lysolecithin to the nerve. Table 4.4 shows the
mean percentage reversals of ipsilateral sensitisation produced by 10 nmol icilin in
119
the CCI, CFA and lysolecithin models, calculated over 15-30 minutes following
injection. The effect of icilin is strongest in the CCI model and weakest in the CFA
model, but the differences are not substantial (perhaps with the exception of the
relatively poor reversal of CFA-induced mechanical sensitisation).
In further experiments on lysolecithin-demyelinated animals, the effect of icilin on
the SPET test of cold allodynia was measured. Intrathecal icilin (10 nmol)
significantly reduced withdrawal responses to 4 °C cold as measured by the SPET
test (Figure 4.4f). This shows that cold allodynia can also be reversed by TRPM8
activation, thereby distinguishing the function of subpopulations of cold-sensitive
afferents.
As with topical application, intrathecal icilin had no discernible effect in normal
animals - with no injury model performed - (Figure 4.4g), again indicating that the
analgesic effect of icilin is specific to sensitised pain states.
Pain Model
Mean % reversal of
thermal sensitisation
(± SEM)
Mean % reversal of
mechanical
sensitisation (± SEM)
CCI 84.7 ±6.0 76.8 ± 5.3
CFA 66.0 ±7.5 42.6 ±2.8
Lysolecithin 69.2 ± 5.1 63.3 ±6.4
Table 4.4: Reversal of sensitisation by intrathecal icilin (10 nmol) in different
pain models.
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Figure 4.4 Central TRPM8 activation is also analgesic following CCI
a, b) Behavioural data from CCI animals show that intrathecal injection of both (a)
icilin (10 nmol) and (b) (-)-menthol (200 nmol) significantly reversed thermal and
mechanical reflex sensitisation ipsilateral to CCI, with no effect on contralateral
threshold.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
stimulus and PWT (mN/mm2) to graded mechanical stimuli. O: ipsilateral paw
values, ■: contralateral paw values. * indicates significant (p<0.05) ipsilateral-
contralateral differences, as measured by Student's t-test for thermal data, and
Wilcoxon test for mechanical data; t indicates a significant (p<0.05) difference from
pre-drug baseline values, as measured by One-Way RM ANOVA followed by
Dunnett's post-hoc test for thermal data, and Friedman ANOVA on Ranks followed
by Dunn's post-hoc test for mechanical data.
c) Dose-response curve shows the mean percentage reversal ± SEM of ipsilateral
sensitisation produced by intrathecal icilin in CCI animals, for thermal (O) or
mechanical (♦) tests, plotted on a logarithmic scale. Values calculated over 20-35
min following injection with doses of 0.125, 0.5, 2.5 and 10 nmol icilin, with an n of
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d, e, f) Behavioural data show that intrathecal injection of icilin (10 nmol) in (d)
CFA-injected animals, and (e) lysolecithin-treated animals significantly reversed the
thermal and mechanical reflex sensitisation of the ipsilateral hindpaw in both of these
pain models, and the cold allodynia which develops ipsilateral to lysolecithin
treatment.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
stimulus, PWT (mN/mm2) to graded mechanical stimuli, and suspended paw
elevation time (SPET (s) to 4°C cold water over a 20 s immersion. O: ipsilateral paw
values, ■: contralateral paw values. * indicates significant (p<0.05) ipsilateral-
contralateral differences, as measured by Student's t-test for thermal data, and
Wilcoxon test for mechanical data; f indicates a significant (p<0.05) difference from
pre-drug baseline values, as measured by One-Way RM ANOVA followed by
Dunnett's post-hoc test for thermal data, and Friedman ANOVA on Ranks followed






























































g) Behavioural data show that intrathecal injection of icilin (10 nmol) had no effect
in naive animals.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
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4.5 Localisation of TRPM8 in afferents and superficial dorsal horn
4.5.1 Western blot demonstration of TRPM8 presence in DRG and spinal cord
The presence and localisation of TRPM8 in DRG and spinal cord were
investigated by immunoblotting. Tissue was homogenised in Laemmli lysis buffer
and boiled to break non-covalent bonds in protein structures and generate soluble,
linearised proteins, and the resulting homogenate was separated by SDS-PAGE.
Immunoblots were then probed with a rabbit polyclonal antibody raised to TRPM8
residues 278-292 and 1090-1104 (human). Initial experiments separated proteins on a
4 - 12% gradient gel, and resulting immunoblots showed bands at 128 kDa - the
predicted molecular weight of TRPM8 - and further, somewhat weaker bands at
approximately 170, 60 and 50 kDa. These additional bands could represent
breakdown fragments of the TRPM8 protein (or in the case of the 170 kDa band,
breakdown of TRPM8 multimers) or non-specific interactions of the antibody. In
order to improve the immunoblot results, a more rapid homogenisation process was
employed (collecting tissue directly onto ice-cold foil and weighing and
homogenising immediately), in order to decrease protease breakdown of TRPM8 to
fragments. In one trial 6 M urea and 2 M thiourea was included in the lysis buffer to
help break non-covalent bonds; however, there was no effect of such treatment on
the TRPM8 banding pattern, and therefore in all further blots tissue was
homogenised in normal Laemmli buffer. Samples were heated to 70°C rather than
100°C, as higher temperatures can cause aggregation of proteins which contain
significant stretches of hydrophobic amino acids, such as membrane proteins like
TRPM8 (Chemicon online guide to Western blotting). Proteins were separated on 3 -
8% gradient gels, which are designed to give a better separation of higher molecular
weight proteins. Under these conditions, I observed a single, strong band at 128 kDa,
with very much weaker bands at 170, 60 and 50 kDa (Figure 4.5a).
To further assess any importance of these additional bands and to assess antibody
specificity, antigen-pre-absorption and antisense-knockdown controls were carried
out. Both controls were consistent with this antibody specifically recognising
TRPM8 protein at approximately 128 kDa under the conditions used. Pre-incubation
of the antibody with membranes from COS 7 cells transfected with TRPM8
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expression plasmid abolished the band at 128 kDa, whereas sham pre-absorption
with membranes from cells transfected with empty vector did not (Figure 4.5a).
Antisense knockdown was carried out by intrathecal delivery of TRPM8 antisense
oligonucleotide from implanted osmotic minipumps in naive (non-CCI) rats over 5
days to downregulate expression of the TRPM8 receptor protein. Intrathecally
delivered fluorescent-labelled oligonucleotides have been shown to effectively
penetrate the DRG, as soon as 4 hours after initial delivery (Lai et al., 2002); hence
intrathecal delivery is a reasonable method of delivering oligonucleotides to the
DRG. Antisense pre-treatment also resulted in almost complete knockdown of the
128 kDa band (Figure 4.5a), whereas mis-sense control oligonucleotide was
ineffective (see below). The faint bands, at 50 and 60 kDa at least, remained present
in each case and so are likely to represent non-specific interactions of the antibody
under these conditions. The housekeeping enzyme GAPDH (36 kDa), used as a
loading control, was evenly present in each lane. As a further control, it was shown
that the related sensory TRP receptor, TRPV1, was unaffected by treatment with the
TRPM8 antisense reagent (Figure 4.5a).
In further support of these results, an alternative antibody, primarily used for
immunohistochemistry, produced a similar band at 128 kDa, with almost complete
knockdown in antisense-treated tissue (Figure 4.5d). The similarity in the patterns for
these two antibodies, and the abolition of the band at 128 kDa by both antibody pre-
absorption and antisense knockdown of TRPM8, very strongly suggests that the band
at 128 kDa on Western blots does indeed represent the TRPM8 protein. For this
reason, only this band is shown on further blots, rather than whole gels.
4.5.2 TRPM8 increases ipsilateral to CCI
Following nerve injury, there was a marked increase in expression of the 128 kDa
TRPM8-immunoreactive band specifically in ipsilateral, but not contralateral DRG
(Figure 4.5b), whereas immunoreactivity for GAPDH was unaltered. As assessed by
semi-quantitative densitometry and expressed as a percentage (± SEM) of the
GAPDH signal, the TRPM8 signal was 80.7 ± 4.1% in ipsilateral DRG, which is
significantly different to both contralateral (49.3 ± 3.2%) and naive (50.7 ± 2.7%)
(p<0.05, One-Way ANOVA, n=5-6) signals.
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L4-5 spinal cord lysates showed that TRPM8 immunoreactivity was present
centrally. There was no alteration in TRPM8 immunoreactivity in these lysates
(staining density as a percentage (± SEM) of the GAPDH signal was 31.2 ± 5.8% in
ipsilateral spinal cord, 26.4 ± 6.8% in contralateral cord and 36.2 ± 3.1% in na'ive
cord, n=6). The lack of differences could be due to low levels of TRPM8 present in
the spinal cord, which are simply too low to show a significant difference between
ipsilateral and contralateral levels. Therefore I prepared a crude particulate fraction
(by centrifugation at 11 OOOg for 45 min) to enrich the membrane component. In
such preparations, consistent increases in expression ipsilateral to injury were
observed (Figure 4.5b). There are no appropriate loading controls for membrane or
particulate fractions and therefore TRPM8 densitometry values are expressed as a
percentage of na'ive values. Ipsilateral staining density was 198.0 ± 6.7% of naive,
contralateral was 125.0 ± 7.1, which represents a significant difference between
ipsilateral and contralateral, and between ipsilateral and naive staining (p<0.05, One-
Way ANOVA, n=5).
In contrast, in DRG lysates from CFA-injected and control saline injected animals,
there was no difference between ipsilateral and contralateral DRG, or between CFA-
injected and saline-treated animals (Figure 4.5c). Staining density as a percentage of
GAPDH was 46.3 ± 4.9% ipsilateral to CFA, 50.4 ± 5.2% contralateral to CFA, 43.2
± 5.6% ipsilateral to saline, and 42.7 ± 6.8% contralateral to saline treatment.
4.5.3 Immunohistochemical analysis of TRPM8 expression
Immunohistochemistry was carried out using a rabbit polyclonal antibody raised to
TRPM8 residues 656-680 (rat) (Brauchi et al., 2004). Antibody concentration and
protocol was optimised and the specificity of the antibody was assessed by antigen
pre-absorption and antisense knockdown controls. The labelling observed in a
discrete subpopulation of DRG cells was abolished following pre-incubation of the
antibody with the peptide antigen (Figure 4.5e). When processed with the antigen-
pre-incubated antibody no positive cells were seen, compared with 5.3 ± 0.4
TRPM8-positive cells per 500 pm DRG section following sham treatment of
antibody, and 5.1 ± 0.5 TRPM8-positive cells per 500 pm DRG section with the
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untreated antibody, mean ± SEM, counted over 12 sections in each condition. When
run on immunoblots, the antibody also labelled a single band at approximately 128
kDa in naive DRG tissue that was abolished either by pre-absorption with the peptide
antigen or by prior 5 day intrathecal infusion of TRPM8 antisense reagent (Figure
4.5d). GAPDH immunoreactivity was unaffected by either treatment. This reflects
the result obtained with antisense-treated tissue and the alternative antibody used
above (Figure 4.5a).
4.5.4 TRPM8 localisation on afferent terminals in spinal cord
Immunohistochemistry showed TRPM8 protein in the superficial dorsal horn of
the spinal cord, like the afferent C fibre marker, peripherin (Amaya et al., 2000), as
shown in Figure 4.5f,g. To examine the origin of this spinal TRPM8
immunoreactivity, a dorsal root rhizotomy was performed at spinal cord levels L2-L6
and tissue taken 8 days later for immunohistochemical analysis. Dorsal rhizotomy
removes peripheral afferent input to the spinal cord; proteins remaining in the spinal
cord following this procedure are, generally speaking, due to expression by neurons
intrinsic to the spinal cord. The vast majority of TRPM8 immunoreactivity was lost
ipsilateral to rhizotomy, indicating that spinal TRPM8 originates largely from
afferents. Figure 4.5f shows a spinal cord section following rhizotomy, stained for
TRPM8 and peripherin. Localisation of TRPM8 protein in the superficial dorsal horn
is apparent in contralateral side, and this staining is virtually abolished ipsilateral to
rhizotomy, together with peripherin expression. Fluorescence intensity was reduced
by approximately 80-90% compared with control contralateral side, demonstrating a
substantial decrease (although fluorescence intensity is non-linear and therefore
cannot easily be correlated with protein expression).
4.5.5 TRPM8 increases in dorsal horn ipsilateral to CCI
Immunohistochemical staining of L4-L6 spinal cord sections from CCI animals
confirmed that TRPM8 levels were increased in the dorsal horn ipsilateral to injury
compared with contralateral control (an approximate increase in fluorescence
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intensity of 70-80%), but retained a similar distribution in superficial laminae. Figure
4.5g shows a typical section immunostained for TRPM8 and neuronal nuclei.
4.5.6 TRPM8 expression alters in primary afferent subponulations
To establish whether the increases in afferent TRPM8 expression occurred in
specific subpopulations of DRG cells, I investigated TRPM8 co-localisation with
neurofilament-200 (NF-200), which marks myelinated afferents (Lawson et al.,
1984; Lawson & Waddell, 1991) and peripherin, which labels unmyelinated afferents
(Amaya et ah, 2000). In naive rats, TRPM8 immunoreactivity was largely confined
to a subpopulation of unmyelinated DRG cells (8.3 ± 0.2% of peripherin-positive
cells; 34 of 408 cells) and only minimally expressed in myelinated, NF-200-positive
cells (1.3 ± 0.5%; 6 of 445 cells). TRPM8-expressing peripherin-positive cells were
small diameter (mean diameter 18.4 ± 0.7 pm). However, following CCI, TRPM8
expression was significantly increased ipsilaterally in both NF-200- and peripherin-
positive cells to 7.9 ± 1.2% (31 of 390 cells) and 15.5 ± 0.8% (64 of 412 cells),
respectively. Corresponding contralateral values were unaltered from naives at 2.0 ±
0.4 % (14 of 346 cells) and 9.2 ± 0.4% (42 of 452 cells) (Figure 4.5h,i,j,k). Data are
taken from 3 CCI and 3 nai've animals, counted across 15-21 sections. The
additional TRPM8-expressing NF-200-positive cells were small (mean diameter:
19.7 ± 0.8 pm), presumed A5 myelinated neurons (Harper & Lawson, 1985). There
were no significant differences in the diameters of NF-200- or peripherin-positive
cells or in the numbers of NF-200- or peripherin-positive DRG cells per section,
between ipsilateral, contralateral and nai've conditions.
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Figure 4.5 TRPM8 immunoreactivity is present in DRG and spinal cord, arises
from afferents and is increased ipsilateral to CCI
a) Immunoblots of DRG show whole gels with TRPM8 protein running at 128 kDa
and additional faint bands at approximately 170, 60 and 50 kDa, in normal rat DRG
with specific knockdown of the 128 kDa band in DRG from antisense-treated
animals. Pre-incubation of TRPM8 antibody with membranes from TRPM8-
expressing cells also removed the 128 kDa immunoreactive band, whereas sham-
treatment had no effect. GAPDH loading controls are also shown. TRPV1 expression
(single band at ~90 kDa) was unaltered in DRG from TRPM8 antisense-treated
animals.
b) Immunoblots for TRPM8 protein show a clear increase in expression of the
specific 128 kDa band in DRG ipsilateral (ipsi) to nerve injury compared to
contralateral (con) and naive DRG. Levels of the housekeeping protein, GAPDH
were unchanged. Spinal cord (SC) whole lysates showed no discernible changes in
TRPM8 levels, however, increased levels were seen in crude particulate fractions
ipsilateral to nerve injury.
c) Immunoblots for TRPM8 protein show no alteration in expression of the 128 kDa
band in DRG ipsilateral or contralateral to CFA treatment, or between CFA and
saline-injected animals. GAPDH is shown as a loading control.
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d) Immunoblots of DRG from naive or TRPM8 antisense-treated rats probed with
the TRPM8 antibody used for immunohistochemistry (raised to residues 656-680)
also show a specific band at -128 kDa, which was removed by pre-incubation of the
antibody with the antigenic peptide or by TRPM8 antisense treatment.
e) DRG sections stained with anti-TRPM8 antibody (red) following pre-incubation
with peptide antigen ("blocked", right-hand side) or sham treatment ("sham", left-
hand side). Staining is completely abolished by pre-incubation with peptide antigen.




















f) L5 spinal cord dorsal horn section taken 8 days after dorsal rhizotomy at levels L2-
L6, immunostained for peripherin (green) and TRPM8 (red) visualised under a
confocal microscope. Both peripherin and TRPM8 staining are strongly reduced
ipsilateral (ipsi) to rhizotomy compared with contralateral (con). Scale bar is 500 pm.
g) L5 spinal cord dorsal horn section from CCI animal, immunostained for TRPM8
(red) and neuronal nuclei (green), visualised under a confocal microscope. TRPM8
increases ipsilateral (ipsi) to CCI with no change in distribution. NeuN levels are






h, i) show DRG sections ipsilateral (ipsi) or contralateral (con) to CCI and from
naive animals, immunostained for TRPM8 (red) with (h): the myelinated A-fibre
marker NF-200 (green) or (i): the C-fibre marker peripherin (green), visualised under
a confocal microscope. In nai've animals, TRPM8 is mainly located in peripherin-
positive C-fibres with little or no apparent expression in myelinated (NF-200) cells.
Flowever, ipsilateral to CCI, TRPM8 expression increases markedly in small NF-
200-positive cells (mean diameter 19.7 ± 0.8pm). A similar, but less marked increase
in TRPM8:peripherin co-expression was also observed. Scale bar is 50pm.
j, k) show the percentage co-expression (mean ± SEM) for TRPM8:NF-200 and
TRPM8:peripherin respectively; actual cell counts are shown above columns.
Statistically significant increases in the percentage co-expression values are indicated

























4.6 Molecular identification of TRPM8 as the mediator of icilin-induced
analgesia
4.6.1 Abolition of icilin-mediated analgesia following TRPM8 knockdown
To verily the specific involvement of TRPM8 in icilin-induced analgesia I used an
antisense knockdown strategy. TRPM8 antisense or mismatched control mis-sense
oligonucleotides were delivered intrathecally by implanted osmotic minipumps over
13 days. As mentioned earlier (section 4.5.1), there is evidence that intrathecally
delivered oligonucleotides can penetrate the DRG (Lai et al., 2002), which would be
expected to affect peripheral levels of TRPM8. CCI surgery was performed at the
same time as minipump implantation. The development of CCI-induced behavioural
sensitisation was unaffected by either antisense or mis-sense treatment, with no
difference in timecourse from standard CCI animals. This included development of
withdrawal responses to 4°C cold. 9-11 days after CCI surgery, control CCI animals
had a mean SPET value of 8.1 ± 0.5 s on ipsilateral paw, whereas corresponding
values in antisense-treated CCI animals were 7.6 ± 0.6 s. This suggests that TRPM8
is not required for the development of cold allodynia, in agreement with results from
other groups (Katsura et al., 2006).
However, the reversal of behavioural sensitisation normally produced by topical
application of 80 pM icilin (as in Figure 4.3a) was largely abolished by treatment
with antisense (Figure 4.6a), but not mis-sense (Figure 4.6b) oligonucleotides. Mean
± SEM percentage reversals of ipsilateral sensitisation over 10-25 minutes after icilin
treatment in antisense- and mis-sense-treated animals were 7.7 ± 7.4% and 82.8 ±
6.9% respectively for PWL, and 9.4 ± 8.2% and 58.7 ± 8.2% for PWT; with mis-
sense-treated, but not antisense-treated animals, retaining significant effects of icilin
(p<0.05). Icilin tests were carried out between 9-13 days post-surgery, at peak CCI
sensitisation and before depletion of minipumps. When minipumps were depleted (5
days after calculated end-time of pump), but animals were still neuropathic, a
significant analgesic effect of icilin was restored in antisense animals (Figure 4.6c),
to 83.7 ± 10.1% reversal of sensitisation for PWL, and 54.0 ± 7.2% for PWT.
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4.6.2 Assessment of the efficacy of knockdown
Western blotting and peripheral afferent recordings were performed in order to
assess the effectiveness and specificity of antisense knockdown. TRPM8 expression
in both ipsilateral and contralateral DRG was greatly reduced by the antisense
reagent and the increase in TRPM8 expression normally seen ipsilateral to nerve
injury was prevented (Figure 4.6d). The mis-sense reagent had no effect (Figure
4.6d) showing TRPM8 expression similar to untreated animals (Figure 4.5a). In mis-
sense treated animals, TRPM8:GAPDH percentage ratios were 77.9 ± 2.0%
ipsilateral to CCI and 52.9 ± 2.1% contralateral, whereas in antisense-treated
animals, values were much lower (19.8 ± 2.2% and 14.9 ± 2.1%, respectively, mean
± SEM, n=5), representing a significant difference from mis-sense values (p<0.05,
One-Way ANOVA). As demonstrated in previous immunoblots, there was no effect
of antisense treatment on levels of the related sensory TRP receptor, TRPV1 (Figure
4.5a).
To confirm that antisense knockdown of TRPM8 resulted in associated functional
changes in afferents, saphenous nerve recordings were made from nai've animals
receiving intrathecal delivery of TRPM8 antisense or mis-sense oligonucleotides, 4-5
days after insertion of the pump. These were performed in the same way and with the
same icilin concentration as those described above in section 4.3.6. There was very
little icilin-evoked increase in firing frequency in animals receiving antisense. Only
8.8% (3 out of 34) of recorded fibres showed a partial activation in response to the
drug, increasing firing approximately 2-fold from a baseline of 5.8 ± 1.4 to 12.7 ±
0.6 spikes per minute, compared with the 7-fold increase observed in over 20% of
line afferents in naive animals. In contrast, in mis-sense animals, icilin activated 25%
(10 out of 40) of fine afferents, producing a 7-fold increase in firing frequency (from
a baseline of 3.3 ± 0.7 to 23.1 ± 3.2 spikes per minute), similar to results from naive
animals. Typical examples of few-fibre recordings from mis-sense and antisense
treated animals are shown in Figure 4.6e.
Similarly, in mis-sense-treated animals, topical (-)-menthol (4 mM in water with
25% ethanol) produced an approximately 8-fold increase in mean firing frequency
(from 4.5 ± 2.9 to 38.9 ± 7.6 spikes per minute), activating 20% of fibres (35
identified afferents recorded). This compared with no obviously activated afferents in
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antisense-treated animals (mean firing frequency 4.0 ±1.8 spikes per minute at
background, 4.8 ± 1.9 spikes per minute post-drug application, 28 identified afferents
recorded). Example traces are shown in Figure 4.6f.
Attempts were made to measure responses to cool temperatures (between 12 and
18°C) of afferents in antisense and mis-sense- treated animals. However, there was
great difficulty in maintaining the temperature of the receptive field of the rat
hindpaw while recording from afferents in the nearby exposed saphenous nerve.
Therefore experiments concentrated solely on responses to chemical agonists, which
were easier to apply and which were used for the majority of behavioural studies.
To further investigate the specificity of TRPM8 antisense treatment, we recorded
the responses of afferents to topically applied resiniferatoxin (1 mM in ethanol),
which is a potent agonist of the heat-and-capsaicin receptor, TRPV1, and which is
expected to activate a subpopulation of heat-sensitive polymodal nociceptive
afferents, in a similar manner to capsaicin (Kenins, 1982). Resiniferatoxin was used
in preference to capsaicin, as similar experiments had previously been conducted in
the laboratory using resiniferatoxin. In support of the specificity of antisense
treatment, resiniferatoxin-evoked responses were present in both antisense and mis-
sense treated animals. In antisense-treated animals, resiniferatoxin evoked a 6-fold
increase in firing frequency in activated afferents (from 4.5 ± 0.7 baseline to 25.9 ±
1.8 spikes per minute at peak response, 16 afferents activated out of 28 recorded),
which was similar to responses in mis-sense-treated animals (showing a mean 5-fold
change in firing frequency from 4.6 ± 2.8 to 24.8 ± 3.1 spikes per minute). Example
traces are shown in Figure 4.6g.
In addition, the mechanoreceptive response to light tactile stimulation of the
receptive field was observed to still be present in antisense-treated animals,
supporting the specificity of antisense treatment.
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Figure 4.6: Specific TRPM8 knockdown by antisense oligonucleotide prevents
icilin-induced analgesia following CCI
a, b, c) Behavioural data show response to topical icilin in CCI animals treated with
antisense (n=12) or mis-sense (n=10) oligonucleotides to TRPM8. (a): following
treatment with antisense, icilin had no analgesic effect on ipsilateral behavioural
reflex responses indicated by the persistence of ipsilateral-contralateral differences,
(b): in contrast, following mis-sense treatment, icilin produced a significant reversal
of sensitisation similar to untreated CCI animals, (c): 5 days after calculated end of
antisense delivery, the analgesic effect of icilin was restored.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
stimulus and PWT (mN/mm2) to graded mechanical stimuli.
O: ipsilateral paw values, ■: contralateral paw values. * indicates significant
(p<0.05) ipsilateral-contralateral differences, as measured by Student's t-test for
thermal data, and Wilcoxon test for mechanical data; f indicates a significant
(p<0.05) difference from pre-drug baseline values, as measured by One-Way RM
ANOVA followed by Dunnett's post-hoc test for thermal data, and Friedman
ANOVA on Ranks followed by Dunn's post-hoc test for mechanical data,
d) Immunoblots of DRG tissue probed for TRPM8 and GAPDH protein levels
following antisense knockdown of TRPM8, compared with mis-sense controls. The
128 kDa band for TRPM8 and, notably, the nerve-injury-induced ipsilateral increase
in expression, was selectively reduced by antisense, but not mis-sense infusion;
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e, f) Electrophysiological recording from few-fibre preparations of C afferents in
animals (without nerve injury) treated with mis-sense oligonucleotides or antisense
oligonucleotides, a minimum of 4 days previously.
(e): topical icilin (200 pM) to the receptive field evoked an increase in firing in mis-
sense animals similar to that evoked in naive animals (Figure 4.3h), but had almost
no effect in antisense treated animals, (f): similarly, topical (-)-menthol (4 mM)






















g) Electrophysiological recording from few-fibre preparations of C afferents in
animals (without nerve injury) treated with mis-sense oligonucleotides or antisense
oligonucleotides, a minimum of 4 days previously.
Topical application of the TRPV1 agonist resiniferatoxin (1 mM) to the receptive
field evoked an increase in firing in both antisense and mis-sense treated animals,
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4.7 Activation of TRPA1 is hyperalgesic and this effect is reversed by TRPM8
activation
4.7.1 Intrathecal and topical activation of TRPA1 produces hyperalgesia
The TRPA1 receptor has also been identified as cold-sensitive (Story et ah, 2003),
and icilin is also an agonist of TRPA1, albeit to a lesser extent than at TRPM8. To
identify the effect of TRPA1 activation in vivo, and to establish whether or not there
is a role for this receptor in icilin-induced analgesia, specific agonists of the TRPA1
receptor were administered in nerve-injured and na'fve animals. In contrast to the
effect of TRPM8 activators, TRPA1 activation produced a hyperalgesic effect, in
both nerve-injured and naive animals, in agreement with other groups (Bandell et ah,
2004; Namer et ah, 2005).
Intrathecal cinnamaldehyde (75 nmol in saline) produced sensitisation of thermal
and mechanical behavioural reflexes in naive animals. The same dose produced
contralateral thermal and mechanical sensitisation in CCI animals, and produced an
increase in ipsilateral thermal sensitisation, and a small, but significant increase in
mechanical sensitisation (Figure 4.7a,b). A lesser effect was seen with a lower dose
(25 nmol) in naive animals: this evoked a mean percentage reduction ± SEM in
baseline values of 17.8 ± 4.2 for thermal and 30.1 ±3.7 for mechanical, compared
with 35 ± 1.1% for thermal and 43 ± 3.8% for mechanical for the 75 nmol dose, over
20-30 minutes post-injection. The higher dose (75 nmol) was used in all further
experiments as it produced a stronger effect. There was no effect of vehicle (0.9%
saline). Co-injection of the broad spectrum TRP channel antagonist, ruthenium red
(0.25 nmol in saline), which blocks TRPA1, but not TRPM8 (Macpherson et al.,
2005; Weil et al., 2005) blocked the hyperalgesic effect produced by
cinnamaldehyde, but not the analgesic effect of icilin, ipsilateral to CCI (Figure
4.7c). This data supports the idea that the hyperalgesic effect of cinnamaldehyde is
mediated through TRPA1, whereas the analgesic effect of icilin is mediated through
TRPM8. The further TRPA1 activating compounds, allicin and diallyl disulphide,
which are pungent compounds derived from garlic (Bautista et al., 2005; Macpherson
et al., 2005), also produced sensitisation in naive animals. Intrathecal allicin (25
nmol) produced a mean percentage reduction from baseline values (over 15-25
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minutes post-injection) of 33.2 ± 5.9%for PWL and 20.7 ± 8.2% for PWT. Similarly,
diallyl disulphide (50 nmol) produced reductions (over 15-25 minutes post-
injection) of 25.9 ± 7.0% for PWL and 28.5 ± 6.2% for PWT (shown in Figure 4.7d).
Cinnamaldehyde was also applied topically in small foot-tubes. The same
concentration (1.5 mM in water) used for the higher dose of intrathecal
cinnamaldehyde was utilised. This topical application also produced bilateral
sensitisation of behavioural reflexes in naive animals, with a mean percentage
reduction from baseline values (over 15-25 minutes) of 32.0 ± 8.6%in PWL and
20.2 ± 8.2% in PWT, (shown in Figure 4.7e).
4.7.2 TRPM8 activation reverses TRPAl-mediated sensitisation
To investigate the interaction between TRPM8 and TRPA1 activation, icilin (10
nmol) was intrathecally injected with cinnamaldehyde (0.75 nmol). Icilin blocked the
sensitising effect of cinnamaldehyde in nai've animals (Figure 4.7f) so that overall,
there was no observable change in sensory threshold. Further, icilin blocked
contralateral sensitisation and produced a slight ipsilateral analgesia when co-
injected with cinnamaldehyde in CCI animals (Figure 4.7g). The finding that TRPA1
agonists exert the opposite effect to icilin supports the findings of the antisense
studies that icilin acts through TRPM8 to produce analgesia. The inhibitory effect of
icilin on cinnamaldehyde-induced analgesia could be due to icilin activating
TRPM8-expressing afferents and causing an inhibition of the hyperalgesia produced
by activation of TRPA1-expressing afferents. However, icilin is also a TRPA1
agonist (Story et al., 2003), and its pharmacology is consistent with that of a partial
agonist (S. Bevan, personal communication). It could therefore inhibit the effects of
cinnamaldehyde by acting as a partial agonist at TRPA1 and thus a competitive
antagonist of cinnamaldehyde. This possibility cannot be ruled out as an explanation.
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Figure 4.7 TRPA1 activation is hyperalgesic in naive and CCI animals
a, b) Behavioural data show the effect of intrathecal injection of cinnamaldehyde (75
nmol) in (a) nai've and (b) CCI animals. In naive and CCI animals, cinnamaldehyde
produced behavioural reflex sensitisation (both ipsilateral and contralateral to CCI),
as shown by lowered threshold to thermal and mechanical stimuli.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
stimulus and PWT (mN/mm ) to graded mechanical stimuli.
O: ipsilateral paw values, ■: naive/contralateral paw values. * indicates significant
(p<0.05) ipsilateral-contralateral differences, as measured by Student's t-test for
thermal data, and Wilcoxon test for mechanical data; | indicates a significant
(p<0.05) difference from pre-drug baseline values, as measured by One-Way RM
ANOVA followed by Dunnett's post-hoc test for thermal data, and Friedman
ANOVA on Ranks followed by Dunn's post-hoc test for mechanical data,
c) Bar chart displays data from ipsilateral paw in CCI animals, which shows that co-
injection of the non-selective TRPA1 blocker ruthenium red (0.25 nmol) inhibits
thermal and mechanical sensitisation produced by intrathecal cinnamaldehyde (75
nmol), but not the thermal and mechanical analgesia produced by intrathecal icilin
(10 nmol). Values are ipsilateral response threshold as a percentage of baseline
value, mean ± SEM. Statistically significant changes in thermal/mechanical threshold
values due to cinnamaldehyde or icilin (|) compared to pre-drug baseline are
indicated, (p<0.05, One-Way ANOVA for thermal, Friedman ANOVA on ranks for
mechanical) and statistically significant reversal of the effect of cinnamaldehyde in
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d) Intrathecal injection of the TRPA1 agonist diallyl disulphide (DADS; 50 nmol)
produces thermal and mechanical behavioural reflex sensitisation in nai've animals.
e) Topical application of cinnamaldehyde (5 min paw immersion in foot-tubes
containing 1.5mM cinnamaldehyde at 30 °C) produces thermal and mechanical
behavioural reflex sensitisation in naive animals.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
• 9 •
stimulus and PWT (mN/mm ) to graded mechanical stimuli.
■ : naive paw values, f indicates a significant (p<0.05) difference from pre-drug
baseline values, as measured by One-Way RM ANOVA followed by Dunnett's post-
hoc test for thermal data, and Friedman ANOVA on Ranks followed by Dunn's post-
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f) Behavioural data show that co-injection of icilin (10 nmol) together with
cinnamaldehyde (75 nmol) blocks the sensitisation of thermal and mechanical
thresholds produced by cinnamaldehyde in nai've animals, with no net change in
reflex responsiveness.
g) Behavioural data show that co-injection of icilin (10 nmol) with cinnamaldehyde
(75 nmol) in CCI animals produces an ipsilateral analgesia which reverses the
cinnamaldehyde-mediated sensitisation shown above in b).
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
stimulus and PWT (mN/mm2) to graded mechanical stimuli.
O: ipsilateral paw values, ■: naive/contralateral paw values. * indicates significant
(p<0.05) ipsilateral-contralateral differences, as measured by Student's t-test for
thermal data, and Wilcoxon test for mechanical data; f indicates a significant
(p<0.05) difference from pre-drug baseline values, as measured by One-Way RM
ANOVA followed by Dunnett's post-hoc test for thermal data, and Friedman
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4.8 The central mechanism of TRPM8-mediated analgesia involves Group II/III
metabotropic glutamate receptors
4.8.1 Rationale
As topical icilin increases activity in fine afferents, and both intrathecal and topical
icilin reverse nerve injury-induced sensitisation, centrally-mediated events are likely
to be important in icilin-mediated analgesia. Icilin-responsive afferents are expected
to release glutamate, so inhibitory glutamate receptors in the dorsal horn of the spinal
cord could underlie icilin-induced analgesia. Group II/III mGluRs are antinociceptive
in models of inflammatory, neuropathic and acute pain (Chen & Pan, 2005; Fisher &
Coderre, 2002; Simmons et al., 2002) and inhibit transmission between primary
afferent and spinal cord neurons in sensitised states (Gerber et al, 2000; Neugebauer
et ah, 2000), and are therefore strong candidates for mediators of inhibition. These
receptors are discussed in greater detail in Introduction section 1.8.6 - 8.
4.8.2 Group II/III mGluR antagonists reverse icilin-induced analgesia
To assess whether icilin-analgesia is mediated through Group II/III mGluRs,
Group II/III antagonists were co-injected with icilin. I used the selective Group II
mGluR antagonist LY 341495 and the selective Group III antagonist UBP 1112.
Trials of lower doses of these compounds (0.5 nmol and 2.5 nmol of each compound,
in saline vehicle) had no apparent effect on the effect of intrathecal icilin. When the
2.5 nmol dose of LY 341495 was co-injected with icilin, there was an icilin-induced
mean percentage reversal of ipsilateral sensitisation over 15-30 minutes of 67 ±
6.5% for PWL and 61.9 ± 7.9% for PWT (mean ± SEM). Icilin-induced mean
percentage reversal of ipsilateral sensitisation (over 15-30 minutes) when co-
injected with 2.5 nmol UBP 1112 was 77 ± 7.3% for PWL and 66.8 ± 5.6% for PWT
(mean ± SEM). These values, although slightly lowered, are comparable to those for
10 nmol icilin alone (84.7 ± 6.0% for PWL, 76.8 ± 5.3% for PWT). However, higher
doses of LY 341495 (5 nmol in saline) and UBP 1112 (10 nmol in saline) each
produced a strong, almost complete block of the analgesic effect of 10 nmol icilin
(Figure 4.8a,b). Neither LY 341495 nor UBP 1112 had any effects alone in CCI or
nai've animals at these doses (10 nmol UBP 1112 in CCI animals is shown as an
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example in Figure 4.8d), suggesting that Group II/III mGluRs show little tonic
activation but are specifically activated downstream of icilin action. In contrast, co-
injection of the p-opioid receptor antagonist naloxone (25 nmol in saline) had no
effect on the analgesic action of icilin (Figure 4.8c), showing that icilin-analgesia is
opioid-independent. Matching the profile of icilin, the analgesia produced by
intrathecal (-)-menthol (200 nmol, as shown in Figure 4.4b) was reversed by
intrathecal LY 341495 and UBP 1112. The mean percentage reversal ± SEM of
sensitisation over 20-30 minutes post-injection was 86.1 ± 8.1% for PWL and 80.6 ±
4.2% for PWT with menthol alone, 22.0 ± 6.9% for PWL and 7.1 ± 7.1% for PWT
with menthol and LY 341495 (5 nmol), and 9.2 ± 6.9% for PWL and 0.0 ± 0.0% for
PWT with menthol and UBP 1112 (10 nmol). As lower doses of LY 341495 and
UBP 1112 were ineffective against icilin analgesia, I did not investigate the effect of
these doses on menthol.
In order to eliminate the possibility that there are non-specific interactions between
the two drugs (icilin plus antagonist) when administered intrathecally, these
experiments were performed administering icilin topically, but the mGluR
antagonists intrathecally. Figure 4.8e shows that icilin-mediated (80 pM, topically
applied in small foot-tubes) reversal of thermal and mechanical sensitisation was
prevented by intrathecal LY 341495 (5 nmol) or UBP 1112 (10 nmol). The reversal
ofmechanical sensitisation produced by skin cooling to 16 °C (Figure 4.3i) was also
prevented by intrathecally applied LY 341495 or UBP 1112. The mean percentage
reversal of ipsilateral CCI-induced reductions in PWT caused by cooling was 0.0 ±
0.0% in the presence of either drug. Therefore the inhibition of the effect of icilin is
still present when the two drugs are administered separately, indicating that the
inhibition is not due to non-specific interactions. This result further indicates that the
effect of peripheral icilin or cooling is mediated centrally, as it is blocked by
centrally administered mGluR antagonists.
4.8.3 Group II/III mGluR agonists mimic the effect of icilin
To assess whether activation of Group II/III mGluRs mimics icilin reversal of
neuropathic sensitisation, I intrathecally injected the selective Group II mGluR
agonist 2R, 4R-APDC, and the Group III mGluR agonists ACPT-III and AP-4. 2R,
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4R-APDC (15 nmol) caused reversal of ipsilateral thermal and mechanical
sensitisation, with no effect on contralateral responses, in CCI animals (Figure 4.8f)
(mean percentage reversal of ipsilateral-contralateral differences was 72.1 ± 6.4% for
thermal and 56.0 ± 10.9% for mechanical). ACPT-III (Figure 4.8g) and AP-4 (Figure
4.8h) (150 nmol each) also reversed thermal sensitisation (by 83.6 ± 6.3% and 60.8 ±
6.7%, respectively), as well as mechanical sensitisation (65.7 ± 11.4% and 60.7 ±
8.0%), again with no effects contralaterally. (All quoted data is mean ± SEM,
calculated over 15-30 min post-injection). There were no additional behavioural or
other physiological effects observed following agonist application, which was a
concern, as mGluRs in the central nervous system are implicated in a wide range of
functions (Neugebauer, 2002). This is in agreement with previously published results
using Group II/III mGluRs in pain models (Chen & Pan, 2005; Fisher et al., 2002;
Simmons et al., 2002), which also did not report any additional behavioural effects of
such agonists.
159
Figure 4.8 Icilin-induced analgesia following CCI is prevented by Group II and
III mGluR antagonists
a, b, c) Behavioural data show that the analgesic effect of intrathecal icilin (10 nmol)
in CCI animals is blocked by co-administration of (a) the Group II mGluR antagonist
LY 341495 (5nmol) and (b) the Group III mGluR antagonist UBP 1112 (10 nmol)
but not (c) the opioid antagonist naloxone (25 nmol). Blockade of icilin's action is
indicated by the persistence of ipsilateral-contralateral differences (*) and by the lack
of significant drug alteration of baseline.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
stimulus and PWT (mN/mm2) to graded mechanical stimuli.
O: ipsilateral paw values, ■: contralateral paw values. * indicates significant
(p<0.05) ipsilateral-contralateral differences, as measured by Student's t-test for
thermal data, and Wilcoxon test for mechanical data; | indicates a significant
(p<0.05) difference from pre-drug baseline values, as measured by One-Way RM
ANOVA followed by Dunnett's post-hoc test for thermal data, and Friedman
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d) Behavioural data show the effect of the mGluR antagonist UBP 1112 (lOnmol)
alone administered intrathecally in CCI animals. There is no significant effect of
drug upon thermal or mechanical thresholds.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
stimulus and PWT (mN/mm2) to graded mechanical stimuli.
O: ipsilateral paw values, ■: contralateral paw values. * indicates significant
(p<0.05) ipsilateral-contralateral differences, as measured by Student's t-test for
thermal data, and Wilcoxon test for mechanical data; f indicates a significant
(p<0.05) difference from pre-drug baseline values, as measured by One-Way RM
ANOVA followed by Dunnett's post-hoc test for thermal data, and Friedman
ANOVA on Ranks followed by Dunn's post-hoc test for mechanical data.
e) Bar chart shows the mean percentage reversal of thermal and mechanical
ipsilateral sensitisation in CCI animals by topical icilin with concurrent intrathecal
injection of the Group II mGluR antagonist LY 341495 (5 nmol) or the Group III
mGluR antagonist UBP 1112 (10 nmol) or icilin, LY 341495 or UBP 1112 alone.
Values are mean percentage reversal ± SEM, calculated over 15-25 min following
paw immersion and intrathecal injection, t indicates significant difference from pre-
drug baseline, as measured by One-Way RM ANOVA followed a by Dunnett's post-
hoc test for thermal data, and Friedman ANOVA on Ranks followed by Dunn's post-
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f, g, h) Behavioural data show that intrathecal administration of the Group II mGluR
agonist 2R,4R-APDC (15nmol), and the Group III mGluR agonists ACPT-III (150
nmol) and L-AP4 (150 nmol) in CCI animals produces a reversal of ipsilateral
sensitisation, similar to the effect of intrathecal icilin, with no effects on contralateral
paw values.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
9 ...
stimulus and PWT (mN/mm ) to graded mechanical stimuli.
O: ipsilateral paw values, ■: contralateral paw values. * indicates significant
(p<0.05) ipsilateral-contralateral differences, as measured by Student's t-test for
thermal data, and Wilcoxon test for mechanical data; f indicates a significant
(p<0.05) difference from pre-drug baseline values, as measured by One-Way RM
ANOVA followed by Dunnett's post-hoc test for thermal data, and Friedman
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4.9 Icilin-inhibition and mGluR-dependency are apparent at the level of dorsal
horn neurons
To confirm the analgesic effect of icilin at the level of single spinal cord neurons,
in vivo extracellular recordings were made of large LI and LIII/IV neurons in CCI
animals. Laminar location was assessed based on depth of electrode penetration and
previous results which used dye ejection to identify the lamina reached by different
depths (Moss et ah, 2002). Receptive fields were identified by innocuous
brush/stroking stimulus, and neurons were identified as WDR neurons by response to
both innocuous brush and noxious pinch stimulus. Neurons were then stimulated by a
motorised rotating brush applied to the receptive field area. This stimulus is normally
innocuous, but would be expected to be noxious ipsilateral to CCI, due to the
mechanical allodynia associated with sensitisation, and therefore would be expected
to be attenuated by icilin.
Icilin was administered at the same concentration (200 pM) and in the same
manner (via a drug-soaked gauze patch applied to part of the peripheral receptive
field of the neuron) as in saphenous afferent recording experiments. Topical
administration of icilin, but not vehicle (0.2% DMF in water), to the peripheral
receptive field area ipsilateral to CCI caused inhibition of neuronal responses to
motorised rotating brush (Figure 4.9a,b). In the 8 neurons out of 12 which were
affected by icilin (2 in lamina I and 6 in laminae III/IV) brush-induced responses
were reduced to 37.4 ± 5.5% of baseline firing frequency, (p<0.001, ANOVA on
Ranks). The mean time until peak icilin inhibition was approximately 4.5 minutes,
which is similar to the results obtained from afferent recordings and from
behavioural tests with topical icilin. Contralateral neurons were unaffected by topical
icilin, with a mean firing frequency of 111.9 ± 8.9% of baseline (p>0.05, n=6),
shown in Figure 4.9c.
As an example of one of the Group II/III mGluR antagonists, UBP 1112 was
ionophoresed in the vicinity of recorded dorsal horn neurons at currents of 20-60 nA.
UBP 1112 (200 pM in saline, the same concentration as that applied intrathecally in
behavioural tests) reversed the effect of icilin on 7 of the 8 icilin-inhibited ipsilateral
neurons; the brush-induced firing rate reverted to 80.2 ± 9.3% of control values
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(Figure 4.9b), and, on removal of the ionophoresis current, icilin-mediated inhibition
was restored. Neither UBP 1112 nor saline current control (20-60 nA) had any effect
alone. These results are summarised in Table 4.5. Ionophoresis of UBP 1112 was not
investigated on contralateral neurons due to the lack of icilin effect on these neurons.
The primary aim of these experiments was to identify an inhibitory effect of icilin
and examine whether UBP 1112 would reverse this, rather than to examine the
timecourse of the icilin effect, and icilin was applied for the duration of the
experiments by means of an icilin-soaked gauze patch, so it is impossible to conclude
how long the effect of icilin would last independent of further application.
Nevertheless, there was clearly no desensitisation to the effect of icilin as, in the one
neuron that was inhibited by icilin but showed no effect of UBP 1112, the effect of
icilin was apparent for at least 18 minutes (when the experiment was terminated).
Further, in those neurons where UBP 1112 did exert an effect, icilin-mediated
inhibition was restored on removal of the ionophoresis current, which was up to 13
minutes after initial application.
These results at the level of single spinal cord neurons mirror behavioural results,
demonstrating that icilin has an inhibitory effect which is specific to sensitised pain
states and which is mediated through inhibitory metabotropic glutamate receptors.
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neurons 111.7 ± 111.9 ± 8.9 - - -
(n=6) 10.2
Table 4.5 Summary of dorsal horn neuron recording following topical
icilin/vehicle and ionophoresis of UBP 1112.
* denotes significant difference from baseline brush-evoked activity (p<0.05,
ANOVA on Ranks)
f denotes significant effect of ionophoresed UBP 1112 on icilin-inhibition of
brush-evoked activity (p<0.05 ANOVA on Ranks)
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Figure 4.9 Icilin inhibits the sensitised response of ipsilateral dorsal horn
neurons in neuropathic animals, which is reversed by a Group III mGluR
antagonist
Figure shows responses of single dorsal horn neurons ipsilateral (a, b) and
contralateral (c) to CCI, activated by motorised rotating brush stimulus to the
receptive field. Neuronal firing is displayed as action potentials per second plotted
against time.
a): Vehicle (0.2% DMF in saline, 30°C) topically applied to the receptive field area
of the hindpaw (adjacent to motorised brush stimulus) had no effect on ipsilateral
dorsal horn neuronal firing.
b): Typical example of the effect of icilin (200 pM in saline, 30°C) topically applied
to the receptive field area of the hindpaw (adjacent to motorised brush stimulus) on
an ipsilateral dorsal horn neuron, (i): Brush-evoked firing in neurons ipsilateral to
nerve injury (reflecting mechanical allodynia) was inhibited by topically applied
icilin, (ii): this effect was reversed by ionophoresis of UBP 1112 (200 pM) at
currents of 20-60 nA; (iii): recovery was observed following removal of the UBP
1112 ejection current. Similar effects were observed in 8 out of 12 ipsilateral
neurons. The icilin-induced reduction in mean firing frequency of the affected dorsal
horn neurons was statistically significant (p<0.001, ANOVA on Ranks) as was its
reversal in the presence ofUBP 1112 (p<0.05).
c): Typical example of the effect of icilin (200 pM in saline, 30°C) topically applied
to the receptive field area of the hindpaw (adjacent to motorised brush stimulus) on a
contralateral dorsal horn neuron. There is no apparent change in firing frequency.
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4.10 Possibility of a postsynaptic mechanism of action by icilin
As some Group II/III mGluRs may be postsynaptic, I investigated whether icilin
could reverse the additional sensitisation of behavioural reflex responsiveness caused
by intrathecally applied NMDA in nai've and CCI animals.
Initial experiments injecting NMDA (30 nmol in saline) showed no effect on
behavioural thresholds (mean percentage change in baseline was -3.5 ± 4.2% for
PWL and 0.0 ± 0.0% for PWT, values from 15-30 minutes post-injection, mean ±
SEM, n of 6 animals). However, co-injection of NMDA (30 nmol) with the drug
ACPC (6 nmol in saline), which acts as a co-agonist at the glycine site of the NMDA
receptor did elicit thermal and mechanical sensitisation in naive animals (Figure
4.10a). This model of sensitisation was then used to investigate the effect of icilin.
NMDA and ACPC-induced sensitisation was blocked by co-injection of icilin (10
nmol, Figure 4.10b), demonstrating that icilin is active against NMDA-induced
hypersensitivity. This was further investigated in CCI animals, where a lower dose of
NMDA (3.75 nmol) and ACPC (0.75 nmol) was used to produce an additional
ipsilateral sensitisation without affecting contralateral thresholds (Figure 4.10c).
Icilin (10 nmol) clearly attenuated the additional ipsilateral sensitisation induced by
the NMDA and ACPC (Figure 4.1 Od), and also went some way to reversing the CCI-
induced sensitisation, similar to its effects when injected alone. The blockade of
NMDA-mediated hypersensitivity suggests that a component of the central events
elicited by icilin may therefore be postsynaptic, although it is important to note that
functional NMDA receptors are also present on afferent terminals (Bardoni et al.,
2004; Liu et al., 1994).
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Figure 4.10 Icilin inhibits the behavioural sensitisation produced by intrathecal
NMDA
a, b) Behavioural data show that in naive animals (a) intrathecal injection ofNMDA
(30 nmol) together with its glycine site co-agonist ACPC (6 nmol) produce
sensitisation of behavioural reflexes to thermal and mechanical stimuli, and that (b)
this effect is blocked by co-injection of icilin (10 nmol), with no net effect on
thresholds to stimuli.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
2 •stimulus and PWT (mN/mm ) to graded mechanical stimuli.
■ : nai've paw values, f indicates a significant (p<0.05) difference from pre-drug
baseline values, as measured by One-Way RM ANOVA followed by Dunnett's post-
hoc test for thermal data, and Friedman ANOVA on Ranks followed by Dunn's post-
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c, d) Behavioural data show that in CCI animals (c) intrathecal injection of NMDA
(3.75 nmol) together with its glycine site co-agonist ACPC (0.75 nmol) produce a
further sensitisation of ipsilateral behavioural reflexes to thermal stimuli and a small
but significant sensitisation of reflexes to mechanical stimuli, with no discernible
effect on contralateral paw values, and that (d) co-injection of icilin (10 nmol)
produces an ipsilateral analgesia, which cancels out the NMDA-induced
sensitisation.
Data show mean ± SEM (from an n of 6 animals) PWL (s) to a noxious thermal
stimulus and PWT (mN/mm ) to graded mechanical stimuli.
O: ipsilateral paw values, ■: contralateral paw values. * indicates significant
(p<0.05) ipsilateral-contralateral differences, as measured by Student's t-test for
thermal data, and Wilcoxon test for mechanical data; t indicates a significant
(p<0.05) difference from pre-drug baseline values, as measured by One-Way RM
ANOVA followed by Dunnett's post-hoc test for thermal data, and Friedman
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4.11 Protein expression of Group II/III metabotropic glutamate receptors
4.11.1 Western blots show no change in levels of Group II/III mGluRs
Alterations in mGluR expression could lead to increased efficacy of the TRPM8-
mGluR axis, and might underlie the effectiveness of icilin in CCI. To investigate this
mGluR expression was analysed by Western blots. I examined the expression of
mGluR7, mGluR4 (Group III mGluRs), and ofmGluR2/3.
Immunoblotting with an antibody against mGluR7 showed a band at
approximately 97 kDa (the predicted molecular weight ofmGluR7; Yao et al., 2005).
This band showed no change in expression in DRG or spinal cord whole lysates
compared between ipsilateral or contralateral CCI tissue and compared with naive
tissue (Figure 4.1 la).
Immunoblotting with an antibody against mGluR4 showed a single, albeit faint,
band at -100 kDa in DRG samples, consistent with the predicted molecular weight
of mGluR4 (Yao et ah, 2005). There was no signal in spinal cord tissue (blot not
shown) and expression was unchanged in ipsilateral or contralateral DRG (Figure
4.11b).
Immunoblotting with an antibody against mGluR2/3 showed a single band at -100
kDa, consistent with the predicted molecular weight of these subtypes (predicted
molecular weight 100-110, Yao et ah, 2005). There was no alteration in the staining
pattern in DRG or spinal cord samples following CCI (Figure 4.11c). As mGluR3 in
particular is found located postsynaptically (Tamaru et al., 2003), spinal cord
samples were also probed with an antibody specific to mGluR3. This similarly gave
a single band at -100 kDa, with no change in staining intensity following CCI.
However, mGluR3 appeared significantly upregulated ipsilateral to CFA treatment
(Figure 4.1 Id), although this was not pursued further, as the CCI was our primary
model of interest. This confirms previous reports that mGluR3 increases in models of
chronic inflammatory pain (Boxall et al., 1998; Dolan et al., 2003). All blots used
GAPDH as a loading control. Therefore alterations in mGluR expression do not seem
to occur following CCI. This is consistent with the suggestion that such alterations
do not underlie the increased efficacy of icilin in this pain state.
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4.11.2 Immunohistochemistry shows mGluR7 in DRG
As an example of an inhibitory glutamate receptor, the expression of mGluR7 was
analysed by immunohistochemistry. Immunostaining of DRG for mGluR7 revealed
the presence of mGluR7 in the majority of peripherin-positive cells, with no
alteration following CCI, Figure 4.1 le. mGluR7 was found in 70 ± 1.3% peripherin-
positive cells ipsilateral to CCI, 68 ± 2.2% contralateral to CCI and 73 ± 1.8% in
naive animals (no significant differences, p>0.05, n=3 CCIs, 3 nai've animals). This
confirms Western blots and agrees with previously published results (Li et al., 1996),
and suggests that mGluR7 is expressed by a large number of putative nociceptive
afferents and could therefore mediate icilin-induced inhibition of nociceptors via a
presynaptic location on afferent terminals.
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Figure 4.11: There is no alteration in expression of Group II/III mGluRs in CCI
animals
a) Immunoblots of DRG and spinal cord whole lysate probed for mGluR7 show
protein running at ~ 97 kDa, together with GAPDH loading control at approximately
36 kDa. There is no discernible difference in mGluR7 band intensity in DRG or
spinal cord between ipsilateral and contralateral and na'ive samples.
b) Iminunoblot of DRG whole lysate probed for iiiG1uR4 shows protein running at
-100 kDa, together with GAPDH loading control at approximately 36 kDa. There is
no discernible difference in mGluR4 band intensity in DRG between ipsilateral and
contralateral samples.
c) Immunoblots of DRG and spinal cord whole lysate probed with an antibody which
detects mGluR2 and mGluR3 show protein running at -100 kDa, together with
GAPDH loading control at approximately 36 kDa. There is no discernible difference
in mGluR2/3 band intensity in DRG or spinal cord between ipsilateral and
contralateral and na'ive samples.
d) Immunoblots of spinal cord whole lysate probed for mGluR3 show protein
running at -100 kDa, together with GAPDH loading control at approximately 36
kDa. There is no discernible difference in mGluR3 band intensity in CCI spinal cord
between ipsilateral and contralateral and nai've samples. However, in spinal cord
whole lysate from CFA-treated animals, there is a significant increase in staining
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e) shows DRG sections ipsilateral (ipsi) or contralateral (con) to CCI and from naive
animals, immunostained for mGluR7 (red) and the C-fibre marker peripherin (green),
visualised under a confocal microscope. mGluR7 is predominantly expressed in
small, peripherin-positive cell bodies and there is no discernible difference in





5.1 Review of animal models of chronic pain states used in this study
This study utilised several models of chronic pain, which produced changes in the
sensitivity of behavioural reflexes. The principal model used was the CCI model of
neuropathic pain, which produced robust and consistent thermal hyperalgesia, and
mechanical and cold allodynia, ipsilateral to injury, which were maximal between
post-operative days 9 to 17. This model has been well-studied, and these
observations are in agreement with results reported by other groups (Bennett & Xie,
1988; Kim et ah, 1997). Although contralateral behavioural changes have been
observed in other models of neuropathy - the PNL (Seltzer et ah, 1990) and the SNI
(Erichsen & Blackburn-Munro, 2002) models - in my use of the CCI model, I never
observed significant effects on contralateral threshold, suggesting that if the CCI
model does produce changes in contralateral neuronal processing, they are not strong
enough to sustain behavioural changes. Therefore the difference between
contralateral and ipsilateral behavioural thresholds, which was used in drug tests as a
measure of sensitisation, does seem to be a valid measurement, as the contralateral
threshold never differed significantly from the naive, pre-surgery baseline in the CCI
model in the present study.
Alternative surgical neuropathic models, such as the PNL, SNI and SNL models,
were not investigated. An investigation and comparison of multiple models of
surgical neuropathy was beyond the scope of this project, and further experiments
investigated models of other sensitised pain states, such as inflammatory,
demyelination-induced and NMDA-induced sensitisation.
A model of demyelination-induced pain, as developed by Wallace et al. (Wallace
et ah, 2003) was also studied. In this model, topical application of lysolecithin to the
sciatic nerve produces focal demyelination of myelinated A fibres, with no axonal
loss (Wallace et al., 2003). As a result of this treatment, thermal hyperalgesia and
mechanical allodynia develops, and in parallel with behavioural sensitisation,
alterations in afferents are observed that resemble those seen in surgical models of
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peripheral nerve damage, including heightened spontaneous firing in afferents,
decreased expression of the Na+ channel Nav1.8 and increased expression of Nav1.3,
and increased NPY expression (Wallace et ah, 2003). In agreement with results
reported by Wallace et ah, the development of thermal hyperalgesia and mechanical
allodynia was observed ipsilateral to injury. In addition, the animals also developed
cold hypersensitivity, characterised by withdrawal of the injured paw to a 4°C
stimulus, an effect which was not reported by Wallace et al. The response to cold
developed over the same timecourse as the thermal and mechanical sensitisation.
Cold allodynia - the perception of normally innocuous cold temperatures as noxious -
is a common feature of clinical neuropathic pain (Woolf & Mannion, 1999), and has
also been reported as a feature of peripheral demyelinating diseases (Carter et ah,
1998; Ochoa & Yarnitsky, 1994). Therefore, the demonstration of cold allodynia in
the lysolecithin model further supports the use of this model as a model of peripheral
demyelination-induced pain states, and supports the idea that this model shows some
similarities with neuropathic pain states.
Additional studies utilised a model of inflammatory pain generated by injection of
CFA into the hindpaw, in which the development of thermal hyperalgesia and
mechanical allodynia was observed ipsilateral to injection, in agreement with others
(Raghavendra et ah, 2004; Stein et ah, 1988). Therefore, in all the models used in
this study robust significant changes were seen in behavioural thresholds ipsilateral
to injury. This allowed the investigation of the effect of drugs on both the sensitised
behavioural responses of the ipsilateral paw, and on the non-sensitised responses of
the contralateral limb and na'ive animals.
5.2 Background to study of cooling and nain
The phenomenon of analgesia produced by cutaneous cooling has been known for
centuries (Adams, 2006; Siegel, 1970; Sprengell, 1735). Clinical trials have
demonstrated an analgesic effect of local cooling on a variety of pain states including
chronic back pain, post-operative pain, dental pain and muscle injuries (Melzack et al
1980a,b; review by Sauls, 1999), and psychophysical studies show an analgesic
effect of local cooling on microelectrode stimulation-induced pain (Bini et al., 1984;
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Bugaj, 1975; Saeki et al., 2002). Similarly, substantial evidence supports an
analgesic role ofmenthol and mint oil. Topical mint oil is used in traditional Chinese
and European medicine for relief of neuralgia (Wright, 1870; Blumenthal, 1998), and
was recently shown to effectively relieve pain in a clinical case study of postherpetic
neuralgia (Davies et al., 2002). Topical menthol has been shown to be analgesic in
psychophysical studies (Green & McAuliffe, 2000; Gobel et al., 1994), and systemic
menthol increased pain thresholds in the mouse hot-plate and acetic acid writhing
tests (Galeotti et al., 2002). It has recently been shown that cold and menthol activate
a common molecular transduction mechanism, the TRPM8 receptor, which is
expressed in subpopulations of sensory neurons (McKemy et al., 2002; McKemy,
2005; Peier et al., 2002b; Reid, 2005). It was hypothesised that, as it is activated by
both cold and menthol, TRPM8 might at least partially mediate the analgesic effects
of both these stimuli. This led us to investigate the effect of chemical agonists of the
TRPM8 receptor in both naive and sensitised pain models, to see whether TRPM8
activation produced analgesia.
5.3 Analgesia produced by topical application of TRPM8 activators
5.3.1 Analgesia produced by topically applied icilin and menthol
Topical application of icilin, which is a highly potent and efficacious agonist of
TRPM8 (Behrendt et al., 2004), to the paws produced a strong and long-lasting
reversal of ipsilateral behavioural sensitisation in the CCI model, in a concentration-
dependent manner. Similar effects were seen with topical application of menthol.
Although neither icilin nor menthol is a completely selective agonist at TRPM8, as is
discussed further below in section 5.6, the fact that both icilin and menthol produced
analgesia supports the idea that the analgesia is mediated through the common target
of these drugs, the TRPM8 receptor. Effects of menthol were seen with several
stereoisomers: (-)-menthol, (+)-menthol, and (+)-isomenthol. However, the latter two
required higher concentrations in order to exert an effect. Prior to the discovery of
TRPM8, it was observed that (-)-menthol exerted a greater potentiation of cold-
sensitive currents in sensory neurons than (+)-menthol (Schafer et al., 1986). It has
since been shown that (-)-menthol is a more potent activator of TRPM8 than (+)-
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menthol, with an EC50 of 4.1 ± 1.3 pM, compared with 14.4 ± 1.3 pM for (+)-
menthol in similar conditions (Behrendt et al., 2004). Similarly, (-)menthol appears
to have a slightly higher potency at TRPM8 than (+)-isomenthol (Bandell et al.,
2006). Therefore the observation that (-)-menthol is a more potent analgesic agent
than (+)-menthol and (+)-isomenthol is broadly supportive of an analgesic
mechanism mediated through the TRPM8 receptor.
These results are exciting because they identify menthol and icilin as novel
potential treatments for neuropathic pain conditions. Current treatment options for
neuropathic pain are limited (Morley-Forster, 2006; Moulin et al., 2006; Woolf &
Mannion, 1999); the most effective medications in current use, which are anti¬
convulsants and anti-depressants, achieve clinically significant effects in less than
50% of patients (Bridges et al., 2001; Sindrup & Jensen, 1999) and cause deleterious
side effects. Therefore the identification of compounds that act as analgesics in
neuropathic pain models is potentially very promising for the clinical treatment of
neuropathic pain. Icilin and menthol reversed the behavioural sensitisation of the
ipsilateral injured hindlimb, but had no effect on contralateral thresholds and
similarly had no effect in naive animals. This ability to reverse sensitisation without
affecting normal responses to noxious stimuli is a highly desirable characteristic in
an analgesic drug. Very low doses of menthol and icilin were effective in reversing
sensitisation, which suggests that such drugs could be used at doses that may be
unlikely to produce significant side effects. Furthermore, topical application was
effective, indicating a readily usable, non-invasive method of application. Therefore
the profile of these drugs shown here is very promising for clinical use.
The effectiveness of menthol in a neuropathic pain model demonstrated here is in
line with recent findings in which a case of postherpetic neuralgia (which is a
neuropathic condition, although of a distinct aetiology from the surgical models used
here) was successfully treated with topical peppermint oil (Davies et al., 2002). The
results of this thesis also support the validity of the use of peppermint oil in
traditional Chinese and European herbal medicine for treating neuralgia (Wright,
1870; Blumenthal et al., 1998).
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5.3.2 Analgesia produced by cold temperatures
In addition to the analgesic effect of TRPM8-activating compounds, physical
cooling was also observed to produce an analgesic effect. An analgesic effect was
observed on mechanical thresholds of paw immersion in temperatures between 16-
20°C. This was fully recovered by 5 minutes later after paw removal. Recordings
from a subcutaneous thermistor in anaesthetised animals showed that deep skin
temperatures (which presumably reflects more closely the actual temperature of
peripheral afferent terminals in the skin) were approximately 0.5°C above bath
temperatures after 5 minutes in similar conditions, and therefore could be considered
to represent the stimulus temperature.
TRPM8 expressed in heterologous systems has a mean activation threshold of
between 19-24°C, and continues to be active at temperatures well below this, with
currents saturating at around 10°C (Peier et al., 2002b; McKemy et al., 2002);
whereas the presumed TRPM8 current in native sensory neurons has a mean
activation threshold of around 28°C, but is still active at temperatures in the range 16
- 20°C (Reid, 2005; Reid et ah, 2002). Therefore, it is indeed likely that TRPM8 will
be activated by the temperature range in which an analgesic effect was observed.
However, other cold-sensitive receptors may also be activated in this temperature
range. Alternative cold-sensitive transduction mechanisms, for example an outward
K+ current (Reid & Flonta, 2001b; Viana et ah, 2002), and the epithelial sodium
channel (Askwith et ah, 2001), have been proposed to contribute to cold sensitivity,
and it is possible that such mechanisms are also affected by the waterbath
temperatures applied. Therefore it is clear that temperature-based stimuli are not as
precise in terms of experimental challenges in pain models as chemical agonists for
investigating the receptor-based mechanism of cooling-induced analgesia. The
difficulty in interpreting temperature-based stimuli with regard to activation of
molecular receptors led us to concentrate on chemical means of activating TRPM8 in
further experiments.
Immersion temperatures below 14°C elicited withdrawal reflexes of the ipsilateral
paw for the duration of the immersion period. This is in agreement with other results
describing cold-induced ipsilateral withdrawal reflexes beginning at a threshold of a
15°C (applied temperature) in rats with SNI or SNL nerve injuries (Allchorne et ah,
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2005), and with psychophysical experiments that describe noxious cold sensation in
humans beginning at temperatures below 15°C (Chen et al., 1996; Chery-Croze,
1983; Wolf & Hardy, 1941). These data suggest that temperatures below ~15°C can
activate noxious cold-sensitive neurons and elicit behavioural responses to noxious
cold, particularly following neuropathy. Such temperatures may activate additional
receptors with lower temperature-activation thresholds than TRPM8. Antisense
knockdown of TRPM8 did not alleviate the cold allodynia observed in the SNL
model (Katsura et al., 2005), or the CCI model (Results section 4.6.1), indicating that
TRPM8 is unlikely to contribute to neuropathy-induced cold allodynia. Other
receptor mechanisms may therefore be involved in cold allodynia, such as the
putative cold receptor TRPA1. Antisense knockdown of TRPA1 has been shown to
suppress the development of cold allodynia following SNL (Katsura et al., 2006;
Obata et al., 2005). Moreover, TRPA1 has been reported to respond maximally to
temperatures below 17°C (Story et al., 2003), which indicates a range more in line
with the temperatures that evoked withdrawal reflexes in my results and those of
other groups (Allchorne et al., 2005), although, given the controversy surrounding
whether TRPA1 is actually sensitive to cold (as described in Introduction section
1.25.1), the role of TRPA1 in cold allodynia is by no means certain.
5.3.3 Regional specificity of application of TRPM8 activators for anti-
sensitisation analgesia
Behavioural experiments demonstrated that it was necessary to apply icilin to the
same dermatome as the area of sensitisation in order to have an effect, as application
only to the contralateral hindpaw had no effect on ipsilateral paw sensitivity. The
relief of pain is therefore specific to the dermatomes over which the drug is applied.
This specificity suggests that the drug acts specifically at afferent neurons in the
injured paw. It further suggests that the analgesic action is not a generalised, whole-
body inhibition of sensitised responses, such as would result from a humoural
mechanism, but must be specific to the nervous signals from the area over which the
drug is applied.
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5.3.4 Hyperalgesia evoked by high doses of icilin
Topical application of high concentrations of icilin (5 mM) caused a generalised
increase in sensitivity. This effect was not specific to the sensitised state, affecting
CCI animals bilaterally and nai've animals in a similar fashion. The fact that the
hyperalgesia is not specific to the sensitised state suggests a separate mechanism to
that which mediates analgesia. It is possible that there is spillover of drug onto other,
non-TRPM8 receptors, such as TRPA1, activation of which was observed to elicit
bilateral hyperalgesia. Alternatively, this hyperalgesic effect could be due to
activation of TRPM8-expressing nociceptive afferents. The extent to which TRPM8
is expressed in nociceptive afferents is uncertain. Electrophysiological and imaging
experiments in sensory neurons (both cultured and acutely dissociated cells) have
shown that some menthol-responsive cells show properties suggestive of nociceptive
neurons, such as responsiveness to capsaicin (Babes et al., 2004; McKemy et al.,
2002; Xing et al., 2006), sensitivity to ATP, and expression of both TTX-S and TTX-
R Na+ currents (Xing et al., 2006). However, in situ hybridisation and
immunohistochemical studies are consistent with a location for TRPM8 in
predominantly non-nociceptive neurons, as several studies have observed that
TRPM8 is not co-expresssed with TRPV1 (Kobayashi et al., 2005; Peier et al.,
2002b) or with CGRP or IB-4 (Peier et al., 2002b), which are markers typically
expressed in nociceptive populations. This suggests that TRPM8 is expressed to a
large extent in non-nociceptive neurons. However, TRPM8 may also be expressed in
polymodal nociceptive neurons, and it is possible that higher doses of icilin activate
such neurons to elicit hyperalgesia.
Analgesic effects of icilin were seen at 200-fold lower concentrations than those
causing non-specific sensitisation. This suggests that there is quite a large potential
therapeutic window, in which analgesia could be produced by low doses of agonist,
without the complication of hyperalgesia elicited by higher doses.
5.4 Afferent subponulations responsive to icilin and menthol
Topical application of icilin (at the low doses used to produce analgesia) to the
receptive field activated a subset of saphenous nerve afferents with conduction
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velocities in the A8/C fibre conduction velocity range, the majority (95%) of which
were C fibres. There was no significant effect of icilin on a range of afferents that
were responsive to innocuous mechanical stimuli and had conduction velocities
consistent with AS and A(3 fibre neurons.
The afferent populations activated by icilin are consistent with populations of
cold-sensitive neurons, including both low-threshold cold-sensitive afferents, which
in rodents are predominantly C fibre neurons (Fang et ah, 2005; Iggo, 1969;
Iriuchijima & Zotterman, 1960; Lynn & Carpenter, 1982; Leem et ah, 1993), and
cold-sensitive nociceptive neurons, which in rodents are associated with AS and C
fibres (Fang et ah, 2005; Koltzenburg et ah, 1997; Lynn & Carpenter, 1982; Leem et
ah, 1993). The lack of effect of icilin on Ap fibres shows that the effect of icilin on
afferents is indeed specific to a subset of neurons. These recordings are also
consistent with icilin-mediated activation of TRPM8-expressing populations.
TRPM8 appears to be expressed selectively in small-diameter sensory neurons,
consistent with expression in C and possibly AS fibre neurons (Kobayashi et ah,
2005; Okazawa et ah, 2004; Peier et ah, 2002b; results section 4.5).
Similar increases in firing frequency in C fibre neurons were observed following
topical application of menthol to the receptive field area. This was performed as part
of the study investigating the effect of treatment with intrathecal antisense or mis-
sense oligonucleotides directed at TRPM8. In animals that had been treated with mis-
sense against TRPM8, and therefore would be expected to still express TRPM8,
menthol elicited increases in firing frequency in C fibre neurons. This indicates that
icilin and menthol produce similar effects at the level of primary afferent neurons,
supporting an effect on afferent firing mediated via their common target, TRPM8.
Similar effects of both menthol and icilin were observed in afferent recordings.
These two agonists have marked differences in their mode of activation of TRPM8
channels as analysed in vitro. When applied to transfected cells, icilin activates
TRPM8 with a delay of variable latency (~10 s) (Andersson et ah, 2004; Chuang et
9+
ah, 2004) and requires an increase in intracellular Ca for full agonist action
(Chuang et ah, 2004; McKemy et ah, 2002), whereas menthol shows neither of these
properties. At the molecular level, different parts of the TRPM8 receptor are critical
for conferring menthol and icilin sensitivity: the putative TM segment 2 and part of
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the C-terminal domain confer menthol sensitivity (Bandell et al., 2006); whereas the
intracellular loop between TM segments 2 and 3 is critical for icilin-activation of the
channel (Chuang et al., 2004), indicating distinctive mechanisms of activation.
Despite these differences in the molecular mechanism of activation, menthol and
icilin showed similar effects in in vivo recordings of saphenous nerve fine afferents.
This could be partly explained by experimental differences - for example, the latency
associated with icilin activation of TRPM8 recorded in whole-cell voltage-clamp
recordings of TRPM8-expressing cells could not be measured in these experiments,
as a far more substantial delay would occur due to the time required for topically
applied icilin (or menthol) to reach its target receptors and activate afferents.
Nevertheless, the remarkably similar effects of these agonists on afferent recordings
suggest that the differences between these two agonists at the levels of the single
channel may not significantly affect the responses of afferent neurons to these drugs
in vivo.
5.5 Analgesia produced by central activation of TRPM8
Intrathecal application of icilin and menthol also reversed ipsilateral behavioural
sensitisation in the CCI model, for up to 55 minutes following injection. The ED50 of
icilin was 0.17 ± 0.02 and 0.31 ± 0.02 nmol, for reversal of thermal and mechanical
sensitisation respectively, again demonstrating the effectiveness of low doses of
icilin. Intrathecal (-)-menthol exerted similar effects, supporting a TRPM8-mediated
action. Therefore central activation of TRPM8 is also effective in reducing
behavioural sensitisation, which suggests that the analgesia produced by TRPM8
activation may be centrally mediated, as it can be produced by central activation of
TRPM8 receptors, downstream of the sensitised area. In agreement with topical data,
intrathecal icilin had no effect in naive animals or on contralateral thresholds, again
demonstrating a selective effect on sensitised responses.
Intrathecal administration of icilin also reversed behavioural sensitisation in two
other models of chronic pain studied.
Icilin effectively reversed the ipsilateral sensitisation that occurred following CFA
injection into the hindpaw, thereby demonstrating that icilin can produce analgesia in
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inflammatory pain states. Therefore, this mechanism is not confined to neuropathic
states but represents a general mechanism of analgesia in sensitised pain states.
As discussed above (section 5.1), the lysolecithin model is a model of behavioural
sensitisation induced by peripheral demyelination (Wallace et al., 2003). Peripheral
demyelinating diseases are frequently associated with pain: chronic pain has been
reported as a complication in 71% of patients sampled who suffered from forms of
Charcot-Marie-Tooth syndrome (Carter et ah, 1998), and in 54 - 84% of cases of
Guillain-Barre syndrome (Asbury, 1990; Moulin et ah, 1997). The effectiveness of
icilin in the lysolecithin model suggests that TRPM8 activators could be a potential
therapy for the pain associated with peripheral demyelinating diseases.
In additional experiments, intrathecal icilin reversed the withdrawal reflexes to
4°C cold induced by the lysolecithin model of demyelination-induced pain. The
phenomenon of cold allodynia, in which normally innocuous cool temperatures
produce a sensation of burning pain, is frequently observed in neuropathic pain
conditions (Woolf & Mannion, 1999), and in peripheral demyelinating diseases
(Ochoa & Yarnitsky, 1994). The attenuation of cold allodynia by the TRPM8
activator icilin strongly argues against a role for TRPM8 in nerve-injury induced
cold allodynia, which is in agreement with data from this study and others (Katsura
et al., 2006) showing that TRPM8 knockdown has no effect on cold allodynia. This
result suggests that TRPM8 activators may be effective analgesics in neuropathic
pain conditions in which cold allodynia is observed. These experiments were
performed as an initial study of the effects of icilin on cold allodynia. In the future it
would be beneficial to examine the effects of icilin on cold allodynia in additional
models of sensitised pain states.
5.5.1 Comparison of the effects of intrathecal and systemic icilin
When icilin is administered intraperitoneally in rodents, vigorous shaking known
as "wet-dog shakes" is elicited (Wei & Seid, 1983; Werkheiser et al., 2006a,b). I did
not observe this phenomenon following intrathecal injection. This could be due to the
fact that the maximum intrathecal dose was 10 nmol, whereas wet-dog shakes were
reported following doses of -500 nmol. It could also be due to the fact that the drug
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is confined to the spinal cord following intrathecal administration, rather than
becoming systemic (Zhang et al., 2001).
The "wet-dog shakes" phenomenon resembles the effects of morphine withdrawal
syndrome in rats (Collier et ah, 1974), and it was reported to be antagonised
following subcutaneous pre-treatment with agonists of p- or K-opioid receptors, but
only with agonists that are capable of crossing the blood-brain barrier, suggesting a
central effect (Werkheiser et ah, 2006a). Microdialysis experiments showed that
intraperitoneal administration of icilin increased glutamate levels in the dorsal
striatum (Werkheiser et ah, 2006b). Although the mechanism is unclear, these results
suggest that the shaking phenomenon elicited by icilin is mediated in the brain, and
can be modulated by opioidergic transmission. Another study found that
intracerebroventricular administration of adenosine and 2-chloroadenosine produced
dose-dependent inhibition of icilin-induced shaking (Tse & Wei, 1986). The
relationship between the actions of adenosine and of opioids on the action of icilin is
unclear, but both of these studies suggest that the shaking behaviour elicited by icilin
is produced centrally, in the brain, and therefore may be distinct from the action of
icilin at TRPM8 in peripheral sensory neurons.
5.6 TRPM8 as a specific mediator of the actions of icilin and menthol
Neither icilin nor menthol is a completely specific activator of TRPM8. In addition
to its identified agonist properties at TRPM8, menthol is also an agonist of the
TRPV3 warm receptor and an antagonist of TRPA1 (Macpherson et al., 2006).
However, Ca2+-imaging data show that bath application of menthol can effectively
evoke responses in TRPV3-expressing cells only at concentrations reaching ~ 1 - 2
mM, whereas it acts on TRPM8 with an EC50 of 30 pM in similar conditions
(Macpherson et al., 2006), and therefore this effect is unlikely to be important in the
low doses of menthol used in the experiments in this thesis. Similar experiments,
however, show an IC50 value of 68 pM for menthol-mediated inhibition of TRPA1
(following TRPA1 activation by 75 pM cinnamaldehyde) (Macpherson et al., 2006).
This value is in a similar range to the EC50 of menthol acting at TRPM8, and is
therefore likely to be a factor in need of consideration in the overall effect of low-
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dose menthol on sensory neurons (Macpherson et al., 2006). It should be noted that
the doses quoted here in experiments using bath application on transfected cells are
naturally lower than those required to exert effects following topical or intrathecal
application in whole animal studies.
Menthol has also been shown to induce Ca2+ release from intracellular stores, an
effect which has been demonstrated in prostate cancer cell lines (Thebault et al.,
2005; Zhang & Barritt, 2004), skeletal muscle (Palade, 1987), and sensory neurons
(Tsuzuki et al., 2004). This effect was initially thought to be due to menthol acting at
TRPM8 located on intracellular membranes, which has been demonstrated
immunohistochemically in some experiments (Thebault et al., 2005). However,
recent evidence suggests that this menthol-induced Ca2+ release pathway is TRPM8-
independent, as menthol-induced Ca2+ release was observed in non-TRPM8-
expressing HEK293, CHO and COS cells (Mahieu et al., 2006). Furthermore, this
release was inhibited by cooling and potentiated by warming, the opposite of what
would be expected by a TRPM8-mechanism, and was mimicked by compounds
structurally similar to menthol such as linalool, but not by the stronger TRPM8
agonist icilin (Mahieu et al., 2006), suggesting that menthol exerts effects on
intracellular Ca2+ stores via a TRPM8-independent mechanism. This effect was
observed with menthol doses between 1-3 mM (bath application to whole cells),
which is significantly higher than the concentration required to activate TRPM8 in
similar conditions, suggesting that this action of menthol can be avoided, and
TRPM8 selectively activated, by the use of low doses ofmenthol.
Icilin is also an agonist at receptors other than TRPM8. Icilin is an activator of
TRPA1, but acts with lower potency at this receptor compared with TRPM8,
requiring concentrations of 25 pM for activation in transfected oocytes, whereas
TRPM8 transfected cells were activated by 1 pM icilin (Story et al., 2003),
suggesting that low doses of icilin will selectively activate TRPM8. However, icilin
appears to act as a partial agonist of TRPA1 (S. Bevan, personal communication) and
it is possible that therefore it could function as a competitive antagonist of TRPA1
agonists.
Icilin is also reportedly an agonist acting at the ENaCS channel subunit (epithelial
sodium channel 8) (Yamamura et al., 2005). However, this effect is unlikely to
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impact on the experiments of this thesis: firstly because icilin has a much lower
potency acting at this channel, with an EC50 of 30 pM compared with 0.2 pM at
TRPM8 in similar conditions; and secondly because the ENaCS subunit is principally
expressed in the brain, with relatively little expression in sensory neurons
(Yamamura et ah, 2005).
The interactions of icilin and menthol with these alternative targets or with other
currently unidentified targets, appear not to play a role in icilin and menthol-induced
analgesia. Firstly, both icilin and menthol elicited analgesia, suggesting that these
drugs are working through their common target, TRPM8, rather than their individual
alternative targets. Secondly, the effects of these drugs were eliminated by specific
knockdown of TRPM8. Pretreatment with an antisense oligonucleotide to
knockdown expression of TRPM8 abolished the analgesic effect of topical icilin in
CCI animals, whereas mis-sense treatment was ineffective. This result suggests that
the analgesia mediated by icilin and menthol is indeed mediated through the TRPM8
receptor. Following TRPM8 knockdown, there was no effect of icilin on behavioural
thresholds or on observed behaviours in general, suggesting that icilin does not exert
significant effects on behavioural thresholds through non-TRPM8 mechanisms.
Therefore, the evidence is consistent with a local analgesic mechanism at least
partially dependent on TRPM8, and which can be recruited by agonists such as icilin
and menthol in the correct doses.
Antisense knockdown of TRPM8 abolished activation of the subset of slowly-
conducting afferents by topical icilin and menthol. This result strongly supports the
idea that the activation of afferents by topical icilin and menthol is indeed mediated
specifically through activation of TRPM8 expressed in afferent neuron terminals.
The abolition of the effect of icilin and menthol on afferents also supports the
effectiveness of antisense treatment, suggesting that functional TRPM8 in primary
afferent peripheral terminals is indeed lost following intrathecal antisense treatment
to knock down sensory neuron expression of TRPM8. Responses evoked by the
TRPV1 agonist, resiniferatoxin, were unaltered, demonstrating the specificity of
antisense treatment to TRPM8, rather than affecting all sensory TRP receptors, and
rather than causing a generalised toxic effect on sensory neurons.
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TRPM8 antisense treatment had no effect alone on baseline behavioural values or
on CCI-induced thermal hyperalgesia and mechanical and cold allodynia. Therefore
TRPM8 does not appear to be involved in setting thresholds for normal or sensitised
nociceptive responses. The lack of effect of TRPM8 antisense knockdown on CCI-
induced cold allodynia suggests strongly that abnormal responses to noxious cold in
nerve-injury models are mediated through non-TRPM8 mechanisms, in agreement
with another study, which also showed that antisense knockdown of TRPM8 had no
effect on the development of cold allodynia in the SNL model of neuropathic pain
(Katsura et ah, 2006).
5.7 TRPM8 expression and its alteration in neuropathic pain states
5.7.1 TRPM8 expression in DRG
In order to analyse the expression of TRPM8 in different subpopulations of DRG
sensory neurons I examined TRPM8 co-localisation with NF-200, which selectively
marks myelinated afferents (Lawson et al., 1984; Lawson & Waddell, 1991) and with
peripherin, an intermediate filament protein which selectively labels unmyelinated
afferents (Amaya et al., 2000). In nai've animals, TRPM8 expression was observed in
a subpopulation (8.3 ± 0.2 %) of peripherin-positive DRG neurons, which all had
small-diameter cell bodies (mean diameter of 18.4 ± 0.7 pin). TRPM8 was minimally
expressed in myelinated fibres (1.3 ± 0.5 %), which all had small-diameter cell
bodies (mean diameter: 19.7 ± 0.8 pm) and are therefore assumed to be AS fibres.
These results are in agreement with previously published results, which show
TRPM8 expression in a subpopulation of small-diameter primary afferents. Peier et
al. found TRPM8 mRNA expression in 5 - 10% of DRG neurons, with a diameter
consistent with that for C fibre neurons in the mouse (Peier et al., 2002b), and
McKemy et al. also observed TRPM8 mRNA in under 20% of DRG neurons,
predominantly small-diameter neurons (mean diameter of 18.2 pm) (McKemy et al.,
2002). Another group, using both high-sensitivity cRNA hybridisation and
immunohistochemistry, observed TRPM8 in approximately 23% of DRG neurons
(Katsura et al., 2006; Kobayashi et al., 2005), and this group also observed TRPM8
mRNA in up to 19% of NF-200-positive afferents in naive animals (Kobayashi et al.,
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2005). The reason for the somewhat higher expression levels observed by this group,
compared with my results, is unclear. It is possible that the differences with the in
situ hybridisation experiments could be explained if not all of the mRNA observed is
expressed as protein. The immunohistochemistry studies utilised different antibodies,
and may have used different threshold criteria for what constituted a positive cell,
which could account for the different levels of expression observed by this group and
by ourselves.
Overall however, the observation of TRPM8 expression predominantly in small-
diameter, unmyelinated sensory neurons, is in broad agreement both with other
expression studies, and with the afferent recording experiments, where it was
observed that topical icilin and menthol selectively activated a population of mainly
C fibre afferents, with some AS neurons.
As described in the introduction, changes in the expression of a variety of proteins
occur in primary afferent neurons following peripheral nerve damage. I therefore
analysed tissue from CCI animals to see whether TRPM8 levels are altered in this
model. Both Western blot and immunohistochemistry showed a significant increase
in TRPM8 protein levels in ipsilateral DRG following CCI.
In DRG neurons, I observed an increase in TRPM8 expression in both peripherin-
positive neurons (an increase of 86% from nai've levels) and especially prominently
in NF-200 positive cells, from a naive level of 1.3 ± 0.5%, to 7.9 ± 1.2% ipsilateral to
CCI. This upregulation in co-expression with NF-200 from a naive level of almost
zero suggests that TRPM8 expression in myelinated afferents is significantly altered
in neuropathy, so that it becomes expressed in a population of cells, which do not
normally express this receptor.
Somewhat different findings to ours were reported in the SNL model, where levels
of TRPM8 mRNA and protein did not change in the spared L4 DRG, and levels of
TRPM8 mRNA decreased in the L5 DRG, in tissue taken at the time of peak
behavioural sensitisation (Katsura et al., 2006). However, Katsura et al. did not study
co-expression of TRPM8 with markers of myelinated and unmyelinated cells, and
therefore it is possible that the pattern of TRPM8 expression was altered in a similar
manner to ours, without changes in the overall expression level. Alternatively,
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differences between the SNL and CCI models could account for these different
results.
The functional consequences of the significant alterations in TRPM8 expression
that I observed in the CCI neuropathic pain model are not entirely clear. The
increased expression of TRPM8 ipsilateral to CCI could at least partially account for
the selective analgesic effect of icilin and menthol on ipsilateral responses. The
alteration in expression pattern could also be important: it is possible that the
analgesia produced by icilin is selectively mediated by the A5 fibre population in
which TRPM8 is newly expressed following CCI, and this would explain the
selectivity of analgesia to the ipsilateral responses. However, icilin also reversed
sensitisation induced by intrathecal injection ofNMDA or cinnamaldehyde. In these
models, sensitisation develops within 15 minutes following intrathecal injection,
which is too short a time period for alterations in protein expression in the DRG to
occur. These results suggest that an increase in TRPM8 expression or a change in the
pattern of TRPM8 expression is not required for an analgesic effect of TRPM8
activation. The functional consequences of the change in TRPM8 expression
observed in the CCI model therefore remain unclear. However, the increased TRPM8
expression, while not critical for mediating TRPM8-induced analgesia, could
nevertheless facilitate this phenomenon. The increase in TRPM8 levels and the
resultant facilitation of analgesia could represent a coping mechanism for sustained
long-term painful conditions.
In future experiments it would be interesting to examine TRPM8 expression in the
CFA model by immunohistochemistry. Western blots of tissue from CFA-treated
animals showed no changes between ipsilateral and contralateral, or between CFA-
treated and saline-treated DRG tissue. However, it is possible that the pattern of
TRPM8 expression alters in the CFA model, with an upregulation in AS fibres
similar to that seen in the CCI model, but with no obvious change in the overall
level, and therefore it would be interesting to examine this expression pattern with
immunohistochemistry experiments. Similarly, although TRPM8 expression in the
lysolecithin model of demyelination was not examined, future experiments could
address possible changes in expression in this model. It would also be interesting to
investigate the timecourse of changes in TRPM8 expression, as the results reported
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above examined tissue taken from animals at the peak of neuropathic sensitisation,
and stages of intermediate neuropathic development were not examined.
No experiments have as yet addressed the expression of TRPM8 in human
neurons. It is possible that there could be differences in afferent populations
expressing TRPM8 between humans and rodents, and these differences could affect
the ability of TRPM8 agonists to induce analgesia. It is known that there are
significant differences between rodents and humans with regard to populations of
cold-sensitive afferent neurons. Innocuous cold-sensitive afferents are reported to be
mainly or exclusively C fibres in rodents (Iggo, 1969; Iriuchijima & Zotterman,
1960; Lynn & Carpenter, 1982; Leem et al., 1993), but in primates, innocuous cold-
sensitive afferents are exclusively A5 fibres in glabrous skin and a mixture of AS and
C fibres in hairy skin (Campero et al., 1996; Darian-Smith et al., 1973; Iggo, 1969).
TRPM8-expressing populations in humans would therefore be expected to comprise
a much greater proportion of A fibres than in rodents, and this may affect the
mechanism of TRPM8-mediated analgesia.
The present study only addressed co-expression with the markers NF-200 and
peripherin. Future studies could address co-expression of TRPM8 with other markers
of afferent neurons, in order to identify in more detail the neuronal populations that
express TRPM8. Co-expression studies to date have indicated that TRPM8 is not co-
localised with IB-4 or CGRP (Peier et al., 2002b), but that 98% of TRPM8-
expressing neurons express the NGF receptor trkA (Kobayashi et al., 2005, Peier et
al., 2002b). There is still controversy regarding the extent of possible TRPM8 co-
localisation with TRPV1. In situ hybridisation and immunohistochemical studies
have reported that between 0% (Kobayashi et al., 2005; Peier et al., 2002b) and 29%
(Okazawa et al., 2004) of TRPM8-expressing cells also express TRPV1, and studies
of cultured DRG neurons have similarly reported a varying degree (up to 50%) of
overlap in capsaicin and menthol responsiveness (Babes et al., 2004; McKemy et al.,
2002; Xing et al., 2006). Therefore, this issue is still not fully resolved. In addition,
the degree of TRPM8 and TRPV1 co-localisation may alter in chronic pain states,
and this has not been studied at all. Increased levels of NGF have been reported to
correlate with increased TRPV1/TRPM8 co-expression (Babes et al., 2004; Story et
al., 2003) and therefore, given the altered exposure to neurotrophic factors in
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neuropathic pain states (Pezet & McMahon, 2006) it is plausible that alterations in
co-expression could occur in such pain states. Future experiments could address
these issues.
5.7.2 TRPM8 expression in the spinal cord
Electrophysiological studies of primary afferent-dorsal horn neuron synapses in
spinal cord slices (Baccei et al., 2003) and in DRG-dorsal horn neuron co-cultures
(Premkumar et ah, 2005; Tsuzuki et ah, 2004) have demonstrated a facilitatory effect
of the TRPM8 agonist menthol at this synapse. Menthol elicited an increase in the
frequency, although not the amplitude, of mEPSCs at the primary afferent-dorsal
horn neuron synapse, which is suggestive of a presynaptic mechanism to cause
increased glutamate release from the afferent neurons. The effect of menthol on
dorsal horn synapses suggested that TRPM8 protein is also present in the spinal cord,
on the terminals of primary afferents.
Analysis with both Western blot and immunohistochemistry revealed that TRPM8
protein is found in the spinal cord. TRPM8-immunoreactivity was observed in the
superficial laminae of the spinal cord, and was almost entirely abolished by dorsal
rhizotomy, indicating a localisation largely on the terminals of primary afferents.
Therefore the effects of TRPM8 agonists at the primary afferent-dorsal horn neuron
synapse, and in intrathecal drug tests, are presumably mediated by TRPM8 receptors
located on the presynaptic terminals of afferents. The distribution of TRPM8-
expressing afferent terminals in superficial laminae is consistent with TRPM8
expression by C and AS fibre neurons, which terminate predominantly in superficial
laminae (Braz et al., 2005; Craig, 2003; Willis & Coggeshall, 1991). The pattern of
TRPM8-immunoreactivity I observed in spinal cord is similar to that reported for the
heat-sensitive TRPV1 receptor, which is similarly localised in superficial laminae
and eradicated following dorsal rhizotomy (Tominaga et al., 1998), suggesting that
sensory TRP receptors may be commonly expressed on the central terminals, as well
as the peripheral terminals, of afferent neurons.
The increased level of TRPM8 seen in DRG tissue ipsilateral to CCI was also
observed in immunohistochemical experiments in the spinal cord and in Western
blots of a spinal cord preparation with an enriched membrane component. Therefore
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the increase in TRPM8 in sensory neuron cell bodies does appear to correlate with
increased expression at the central terminals of primary neurons in the spinal cord.
This increased expression could facilitate the effect of TRPM8 agonists administered
intrathecally in CCI animals.
5.8 TRPA1 activation produces hyperalgesia
In contrast to the analgesic role of TRPM8, I found that topical application of the
selective TRPA1 activator cinnamaldehyde, or intrathecal application of the TRPA1
agonists cinnamaldehyde, allicin and diallyl disulphide induced thermal and
mechanical hyperalgesia in nai've animals. Intrathecal cinnamaldehyde also sensitised
contralateral responses and increased ipsilateral sensitisation in the CCI model. This
effect of cinnamaldehyde was blocked by co-injection of the broad-spectrum TRP
channel blocker, ruthenium red, which blocks TRPA1 (Macpherson et ah, 2005) but
not TRPM8 (Reid, 2005; Weil et ah, 2005), in support of a TRPA1-mediated effect
of cinnamaldehyde. Co-injection of ruthenium red with icilin had no effect on the
analgesic effect of icilin, again supporting the idea that icilin does not exert its
analgesic effect through the TRPA1 channel.
These results and those of other groups define a role for TRPA1 in transduction of
noxious chemical stimuli. TRPA1 agonists such as allicin and diallyl disulphide (the
active ingredients in garlic), allyl isothiocyanate (the active ingredient in mustard and
horseradish), and acrolein (a toxic chemical present in tear gas, vehicle exhaust, and
smoke) are well known for their production of a painful, pungent sensation when
applied topically or orally (Bandell et ah, 2004; Bautista et ah, 2005, 2006; Jordt et
ah, 2004; Macpherson et ah, 2005). TRPA1 is also activated indirectly by the
endogenous proalgesic chemical bradykinin, which acts on BK2 receptors to cause
activation of TRPA1, through an imprecisely-defined pathway that is dependent on
PLC activity (Bandell et ah, 2004). Cinnamaldehyde (10%, equivalent to 75 mM)
applied topically to the forearm in human subjects induces spontaneous pain, and
thermal and mechanical hyperalgesia (Namer et ah, 2005); intraplantar
cinnamaldehyde (doses of 6.6 and 21.7 pg, delivered in 10 pi volume) causes licking
and flinching behaviour in mice, and the development of thermal hyperalgesia
200
(Bandell et al., 2004). Studies of TRPA1 knockout mice showed decreases in the
licking and flinching behaviour evoked by topical mustard oil (Bautista et al., 2006),
intraplantar mustard oil (Kwan et al., 2006) or intraplantar bradykinin (Bautista et al.,
2006; Kwan et al., 2006). These results and ours point to a critical role for the
TRPA1 receptor in mediating the response to multiple noxious chemical stimuli, and
in evoking nociceptive responses.
In humans, the sensory effect produced by chemical activators of TRPA1
generally includes a burning hot feeling (in contrast to the purported role of TRPA1
in mediating cold sensation). So intuitively, TRPA1 agonists might be expected to
produce a thermal hyperalgesia. However, the reason for the mechanical
hypersensitivity observed with cinnamaldehyde is less clear. It is possible that
TRPA1 is expressed in polymodal nociceptors, and that activation of TRPA1
produces a sensitisation of the nociceptor terminal, allowing activation by lower
levels of all activating stimuli, including thermal and mechanical stimuli. There
could also be an induction of central sensitisation, following stimulation of TRPA1-
expressing nociceptors, facilitating both thermal and mechanical inputs in the spinal
cord. Alternatively, TRPA1 has been proposed to be involved in
mechanotransduction (Introduction section 1.25.1), and therefore it is possible that a
facilitation of TRPA1 produced by the agonist cinnamaldehyde could facilitate
mechanotransduction by this receptor, contributing to mechanical hypersensitivity.
The behavioural sensitisation produced by administration of TRPA1 activators
was blocked by icilin, suggesting that TRPM8 activation directly opposes the effect
of TRPA1 activation. This result also demonstrates that TRPM8 activation produces
analgesia in a sensitised pain state with a comparatively short timecourse. The
models investigated above - CCI, CFA and lysolecithin - all develop over a period
of days, whereas cinnamaldehyde-induced sensitisation is apparent within 15
minutes following intrathecal injection. The action of icilin on cinnamaldehyde-
induced sensitisation indicates that although the effect of icilin is selective to a
sensitised pain state, it does not require chronic changes in nervous system function
(such as alterations in gene and protein expression, which would require longer than
15 minutes to occur).
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It is widely agreed that TRPM8 and TRPA1 are not co-expressed (Kobayashi et
al., 2005; Nagata et al., 2005; Story et al., 2003), and so the opposing effects of
TRPM8 and TRPA1 agonists must be assumed to be mediated by different neurons.
This implies that, in order for TRPM8-activators to attenuate TRPA1-induced
hyperalgesia, there must be a centrally-mediated mechanism of analgesia.
Recent results show that cinnamaldehyde, in addition to activating TRPA1, also
acts as an antagonist of the TRPM8 receptor (Macpherson et al., 2006). However,
much higher concentrations are required for the antagonist action of cinnamaldehyde
at TRPM8 in comparison with the concentrations required to activate TRPA1:
antagonistic effects of cinnamaldehyde on TRPM8 were only achieved at a bath
concentration of 1.5 mM in whole cell recordings (Macpherson et ah, 2006), and
therefore it is unlikely that the 1.5 mM concentration applied topically to the skin
here and intrathecally will have exerted much effect on TRPM8. Icilin itself interacts
with the TRPA1 channel, but, as discussed above, with a significantly lower potency
than at TRPM8 (Story et ah, 2003). Furthermore, the analgesic effect of icilin shown
in behavioural experiments is entirely different from the pro-nociceptive profile of
TRPA1 activators, and icilin had no effect on behavioural responses in animals
which had undergone antisense-knockdown of TRPM8, suggesting that, at the doses
used, icilin had no effect on behavioural responses through TRPA1-mediated
mechanisms
5.9 Central mediation of TRPM8-induced analgesia through Group Il/III
mGluRs
Central activation of TRPM8 was analgesic, suggesting that central processing
mechanisms may be involved in the analgesic effect of TRPM8 activation. The idea
of central processing is also indicated by the fact that TRPM8 is expressed by a
relatively small population of innocuous cold-sensitive neurons and possibly by
some cold-sensitive nociceptors. Therefore it is unlikely that TRPM8 is expressed by
a large proportion of the fibres that mediate the sensitised responses to thermal and
mechanical stimuli, suggesting that, in order for TRPM8 activation to produce a
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strong reversal of thermal and mechanical sensitisation, a central mechanism must be
involved.
TRPM8 analgesia appears to be independent of spinal opioidergic mechanisms, as
it was not blocked by spinal administration of the non-selective opioid antagonist
naloxone. This is perhaps unsurprising, as icilin was highly effective in producing
analgesia in a neuropathic pain model, and the effects of opioids on responses to
painful stimuli and on the responses of dorsal horn neurons are decreased in
neuropathic pain states (Dickenson & Suzuki, 2005; Moulin, 2006; Woolf &
Mannion, 1999).
Instead, the analgesia induced by intrathecal icilin and menthol was found to be
dependent on Group II/III metabotropic glutamate receptors, as it was reversed by
co-injection of antagonists of these receptors. The mGluR action is not due to a non¬
specific interaction between the two drugs, and also appears to be engaged
downstream of TRPM8 activation, as intrathecal injection of Group II/III mGluR
antagonists reversed the analgesic effect of peripheral menthol and icilin application,
and of skin cooling to 16°C. The antagonists were without effect alone in either CCI
animals or naive animals, suggesting that Group II/III mGluRs are not active
tonically but are specifically activated downstream of TRPM8 activation. This
evidence, together with supporting electrophysiological evidence, strongly suggests a
role for Group II/III mGluRs in the mediation of TRPM8-induced analgesia.
Results further showed that agonists of Group II/III mGluRs mimicked the effects
of icilin, selectively inhibiting the sensitised responses ipsilateral to CCI. Previous
experiments have shown that intrathecally administered Group II mGluR agonists
reverse sensitisation in models of inflammatory (Dolan & Nolan, 2002; Fisher et al.,
2002; Simmons et al., 2002) and neuropathic pain (Fisher et al., 2002; Simmons et
al., 2002), and that Group II mGluR agonists reverse capsaicin- or inflammation-
induced sensitisation of spinal projection neuron responses to mechanical and
electrical stimulation, with little effect on normal responses (Neugebauer et al., 2000;
Stanfa & Dickenson, 1998). Therefore, these receptors are implicated in the selective
reversal of sensitised pain states, and in agreement with this a selective reversal of
sensitised ipsilateral responses in CCI animals was observed.
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Somewhat differently to the Group II mGluRs, several studies suggest that Group
III mGluRs inhibit both normal and sensitised responses to sensory stimuli. Agonists
of these receptors inhibit normal responses to mechanical brush and pinch stimuli
and electrical stimulation, as well as the sensitisation of these responses produced by
peripheral capsaicin or inflammation (Gerber et al., 2000; Neugebauer et ah, 2000;
Stanfa & Dickenson, 1998). However, another study showed that agonists selectively
inhibit sensitised behavioural responses in the SNL model of neuropathy, with no
effect in normal rats, and inhibited responses of dorsal horn projection neurons to
mechanical stimulation in SNL but not in nai've rats, suggesting that Group III
mGluR inhibitory function may be elevated in neuropathy (Chen & Pan, 2005). This
is consistent with my behavioural observations, showing a selective reversal of
ipsilateral sensitisation in CCI animals, with no effect on contralateral thresholds.
Extracellular recordings of single dorsal horn neurons in CCI animals showed
results that mirrored behavioural findings. Application of icilin to part of the
neuronal receptive field inhibited the sensitised responses of ipsilateral neurons to
motorised rotating brush, with no effect on contralateral neurons. It is reasonable to
assume that this brush stimulus represents a noxious effect ipsilateral to CCI. In
neuropathic pain syndromes, allodynia develops so that innocuous mechanical
stimuli such as brushing of the skin are perceived as noxious (Koltzenburg et al.,
1994; Maihofner et al., 2003), and in peripheral nerve injury models, the responses of
spinal cord neurons to innocuous brush stimuli are sensitised, and show a
significantly higher discharge frequency ipsilateral to injury (Leem et al., 1995;
Palecek et al., 1992), indicating that the response to innocuous mechanical input has
become sensitised and that this innocuous brushing now represents a noxious
stimulus.
The neurons recorded from were multireceptive neurons, identified by their
response to both innocuous brush and a noxious pinch stimulus, and a majority were
located in LIII/IV, with some (25%) in LI. The effect of icilin on LIII/IV neurons
indicates that mechanisms must be engaged downstream of TRPM8 activation, as
immunohistochemistry showed that TRPM8 expression is confined to the superficial
laminae of the dorsal horn. The Group II/III mGluRs may be this downstream
mechanism, as evidenced by behavioural experiments and by the fact that the Group
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Ill mGluR selective antagonist UBP 1112 blocked the inhibitory effect of topically
applied icilin on ipsilateral neuron responses. UBP 1112 was used as an example of a
Group II/III mGluR antagonist, and the effects of Group II selective antagonists were
not examined. Further experiments could address this issue, to see whether these
antagonists produced a similar effect to UBP 1112.
The results obtained suggest that the Group II/III mGluRs play an important role
in mediating TRPM8-induced analgesia. This does not appear to be due to a change
in expression however, as no change in expression levels of any of these -
mGluR2/3, mGluR4 and mGluR7 - was observed in Western blots of DRG and
spinal cord in CCI and naive animals, or in immunohistochemical analysis of
mGluR7 in DRG.
5.10 Possible postsynaptic component of TRPM8-mediated analgesia
To further investigate the effect of TRPM8 activation on sensitised responses in
the spinal cord, the effect of icilin was examined on sensitisation evoked by
intrathecal NMDA application. The NMDAR is critically implicated in the
generation of increased spinal cord excitability and sensitised pain states, as
demonstrated by results showing that the facilitation, although not the response itself,
of dorsal horn neurons following repeated stimulation of nociceptive fibres, is
selectively reduced by NMDAR antagonists (Davies & Lodge, 1987; Dickenson &
Sullivan, 1987; Dickenson & Aydar, 1991; Dougherty & Willis, 1991; Woolf &
Thompson, 1991), and that intrathecally administered NMDAR antagonists attenuate
neuropathic pain behaviours (Chaplan et al., 1997; Mao et ah, 1992; 1993; Tal &
Bennett, 1993). Intrathecal administration ofNMDA produces hyperalgesia in naive
animals (Aanonsen & Wilcox, 1987; Kolhekar et ah, 1994; Liu et ah, 1997) and
therefore this was used as a model of a spinally-generated, sensitised pain state, in
which to investigate the effect of icilin.
Co-injection of icilin with NMDA prevented this development of sensitisation. In
CCI animals, co-injection of icilin also prevented the further increase in ipsilateral
sensitivity evoked by lower doses of NMDA that were insufficient to affect
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contralateral or naive responses. Therefore TRPM8 activation is also effective in
producing a reversal ofNMDA-mediated sensitisation.
The majority of NMDARs are located postsynaptically, and are implicated in
postsynaptic facilitation of spinal cord neurons (Dickenson & Sullivan, 1987).
Therefore, the fact that icilin reversed NMDA-induced sensitisation suggests that
icilin may act through a partially postsynaptic mechanism of action. However,
NMDARs may also be located presynaptically on afferent terminals (Liu et al., 1994)
and therefore it is possible that part of the action of intrathecal NMDA is mediated
through these presynaptic receptors. It is thought that the activation of presynaptic
NMDARs may contribute to the release of the neuropeptide substance P (SP) from a
subset of primary afferents in the rat dorsal horn. Intrathecal NMDA induces
internalisation of the SP receptor into dorsal horn neurons, which is an effect
generally taken to indicate SP release (Mantyh et al., 1995), and this internalisation,
and the hyperalgesic effect of intrathecal NMDA, are reduced by co-injection of SP
receptor antagonists or by elimination of TRPV1-containing nociceptive primary
afferents with capsaicin (Liu et al., 1997). These results therefore suggest that part of
the nociceptive effect of NMDA is mediated by inducing SP release from primary
afferents (Liu et al., 1997). However, it has also been suggested that presynaptic
NMDARs can play an inhibitory role (Bardoni et al., 2004), as in spinal cord slice
experiments, NMDA evoked primary afferent depolarisation (an electrophysiological
phenomenon which results in primary afferent inhibition) and a depression of the
frequency of action potential-evoked EPSCs and an increase in latency and in
transmission failures (Bardoni et al., 2004), which are taken to indicate a presynaptic
effect (Engelman & Macdermott, 2004). While activation of presynaptic NMDARs
could contribute to the facilitatory effect of intrathecal NMDA, by stimulating SP
release, or, conversely, could inhibit sensitisation by inhibiting glutamate release
from nociceptive afferents, it is reasonable to assume that the effect of intrathecally-
injected NMDA is mediated substantially via postsynaptic receptors, due to the high
levels of postsynaptic receptors (Petralia et al., 1994; Tolle et al., 1993). Therefore,
the complete block of NMDA-mediated sensitisation by icilin suggests that some of
icilin's action may be mediated through a postsynaptic mechanism.
206
5.11 Schematic model of results
Figure 5.1 shows a schematic outline of a model which summarises the findings of
this thesis. In this model, activation of TRPM8 by peripheral or central means causes
the release of glutamate from TRPM8-expressing afferents, which then acts on
Group II/III mGluRs, located presynaptically on nociceptive afferents and/or
postsynaptically on spinal neurons, to result in attenuation of both neuronal
sensitisation and pain behaviours. In support of this model, TRPM8-activating
compounds have been shown to activate a subpopulation of afferents. Other
experiments have shown that menthol increases mEPSC frequency, but not
amplitude, at synapses between afferent and dorsal horn neurons in slices (Baccei et
al., 2003) and in DRG-dorsal horn neuron co-cultures (Premkumar et al., 2005;
Tsuzuki et al., 2004) which is presumably due to a activation of TRPM8-containing
afferents and increased release of glutamate from presynaptic terminals. Peripheral or
central administration of TRPM8 agonists produced analgesia and inhibition of
dorsal horn neurons in sensitised pain states, and this was dependent on spinally
located Group II/III metabotropic glutamate receptors.
A large proportion of Group II/III mGluR expression is indicated to be presynaptic
on primary afferent terminals (Azkue et al., 2001; Carlton et al., 2001; Ohishi et al.,
1995a,b), suggesting a presynaptic mechanism of action. However, as discussed
above, inhibition of NMDA-induced sensitisation suggests an at least partially
postsynaptically mediated mechanism.
This model represents a gating mechanism, in which signals from nociceptive
afferents are inhibited by activity in other afferents, presumably cold-sensitive
TRPM8-expressing afferents, via a central spinal mechanism. The ability of non-
nociceptive information to gate nociceptive signalling via a spinal mechanism was
first suggested in the gate control theory of Melzack & Wall (Melzack & Wall,
1965). In the mechanism identified here, cold-sensitive afferents appear to gate the
activity of nociceptive afferents, via the activation of inhibitory mGluRs. Further
questions regarding this mechanism, including its relationship to the gate control
theory, and the role of pre and postsynaptic mGluRs, will be discussed further below
in section 5.15.2
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H Group il/lll mGluR
□ TRPM8
Figure 5.1 Schematic representation of a possible mechanistic basis
for TRPM8-mediated-analgesia
In this simplified hypothetical model, activation of TRPM8 in a subpopulation
of afferents, by icilin, menthol or moderate cooling leads to central synaptic
release of glutamate (Glu) which then acts through inhibitory Group Il/lll
mGluR receptors located either presynaptically on injury-activated
nociceptive afferents or perhaps also postsynaptically on dorsal horn
neurons, thereby attenuating neuropathic sensitisation
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5.12 Overall significance of results
These results considered as a whole describe an analgesia which can be produced
by activating TRPM8 receptors located on primary afferents, is mediated centrally
through Group II/III metabotropic glutamate receptors in the spinal cord, and is
specific to sensitised pain states. The key significance of these results is that they
identify a mechanism underlying the effect of analgesia produced by cutaneous
cooling and by menthol or mint oil, and identify a novel endogenous analgesic
system which may be exploited for new clinical treatments of chronic pain. This
study is also notable in that it is one of the first in vivo studies of the effects of
TRPM8 activation. Extensive in vitro studies have characterised the properties of the
channel (McKemy, 2005; Reid, 2005), and studies have also addressed the
localisation of this receptor (Kobayashi et al., 2005; Okazawa et ah, 2004; Peier et
ah, 2002b). However, this is the first time that the effects of TRPM8 activation have
been examined in detail in vivo in afferent and spinal dorsal horn neuron recordings,
and behavioural experiments.
The relationship of these findings to previous knowledge about the analgesia
produced by cooling and mint oil, and their relevance to clinical applications, will be
considered below.
5.13 Identification of a mechanism of analgesia produced by cutaneous cooling
These results identify a mechanistic basis for the phenomenon of cooling-induced
analgesia, which has been known since ancient times (Adams, 2006; Sprengell,
1735; Siegel, 1970). Activation of TRPM8 by cooling or chemical agonists produces
a strong analgesia in sensitised pain states, which is abolished by TRPM8
knockdown, suggesting that both the analgesic effect of cutaneous cooling, and the
analgesic effect of topical menthol or mint oil, are at least partially mediated through
activation of the TRPM8 receptor.
Other mechanisms have been proposed to account for cooling-induced analgesia.
Cooling-induced inhibition of peripheral nociceptive transduction processes has been
proposed as a mechanism (Koltzenburg et ah, 1992), and it has been demonstrated
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that cooling inhibits capsaicin-induced currents through TRPV1 in DRG cells (Babes
et ah, 2002), and inhibits capsaicin-induced stimulation of CGRP release in rat skin
(Kichko & Reeh, 2004), although no studies have shown a specific inhibitory effect
of cooling on receptors for non-thermal noxious stimuli. Cooling may also inhibit
local inflammatory responses by promoting vasoconstriction. Very strong local
cooling (<0°C), which produces a block of nervous conduction, inhibits pain
perception by preventing conduction by nociceptive afferents (Abramson et al.,
1966; Evans, 1981; Lee et al., 1978). The mechanism described in this thesis does
not rule out other mechanisms such as these. In the analgesia produced by low
(<0°C) temperatures, mechanisms such as cold-induced block of nervous conduction,
or the activation of descending inhibitory pathways elicited by noxious stimuli are
likely to predominate. Similarly, in conditions in which peripheral tissue
inflammation is an important factor, cooling-induced inhibition of TRPV1 and
cooling-induced vasoconstriction may play a significant role.
However, by using selective activators of TRPM8, rather than physical cooling
(and antisense knockdown of TRPM8), TRPM8 activation is strongly implicated in
the analgesia produced by moderate cutaneous cooling. Furthermore, this effect (and
that of moderate cutaneous cooling) is apparent in the CCI model of neuropathic
pain, in which peripheral inflammation will play a relatively small role, as the injury
is set up proximal to the periphery, and as neuropathic models are thought to rely
predominantly on changes in afferent neurons and in the spinal cord, rather than on
peripheral inflammation (Bridges et al., 2001; Ji et al., 2003; Campbell & Meyer,
2006).
The results described identify a powerful endogenous mechanism of analgesia that
can be elicited by local stimulation of TRPM8 in sensitised pain states. This
mechanism is active in neuropathic, inflammatory, demyelination-induced and
chemical models of sensitised pain states, suggesting a general mechanism for
coping in sensitised pain states. The extent to which this mechanism is activated
naturally in sensitised pain states is unclear. Peripherally located TRPM8 can be
activated by cool temperatures, and humans and animals could use local peripheral
cooling as a means of relieving pain. However, as described in the introduction,
chemical modulators of TRPM8 exist, and the central location of TRPM8 (in the
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spinal cord) suggests that chemical agonists of TRPM8 must exist. In sensitised pain
states, it is possible that endogenous chemical agonists could be released, which
activate or facilitate TRPM8, partially inhibiting the increased pain signalling and
allowing the animal to cope. This mechanism could have evolved as a coping
mechanism, allowing the induction of local analgesia to permit animals to survive
and deal with injury.
It is generally accepted that other mechanisms, at present poorly identified, also
contribute to the sensory detection of cold temperatures (Madrid et al., 2006; Munns
et al., 2006; Reid, 2005; Story et al., 2003; Viana et al., 2002, 2006). In addition to
TRPA1, the role of which in cold sensitivity is still under debate, studies suggest
additional cold-sensitive mechanisms. Populations of sensory neurons have been
identified that respond to decreases in temperature within the range of 30 - 20°C, but
not to activators of either TRPM8 or TRPA1 (Babes et al., 2004), and that do not
express TRPM8 or TRPA1 (Babes et al., 2006). Additional cold-sensitive currents in
sensory neurons have been identified, such as a hyperpolarising K+ current which is
deactivated by decreasing temperature (Reid & Flonta, 2001b; Viana et al., 2002).
Additional ion channels have been shown to respond to decreases in temperature,
including the K+ channels TREK-1 and TREK-2 (Lesage et al., 2000; Maingret et al.,
2000), and the epithelial Na+ channel ENaC (Askwith et al., 2001). The role of such
alternative transduction mechanisms in cooling-induced analgesia is currently
unclear. It is possible that these other cold-activated currents could play a role in the
analgesic effect of cutaneous cooling, but they presumably do not play a role in the
analgesic effect of TRPM8-specific agonists, particularly as icilin and menthol had
no effect following TRPM8 knockdown. On balance, the strong analgesic effect of
TRPM8 activators suggests that this receptor may play a dominant role in cooling-
induced analgesia. This strong analgesic effect of specific TRPM8 activators,
together with the difficulty associated with applying precisely defined cold
temperatures and the fact that more intense cold temperatures can be noxious,
suggests that chemical agonists of TRPM8 may be a far more specific and powerful
means of producing clinical analgesia than physical cooling.
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5.13.1 Argument against a desensitisation mechanism of icilin and menthol-
induced analgesia
A possible explanation for analgesia mediated by menthol or icilin administration
could be that these agonists cause desensitisation of the TRPM8 receptor. In this
scenario, TRPM8 would be predominantly located on nociceptive neurons,
contributing to nociceptive transmission and to sensitised pain behaviours, and
agonists would cause TRPM8 desensitisation, resulting in inhibition of nociceptive
signalling. However, this is unlikely to account for the effects observed here for the
following reasons. Firstly, desensitisation would be a purely peripheral mechanism,
occurring at the peripheral receptor, with no requirement for effects downstream, but
the analgesic effect of icilin appears to be dependent on metabotropic glutamate
receptors in the spinal cord. Secondly, antisense knockdown of TRPM8 had no
effect on behavioural thresholds or on the sensitisation of these that occurs ipsilateral
to CCI. If the TRPM8 receptor was involved in nociceptive signalling, then antisense
knockdown itself would be expected to affect behavioural sensitivity to noxious
stimuli. Thirdly, saphenous nerve recordings demonstrated that icilin and menthol
caused a prolonged stimulation of afferent firing, that was evident over 12 minutes
following application of the drug, arguing that icilin and menthol, at the doses used,
do not have a rapid desensitising effect on the firing of afferents. Fourthly, agonist-
mediated desensitisation of TRPM8 would only be expected to affect TRPM8-
expressing neurons. As TRPM8 is expressed by a relatively small proportion of DRG
neurons, and is not co-expressed with several markers of nociceptive neurons (Peier
et al., 2002b), it is unlikely that TRPM8 will be expressed to a great extent in the
neuronal populations that mediate the CCI-sensitised responses to thermal and
mechanical stimuli. Therefore desensitisation of TRPM8 would not be likely to
account for the strong reversal of thermal and mechanical sensitisation observed with
TRPM8 agonists. On balance, it appears highly unlikely that icilin and menthol-
mediated analgesia occurs through desensitisation of TRPM8.
5.13.2 Argument against a counter-irritation-induced mechanism of analgesia
A mechanism which has previously been proposed to account for the analgesic
effect of topically applied menthol is that of counter-irritation. The principle of
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counter-irritation is that pain can be overcome by eliciting a second irritant
stimulation which detracts from the first pain. Psychophysical studies show that high
doses of topical menthol (40%) produce feelings of pain, including pinprick
sensations and punctate hyperalgesia (Green, 1985; Hatem et al., 2006; Namer et al.,
2005; Wasner et al., 2004). Therefore it has been suggested that topical menthol
produces analgesia by acting as a counter-irritant, presumably by noxious event-
induced activation of descending inhibitory pathways from the brain, which are
known to be activated by noxious stimulation (Le Bars et al., 1979a,b). However, the
results reported here argue against this, as analgesic effects were observed with much
lower concentrations of menthol (4 mM menthol, which is equivalent to a 0.6%
solution) than those reported to produce pain. Additionally, topical icilin was
observed to produce analgesia at low doses, but hyperalgesia at high doses, which
argues against a mechanism of counter-irritation, where increasing doses would be
expected to continually increase the analgesic effect.
5.14 TRPM8-induced analgesia: potential for clinical use
TRPM8 activation stimulates a natural mechanism of the nervous system to
suppress pain signalling. This analgesia is effective in a variety of sensitised pain
states and is specific to sensitised responses. TRPM8 is therefore a promising target
for novel analgesic therapies. TRPM8 agonists could be used clinically to exploit this
endogenous mechanism of analgesia without affecting normal acute pain sensation.
The effectiveness of topical TRPM8 activators is notable, as it would allow a non¬
invasive therapy, and would reduce possible side effects associated with central
administration of drugs or their vehicles. Although intrathecal administration of
agonists was also shown to be analgesic, this is a far more invasive procedure, and
would therefore be less desirable for clinical use. The Group II/III mGluRs are
another potential target for clinical therapies; however, these receptors are implicated
in a variety of functions and dysfunctions in the central nervous system, including
motor control, anxiety and depression, learning and memory, and epileptic seizures
(Conn & Pin, 1997). Therefore Group II/III mGluR agonists might be expected to
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have more undesirable side effects than TRPM8 agonists, and are thus a less
promising clinical target.
5.14.1 Effectiveness of TRPM8 activators in other pain states
In order to fully assess the potential clinical use of TRPM8 agonists it would be
useful in further experiments to investigate the range of conditions in which TRPM8
agonists produce analgesia. It could be useful to investigate the effect of TRPM8
agonists in other models of chronic pain, such as models of bone cancer-induced pain
(Honore et al., 2000); postherpetic neuralgia (Fleetwood-Walker et al., 1999);
neuropathic pain produced by chemotherapy drugs, and other models of
inflammatory pain. However, the experiments reported here have revealed a
significant analgesic effect of icilin in a number of sensitised pain states:
neuropathic, demyelination-induced, inflammatory, NMDA-sensitised and
cinnamaldehyde-sensitised, suggesting that TRPM8 agonists will be effective in
many sensitised pain states. Therefore it may be more beneficial to concentrate on
the mechanism of analgesia produced by local cutaneous cooling.
In addition to the inhibitory role in sensitised pain states demonstrated here,
previous work has identified icilin, menthol and cooling as effective anti-pruritic
agents. Both topical menthol (1%) and cooling the skin (from 32 to 29°C) reduced
the intensity of itch induced by the histamine skin-prick test in psychophysical
experiments (Bromm et al., 1995). Weaned hairless rats on a low magnesium diet
develop pruritus-like symptoms including a rash, and biting and scratching, which
are reduced by topical icilin (Wei & Meingassner, 2005). Thus TRPM8 may be a
common mediator of relief of both pain and itch, adding to the clinical potential of
TRPM8 activators. It would be interesting to investigate animal models of itch to see
whether the relief of itch by icilin and menthol is mediated through a similar
pathway, perhaps also involving inhibitory glutamate receptors. Itch and pain are
mediated through anatomically distinct primary afferent (Schmelz et al., 1997) and
spinal cord pathways (Andrew & Craig, 2001), but frequently involve similar
molecular mediators (such as histamine and bradykinin activation) and mechanisms
(such as central sensitisation of dorsal horn neurons) (Ikoma et al., 2006). It would
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therefore be interesting to know to what extent TRPM8 activation relieves itch and to
what extent it operates through similar spinal mechanisms.
5.14.2 Alternative TRPM8 activating compounds
This study used menthol and icilin, which are the most well-studied TRPM8
agonists and among the most potent and efficacious (Behrendt et al., 2004).
However, there are a variety of other chemical agonists of TRPM8. Many of these
are based on the structure of menthol and were developed many years before the
discovery of TRPM8, for the property of producing a cooling sensation when applied
to the skin (Leffingwell, 2006; Watson et al., 1978). A second group of cooling
compounds are based on the tetrahydropyrimidine-2-one structure of icilin (Wei,
2003), and a third group of cooling compounds are cyclic a-ketoenamines (Bassoli et
al., 2005). Until recently, icilin was the most potent and efficacious agonist of
TRPM8. However, the Wilkinson Sword-developed cooling chemical WS-12
appears to have an even higher affinity for TRPM8 than icilin, with an EC50 of 39
nM compared with 500 nM for icilin in similar conditions (Beck et al., 2006). It
would be beneficial to further characterise the actions of WS-12 at TRPM8 to
investigate whether this chemical indeed is an effective and specific agonist of
TRPM8. If so, WS-12 could be a valuable tool for further study of TRPM8, and a
potential candidate for clinical use as a TRPM8 activator to produce analgesia.
If TRPM8 agonists are to be used clinically it is important that they are of low
toxicity and with as few side-effects as possible. Icilin itself fits this description well
as it has few known side-effects and a structure which suggests low toxicity (E.T.
Wei, personal communication). Although less potent, menthol has been used safely
in over-the-counter topical preparations for many years and therefore is another
candidate for clinical use. The downside of both of these compounds is that they
have agonist properties at receptors other than TRPM8. It is possible that other
TRPM8 agonists, possibly including WS-12, have fewer non-TRPM8 actions and
therefore could be more suitable for potential clinical use.
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5.14.3 Potential effects of TRPM8 agonists in non-target tissues
TRPM8 expression has been shown outside the peripheral sensory nervous
system, most notably in prostate and bladder epithelial cells and also in arterial
smooth muscle (Stein et al., 2004; Yang et al., 2006; Zhang & Barritt, 2004). In some
of these tissues, TRPM8 may have a pathological function, as its expression is
upregulated in prostate cancer, and TRPM8 expression appears de novo in primary
breast, lung and skin tumours (Tsavaler et al., 2001). The TRPM8 activator menthol
induces apoptosis of prostate cancer cells (Zhang & Barritt, 2004), suggesting that
this channel may play a role in tumour cell development or survival (Zhang &
Barritt, 2004, 2006).
While the effects of TRPM8 activation in such non-nervous tissues are outside the
scope of this thesis, they are relevant to the use of TRPM8 agonists in a clinical
setting. It would seem to be sensible to avoid tissues outside the nervous system
which express TRPM8, when administering TRPM8 agonists, and particularly to
avoid cancerous tissue until the role of TRPM8 in tumour development is more
clearly known. It is suggested that TRPM8 agonists could play a positive role in
tumour therapy, by stimulating apoptosis of tumour cells (Beck et al., 2006), but
from a clinical point of view it would still be undesirable to have TRPM8 agonists
administered as pain treatments interacting to an unknown extent and with unknown
effects at tumour sites. Therefore systemic administration of TRPM8 agonists should
be avoided, as this could result in activation of TRPM8 in these non-target areas and
thus potential unwanted side effects. Topical TRPM8 activators applied locally to the
area of peripheral innervation would avoid such effects, as would intrathecally
delivered drugs, which are confined to the spinal cord.
5.15 Further questions regarding the mechanism of TRPM8-mediated analgesia
There are several key remaining questions regarding the mechanism of TRPM8-
mediated analgesia, including: the role of modulation of TRPM8 activity by
intracellular signalling pathways; the nature of the spinal cord connections that
produce inhibition, including whether it is pre- or postsynaptic; and the involvement
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of specific subtypes of inhibitory mGluRs and intracellular signalling pathways
engaged by mGluRs. These will be discussed in turn below.
5.15.1 Involvement of intracellular signalling pathways modifying TRPM8
A number of interactions of TRPM8 with endogenous signalling molecules have
been identified (Huang et al., 2006). The involvement of these in TRPM8-mediated
analgesia was beyond the scope of these experiments, especially as many of the
molecules which modify TRPM8 are ubiquitous and are therefore difficult to
investigate in in vivo experiments. Nevertheless, endogenous modulation of TRPM8
may well impact on the analgesia mediated through this receptor. Indeed, it is
possible, as mentioned above, that endogenous chemical agonists could be released
under some circumstances in sensitised pain states to activate TRPM8, partially
inhibiting the pain signal.
One key endogenous modulator of TRPM8 is PI(4,5)P2, which has been shown to
activate TRPM8 and is required for cold and menthol activation of the channel
(covered in more detail in introduction; Rohacs et al., 2005; Liu & Qin, 2005).
Therefore it would be expected that stimulation of PI(4,5)P2 formation would
facilitate the analgesic effect of icilin and menthol, whereas perturbations that result
in PI(4,5)P2 depletion would inhibit analgesia. So it is possible that under some
circumstances in vivo, a stimulation of PI(4,5)P2 formation could lead to TRPM8
activation or facilitation, producing an inhibition of pain signalling and of sensitised
pain states.
In contrast, a number of key inflammatory signalling molecules are associated
with downregulation of TRPM8, although the function of these has not been assessed
in vivo. Application of the proalgesic agent bradykinin decreases the sensitivity of
TRPM8-expressing neurons to cooling and TRPM8 agonists, and this effect is
dependent on PKC activity (Linte et al., 2006; Premkumar et al., 2005). Another
endogenous pro-inflammatory agent, PGE2, has similar effects, decreasing the
sensitivity of TRPM8-expressing neurons to cooling (Linte et al., 2006). Decreases
in extracellular pH, to levels that occur in inflamed tissue, can inhibit the activation
of TRPM8 by icilin and cold, but not menthol (Andersson et al., 2004). Thus TRPM8
function may be inhibited in inflammatory pain states as a result of these signalling
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effects, although it is by no means certain that the overall effect of inflammation on
TRPM8 in vivo is inhibitory - it is possible that other signalling pathways are
activated which result in facilitation of TRPM8. However, an inhibition of TRPM8
in inflammatory pain states could have two alternative consequences. One is that
peripherally applied TRPM8 activators might produce a weaker analgesic effect, due
to inhibition of TRPM8 by inflammatory mediators. Conversely, it could be true that
exogenous application of TRPM8 agonists is particularly helpful in such states, by
countering the natural inhibition of TRPM8 function produced by inflammatory
mediators.
It is likely that in the future, more functional interactions of TRPM8 with adapter
or signalling molecules will be described. It is possible that, in sensitised pain states,
one or more signalling pathways results in facilitation of the TRPM8 receptor, so that
it is more easily activated. Facilitation could occur at centrally located TRPM8
receptors or at peripherally located receptors, or both, and could explain the apparent
selectivity of TRPM8-induced analgesia to sensitised pain states. Facilitation of
TRPM8 would lead to increased glutamate release by TRPM8-expressing fibres and
thus to an increased inhibition of nociceptive signalling through mGluRs. Such
effects could explain the selectivity we have observed with icilin and menthol-
induced analgesia.
5.15.2 Further questions regarding the mechanism of spinal cord inhibition
The results in this thesis led to the suggested schematic shown in Figure 5.1, in
which activation of TRPM8-expressing afferents causes release of glutamate, which
activates Group II/III mGluRs located presynaptically on the terminals of nociceptive
afferents or postsynaptically on dorsal horn neurons. However, the precise spinal
circuitry underlying this inhibition remains unknown.
Group II mGluRs are pre and postsynaptically located in the spinal cord. One
study indicated that they were predominantly presynaptic on afferent terminals in
superficial laminae (as shown by rhizotomy) and located on intrinsic spinal neurons
in deeper laminae (Carlton et ah, 2001), but another study suggested some
localisation on spinal cord neurons throughout the cord (Jia et ah, 1999), suggesting
that they are found both pre and postsynaptically in the spinal cord. They may be
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expressed on spinal cord neurons at postsynaptic terminals, or on the presynaptic
terminals of spinal interneurons (Jia et al., 1999). Group II mGluR2/3
immunoreactivity is also shown by spinal cord astrocytes (Silva et ah, 1999).
Electron microscopy shows a predominantly extrasynaptic location at neuron
terminals, suggesting a heterosynaptic function (Azkue et al., 2000). Of the Group III
mGluRs, mGluR7 appears to be found primarily at presynaptic afferent terminals in
superficial laminae, as immunostaining is removed by rhizotomy, (Kinoshita et ah,
1998, Li et al., 1997; Ohishi et al., 1995a,b). However, some immunoreactivity
remains following rhizotomy, and low levels of mGluR7 mRNA are found in the
spinal cord, suggesting some expression by spinal neurons as well (Berthele et al.,
1999; Boxall et al., 1998; Neugebauer et al,. 2002; Valerio et al., 1997). mGluR4 is
also expressed in the dorsal horn, with dense staining, observed in the superficial
laminae, localised predominantly in presynaptic terminals (Azkue et al., 2001).
Broadly speaking, the expression pattern of Group II/III mGluRs is consistent with
a presynaptic or postsynaptic inhibitory mechanism, and the studies described in this
thesis do not distinguish between such mechanisms. It might be possible to elucidate
more information about the mechanism of icilin-induced anti-sensitisation analgesia
and whether it is pre or postsynaptically mediated, from further electrophysiological
experiments. In particular, in preparations such as patch-recordings in spinal cord
slice preparations, the contribution of individual inputs and outputs can be more
closely examined than in in vivo extracellular recordings. Various
electrophysiological phenomena are used to distinguish pre and postsynaptic
mechanisms. Effects of a drug on the latency of monosynaptic EPSCs, or effects on
the number of transmission failures (failure of a presynaptic action potential to evoke
a postsynaptic current) are generally taken as evidence of a presynaptic action
(Engelman & MacDermott, 2004). An alteration in the frequency of mEPSCs
(miniature EPSCs, which are produced in the absence of action potentials) without a
change in their amplitude, is also generally accepted as being due to presynaptic
effects (Engelman & MacDermott, 2004; Tsuzuki et al., 2004). These experiments
could be used to distinguish between a pre or postsynaptically-mediated mGluR
effect in the mechanism of TRPM8-mediated analgesia.
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5.15.3 Presynaptically-mediated inhibition
Activation of presynaptic mGluRs is consistent with a potential inhibition of
nociceptive transmission, as both Group II and Group III are expressed at high levels
by nociceptive afferents. Group II mGluRs are found at high levels in afferent
neurons expressing the nociceptive marker IB-4, and in the dorsal horn, staining is
particularly high in inner LII, which is predominantly innervated by nociceptive
afferents (Carlton et al., 2001). Similarly, mGluR7 is found at high levels in small-
diameter DRG neurons, and approximately half of mGluR7-labelled afferents also
express the nociceptive markers IB-4 and SP (Li et al., 1997). mGluR4 protein is
seen at high levels in small-diameter DRG neurons, and in LII, consistent with
expression on the presynaptic terminals of nociceptors (Azkue et al., 2001).
Nociceptive afferents terminate predominantly in the superficial dorsal horn and can
activate dorsal horn neurons in both superficial laminae and, via an interneuronal
connection, neurons in deeper laminae (Basbaum & Jessell, 2000). TRPM8-
expressing afferents could activate mGluRs on the presynaptic terminals of
nociceptive afferents in the superficial dorsal horn, to inhibit the release of glutamate
from the nociceptive afferents. This would decrease the activity of dorsal horn
neurons driven by the nociceptive afferents, including those in both superficial and
deeper laminae. This is consistent with electrophysiological recordings showing that
icilin inhibited the firing ofWDR neurons in both superficial and deeper laminae.
If the mechanism of mGluR-mediated inhibition is presynaptic, it could operate
either directly or indirectly. As illustrated in Figure 5.2a, TRPM8-expressing cold-
sensitive afferents could release glutamate which activates the terminals of
neighbouring nociceptive afferents in a heterosynaptic inhibitory mechanism. In a
heterosynaptic mechanism, the neurotransmitter is released from a different neuron
to the neuron on whose terminal it acts, in contrast to homosynaptic inhibition, in
which neurotransmitter released from one neuron acts on receptors located on the
terminal of the releasing neuron itself. Both nociceptive afferents and TRPM8-
expressing afferents terminate primarily in superficial laminae (Basbaum & Jessell,
2000; Results section 4.5.4), and therefore the terminals could be anatomically close
enough to allow such an interaction. Electron microscopy studies show that a large
proportion of Group II mGluR expression is extrasynaptic, rather than at the
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presynaptic terminal itself, which suggests a heterosynaptic mechanism of activation
for these receptors (Azkue et al., 2000), and heterosynaptic activation of mGluRs has
been demonstrated in other areas of the nervous system, such as the cerebellum and
the hippocampus (Mitchell & Silver, 2000; Scanziani et al., 1997). The inhibition of
glutamate release from presynaptic afferent terminals would lead to inhibition of
downstream dorsal horn neurons.
Alternatively the mechanism could operate through interneurons (as shown in
Figure 5.2b). Glutamate released from TRPM8-expressing afferents could activate
glutamate-releasing interneurons, which in turn synapse onto the terminals of
nociceptive primary afferents to activate inhibitory glutamate receptors. Such
glutamatergic interneurons synapsing onto primary afferent terminals have been
shown in immunohistochemical studies (Vesselkin et al., 2003).
An interneuronally-mediated mechanism resembles the gate control theory of
Melzack and Wall (Melzack & Wall, 1965). In this theory, large AP fibre
mechanoreceptors were proposed to produce inhibition of nociceptive fibres via
interneurons which synapse onto the nociceptor terminals to inhibit firing (see
Introduction Figure 1.2). The suggestion outlined in this thesis is that input from
cooling-sensitive afferents, which could be either C or A5 fibres, produces an
inhibitory gate control over nociceptive populations. The original theory had AP
fibres exerting the inhibitory gate, rather than C or A5 fibres. However, it was not
crucial to the theory that the inhibitory neurons were AP fibres, only that they were a
different group of afferents to the nociceptive afferents, and produced inhibition of
the nociceptive afferents. There is evidence for presynaptic inhibition of nociceptive
afferents produced by activity in other small-diameter afferents: one study showed
that repetitive activation of sciatic A5 fibres produced a presynaptically-mediated
inhibition of saphenous C afferents (Jones et al., 2005), and A8 fibre stimulation has
been shown to produce a long-term depression of C fibre-evoked spinal field
potentials (Liu et al., 1998).
A second difference from the original gate control theory is that the interneurons
proposed by Melzack & Wall were suggested to be inhibitory GABAergic neurons,
rather than glutamatergic neurons. However, the importance of these neurons is that
they are functionally inhibitory, regardless of the transmitter released. Therefore it is
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possible that glutamatergic interneurons activated by TRPM8-expressing afferents
could mediate an inhibitory gate over nociceptive information and thereby explain
the results found here.
5.15.4 Postsynaptically-mediated inhibition
It is possible that TRPM8-expressing afferents could also activate postsynaptically
located Group II/III mGluRs, reducing the likelihood of postsynaptic excitation and
thereby reducing transmission of nociceptive information through the spinal cord. A
postsynaptic mechanism could account for the inhibitory effect of icilin on NMDA-
mediated hypersensitivity, which, as described above, is thought to be mainly
postsynaptically mediated. We saw inhibitory effects of icilin on WDR neurons in
deeper laminae. This could be mediated postsynaptically by an inhibition of
excitatory interneurons that relay signals from nociceptive afferents to deep WDR
neurons, or by the TRPM8-mediated activation of an inhibitory interneuronal
pathway that terminates on the deep WDR neurons. There are two apparent problems
with a postsynaptically mediated mechanism. Firstly, glutamate acting on
postsynaptic terminals would be expected to have a mainly excitatory effect, due to
the high prevalence of AMPARs and NMDARs on postsynaptic terminals, and it is
not clear how an inhibitory Group II/III mGluR-mediated effect could be selectively
produced by glutamate acting on postsynaptic neurons. Secondly, the majority of
Group III mGluR localisation is thought to be presynaptic on afferent terminals
(Azkue et al., 2001; Ohishi et al., 1995a,b). Therefore it is unclear to what extent a
postsynaptic mechanism could operate.
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Nociceptive neurons
Figure 5.2 Possible mechanisms of inhibition
a) Activation of TRPM8-expressing cool-sensitive non-nociceptive afferents releases
glutamate, which then acts through inhibitory mGluRs located on the presynaptic
terminals of nociceptive afferents in superficial laminae. This consequently results in
inhibition of the WDR dorsal horn neurons driven by the nociceptive afferents,
including those in deeper laminae contacted by an interneuronal pathway.
b) TRPM8-expressing neurons release glutamate to activate interneurons which in
turn feed back onto nociceptive terminals, activating inhibitory mGluRs. This then
inhibits the nociceptive afferent-driven activation of dorsal horn WDR neurons.
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5.16 Overall conclusions
In summary, the experiments in this thesis have demonstrated a common
mechanism underlying the phenomenon of analgesia produced by cutaneous cooling
and the phenomenon of analgesia produced by menthol and mint oils. Study of the
function of TRPM8 in vivo has shown that peripheral or central activation of TRPM8
produces analgesia which is effective in chronic pain states, including neuropathic
pain, and is dependent on Group II/III mGluRs. Therefore TRPM8 is indicated as a
novel target for analgesic therapies for use in chronic pain states. Group II/III
mGluRs could also be potential targets for analgesic drugs, although would be more
likely to produce additional side effects. These results demonstrate a phenomenon in
which activation of one class of sensory afferent inhibits transmission from
nociceptive afferents through a central mechanism. This work points the way to
further research, both to develop TRPM8 activators as a strategy for clinical
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Background: Chronic established pain, especially that
following nerve injury, is difficult to treat and represents
a largely unmet therapeutic need. New insights are ur¬
gently required, and we reasoned that endogenous pro¬
cesses such as cooling-induced analgesia may point the
way to novel strategies for intervention. Molecular re¬
ceptors for cooling have been identified in sensory
nerves, and we demonstrate here how activation of
one of these, TRPM8, produces profound, mechanisti¬
cally novel analgesia in chronic pain states.
Results: We show that activation of TRPM8 in a subpop-
ulation of sensory afferents (by either cutaneous or intra¬
thecal application of specific pharmacological agents or
by modest cooling) elicits analgesia in neuropathic and
other chronic pain models in rats, thereby inhibiting
the characteristic sensitization of dorsal-horn neurons
and behavioral-reflex facilitation. TRPM8 expression
was increased in a subset of sensory neurons after nerve
injury. The essential role of TRPM8 in suppression of
sensitized pain responses was corroborated by specific
knockdown of its expression after intrathecal applica¬
tion of an antisense oligonucleotide. We further show
that the analgesic effect of TRPM8 activation is centrally
mediated and relies on Group ll/lll metabotropic gluta-
mate receptors (mGluRs), but not opioid receptors. We
propose a scheme in which Group ll/lll mGluRs would
respond to glutamate released from TRPM8-containing
afferents to exert an inhibitory gate control over noci¬
ceptive inputs.
Conclusions: TRPM8 and its central downstream medi¬
ators, as elements of endogenous-cooling-induced
analgesia, represent a novel analgesic axis that can be
exploited in chronic sensitized pain states.
'Correspondence: s.m.fleetwood-walker@ed.ac.uk (S.M.F-W.); rory.
mitchell@ed.ac.uk (R.M.)
Introduction
Chronic neuropathic pain arising from peripheral nerve
damage is a severe clinical problem with limited treat¬
ment options [1], Changes in both damaged and undam¬
aged primary afferent neurons as well as central (spinal
cord) sensitization lead to hyperalgesia (accentuated re¬
sponses to painful stimuli), allodynia (pain in response to
normally innocuous stimuli), and spontaneous pain. We
hypothesized that elucidating the poorly understood
mechanisms underlying cold-induced analgesia might
lead the way to novel neuropathic analgesics.
Since Hippocrates and Galen [2, 3], sporadic reports
have described the use of cooling to produce analgesia
[4], Clinical trials show beneficial effects of cooling on
chronic back pain, dental pain, postoperative pain,
and muscle injuries [5]. Preparations containing men¬
thol, which produces a cool sensation, are used topi¬
cally to relieve neuralgia in traditional Chinese and Euro¬
pean medicine [6, 7], Mint oil has been reported to
alleviate thermally elicited pain and postherpetic neural¬
gia [8, 9], and oral menthol can cause short-term analge¬
sia [10]. Furthermore, in mice, oral or intracerebroven-
tricular application of menthol decreased nociceptive
responses to the hot-plate test and acetic-acid writhing
test [11]. Despite this history, no definitive mechanism
has been established for cool-induced analgesia.
The recent isolation of the transient receptor potential
(TRP) cation channels present in primary sensory neurons
has revolutionized our understanding of cutaneous tem¬
perature detection. The best-characterized example is
the capsaicin- and heat-sensitive TRPV1 receptor [12],
and although much less is known about cool-sensitive
TRPs, they are the target of intensive research [13].
TRPM8 is activated at innocuous cool temperatures
(with 50% activation around 18°C-19°C [14]) and by men¬
thol and icilin [15,16], which act as selective (but not totally
specific) activators of the channel [14, 17]. The TRPM8
channel is expressed by a subpopulation of sensory neu¬
rons in dorsal root ganglia (DRG) and trigeminal ganglia
[15, 16], where responses to cooling correlate well with
mRNA expression and menthol sensitivity [18-20],
The TRPA1 channel is also expressed in DRG and tri¬
geminal ganglia [14, 21] and is reportedly activated by
cooling temperatures beginning 5°C-6°C lower than
that for TRPM8 [14, 22] and by noxious chemicals
such as cinnamaldehyde and mustard oil [14, 22, 23],
However, the role of TRPA1 in physiological cold sen¬
sation is currently unclear [13], with some reports of
TRPA1 not being activated by cold [21,23] and of normal
cold sensitivity in TRPA1 knockout mice [24], In con¬
trast, another study of TRPA1 knockout mice reported
attenuated responses to noxious cold [25], and anti-
sense knockdown studies show a decrease in develop¬
ment of nerve-injury- or inflammation-induced hyper¬
algesia to intense cold stimuli [26, 27]. On balance,
TRPA1 seems a less likely candidate than TRPM8 for
the mediator of cooling-induced analgesia.
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A central spinal mechanism of analgesia is suggested,
because cutaneous cooling can prevent pain produced
by afferent stimulation [4]. Glutamate-receptor-depen-
dent plasticity in spinal cord neurons commonly under¬
lies chronic pain states with both ionotropic and metab-
otropic receptors participating at pre- and postsynaptic
sites. Although most glutamate receptors are excitatory,
the Group ll/lll metabotropic receptor (mGluR) subtypes
exert inhibitory influences, suggesting the hypothesis
that they could potentially underpin cooling-induced an¬
algesia. Indeed, Group II and III mGluRs are present in
the spinal cord largely on afferent terminals, but with
some glial and postsynaptic expression [28, 29], and
their activation inhibits both nerve-injury- and inflamma¬
tion-induced sensitization of neuronal and behavioral
responses [30-32],
Here we demonstrate marked analgesic effects of pe¬
ripherally or centrally applied TRPM8 activators (such as
icilin or menthol), or mild cooling of the skin, in a model
of neuropathic pain. TRPM8 levels in DRG and superfi¬
cial dorsal horn were increased after nerve injury. Anal¬
gesia was restricted to injury-sensitized responses and
abolished after antisense knockdown of TRPM8. Pe¬
ripheral application of icilin or menthol also activated
slowly conducting afferents (in a TRPM8-antisense-sen-
sitive manner) and suppressed the increased respon¬
siveness of single dorsal-horn neurons ipsilateral to
nerve injury. In contrast, activation of TRPA1 produced
hyperalgesia (in both naive animals and nerve-injured
animals). TRPM8-mediated analgesia was selectively
reversed by intrathecal administration of Group ll/lll
mGluR antagonists and mimicked by agonists, and ion-
ophoresis of a Group III mGluR antagonist, as an exam¬
ple, reversed the inhibitory effect of icilin on sensitized
single neurons. Sensitization-specific analgesia from
TRPM8 activation was also observed in inflammatory
afferent demyelination and TRPA1 activator-induced
pain models.
Results
Reversal of Nerve-Injury-Induced Reflex
Sensitization by Peripheral Activation
of TRPM8 Channels
In order to model potential clinical usage, we adminis¬
tered icilin topically to the paws by placing rats with
chronic constriction injury (CCI) to sciatic nerve in a
bath with 1 -cm-deep drug solution, kept at 30°C to avoid
any effects on local skin temperature. After 5 min, icilin
(80 |xM), but not vehicle (0.2% dimethylformamide in wa¬
ter), caused striking reversal of CCI-induced behavioral-
reflex sensitization to thermal and mechanical stimuli
(Figure 1A). Concentration-dependent effects were ob¬
served from 2.5 nM up to a maximum of 500 nM, with
no effect on contralateral or naive responses (Figure 1B).
At much higher concentrations of icilin, we observed the
beginning of a trend toward increasing reflex sensitivity,
ipsilateral and contralateral to CCI and in naive animals
(Table 1), that was statistically significant in mechanical
and (after a delay) in thermal tests, only at the highest
concentration tested, 5 mM. This effect was distinct
from the prominent analgesia at low concentrations of
icilin because it was not specific to a sensitized state
and may be due to weak interaction with other targets
or nonspecific actions. Specific reversal of sensitized re¬
sponses was also caused by another selective TRPM8
activator, (-)-menthol (4 mM). The stereoisomers iso-
menthol and (+)-menthol, which are several-fold-less-
potent agonists of TRPM8 [33, 34], also produced rever¬
sal of sensitized responses at concentrations of 8 mM
and 16 mM (Figure 1C).
Icilin is expected to activate TRPM8-containing affer¬
ents, so we recorded firing activity in saphenous-nerve
afferents after topical application of icilin (Figure 1D).
The nerve was dissected to produce small-number
preparations of fine afferents, with conduction velocities
of up to 2.6 m/s (representing C- and A5-fiber afferents
[35]). Icilin (200 nM) applied to the receptive field on
the hind limb caused a significant increase in firing fre¬
quency in 21.6% (40 out of 185) of recorded fine affer¬
ents with a mean 7-fold increase in firing frequency
from baseline of 4.5 ± 2.5 Hz to 31.6 ± 3.4 Hz and
a mean time to peak effect of 3.3 ± 0.5 min. Icilin did
not produce rapid desensitization, agreeing with some
reports [36] but not others [37], Recovery was consis¬
tently observed. Similar results were obtained from
both hairy and glabrous skin. Large myelinated mecha-
noreceptors (conduction velocities 6.8-15 m/s, n = 43)
were unaffected.
Consistent with a TRPM8-mediated mechanism, paw
immersion at 16"C-20°C for 5 min also produced statis¬
tically significant mechanical analgesia (Figure 1E). Re¬
cordings from a subcutaneous thermistor probe showed
that deep skin temperatures were 0.5°C above bath
temperatures after 5 min in similar conditions. This tem¬
perature is in the range expected to activate TRPM8 and
stimulate innocuous cool-sensitive fibers. Immersion
temperatures below 14°C (in the range where other
cold sensors, in addition to TRPM8, are also likely to
be activated) elicited active nociceptive withdrawal re¬
flexes limited to the period of hind paw immersion, in
agreement with the known temperature activation range
for nociceptive cold fibers [38].
Localization of TRPM8 in Afferents and Superficial
Dorsal Horn: Increased Expression after Nerve Injury
The presence and localization of TRPM8 in DRG and the
spinal cord were investigated by immunoblotting and
immunohistochemistry. After rapid homogenization of
DRG in Laemmli lysis buffer and SDS-PAGE, immuno-
blots probed with a rabbit polyclonal antibody raised to
TRPM8 residues 278-292 and 1090-1104 (human) [39]
showed a single, strong band at approximately 128
kDa (the predicted molecular weight of TRPM8), with
faint bands observed at approximately 170, 60, and
50 kDa (Figure 2A). Both antigen-preabsorbtion and
antisense-knockdown controls were consistent with
specificity of this antibody in recognition of TRPM8 at ap¬
proximately 128 kDa under the conditions used. Preincu¬
bation of the antibody with membranes from COS7 cells
transfected with TRPM8 expression plasmid abolished
the band at 128 kDa, whereas sham preabsorbtion with
membranes from cells with empty vector did not (Fig¬
ure 2A). Correspondingly, intrathecal delivery of a
TRPM8 antisense oligonucleotide to naive (non-CCI)
rats over 5 days also resulted in almost complete knock¬
down of the 128 kDa band (Figure 2A), whereas a
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Figure 1. Peripheral TRPM8 Activation and Moderate Cooling Are Analgesic after CCI
(A, B, C, and E) Behavioral data from CCI animals, shown as mean ± SEM; each graph represents n of six animals.
(A) Paw withdrawal latency (PWL; s) to noxious heat and paw withdrawal threshold (PWT; mN/mm2) to mechanical stimuli before and after 5 min
paw immersion in a shallow 30°C water bath containing 80 pM icilin or vehicle. O: ipsilateral paw plus icilin; #: ipsilateral + vehicle; ■: contra¬
lateral plus icilin, ■: contralateral plus vehicle." indicates significant ipsilateral-contralateral differences; f indicates significant difference from
prodrug baseline {p < 0.05).
(B) Concentration-response curve for mean ± SEM percentage reversal of ipsilateral sensitization for thermal (O) or mechanical (♦) tests
calculated over 10-15 min after paw immersion in 2.5-500 pM icilin.
(C) Reversal of ipsilateral sensitization by paw immersion in (-)-menthol at 4 mM, and by higher concentrations of the less-potent stereoisomers
(+)-menthol and isomenthol (8 and 16 mM). Values were calculated over 10-25 min after paw immersion from experiments as shown in (A),
t indicates significant differences from predrug baseline (p < 0.05).
(D) Typical electrophysiological recording from the subpopulation of icilin-responsive C fiber afferent fibers before, 2 min after topical application
of icilin to the receptive field (peak effect), and 12 min later.
(E) Mechanical analgesia measured over 5 min after 5 min immersion of paws at the indicated temperature range. § denotes spontaneous with¬
drawal responses during the immersion period, * denotes significant difference from contralateral paw, and f denotes significant difference from
preimmersion baseline (p < 0.05).
missense control oligonucleotide was ineffective (see
below). Intrathecally delivered fluorescent-labeled oligo¬
nucleotides have been shown to effectively penetrate
the DRG, as soon as 4 hr after initial delivery [40]. The
faint bands, at 50 and 60 kDa at least, remained present
in each case and so are likely to represent nonspecific in¬
teractions of the antibody under these conditions. As fur¬
ther controls, we showed that TRPV1 immunoreactivity
was unaffected by treatment with the TRPM8 antisense
reagent and that the housekeeping enzyme GAPDH (36
kDa) was evenly present in each lane (Figure 2A). After
nerve injury, there was a marked increase in expression
of the 128 kDaTRPM8-immunoreactive band specifically
in ipsilateral, but not contralateral, DRG (Figure 2A),
whereas immunoreactivity for GAPDH was unaltered.
Densitometric ratios for TRPM8 expression as percent¬
age of GAPDH were 80.7 ± 4.1 ipsilateral to CCI, which
was significantly greater than that seen contralateral to
CCI (49.3 ± 3.2) and in naive DRG (50.7 ± 2.7) (mean ±
standard error of the mean [SEM], n = 5-6). L4-5 spinal
cord extracts showed that TRPM8 immunoreactivity
was present centrally, and after preparation of a crude
particulate fraction (centrifugation at 11,000 x g for 45
min), these also showed consistent increases in expres¬
sion ipsilateral to injury. Densitometric values ipsilateral
to CCI were 198% ± 6.7% of those from naive tissue
(p < 0.05; mean ± SEM, n = 5), whereas contralateral
values were 125% ± 7.1 % (p > 0.05).
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Table 1. Analgesic Effects of Topically Administered Icilin against Neuropathic Sensitization Revert at Very High Concentrations to a General
Nociceptive Effect
Reflex Response Sensitivity at Different Times after Icilin Application to Paw
Thermal PWL (s)
Drug Concentration (j.iM) Naive CCI Ipsi CCI Con
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Significant effects of drug on reflex responses are indicated:
"Significant increase from baseline, indicating analgesic effect of icilin.
b Significant decrease from baseline values, indicating hyperalgesic effects.
Immunohistochemistry was carried out with a rabbit
polyclonal antibody raised to TRPM8 residues 656-680
(rat) [41], the specificity of which was addressed by
antigen-preabsorbtion and antisense-knockdown con¬
trols. The labeling observed in a discrete subpopulation
of DRG cells was abolished after preincubation with the
peptide antigen (no positive cells seen, counted over
twelve 500 pm2 sections, compared with a mean of
5.3 ± 0.4 TRPM8-positive cells per 500 pm2 DRG section
with sham treatment of antibody, and 5.1 ± 0.5 TRPM8-
positive cells per 500 pm2 DRG section with untreated
antibody, counted over 12 sections each). In immuno-
blots, the antibody also labeled in naive DRG tissue
a single band, at approximately 128 kDa, that was abol¬
ished either by preabsorbtion with the peptide antigen
or by prior 5 day intrathecal infusion of TRPM8 antisense
(Figure 2B). Immunohistochemical staining in the spinal
cord showed that TRPM8 was largely expressed in the
superficial dorsal horn, like the C fiber marker peripherin
(Figure 2C), and that after dorsal rhizotomy (L2-6), the
vast majority of TRPM8 (and peripherin) immunoreactiv-
ity was lost ipsilaterally (reductions of approximately
80%—90%), suggesting that spinal TRPM8 originates
largely from afferents. In confirmation of the immunoblot
findings, levels of TRPM8-like immunoreactivity were
increased in the dorsal horn ipsilateral to injury (by ap¬
proximately 70%-80%), but retained a similar distribu¬
tion to that in naive animals (Figure 2D).
To establish whether the increases in afferent TRPM8
expression occurred in specific subpopulations of DRG
cells, we investigated TRPM8 colocalization with mark¬
ers of myelinated afferents (neurofilament-200; NF-200
[42]) and unmyelinated afferents (peripherin [43]). In
naive rats, TRPM8 immunoreactivity was largely con¬
fined to a subpopulation of unmyelinated DRG cells
(8.3% ± 0.2% of peripherin-positive cells; 34 of 408 cells)
and only minimally expressed in myelinated, NF-200-
positive cells (1.3% ± 0.5%; 6 of 445 cells). However,
after CCI, TRPM8 expression was significantly increased
ipsilaterally in both NF-200- and peripherin-positive
cells, to 7.9% ± 1.2% (31 of 390 cells) and 15.5% ±
0.8% (64 of 412 cells), respectively. Corresponding con¬
tralateral values were unaltered from naive values, at
2.0% ± 0.4% (14 of 346 cells) and 9.2% ± 0.4% (42 of
452 cells) (Figures 2E and 2F). Data were taken from 3
CCI and 3 naive animals and counted across 15-21 sec¬
tions. The additional TRPM8-expressing NF-200-posi-
tive cells were small (average diameter, 19.7 ± 0.8 gm),
presumed A5 myelinated neurons [35]. There were no
significant differences in the diameters of NF-200- or
peripherin-positive cells or in the numbers of NF-200-
or peripherin-positive DRG neurons per section.
Molecular Identification of TRPM8 as the Mediator
of Icilin-lnduced Analgesia
To define the specific involvement of TRPM8 in icilin
analgesia, we further utilized the antisense-oligonucleo-
tide knockdown strategy. TRPM8 antisense or mis¬
matched control oligonucleotides were delivered intra¬
thecal^ over 13 days to parallel the sensitization
developing after CCI. The development of CCI-induced
behavioral-reflex sensitization was unaffected, includ¬
ing thermal hyperalgesia and mechanical allodynia (Fig¬
ures 3A and 3B) and cold allodynia (control CCI animals
showed elevation of the paw ipsilateral to nerve injury
out of 4°C water for 8.1 ± 0.5 s at peak, 9-11 days after
surgery, whereas corresponding values in antisense-
treated CCI animals were 7.6 ± 0.6 s). In contrast, the
reversal of neuropathic reflex sensitization produced
normally by 80 pM icilin applied to the paws (Figure 1A)
was abolished by treatment with antisense (Figure 3A),
but not missense (Figure 3B), reagents. The mean ±
SEM reversals of ipsilateral sensitization over 10-25
min after icilin treatment in antisense- and missense-
treated animals were 7.7% ± 7.4% and 82.8% ± 6.9%,
respectively, for paw withdrawal latency (PWL), and
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9.4% ± 8.2% and 58.7% ± 8.2% for paw withdrawal
threshold (PWT), with missense-treated, but not anti-
sense-treated, animals retaining significant effects of
icilin (p < 0.05). When antisense osmotic pumps were
depleted, but animals were still neuropathic (18 days af¬
ter surgery for insertion of 14 day minipumps and CCI),
responses to icilin were restored to 83.7% ± 10.1% re¬
versal of sensitization for PWL and 54%.0 ± 7.2% for
PWT. Effectiveness of knockdown was assessed by
SDS-PAGE/immunoblotting. Expression of the 128 kDa
TRPM8-immunoreactive band in both ipsilateral and
contralateral DRG was greatly reduced by the antisense
reagent, and the increase in TRPM8 expression normally
seen ipsilateral to nerve injury was prevented
(Figure 3C). The missense reagent had no effect
(Figure 3C), showing TRPM8 expression similar to that
in untreated CCI animals (Figure 2A). In missense-
treated animals, TRPM8:GAPDH ratios were 77.9% ±
2.0% ipsilateral to CCI and 52.9% ± 2.1 % contralateral,
similar to corresponding control values (Figure 2A and
above), whereas in antisense-treated animals, values
were much lower (19.8% ± 2.2% and 14.9% ± 2.1%,
respectively, mean ± SEM, n = 5).
To confirm that antisense knockdown of TRPM8 re¬
sulted in associated functional changes in afferents,
we made saphenous-nerve recordings from naive ani¬
mals receiving intrathecal delivery of TRPM8 antisense
or missense oligonucleotides, 4-5 days after insertion
of the pump. The increase in firing frequency evoked
by topical icilin (200 ;iM) was strongly reduced in animals
receiving antisense. Only 3 out of 34 recorded slowly
conducting fibers (8.8%) showed a partial activation in
response to the drug, increasing firing by approximately
2-fold from a baseline of 5.8 ± 1.4 to 12.7 ± 0.6 Hz, com¬
pared with the 7-fold increase observed in over 20% of
fine afferents in naive animals. In contrast, missense an¬
imals showed a 7-fold increase in firing frequency in
25% of 40 recorded fibers from a baseline of 3.3 ± 0.7
to 23.1 ± 3.2 Hz, similar to results from naive animals.
Similarly, in missense-treated animals, topical (-)-men-
thol (4 mM) produced an approximately 8-fold increase
in mean firing frequency (from 4.5 ± 2.9 to 38.9 ± 7.6
Hz), activating 20% of fibers (35 identified afferents re¬
corded). This compared with no obviously activated af¬
ferents in antisense-treated animals (mean firing fre¬
quency 4.0 ± 1.8 Hz at background, 4.8 ± 1.9 Hz after
drug application, 28 identified afferents recorded). How¬
ever, TRPM8 antisense treatment did not alter the effect
of topically applied resiniferatoxin (1 mM), a potent
TRPV1 agonist acting as a control. In antisense-treated
animals, resiniferatoxin evoked a 6-fold increase in firing
frequency in activated afferents (from 4.5 ± 0.7 baseline
to 25.9 ± 1.8 Hz at peak response, 16 afferents activated
out of 28 recorded), which was similar to responses
in missense-treated animals (showing a mean 5-fold
change in firing frequency from 4.6 ± 2.8 to 24.8 ±
3.1 Hz).
Central Intrathecal Administration of TRPM8
Activators Also Inhibits Neuropathic Sensitization
Because TRPM8 is present on central terminals of pri¬
mary sensory neurons as well as their peripheral termi¬
nals (Figures 2B and 2C, [44, 45]), we investigated
whether intrathecal application of TRPM8 activators
near the central terminals would also produce analgesia.
Intrathecal injection of icilin (10 nmol) produced robust
reversal of CCI-induced behavioral-reflex sensitization
in thermal and mechanical tests (Figure 4A, p < 0.05
for up to 55 min). Intrathecal injection of (-)-menthol
(200 nmol) in CCI rats also caused a significant reversal
of the sensitized responses, lasting 35-40 min
(Figure 4B). Because of the higher potency and efficacy
of icilin at TRPM8 [15], further experiments mainly uti¬
lized icilin as the representative TRPM8 activator. Icilin
produced dose-dependent analgesic effects restricted
to the nerve injury side in both thermal and mechanical
tests that were statistically significant by 0.125 nmol
and increased to almost complete reversal of sensitiza¬
tion by 10 nmol. Nonlinear curve-fitting indicated that
maximal effects of icilin were similar for PWL and PWT
(91.6% ± 9.9% and 82.6% ± 6.8% reversal of sensitiza¬
tion, respectively), as were EC50 values (dose for 50% of
maximal effect; 0.17 ± 0.02 nmol and 0.31 ± 0.02 nmol,
respectively).
In complete contrast to the effects of TRPM8 activa¬
tors, the TRPA1 activator, cinnamaldehyde [22] (75
nmol injected intrathecally), significantly increased re¬
flex responsiveness in thermal and mechanical tests
and was effective contralateral as well as ipsilateral to
nerve injury (Figure 4C). The sensitizing effects of cinna¬
maldehyde were prevented by coinjection of Ruthenium
Red (0.25 nmol), which can block TRPA1 channels [21,
46], whereas the analgesic effect of intrathecally injected
icilin was unaffected (Figure 4D). Sensitizing effects of
cinnamaldehyde were also seen in naive animals, with
a 36.9% ± 7.9% reduction in PWL and a 41.9% ± 6.7%
reduction in PWT. Similar effects were produced by
two further TRPA1 activators [46, 47], allicin (25 nmol),
where corresponding reductions were 33.2% ± 5.9%
and 20.7% ± 8.2%, respectively, and diallyl disulphide
(50 nmol), with equivalent values of 25.9% ± 7.0% and
28.5% ± 6.2% (mean ± SEM, n = 3-6). In contrast, the
TRPM8 activators icilin (10 nmol) and (-)-menthol
(200 nmol) were without effect in naive animals (data
not shown). Topical application of cinnamaldehyde (1.5
mM) also produced bilateral sensitization of behavioral
reflexes in naive animals (mean decrease of 32.0% ±
8.6% in PWL and 20.2% ± 8.2% in PWT, p < 0.05, n =
6). This corresponds to the licking and shaking behavior
as well as the decrease in PWL reported after intraplantar
injection of cinnamaldehyde [22].
In further experiments, we investigated whether the
sensitized pain behaviors caused by TRPA1 activators
or other pain models were susceptible to icilin-induced
analgesia. Sensitization caused by intrathecal or topical
cinnamaldehyde was markedly attenuated by intrathe¬
cal icilin (Table 2). The effect of topical cinnamaldehyde
was additionally reversed by topical icilin (200 pM, data
not shown). Sensitization caused by focal demyelination
of the sciatic nerve [43] or intraplantar injection of Com¬
plete Freund's Adjuvant (CFA) was also significantly
inhibited by intrathecal icilin (Table 2).
Central Mechanism of Icilin Reversal of Neuropathic
Sensitization Involves mGlu Group ll/lll Receptors
Because topical icilin increases activity in fine afferents
(Figure 1D) and both intrathecal and topical icilin reverse
nerve-injury-induced sensitization, centrally mediated
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Figure 2. TRPM8 Immunoreactivity Is Present in DRG and Spinal Cord, Arises from Afferents, and Is Increased Ipsilateral to CCI
(A) Immunoblots of DRG show whole gels with TRPM8 protein running at 128 kDa and additional faint bands at approximately 170, 60, and
50 kDa, in normal rat DRG with specific knockdown of the 128 kDa band in DRG from antisense-treated animals. In additional controls, when
the TRPM8 antibody was preincubated with membranes from TRPM8-expressing cells, the 128 kDa immunoreactive band was removed,
whereas sham treatment had no effect. Blots additionally show GAPDH loading controls. TRPV1 expression (single band at ~90 kDa) was un¬
altered in DRG from TRPM8 antisense-treated animals. Immunoblots for TRPM8 protein showed a clear increase in expression of the specific
128 kDa band in DRG ipsilateral ("ipsi") to nerve injury compared to contralateral ("con") and naive DRG, with no change in GAPDH. Spinal cord
(SC) whole lysates showed no discernable changes in TRPM8 levels; however, increased levels ipsilateral to nerve injury were seen in crude
particulate fractions.
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Figure 3. Specific TRPM8 Knockdown by Antisense Oligonucleotide Prevents Icilin-lnduced Analgesia after CCI
(A and B) Paw withdrawal latency (PWL, s) to noxious heat and paw withdrawal threshold (PWT; mN/mm2) to mechanical stimuli are shown
ipsilateral (O) or contralateral (■) to CCI animals with antisense (n = 12) or missense (n = 10) treatments. Data show mean ± SEM.
(A) The analgesia normally elicited by topical icilin was not observed after antisense knockdown of TRPM8 receptor indicated by the persistence
of significant ipsilateral-contralateral differences in PWL and PWT (* p < 0.05).
(B) In contrast, aftermissense treatment, icilin produced a significant reversal ofCCI-induced ipsilateral sensitization in PWL and PWT responses
in comparison to baseline values (t p < 0.05), as in untreated CCI animals (Figure 1 A).
(C) Immunoblots of DRG tissue probed for TRPM8 and GAPDH protein levels after TRPM8 antisense or missense treatment. TRPM8 expression
(and the increase in expression normally seen ipsilateral to CCI, Figure 2A) was selectively reduced by antisense, but not missense, infusion,
whereas GAPDH levels were unchanged.
events are likely to be important in icilin action. Icilin-re-
sponsive afferents are expected to release glutamate,
so we hypothesized that inhibitory glutamate receptors
in the dorsal horn might underlie icilin-induced analge¬
sia. Group ll/lll mGluRs could subserve such a role be¬
cause they are antinociceptive in models of inflamma¬
tory, neuropathic, and acute pain [30-32] and inhibit
transmission between primary afferent and spinal cord
neurons in sensitized states [48, 49]. Group II mGluRs
are localized on primary afferent terminals in lamina II,
particularly in small nociceptive afferents [28, 50], al¬
though some are found postsynaptically and on glia
[29]. Group III mGluRs are also found presynaptically
in the dorsal horn and are 45% coexpressed with either
IB4 or Substance P (markers of small nociceptive neu¬
rons [51]). To assess whether activation of Group ll/lll
mGluRs might mimic icilin reversal of neuropathic sensi¬
tization, we intrathecal^ injected the selective Group II
(B) shows western blots of DRG from naive or TRPM8 antisense-treated rats probed with the TRPM8 antibody used for immunohistochemistry
in (C)-(F) below. Pretreatment of the antibody with the antigenic peptide or TRPM8 antisense treatment removed the single specific band
at =128 kDa.
(C) L5 spinal cord sections taken 8 days after dorsal rhizotomy were immunostained for peripherin (green) and TRPM8 (red) and showed marked
reduction of both proteins ipsilateral to rhizotomy.
(D) Immunostaining for TRPM8 (red) and the neuronal marker NeuN (green) in the spinal cord dorsal horn from CCI animals showed that TRPM8
was increased ipsilateral to CCI with no change in distribution, whereas NeuN levels were unchanged. Scale barfor (C) and (D) represents 500 [im.
(E and F) Immunohistochemical colocalization in DRG sections ipsilateral or contralateral to nerve injury and in naive animals of TRPM8 (red) with
(E) NF-200 (green) or (F) peripherin (green). In naive animals, TRPM8 is mainly located in peripherin-positive C fibers, with little or no apparent
expression in myelinated (NF-200) cells. Ipsilateral to nerve injury, TRPM8 expression was increased markedly in small NF-200-positive cells,
whereas a lesser increase in TRPM8:peripherin coexpression was also observed. Scale bar represents 50 pm. The bar charts in (E) and (F)
show the percentage coexpression (mean ± SEM) for TRPM8:NF-200 and TRPM8:peripherin, respectively; actual cell counts are shown above
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Figure 4. Central TRPM8 Activation Is Analgesic after CCI, whereas TRPA1 Activation Is Hyperalgesic
Paw withdrawal latency (PWL, s) to noxious heat and paw withdrawal threshold (PWT, mN/mm2) to mechanical stimuli are shown ipsilateral (O)
or contralateral (■) to CCI. * denotes significant ipsilateral-contralateral differences (* p < 0.05). Data show mean ± SEM, and each test repre¬
sents n of six animals unless otherwise indicated. Rats were intrathecal^ injected (at arrow). The TRPM8 activators (A) icilin (10 nmol) and (B) (-)-
menthol (200 nmol) both significantly reversed ipsilateral thermal and mechanical sensitization in comparison to preinjection values (t, p < 0.05).
(C) In contrast, intrathecal application of the TRPA1 activator cinnamaldehyde (75 nmol) produced bilateral hyperalgesia and allodynia in CCI
animals. § (p < 0.05) shows statistically significant increases in thermal and mechanical reflex responsiveness of both ipsilateral and contralateral
paws.
(D) shows that Ruthenium Red (0.25 nmol) inhibits cinnamaldehyde (75 nmol)-induced hypersensitivity, but not icilin (10 nmol)-mediated anal¬
gesia, ipsilateral to CCI. Values are mean ± SEM, n = 4. Statistically significant changes in PWL/PWT values as a result of cinnamaldehyde or
icilin compared to predrug baseline are shown as § and f, respectively (p < 0.05), and for Ruthenium Red-reversal of the effect of cinnamaldehyde
(tt, P < 0.05).
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Table 2. Reversal of Sensitization by Intrathecal Icilin Administration in Different Pain Models
Pain Model
PWL (s) PWL (s)
Difference Difference
from Control from Control


























































"Significant ipsilateral-contralateral differences in surgical pain models or, in the case of cinnamaldehyde-induced responses, differences from
prior baseline, are indicated (p < 0.05).
"Significant icilin (10 nmol, intrathecal)-induced reversal of sensitization is indicated (p < 0.05).
or III mGluR agonists 2R, 4R-APDC or ACPT-III and AP-
4, respectively. 2R, 4R-APDC (15 nmol) caused 72.1 % ±
6.4% reversal of thermal and 56.0% ± 10.9% reversal of
mechanical reflex sensitization ipsilateral to CCI (15-30
min postinjection) with no effect on contralateral re¬
sponses. ACPT-III and AP-4 (150 nmol each) also re¬
versed thermal sensitization (by 83.6% ± 6.3% and
60.8% ± 6.7%, respectively), as well as mechanical sen¬
sitization (65.7% ± 11.4% and 60.7% ± 8.0%), again
with no effects contralateral^ (p < 0.05 in each case).
Furthermore, selective Group II and Group III mGluR an¬
tagonists LY 341495 (5 nmol, Figure 5A) and UBP 1112
(10 nmol, Figure 5B) each prevented the effect of icilin
(10 nmol, Figure 4A). Similarly, the analgesia produced
by intrathecal (-)-menthol (200 nmol, Figure 4B) was
reversed by intrathecal LY 341495 and UBP 1112. The
mean percentage reversal of sensitization over 20-30
min postinjection was 86.1% ± 8.1% for PWL and
80.6% ± 4.2% for PWT with (-)-menthol alone, 22.0% ±
6.9% for PWL and 7.1% ± 7.1% for PWT with menthol
and LY 341495, and 9.2% ± 6.9% for PWL and 0.0% ±
0.0% for PWT with (-)-menthol and UBP 1112 (n = 6).
Neither LY 341495 nor UBP 1112 had any effects alone
(data not shown), suggesting that Group ll/lll mGluRs
show little tonic activation after CCI, but are specifically
utilized downstream of icilin. In contrast, intrathecal co¬
administration ofthen-opioid receptor antagonist nalox¬
one (25 nmol) with icilin had no effect (Figure 5C), indicat¬
ing that icilin analgesia is opioid independent. To avoid
any possibility of nonspecific drug interactions, we also
administered icilin (200 nM) topically, but the mGluR
antagonists intrathecally. Figure 5D shows that the icilin
reversal of thermal and mechanical sensitization in this
case was again prevented by LY 341495 or UBP 1112.
The analgesic effect of skin cooling to 16°C (Figure 1E)
was also prevented by intrathecally applied LY 341495
(5 nmol) or UBP 1112 (10 nmol). The mean percentage
reversal of ipsilateral CCI-induced reductions in PWT
caused by cooling was 0.0% ± 0.0% in the presence of
either drug (n = 5).
To confirm the analgesic effect of icilin at the level of
single spinal cord neurons, we made in vivo extracellular
recordings of large lamina I and lll/IV neurons (which in¬
tegrate nociceptive and nonnociceptive inputs). Topical
administration of icilin (200 nM) to the peripheral recep¬
tive field area ipsilateral to CCI caused inhibition of the el¬
evated neuronal responses to motorized rotating brush
(Figure 5E). In the eight neurons out of 12 that were af¬
fected by icilin (two in lamina I and six in laminae lll/IV)
brush-induced responses were reduced to 37.4% ±
5.5%, p < 0.001). Vehicle had no effect. Contralateral
neurons were unaffected (111.9% ± 8.9% of control;
n = 6). As an example of one of the Group ll/lll mGluR an¬
tagonists investigated on reflexes, UBP 1112 was iono-
phoresed in the vicinity of recorded dorsal-horn neurons
at currents of 20-60 nA. UBP 1112 reversed the effect of
icilin; the brush-induced firing rate reverted to 80.2% ±
9.3% of control values (Figure 5E), but UBP 1112 had
no effect alone, and nor did saline current controls.
Because some Group ll/lll mGluRs may be postsyn¬
aptic, we asked whether icilin could reverse the addi¬
tional sensitization of behavioral-reflex responsiveness
caused by intrathecally applied NMDA in CCI animals.
Icilin (10 nmol) clearly attenuated the additional ipsilat¬
eral sensitization induced by 3.75 nmol of NMDA plus
0.75 nmol of its coagonist site activator, ACPC, injected
intrathecally. Ipsilateral PWL values in thermal tests
were 10.1 ± 0.6 s at baseline and decreased to 7.9 ±
0.3 s (15-30 min after injection of NMDA/ACPC), but
increased to 14.9 ± 0.6 s in the additional presence of
icilin. Contralateral values were unaltered by icilin or
NMDA/ACPC. Ipsilateral PWT values in mechanical tests
were 1504.2 ± 105.3 mN/mm2 at baseline, 891.6 ± 27.3
mN/mm2 after injection of NMDA/ACPC, and 3482.7 ±
174.3 mN/mm2 with coinjection of icilin (mean ± SEM,
n = 6). Contralateral values again were unaltered. A com¬
ponent of the central events elicited by icilin may there¬
fore be postsynaptic, although it is important to note
that functional NMDA receptors may also be present
on afferent terminals [52],
Discussion
Little is known of the mechanism underlying cooling-
induced analgesia, but a number of cool-sensitive ion
channels, including TRPM8, have recently been identi¬
fied in somatosensory afferents [13]. We now show
that TRPM8 activation reverses nerve-injury-induced
hypersensitivity. TRPM8 can be activated by menthol
[15, 16], which is analgesic in hot-plate and acetic-acid
writhing tests [11], although menthol can produce pain
at very high doses [53, 54]. Here, either topical or intra¬
thecal application of (-)-menthol produced behavioral
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Figure 5. Icilin-lnduced Analgesia after CCI Is Prevented by Group II and III mGluR Antagonists
(A-D) Paw withdrawal latency (PWL, s) to noxious heat and paw withdrawal threshold (PWT, mN/mm2) to mechanical stimuli ipsilateral (O) or
contralateral (■) to CCI. Data represent mean ± SEM, with an n of six animals in each case. Rats were intrathecally injected (at arrow). Icilin
(10 nmol) was coadministered with (A) the Group II mGluR antagonist LY 341495 (5 nmol), (B) the Group III mGluR antagonist UBP 1112 (10
nmol), or (C) the opioid receptor antagonist, naloxone (25 nmol).
(A and B) When either LY 341495 or UBP 1112 was coadministered with icilin, it abolished the analgesic effect of icilin as indicated by the
persistence of sensitized (*, p < 0.05) PWT/PWL responses ipsilateral to nerve injury.
(C) Naloxone coadministration with icilin did not prevent the icilin-induced analgesia seen in PWT and PWL responses ipsilateral to nerve injury
(t, p < 0.05). * indicates significant ipsilateral-contralateral differences, and \ indicates significant ipsilateral analgesic effect of drug (p < 0.05).
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likely by activation of TRPM8. Similar effects were seen
with another TRPM8 activator, icilin [15]. As with men¬
thol, very high doses of icilin were found to cause a gen¬
eralized increase in sensitization, affecting CCI animals
bilaterally and naive animals in a similar fashion (Table
1). Importantly, analgesic effects of icilin were seen at
200-fold-lower concentrations than those causing non¬
specific sensory changes. Specific involvement of
TRPM8 in the reversal of neuropathic sensitization was
confirmed by the abrogation of icilin analgesia after in¬
trathecal infusion of a TRPM8 antisense oligonucleotide
to knock down TRPM8 expression. Furthermore, the an¬
algesic profile was mimicked by cutaneous cooling to
20°C-16°C, a range activating the TRPM8 channel [14].
Iciiin and menthol were applied cutaneously in solution
at 30°C, so any possible drug effects on skin tempera¬
ture were avoided. TRPM8 antisense had no effect alone
on CCI-induced sensitized responses to noxious heat,
mechanical stimuli, or intense cold (Figure 3), similar to
observations made in an alternative neuropathic pain
model [27], A role for the TRPA1 channel in analgesia
seems unlikely because selective TRPA1 activators, cin-
namaldehyde, allicin, and diallyl disulphide, caused
contrasting sensitization/hyperalgesia not only after
CCI, but also in naive animals. The analgesic effects of
icilin were only seen in the sensitized pain state, but
were not restricted to nerve injury, because sensitization
due to peripheral inflammation, afferent demyelination,
and TRPA1 activation was also reduced. The significant
behavioral and electrophysiological effects of topically
applied icilin demonstrate that icilin can cross the skin
sufficiently to excite peripheral afferents, and point to
the likely clinical utility of this or related drugs.
The precise identity of the TRPM8-containing cool-re¬
sponsive afferents is not clear. Subpopulations of A5 fi¬
bers and C fibers are responsive to different ranges of
cool temperatures: ~15°C-30°C and <15°C [55, 38]. In¬
nocuous cooling (15°C-30°C) activates a subpopuiation
of A5 fibers and C fibers in primates, but almost solely
unmyelinated fibers in rodents [55]. In contrast, intense
noxious cold is signaled by unmyelinated polymodal no¬
ciceptors, which also respond to heat and mechanical
stimuli [38]. The TRPM8 activator menthol activates
cool-sensitive fibers and sensitizes stimulus-induced
responses in the range 20°C-30°C [56, 57], Studies of
TRPM8 in vitro identify this channel as a likely trans¬
ducer of moderate cool temperatures [20]. In DRG and
trigeminal cultures, responses to menthol, cooling
(15°C-30°C), and TRPM8 mRNA expression all correlate
closely [18-20]. TRPM8 is expressed in 5%-20% of DRG
cell bodies that are small and presumed A5 fibers or C
fibers [15, 16], but not in large myelinated fibers. We
observed that TRPM8 immunoreactivity is normally
associated with a subpopuiation of peripherin-positive
C fibers, but only minimally with NF-200-positive affer¬
ents, whereas high-sensitivity cRNA hybridization sug¬
gests the presence of some TRPM8 mRNA in up to
19% of NF-200-positive afferents [58], The capsaicin-
and heat-sensitive TRPV1 channel, which contributes
to thermal nociception and inflammatory sensitization
[12], is found both in peptidergic afferents (~85%) and
in nonpeptidergic (isolectin-B4, IB4-positive) cells in
the rat [59], TRPM8 is not categorically associated with
either peptidergic or IB4-positive afferents [15] but is of¬
ten present in those containing the NGF receptor, Trk A
[58]. Different groups have reported coexpression of
mRNAs for TRPM8 and TRPV1 or menthol/capsaicin re¬
sponsiveness of DRG at 29%-50% [15, 20, 60] or close
to zero [14, 16, 58], Overall, it seems likely that TRPM8
is normally expressed in a distinct population of cool-re¬
sponsive afferents and possibly also to an extent in some
nociceptors. Our findings further identified increased ex¬
pression in peripherin-positive C fibers, but induction in
small NF-200-positive presumed A5 fibers [35], suggest¬
ing that plasticity in TRPM8 expression may participate
in icilin analgesia in neuropathic pain. No changes in
DRG expression of TRPM8 were reported in an alterna¬
tive neuropathic pain model (ligation of L5 spinal nerve
or indeed after CFA) [26, 27], suggesting that specific
aspects of the particular model, such as the coexistence
of injured and uninjured afferents in DRG after CCI, may
be important in TRPM8 upregulation.
TRPA1, which has also been proposed as a cool re¬
ceptor [14], appears to play an entirely different role, elic¬
iting reflex pain behaviors in naive animals, as well as in¬
creasing thermal and mechanical responsiveness in the
neuropathic state. This may correspond to clinical ob¬
servations after nerve injury in which moderately cool
stimuli are perceived as painful [1]. TRPA1 is present
mainly in small cells in sensory ganglia [14, 21] and
may increase ipsilateral to nerve injury and inflammation
[26, 27], Nerve-injury- and inflammation-induced hyper¬
algesia to noxious cold (5°C) is reported to be decreased
by antisense knockdown of TRPA1 [26, 27]. Correspond¬
ingly, mutant mice homozygous for targeted disruption
of the TRPA1 gene show reduced reflex withdrawal re¬
sponses to selective TRPA1 activators and reduced sen¬
sitization of noxious heat and innocuous mechanical re¬
sponses caused by these agents [24]. However, the role
of TRPA1 in noxious cold responses is disputed, with re¬
sults from different lines of TRPA1-/~ animals showing
either attenuated or unaltered coldplate withdrawal re¬
sponses [24, 25], Thus the precise role of TRPA1 in
cold sensation remains unclear, but here as in other
studies TRPA1 clearly acts in a pronociceptive manner
[21, 22, 46, 47]. Although icilin may interact with low
(D) The analgesic effects of topically applied icilin (200 jiM at 30°C) were also reversed by intrathecal injection of Group ll/lll mGluR antagonists.
The figure shows mean % reversal of the ipsilateral/contralateral difference in either PWL or PWT measured over 15-30 min after 5 min topical
application of icilin, with or without concurrent intrathecal injection of LY 341495 (5 nmol) or UBP 1112 (10 nmol), or after mGluR antagonists
alone.
(E) Typical extracellular recording of a single dorsal-horn neuron ipsilateral to CCI, responding to continuous motorized brushing of the cutane¬
ous receptive field on the hind paw and the effects of icilin (200 |jM at 30"C) topically applied to an adjacent area of the receptive field. Similar
results were observed in 8 out of 12 neurons with examples in both laminae lll/IV and lamina I. Neuronal firing is displayed as action potentials per
second (Hz) plotted against time. (E,) Brush-evoked firing in neurons ipsilateral to nerve injury was consistently inhibited by topically applied ici¬
lin; (En) this effect was reversed by ionophoresis of UBP 1112 at 20-60 nA; (Em) recovery was observed after removal of the UBP 1112 ejection
current. Neurons contralateral to nerve injury were unaffected by icilin, and topical vehicle had no effect. In addition, ionophoresis of UBP 1112








Sl<jn Figure 6. Schematic Representation of a Pos¬
sible Mechanistic Basis for TRPM8-Mediated
Analgesia after CCI
In this simplified hypothetical model, activa¬
tion of TRPM8 in a subpopulation of affer-
...•Topical icilin ents by icilin, menthol, or moderate cooling
leads to central synaptic release of glutamate
(Glu), which then acts through inhibitory
Group ll/lll mGluR receptors located either
presynaptically on injury-activated nocicep¬
tive afferents or perhaps also postsynapti-





potency at the TRPA1 channel [14], the analgesic profile
of TRPM8 activators here is entirely different from the
pronociceptive profile of TRPA1 activators. The extent
of TRPM8/TRPA1 coexpression in afferents is reported
to be minimal [14, 58],
The analgesia induced by icilin and menthol and by
skin cooling to 16°C was shown to be centrally mediated
and dependent on Group ll/lll mGluRs. The lack of effect
of naloxone suggests independence from classical opi¬
oid analgesia. Furthermore, at the doses used, mGluR
Group ll/lll antagonists selectively reversed icilin and
menthol analgesia in sensitized responses, without any
effects alone. Group ll/lll mGluRs are known to inhibit
nociceptive responses [30-32, 48, 49], and we showed
that Group ll/lll mGluR agonists selectively inhibit sensi¬
tized responses in neuropathic pain. Both Group II and III
mGluR subtypes are expressed in primary afferents,
especially IB4-positive cells [28, 50, 51]. Activation of
Group ll/lll mGluRs can inhibit afferent-evoked poten¬
tials in the dorsal horn [48], because Group II mGluRs
are both pre- and postsynaptic at primary afferent
synapses [29], whereas Group III mGluRs are largely pre¬
synaptic [51]. Menthol is reported to increase mEPSC
frequency at some synapses between DRG and dorsal-
horn neurons in culture and in slices [44,45], presumably
corresponding to the activation of TRPM8-containing
afferents (Figure 1D) and increased release of glutamate.
Figure 6 shows a schematic outline of a model in which
glutamate released from TRPM8-expressing afferents
could mediate icilin-induced analgesia by acting on
Group ll/lll mGluRs (located presynaptically on nocicep¬
tive afferents and possibly also postsynaptically) to
result in attenuation of pain-related sensitization
(Figure 5E) and behavioral analgesia (Figure 5D).
Conclusions
In summary, these novel findings show that both periph¬
eral and central activation of TRPM8 can produce an an¬
algesic effect that specifically reverses the sensitization
of behavioral reflexes elicited by peripheral nerve injury.
This effect is produced by very low concentrations of
topically applied TRPM8 activators, pointing to the likeli¬
hood of its ready utility in a clinical context. Other sensi¬
tized pain states, in addition to that induced by nerve
injury, are similarly sensitive to reversal by TRPM8 acti¬
vation, emphasizing the likely value of TRPM8 activators
and downstream central mediators of TRPM8 action,
such as Group ll/lll mGluRs, as targets for the develop¬
ment of novel analgesics.
Experimental Procedures
Animals
All experiments were conducted in accordance with the UK Animals
(Scientific Procedures) Act, 1986, and guidelines of the University of
Edinburgh. Adult male Wistar rats (Harlan, United Kingdom) weigh¬
ing 120-250 g were used for all experiments.
Neuropathic and Inflammatory Pain Models
Pain models were generated under halothane anesthesia (Zeneca,
Cheshire, United Kingdom). For the chronic constriction injury
(CCI) model of neuropathic pain, four ligatures were tied loosely to
constrict the sciatic nerve at midthigh level (as described previously
[61]). An inflammatory pain model was generated by injecting 100 pi
ofComplete Freund's Adjuvant (CFA, Sigma-Aldrich) into the ventral
surface of the right hind paw [61]. A model of peripheral demyelin-
ation-induced pain was produced by focal application of lysolecithin
to the sciatic nerve [43]. Peak behavioral sensitization was observed
postsurgically between days 10 and 16 for CCI, 1 and 3 for CFA, and
7 and 14 for lysolecithin, when pharmacological and electrophysio¬
logical experiments and tissue removal were conducted.
Behavioral Testing
Thermal sensitivity was assessed by measuring paw withdrawal la¬
tency (PWL, s) in response to a noxious thermal stimulus (Har-
greaves' thermal stimulator, Linton Instrumentation, Diss, United
Kingdom) directed to the hind paw midplantar glabrous surface. Me¬
chanical sensitivity was recorded as the paw withdrawal threshold
(PWT, mN/mm2) to calibrated von Frey filaments (Stoelting, Illinois),
as previously described [61]. Sensitivity to noxious cold was as¬
sessed by placing animals in a water bath with an aluminium floor
containing 1-cm-deep 4"C water and counting the time the paw
was held suspended over a 20 s period.
Intrathecal Application of Drugs
The following drugs were applied intrathecally in a 50 pi volume of
saline-based vehicle at 37°C: icilin (2.5-200 pM in saline with 0.2%
dimethylformamide, DMF); LY 341495 (100 pM in saline); UBP 1112
(200 pM in saline); 2R, 4R-APDC [(2R, 4R)-4-aminopyrrolidine-2,4-di-
carboxylate, 300 pM in saline]; ACPT-III [(1 R,3R,4S)-1 -aminocyclo-
pentane-1,3,4-tricarboxylic acid, 3 mM in saline]; AP-4 [(L-(1)-2-
amino-4-phophonobutyric acid, 3 mM in saline); naloxone (0.5 mM
in saline); NMDA (75 pM in saline) and ACPC (1 -aminocyclopropane-
carboxylic acid, 15 pM in saline) (Tocris Cookson, Bristol, United
Kingdom); (-)-menthol [1R, 2S, 5R-(-)-menthol, 4 mM in saline]; cin-
namaldehyde (1.5 mM in saline); Ruthenium Red (5 pM in saline)
(Sigma-Aldrich, United Kingdom); allicin (0.5 mM in saline with
0.5% DMF); and diallyl disulphide (DADS, 1 mM in saline with
0.5% DMF) (LKT Laboratories, St. Paul, Minnesota). Drugs were in¬
jected into the L5-6 intrathecal space under brief halothane anesthe¬
sia, with a 25-gauge needle microsyringe (BD Biosciences, Oxford),
as described previously [61] in animals that were at peak levels of
TRPM8-Mediated Analgesia in Neuropathic Pain
1603
behavioral sensitization. Behavioral-reflex testing commenced 15
min after injection to allow recovery from anesthesia [43, 62, 63]
and continued every 5 min thereafter until readings returned to base¬
line levels (n = 6 in each case). We, and others [43, 62, 63], find com¬
plete recovery from anesthetic by 15 min. All appropriate controls
were carried out to eliminate the possibility of effects due to vehicle
or to injection procedure.
The TRPM8 channel activators icilin and (—)-menthol were tested
in CCI and naive animals. The effects of icilin were additionally as¬
sessed in animals with CFA-induced inflammation or with lysoleci-
thin-induced demyelination. Icilin was also coadministered with
the jj-opioid receptor antagonist naloxone, the Group II metabo-
tropic glutamate receptor (mGluR) antagonist LY 341495, or the
Group III mGluR antagonist UBP 1112. The effects of these antago¬
nists alone, as well as effects of the Group II mGluR agonist 2R, 4R-
APDC and the Group III mGluR agonists ACPT-III and AP-4, were
assessed in CCI animals. The TRPA1 channel activator cinnamalde-
hyde, alone and with icilin, was tested in CCI animals and in naive
animals. Further TRPA1 channel activators, allicin and diallyl disul-
phide, were assessed in naive animals. Both icilin and cinnamalde-
hyde effects in CCI animals were also investigated in the additional
presence of Ruthenium Red.
Topical Application of Drugs
Icilin was applied at concentrations of 2.5-500 (.iM (in water with
0.2% DMF), by placing CCI or naive rats unrestrained for 5 min in a
1 -cm-deep water bath (sufficient to cover paws), which was thermo¬
statically controlled to a temperature of 30°C, or by very lightly anes¬
thetizing rats and immersing hind paws in small tubes containing 5
ml icilin (500 j.iM-5 mM, with a vehicle of 45% dimethylformamide
in 0.2% aqueous Tween 80) for 5 min, followed by sensory testing
for 60-80 min. The effects of (—)-menthol and its stereoisomers iso-
menthol (1S, 2R, 5R-menthol,) and (+)-menthol [1S, 2R, 5S (+)-men-
thol] (4-16 mM in 80% ethanol) were also assessed. Relevant vehi¬
cles were always assessed in similar experiments. As a contrast,
the effect of cinnamaldehyde (1.5 mM in water) and the effect of cin-
namaldehyde with additional icilin (80 j.iM in water with 0.2% DMF)
were assessed in naive animals. The effects of icilin (80 nM) were fur¬
ther assessed in CCI animals that had undergone antisense and mis-
sense treatment for knockdown of TRPM8 or immediately after
intrathecal injection of either LY 341495 or UBP 1112. Actual skin
temperatures were measured by a subcutaneous thermistor probe
and were found to equilibrate to around 0.5°C above bath tempera¬
ture. The effects of brief paw immersion at different temperatures
(10uC-22cC for 5 min) on CCI rats were assessed by mechanical test¬
ing. The effects of intrathecal LY 341495 or UBP 1112 on the reversal
of ipsilateral sensitization in CCI after a 16°C cool challenge for 5 min
were measured. Reflex testing commenced 5 min after challenge,
unless animals had been anesthetized, in which case 15 min was al¬
lowed for recovery. Six replicate animals were tested in all pharma¬
cological experiments.
Dorsal Rhizotomy
To establish whether TRPM8 expression in the spinal cord was pre¬
dominantly pre- or postsynaptic, we performed a unilateral L2-6
dorsal rhizotomy under anesthesia, following laminectomy to ex¬
pose the dorsal roots. Eight days later, tissue was removed and pro¬
cessed for immunohistochemistry.
Western Blots
Experiments were performed by standard procedures as previously
described [61 ]; formore details see the Supplemental Data available
online.
Immunohistochemistry
Experiments were performed as previously described [43]; for more
details, see Supplemental Data.
Antisense Knockdown of TRPM8
Antisense and missense oligonucleotides were 22 mers with phos-
phorothioate bonds at the last two positions at the 5' and 3' ends
(MWG Biotech, Ebersberg, Germany). Antisense extended from
base -10 to base +12 relative to the start of the open reading frame
for the rat TRPM8 gene: 5' C*T*CGAAGGACATCTTGCCGT*G*G 3',
where * represents phosphorothioate linkages. Missense was de¬
signed with four inversions of C/G or A/T as appropriate at residues
3,11,14, and 22, preserving overall G/C content. BLAST searches of
both oligonucleotides indicated no significant complementarity to
any known gene sequence. Fourteen day or seven day osmotic min-
ipumps (for CCI experiments or naive electrophysiology experi¬
ments, respectively—Alzet Minipump, models 2002, 2001; Charles
River, United Kingdom) containing oligonucleotides (1 ng/nlin sterile
saline) were connected to canulae inserted under the dura of the spi¬
nal cord to level L5-6 and produced a predicted infusion rate of 0.5
nl/hr. CCI surgery was performed at the same time as minipump im¬
plantation. Sensory tests were carried out to assess the time course
of behavioral sensitization in animals that had also undergone a CCI
injury. Icilin was applied topically rather than intrathecal^ so as to
prevent any interference with the infusion canula. Peripheral nerve
recordings and tissue harvesting were carried out after an interval
of 4-5 days to allow time for protein knockdown.
Electrophysiology
Peripheral
Recordings of saphenous (sensory) nerve were made in naive ani¬
mals (n = 7) to assess the effects of topical icilin on primary afferents.
In addition, recordings were carried out on animals that had under¬
gone TRPM8 antisense or missense treatment beginning 4-5 days
previously. Rats were anesthetized (with 0.6 ml 25% urethane/100
g, intraperitoneal), and the saphenous nerve was exposed and dis¬
sected from its associated vein and artery. Further dissection under
liquid paraffin enabled identification of afferent preparations com¬
prising a small number of fibers. The conduction velocity of single
identified afferent fibers was determined by using bipolar electrodes
and the peripheral stimulus technique [64]. After isolation of prepa¬
rations, icilin (200 |.iM in water with 0.2% DMF), (-)-menthol (4 mM in
25% ethanol), resiniferatoxin (1 mM in ethanol), or vehicle alone was
applied to the hind limb receptive fields, and neuronal responses
were recorded with the Chart program (version 3.6).
Central
Recordings of spinal dorsal-horn neurons were made in CCI ani¬
mals, as described previously [61]. After halothane induction, the
jugular vein and trachea were canulated and intravenous anesthetic
was delivered: a-chloralose (0.6 mg/kg, Fisher) and urethane (1.2
mg/kg, Sigma), with small supplementary doses of a-chloralose as
required throughout the experiment. Core body temperature was
maintained at 37°C-38rC by means of a thermostatically controlled
heated blanket. The animal was placed in a stereotaxic frame, and
the thoracolumbar spinal column was supported by three pairs of
swan-necked clamps. A laminectomy was performed at L2-L5,
and agar (2% in saline at 37°C) was delivered over exposed cord
to increase mechanical stability. Above the recording region, the
agar and spinal cord dura were removed, and liquid paraffin was
poured into the pool. Extracellular recordings were made from single
multireceptive neurons in laminae I—IV through the center barrel of
a seven-barrelled glass microelectrode filled with 4 M NaCI (tip-
diameter 4-5 nm, DC resistance 5-8 MQ). The receptive fields of
hair-follicle innervated neurons on the distal hind limb were identi¬
fied by an innocuous brush stimulus [61]. Icilin (200 nM in water
with 0.2% DMF) was applied peripherally to the receptive field of in¬
dividual recorded neurons, and the effect on neuronal response to
a rotating brush was recorded and analyzed with Spike2 program
(Version 3.2, CED). The Group III mGluR antagonist UBP 1112 (20
mM in water), pH 8.5, and control 1 M NaCI, pH 8.5, were ionophor-
esed from the side barrels of the electrode by using currents of
between 20 nA and 80 nA (Neurophore BH2 ionophoresis system,
Medical Systems, Great Neck, New York) to measure effects on neu¬
ronal response to icilin.
Statistics
All data were analyzed for statistical significance by using Sigmastat
software (version 2.03) with p values < 0.05 being considered signif¬
icant. Differences in thermal sensitivity between the paw ipsilateral
to nerve injury and the contralateral paw were assessed with Stu¬
dent's t test. Any effect of drug treatment was analyzed by one¬
way repeated-measures ANOVA followed by Dunnett's post-hoc
multiple-comparisons test. The equivalent nonparametric tests
for mechanical sensitivity were Wilcoxon rank test for
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ipsilaterakcontralateral differences and Friedman repeated-mea¬
sures ANOVA followed by Dunn's test for changes from prodrug
control values. Western blot-densitometric values were compared
by using the Wilcoxon test, immunohistochemistry cell counts
were analyzed by one-way ANOVA, and electrophysiological spike
frequencies were analyzed by one-way ANOVA on ranks.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and are available with this article online at: http://www.current-
biology.com/cgi/content/full/16/16/1591 /DC1 /.
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Chapter 27
The Ubiquitin Proteasome System in
Pain Transmission and Neuropathic
Pain
Clare WJProudfoot, Darren CRobertson, Enter M Garry and
Susan MFleetwood-Walker1
Centre for Neuroscience Research, Division of Veterinary Biomedical Sciences,
University of Edinburgh, EH9 1QH.
ABSTRACT
Chronic pain states involve long-term biochemical and anatomical changes including
plasticity at the first synapse in the spinal cord, which is crucial to the development of
hyperalgesia (increased sensitivity to noxious stimuli) and allodynia (perception of
innocuous stimuli as painful). Spinal dorsal horn neurons become hyperexcitable in the
process of "central sensitisation", which shows partial similarity to other forms of
synaptic plasticity, such as hippocampal long-term potentiation (LTP). Both processes
involve pre- and post-synaptic changes, and rely on the NMDA receptor and associated
proteins. The ubiquitin-proteasome system (UPS) has been implicated in central
sensitisation and the development of neuropathic pain. In an animal model of neuropathic
pain, proteasome inhibitors have been shown to rapidly attenuate behavioural
hyperalgesia and allodynia, inhibited firing of dorsal horn neurons evoked by noxious and
innocuous stimuli in neuropathic animals, or by mustard oil in normal animals.
Expression of the enzyme UCH-L1 (Ubiquitin C-terminal hydrolase) was further
increased in the spinal cord dorsal horn ipsilateral to neuropathy, supporting a central role
for the UPS in neuropathic pain. Studies of other CNS areas have emphasised the
importance of the UPS in regulation of synapse structure and neurotransmitter release and
its role of such changes in plasticity. Postsynaptically, the UPS mediates changes in
composition of the postsynaptic density (PSD) since activity-dependent ubiquitination
regulates PSD composition and several key scaffolding molecules which are involved in
pain sensitisation, undergo activity-dependent ubiquitination. PSD-95 in particular plays a
key role in neuropathic pain. PSD-95 links to the NMDA receptor which is essential for
central sensitisation and may regulate AMPA receptor synaptic insertion. NMDA receptor
activation causes PSD-95 ubiquitination and degradation and blockade of this process
prevents NMDA receptor induced AMPA-receptor recycling and long-term depression.
Since alteration in levels of surface glutamate receptor expression is a key means by
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which synaptic strength is altered, these observations further support the idea of acute
regulation of synapse function by the ubiquitin-proteasome pathway. In addition,
proteasome inhibitors reduce NMDA receptor-dependent activation of the CREB and
ERK/MAPK signalling cascades, indicating a further mechanism by which the UPS may
influence long-term plasticity during chronic pain. The UPS is also involved in synapse
development and in morphological changes in dendritic spines. Thus, a wide array of
changes in protein:protein interactions, signalling events and cytostructural changes
depend on UPS function during the synaptic plasticity that underlies chronic pain states.
These processes may represent promising targets for the development of novel analgesic
strategies.
Key words: Pain, Neuropathy, Ubiquitin, Proteasome, Neuronal plasticity, Posterior
horn, Postsynaptic density.
Abbreviations:
CC1; chronic constriction injury model
CFA; Complete Freund's adjuvant
CNS; central nervous system
COX-2; cyclooxygenase-2
CREB; cyclic AMP response element binding protein
DRG; dorsal root ganglia
El; ubiquitin-activating enzyme
E2; ubiquitin conjugating enzyme
E3; ubiquitin ligases
ERK; extracellular signal-regulated protein kinase
GluR; glutamate receptor (AMPA receptor subtype)
GRIP; glutamate receptor -interacting protein
IKK; IkB kinase
1L; interleukin
LI/II; laminae I and II in superficial dorsal horn of spinal cord
LTP; long-term potentiation
MAGUK; membrane associated guanylate kinase
MAP; mitogen activated protein
mGluR; metabotropic glutamate receptor
NF-L; neurofilament-light
NR; NMDA receptor
NSAlDs; Non-steroidal anti-inflammatory drugs
NSF; N-ethylmaleimide-sensitive fusion protein
PICK1; protein interacting with C kinase 1
PKA; protein kinase A
PWL; paw withdrawal latency




Siahl A; Seven in absentia homolog 1A
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SPAR; spine-associated Rap GTPase activating protein
SPET; suspended paw elevation time
TNF-a; tumour necrosis factor-a
UCH-L1 (Ubiquitin C-terminal hydrolase)
UPS; ubiquitin proteasome system
INTRODUCTION
Normal, physiological pain serves a useful purpose, alerting us to damaging stimuli and
triggering withdrawal reflexes, or forcing a state of rest to promote recovery from injury. On
the contrary, chronic pain, which persists long after the original cause has resolved, serves no
beneficial purpose and presents a major clinical problem. Neuropathic pain is a form of
chronic pain which is caused by damage to the nervous system. It can occur as a result of
trauma, diabetes and demyelinating diseases, viral infections (such as in postherpetic
neuralgia), certain chemotherapeutic agents (all of which damage peripheral nerves) and also
from central nervous system damage. Treatment options are limited [1]; conventional first-
line treatments such as NSAlDs (Non-steroidal anti-inflammatory drugs) and opioids are
ineffective [2], Current prescribed medications are anti-convulsant drugs (e.g. gabapentin),
sodium channel blockers and tricyclic antidepressants, all of which show variable efficacy
and cause deleterious side effects. Under normal circumstances, a sensation of pain is evoked
when noxious stimuli to the periphery evoke action potentials in the terminals of nociceptive-
specific primary afferent neurons. These primary afferents terminate in the dorsal horn of the
spinal cord, synapsing onto central spinal neurons, which form several pathways connecting
to the thalamus and cortex. The synapse in the dorsal horn between primary afferent and
second order neurons plays a key role in pain transmission and processing. Plasticity at this
synapse is a major means by which behavioural sensitisation can develop. This sensitisation is
reflected in hyperalgesia— heightened sensitivity to noxious stimuli, allodynia— perception
of innocuous stimuli as noxious, and spontaneous pain. Various animal models have been
developed in an effort to reproduce the sensory disorders accompanying human peripheral
neuropathies. Partial nerve injury models mimic the most common type of injury seen in
humans. Such models are highly reproducible and result in the hallmark behavioural signs of
neuropathic pain; hyperalgesia and allodynia.
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Figure 1: Peripheral and central mechanisms of neuropathic pain
Changes at the level of peripheral afferents, the dorsal horn of the spinal cord, and descending input
from brain areas. All lead to the development of hyperalgesia (heightened sensitivity to noxious stimuli)
and allodynia (perception of innocuous stimuli as painful) in neuropathic pain.
Sensitisation as a result of plasticity in pain pathways occurs normally following injury,
but is short-term and reverses as the injury heals. However, in neuropathic pain, continuing
modification of the pain pathways, particularly at the early synapses in the dorsal horn, results
in long-term sensitisation, which far outlasts the injury. Damage to the peripheral nerves
causes some axons to degenerate, and remaining neurons display altered properties including
spontaneous and ectopic firing. Phenotypic changes occur in damaged and neighbouring
afferents with alterations in expression of ion channels, receptors, and levels of
neurotransmitters, and de novo expression of certain proteins. In postsynaptic neurons, levels
of receptors and cellular proteins are also altered. These changes result in central
sensitisation, a form of synaptic plasticity with some analogies to hippocampal long-term
potentiation (LTP) and to other forms of central nervous system plasticity resulting in a
facilitation of neurotransmission due to repetitive conditioning stimuli (see Chapter 14-17\
Figure /). Activity-dependent sensitisation has been reported in rodent, cat and primate
dorsal horn neurons [3, 4], A central sensitisation-like phenomenon can also be generated in
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other supraspinal pain processing areas: the rostroventral medulla (RVM), anterior cingulate
cortex, and amygdala [5, 6, 7],
LTP and central sensitisation are both dependent on excitatory glutamatergic
transmission involving AMPA and NMDA subtypes of ionotropic glutamate receptor [8, 9,
10, 11, 12], AMPA receptors are composed of four subunits (GluRl-4), while NR1, NR2
(NR2A-D) and NR3 (NR3A/B) subunits all constitute the NMDA receptor family. All these
subunits are differentially localised in the spinal cord with GluRl and GluR2 subunits of
AMPA receptor and NR1 and NR2B subunits ofNMDA receptor being most concentrated in
the major nociceptive processing area in the superficial dorsal horn (see later). Under basal
conditions, acute nociceptive transmission is mediated by AMPA receptors, while NMDA
2+
receptors are inactive, due to blockade by Mg ions in the NMDA channel pore. Under
conditions of nerve injury, high-frequency stimulation produces a cumulative membrane
2+ . ,
depolarisation which leads to removal of the voltage-dependent Mg ion block in the channel
pore, allowing entry of calcium ions and resultant calcium-dependent intracellular signalling.
Metabotropic glutamate receptors (mGluRl-7) have also been implicated in synaptic
plasticity in hippocampus and cerebellum as well as spinal neuronal sensitisation associated
with chronic pain.
THE UBIQUITIN-PROTEASOME SYSTEM (UPS)
A major intracellular pathway that is now known to act as an important regulator of such
synaptic function is the ubiquitin-proteasome system [13, 14, 15, 16]. The UPS is a highly
conserved multi-enzyme mechanism that targets cytosolic proteins for degradation [17]. A
sequential series of reactions is catalysed by ubiquitin-activating enzyme (El), followed by
ubiquitin conjugating enzymes (E2) and a number of ubiquitin ligases (E3), resulting in
ubiquitin binding to lysine residues in the target protein [18], Activity-dependent
ubiquitination and degradation by the proteasome proteolytic complex is a mechanism by
which synaptic proteins and thus synaptic strength may be regulated. Levels of ubiquitin-
conjugated proteins are strongly linked to synaptic activity level, and this is particularly
pronounced for postsynaptic density (PSD) proteins [19]. This pathway is involved in the
regulation of synaptic plasticity in the hippocampus, whereby the proteasome inhibitors MG-
132 and lactacystin can block long-term depression, a further form of lasting alteration in
synaptic function [16],
LOCALISATION OF THE UPS NEAR TO SYNAPSES:
The UPS has been localised intracellularly in the vicinity of the synapse, making it a
plausible regulator of synaptic function. Confocal microscopy demonstrates that ubiquitin and
the proteasome are abundant in dendrites of cultured hippocampal neurons, in or near putative
spines [15], Ubiquitin conjugation has been demonstrated in synaptosomal and PSD
preparations, indicating that ubiquitination can occur in or near synapses [19], It is possible
that dynamic recruitment of UPS components to synaptic sites could act as a regulator of
function [15]. The UPS is directly involved in affecting growth of dendritic spines by a
mechanism involving degradation of the protein SPAR (spine-associated Rap GTPase
activating protein) which is a postsynaptic scaffolding molecule that binds both filamentous
8 Clare WJ Proudfoot, et al.
actin and the MAGUK (membrane-associated guanylate kinase family adapter protein
prominent in postsynaptic densities, PSD-95. Degradation of SPAR by the UPS is activity-
dependent, and results in depletion of both SPAR and PSD-95 from spines, leading to
dissipation of spines [20].
THE UPS AND NEUROPATHIC PAIN
The UPS is specifically implicated in the sensitisation that occurs in the spinal cord in
chronic pain [21]. Extracellular recordings of multireceptive dorsal horn neurons show
heightened neuronal activity following the topical application of the chemical algogen
mustard oil (allyl isothiocyanate), a selective activator of nociceptive C-fibers [22].
Ionophoresis of the ubiquitin-proteasome inhibitors lactacystin or MG-132 in vivo partially
inhibits the mustard oil-induced increase in firing but had no effects on responses to an
innocuous brush stimulus [21]. This indicates that the UPS is preferentially involved in the
processing of noxious (mustard oil) but not innocuous (brush) sensory stimuli in the spinal
cord under normal conditions {Table 1).
Table 1. Summary of effects of proteasome inhibitors on sensory stimulation-induced
dorsal horn neuronal activity
Normal Nerve injury






Lactacystin - * n/a * 4< *
MG-132 - * n/a * * 4/
Summary of the effects of the ionophoretic application of proteasome inhibitors lactacystin and
MG-132 on dorsal horn neuron responses to innocuous (brush) or noxious (mustard oil or cold)
sensory stimulation. In naive animals, neither drug had any effect (-) on non-nociceptive brush-
evoked firing, while both drugs were capable of reducing (4^) neuronal firing induced by the
noxious mustard oil stimulus. The cold (4°C) stimulus was not tested (n/a) in normal animals, as it
elicits no behavioural reflex withdrawal responses in normal animals, only in neuropathic animals.
Thus normally, the UPS appears to contribute only to the processing of nociceptive sensory
stimuli. In neuropathic animals, proteasome inhibitors are now capable of reducing dorsal horn
responses evoked not only by nociceptive mustard oil and newly nociceptive responses to cold
stimulation but also responses evoked by non-nociceptive brush stimulation. Thus, in the sensitised
state following nerve injury, the UPS is now involved in processing noxious and innocuous
sensory stimuli.
The sciatic nerve chronic constriction injury model (CCI) produces sensitisation in the
neurons of the spinal dorsal horn and the behavioural correlates of hyperalgesia and allodynia
indicative of neuropathic pain [23], Spinal dorsal horn neurons from neuropathic animals
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show elevated responses to brush as well as mustard oil, which is representative of
mechanical allodynia, but there is also a de novo response to noxious (4°C) cold stimulation,
known as 'cold allodynia'. In extracellular recordings from the spinal neurons of neuropathic
animals, the same proteasome inhibitors lactacystin and MG-132 could significantly inhibit
elevated neuronal responsiveness evoked by noxious stimulation with mustard oil or cold
stimulation as well as that evoked by innocuous brush stimulation [21], This further indicates
that ubiquitin is involved in the processing of noxious sensory stimuli, which, following nerve
injury, includes not only mustard oil, but now also brush and cold stimulation (Table 1).
In agreement with the electrophysiological results, administration of the ubiquitin-
proteasome inhibitors MG-132 and epoxomicin into the intrathecal space reversed whole
animal behavioural thermal hyperalgesia and mechanical and cold allodynia which develop
ipsilateral to nerve injury, but had no effect in nai've animals or on uninjured contralateral paw
values [Figure 2; 21]. In both behavioural and electrophysiological experiments, proteasome
inhibitors exerted an effect within 20 minutes of application. Such rapidity of action suggests
that UPS activity is essential for the maintenance of established neuropathic sensitisation.
Biochemical changes were also observed consistent with an involvement of the UPS in
the neuropathic pain state. RT-PCR, in situ hybridisation, and Western blot analysis of the rat
homologue of ubiquitin C-terminal hydrolase, UCH-L1, (also referred to as PGP 9.5), showed
a significant elevation of the expression ofmRNA and protein in the spinal cord ipsilateral to
nerve injury with a time course paralleling the development of sensitised behavioural reflex
withdrawal responses [21]. Thus, there is a clear involvement of the UPS in chronic pain
states. But what are the key targets that have implications for spinal cord sensitisation?
POTENTIAL TARGETS OF THE UPS IN
NEUROPATHIC PAIN
Protein Kinase A (PKA)
One possible target is protein kinase A (PKA). PKA is composed of regulatory and
catalytic subunits, whereby the regulatory subunits normally maintain the kinase in an
inactive state. Upon activation, the regulatory subunits of PKA dissociate and there is a
translocation to the cell nucleus of the now constitutively active catalytic subunit [24],
Ubiquitin-directed proteolysis is known to degrade the regulatory subunits, leading to
persistent kinase activation [13, 24], PKA is involved in pain transmission, as activation of
PKA causes increased dorsal horn neuron responsiveness and leads to hyperalgesia [25, 26,
27] and mice with a knockout of specific regulatory subunits of PKA have reduced responses
in the formalin model of inflammation [28], Furthermore, enzymatic activity of PKA in the
spinal cord is enhanced following nerve injury [21]. This increase is blocked by local spinal
application of the ubiquitin proteasome inhibitors epoxomicin and MG-132 [21]. Thus, UPS













































Figure 2: Reversal of neuropathic pain behaviour following epoxomicin treatment.
The bar chart shows mean percentage difference in nerve-injured ipsilateral (ipsi) paw from uninjured
contralateral paw, at pre-drug baseline (unshaded columns), and 10-25 minutes following intrathecal
administration of the proteasome inhibitor epoxomicin (shaded columns). Data illustrate the percentage
change ipsilateral to nerve injury (compared to the contralateral side) in thermal sensitivity (PWL - paw
withdrawal latency to noxious thermal stimuli: approximately 40% reduction), mechanical sensitivity (PWT -
paw withdrawal threshold to calibrated mechanical stimuli; approximately 80% reduction) and cold allodynia
(SPET - Suspended Paw Elevation Test to 4°C water; response seen only on the ipsilateral side). Data are
shown as mean ± standard error of the mean. * represents significant ipsilateral-contralateral difference
(p<0.05, t-test for thermal, Wilcoxon test for mechanical/cold), t represents significant effect of drug (p<0.05,
One-Way RM ANOVA followed by Dunnett's post-hoc test for thermal, Friedman ANOVA on ranks followed
by Dunn's post-hoc test for mechanical/cold). Nerve-injury induced sensitisation is substantially reduced by
epoxomicin administration, as indicated by thermal, mechanical and cold sensory tests.
A number of downstream targets of PKA have been identified that are likely to be critical
to spinal cord sensitisation and neuropathic pain states and these notably include NMDA and
AMPA type glutamate receptors. The C-terminal domains of the NR1 and NR2 subunits of
NMDA receptors contain sites of PKA phosphorylation that may increase the degree of Ca2+
entry evoked by NMDA receptor stimulation [29, 30, 31, 32], Electrophysiological responses
of spinal neurons to NMDA are known to be facilitated by PKA [12, 25, 26], NR1
897
phosphorylation at serine reside 897 (Ser ) is increased in spinal cord following CCI and in
spinal dorsal horn spinothalamic tract cells following capsaicin injection [33, 34]. However, it
has not yet been established whether there are any PKA regulatory affects on NMDA
receptors involving the UPS.
845
PKA can also phosphorylate serine reside 845 (Ser ) located in the intracellular C-
845
terminal domain of the GluRl AMPA receptor subunit [35, 36], Phosphorylation at Ser
increases AMPA receptor responsiveness through a modulation of channel gating and
channel open probability without affecting channel conductance [37]. GluRl subunit
845
phosphorylation at Ser is known to occur in the superficial (LI/11) spinal dorsal horn in
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response to noxious stimulation with capsaicin [38, 39] and following peripheral nerve injury
[Garry et al., unpublished observations]. This modulation by PKA is required for the insertion
of GluRl-containing receptors into synapses [40], Correspondingly, the adenylyl cyclase
activator forskolin can also elicit recruitment of functional AMPA receptors [16].
NMDA receptors
NMDA receptors are critical to the spinal sensitisation and hyperexcitability that occurs
following injury [41, 42, 43], In the spinal cord, NMDA receptor blockade reduces
frequency-dependent potentiation (wind-up) of cells to repeated C-fiber stimulation and
following mustard oil application [44, 45], The NR1 subunit of the NMDA receptor is
ubiquitinated by Fbx2, and binding of Fbx2 to the subunit is activity-dependent [46],
suggesting that the UPS regulates the NMDA receptor in an activity-dependent manner.
Ubiquitination of NR1 in HEK293 cells is blocked by co-expression with the neuronal
filament protein, neurofilament-light (NF-L), [47] which has implications for NMDA receptor
stability in the PSD [48],
NMDA receptor activation triggers intracellular signalling cascades, which are involved
in long-term plasticity. These include two prominent pathways through the nuclear
transcription factor cyclic AMP response element binding protein (CREB) and the mitogen-
activated ERK-MAP kinase pathways. The CREB pathway activates transcriptional changes,
leading to long-term modification of neuronal biochemistry and function. As well as its own
profile of transcriptional changes, the MAP kinase pathway causes short-term modification of
proteins via phosphorylation, and also activation ofCREB [49]. Both pathways are associated
with development of chronic pain states. Phosphorylation of p38 MAP kinase and
p42/44(ERKl/2) MAP kinase is induced in the ipsilateral dorsal horn of the spinal cord and
dorsal root ganglia following peripheral nerve injury (or inflammation) and inhibition of these
pathways prevents the behavioural sensitisation seen following nerve injury [50, 51, 52, 53,
54]. Increases in phosphorylation of CREB in the spinal cord are observed following partial
sciatic nerve ligation [55] and following chronic constriction injury, with a time-course
paralleling development of thermal hyperalgesia [56]. Both pre-treatment with proteasome
inhibitors and synaptic blockade augmented NMDA receptor dependent activation of ERK-
MAP kinase, and inhibited activation of CREB [57]. CREB is also a prominent target of
PKA, which may be activated by a variety of other non-NMDA receptor inputs and which is
UPS-regulated (see above). Thus the UPS influences a variety of long-term transcriptional
changes through modification of signalling cascades.
AMPA receptors
AMPA receptors are involved in basal nociceptive responses but they are also critical in
mediating sensitised sensory responses [58], Agonists of the AMPA receptor result in
sensitisation of behavioural nociceptive responses and increased activity of dorsal horn
neurons [59, 60]. AMPA receptor antagonists alter acute nociceptive withdrawal responses
and reverse nerve-injury induced pain [9, 58, 61, 62]. Virtually all dorsal horn neurons
express GluR2 predominantly in the superficial (LI/II) dorsal horn, where it is known to
increase following injury [38, 58, 63], GluRl expression is more restricted in the superficial
dorsal horn LI/II where it has been localised at primary afferent synapses due to association
with markers of unmyelinated afferents [38, 63], GluR3 and GluR4 are expressed in ventral
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and deep dorsal (LII1-VI) horn with weak expression in the superficial dorsal horn and are
thus less likely to play a role in pain plasticity [38, 63, 64, 65, 66, 67, 68].
Unlike NMDA receptors, AMPA receptors are rapidly turned over [69, 70], and agonist
binding may cause receptor internalisation and breakdown [14, 71]. Insertion and removal of
AMPA receptor subunits is now thought to be a major component of synaptic plasticity such
that AMPA receptor abundance determines synaptic strength [69, 72, 73], AMPA receptors
undergo rapid endocytosis followed by recycling or degradation in response to ligand
binding, NMDA receptor activation; and during long-term depression [14]. Excitatory
transmission is depressed following AMPA receptor internalisation [71] and AMPA receptor
trafficking from the cytosol to the membrane is thought to be important in hippocampal LTP
in culture [73]. It is generally believed that GluR2/3 containing channels are constitutively
inserted into the synapse while GluRl/4 containing receptor insertion is inducible (eg. by
LTP) [74]. Painful chemical stimulation of the colon or somatosensory nerve injury can cause
delivery of GluRl but not GluR2/3 from cytosol to the plasma membrane in the spinal cord
[76, Garry unpublished observations]. However, there is a nerve injury- and AMPA receptor
stimulation-induced internalisation of spinal GluR2 that can be prevented by inhibitors of
clathrin-coated vesicle endocytosis [58], a mechanism known to regulate AMPA receptor
trafficking [75].
AMPA receptor surface expression is subject to regulation by the UPS [15, 16, 77, 79],
There is ubiquitination of GLR-1, the C Elegans form of mammalian GluRl, and this has
been proposed as a signal for subunit endocytosis [77]. Also, AMPA- (or NMDA-) receptor
activation stimulated internalisation of GluRl and GluR2 in hippocampal dendrites and spinal
cord [14, 15, 58, 78];] is prevented by pre-treatment with the proteasome inhibitors MG-132
and lactacystin [15], These compounds inhibit behavioural reflex sensitisation and suppress
dorsal horn neuron hypersensitivity that occurs in response to peripheral nerve injury and
noxious stimulation, as mentioned above [21]. This suggests that AMPA receptor trafficking
requires UPS-dependent degradation, although no direct ubiquitination of AMPA receptors
has been observed [16]. Nevertheless, ubiquitination may occur via a number of intracellular
proteins in the PSD that interact with AMPA receptor subunits and are subject to degradation
by the UPS[57].
GLUTAMATE RECEPTOR-INTERACTING PROTEINS
While AMPA receptor plasticity is thought to involve changes in the number of receptors
at the synapse [72], NMDA receptor plasticity involves a complex of adapter and signalling
proteins in the PSD [33, 80]].
The PSD matrix is responsible for the organisation of neurotransmitter receptors, scaffold
proteins and signalling enzymes and is dynamically regulated in response to activity. At least
some of these changes are mediated by the UPS. Profound changes in the PSD occur in
response to prolonged activity, and these are prevented by proteasome inhibition [19]. Indeed,
a diverse range of PSD proteins are controlled by UPS-dependent changes.
One such protein is PSD-95, an NMDA receptor-interacting protein that forms
intermolecular complexes with signalling and other molecules to regulate receptor function.
PSD-95 has a critical role in the development of neuropathic reflex behaviours following
nerve injury [33], Mice with a mutation in PSD-95 that disrupts connections to intracellular
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signalling cascades but retains NMDA receptor interacting abilities fail to develop the
expected sensitised responses following CCl-induced nerve injury but display normal
responses to the formalin model of chronic inflammation [33]. This represented the
identification of one of the first proteins underlying a differential processing capacity for
different types of chronic pain [81].
PSD-95 can also interact with AMPA receptors to promote their surface expression
whereby over-expression of PSD-95 increases both AMPA receptor currents and the number
of AMPA receptors at the synapse by inhibition of AMPA receptor internalisation [82, 83,
84, 85, 86, 87], Stimulation of AMPA receptors leads to a reduction in the number and
intensity of PSD-95 puncta in hippocampal dendrites that is sensitive to the UPS inhibitor,
MG-132 [82], This could provide a mechanism for UPS-dependent modulation of AMPA
receptor synaptic accumulation. Furthermore, activation of NMDA receptors causes
ubiquitination and subsequent degradation of PSD-95 that is prevented in the presence of
MG-132 and lactacystin [16]. However, there is some controversy as to the conditions under
which ubiquitination of PSD-95 might occur, ie. basally or in response to NMDA receptor
stimulation [16, 57, 82]. NMDA receptor stimulation also causes a reduction in the number of
synaptic AMPA receptors that is blocked when PSD-95 ubiquitination is prevented [14, 16,
75, 88, 89]; MG-132 can block the loss in synaptic GluRl subunits that occurs following
NMDA receptor activation [15, 16, 78].
PSD-95 interacts indirectly with AMPA receptors through the surface protein stargazin
[84, 86]. This trimeric interaction complex is thought to mediate surface expression and
synaptic targeting of AMPA receptors [84, 90]. The PDZ binding site of stargazin is
regulated by PKA and mutations that mimic this phosphorylation site (T321E and T321D)
can downregulate AMPA receptor function [90, 91].
The GluR2 subunit interacts with a variety of intracellular proteins via sequences in its C-
terminal tail. GRIP (glutamate receptor -interacting protein) and PICK1 (protein interacting
with C kinase 1) have been implicated in AMPA receptor endocytosis [71, 92] and receptor
clustering is decreased in cultured spinal neurons with blockade of these interactions [93],
Consistent with this, there is translocation of both GRIP and PICK1 in the spinal cord
following AMPA receptor stimulation [58]. Local spinal administration of interfering
peptides to block interactions with PICK1 can reverse CCI-induced behavioural reflex
sensitisation [58]. The related protein GRIP is also translocated from the membrane in spinal
cord following AMPA receptor stimulation [58]. The translocation of both of these
intracellular proteins is prevented in the presence inhibitors of the 'clathrin-coated vesicle'
pathway/ clathrin mediated endocytosis [58], However, any involvement of the UPS in this
process has not yet been established.
Another GluR2 interacting protein, NSF (N-ethylmaleimide-sensitive fusion protein) is
involved in receptor exocytosis [89, 94] and blockade of this interaction in the spinal cord
reverses hyperalgesia and allodynia that results from peripheral nerve injury [58]. This
interaction is thought to be necessary for normal synaptic expression of AMPA receptors as
blocking this interaction in culture results in a rundown of synaptic currents in hippocampal
neurons in association with reduced synaptic expression of AMPA receptors [94, 95].
Activity-dependent insertion of AMPA receptors into functionally 'silent' synapses that only
express functional NMDA (but not AMPA) receptors may be responsible for the expression
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of LTP [96, 97], Again, it is not known if the UPS is involved in the regulation of AMPA
receptor interactions with NSF.
METABOTROPIC GLUTAMATE RECEPTORS
Metabotropic glutamate receptors also play an important role in pain processing,
particularly at the level of the spinal cord. Group 1 mGluRs (mGluRl and mGluR5) are
implicated in the development of sensitised pain states [98], and Group 11 (mGluR 2 and 3)
and Group 111 (mGluR4 and 7) receptors are implicated in inhibition of pain signalling [99,
100, 101, 102], Of these, the Group I mGluRs have been shown to undergo ubiquitin-
dependent degradation by the protein SiahlA (Seven in absentia homolog 1A), which binds
to long splice forms of mGluRla and mGluR5 [103]. Other mGluRs may also be potential
targets for ubiquitination and thereby regulation by the UPS.
THE UPS AND NF-kB SIGNALLING
The UPS regulates gene expression via its interaction with the transcription factor NF-kB
[104]. NF-kB normally exists in a dimeric form complexed with the inhibitory regulator, IkB
[105]. The IkB complex prevents the nuclear import of NF-kB, holding it in the cytoplasm
and thereby inhibiting its transcriptional activity [105]. This interaction is mediated by
ankyrin repeats and the ubiquitination and subsequent degradation of IkB by the proteasome
is key to NF-kB regulation. The phosphorylation of IkB by IkB kinase (IKK) at two N-
terminal serine residues is the event, which precipitates the polyubiquitination of IkB and
therefore its degradation [106], Genes over which NF-kB exerts control and are relevant to
neuropathic pain include, proinflammatory enzymes (inducible nitric oxide synthase,
cyclooxygenase-2 (COX-2)), cytokines such as tumour necrosis factor (TNF)-a, interleukin
(IL)-ip, IL-6, chemokines (RANTES, macrophage inflammatory protein, IL-8), adhesion
factors (intracellular adhesion molecule, vascular cell adhesion molecule) and proteins
involved in controlling apoptosis (Fas, FasL) [107], Recent evidence has demonstrated that
the regulation of NF-kB by the UPS has direct relevance to neuropathic pain as in the CCI
model of nerve injury NF-kB activity is increased in rat lumbar DRG ipsilateral to injury
[108]. Furthermore, intraneural introduction of competitive inhibitors for NF-kB has been
shown to reduce hyperalgesia following spinal nerve ligation [109], In a recent study we have
shown that glial release of cytokines including TNF-a plays a key role in the sensitisation of
spinal cord neurons in neuropathic pain [50], Subcutaneous injection of Complete Freund's
adjuvant (CFA), a model of inflammatory pain, has also been shown to cause the immediate
activation of spinal NF-kB [110],
In the CFA model, pre-treatment with intrathecally administered inhibitors of NF-kB
significantly reduces mechanical allodynia and thermal hyperalgesia [111]. Similarly the 1-kB
kinase inhibitor, SI627 has been shown to reduce or reverse allodynia and hyperalgesia in
both the zymosan-induced model of inflammatory pain and the CCI model, by preventing NF-
kB dependant gene expression [107], These changes in UPS function are likely to have
marked effects on NF-KB-mediating signals that bring about central changes in protein
expression, which support the development of chronic pain states.
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CONCLUSIONS
It is clear that the UPS plays an important part in the sensitization of spinal cord neurons
in the neuropathic pain state. Intrathecally administered UPS inhibitors display striking
reversal of neuropathic sensitization even when it has become previously established, so may
have potential as a novel form of analgesic for this currently intractable pain state. We and
others have identified a number of key proteins that are implicated in synaptic plasticity in
either spinal cord or forebrain and whose degradation or function is regulated by the UPS. It
is unlikely that the role of the UPS in neuropathic pain comprises multiple components with
the function ofNMDA, AMPA and metabotropic glutamate receptors and major intracellular
signalling pathways such as PKA and NF-kB being modulated by UPS activity. Important
questions for the future will be unravelling which of these potential contributions are
function-limiting in neuropathic pain, whether specific proteins or targeting mechanisms
underlie dynamic actions of the UPS in synaptic plasticity and whether agents perhaps
targeting such specific actions of the UPS could be developed as useful analgesics. In
principle, ubiquitin-proteasome inhibitors would be expected to be beneficial in
chronic neuropathic pain states, however, some clinical studies indicate that the
first clinically available ubiquitin-proteasome inhibitor, the boronic acid
derivative, bortezomib actually caused peripheral neuropathy de novo or perhaps
exacerbated a pre-existing peripheral neuropathy, such as Charcot-Marie-Tooth
disease [112]. It is not clear if this neuropathy develops because the agent is
blocking the UPS or is a side effect of this particular drug, as is found, for
example with some other chemotherapeutic drugs such as the vinca alkaloid,
vincristine [113, 114], Only trials with other ubiquitin-proteasome inhibitors of
different chemical structures, but the same effect will reveal this.
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